OA19495A - Tricyclic compounds as Histone Methyltransferase inhibitors. - Google Patents
Tricyclic compounds as Histone Methyltransferase inhibitors. Download PDFInfo
- Publication number
- OA19495A OA19495A OA1202000074 OA19495A OA 19495 A OA19495 A OA 19495A OA 1202000074 OA1202000074 OA 1202000074 OA 19495 A OA19495 A OA 19495A
- Authority
- OA
- OAPI
- Prior art keywords
- cancer
- alkyl
- optionally substituted
- aspects
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 443
- 102000011787 Histone Methyltransferases Human genes 0.000 title abstract description 3
- 108010036115 Histone Methyltransferases Proteins 0.000 title abstract description 3
- 239000003697 methyltransferase inhibitor Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 claims abstract description 98
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 208000001284 Hemoglobinopathy Diseases 0.000 claims abstract description 15
- 201000003923 hemoglobinopathy Diseases 0.000 claims abstract description 15
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 266
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 168
- 125000000623 heterocyclic group Chemical group 0.000 claims description 162
- 125000003545 alkoxy group Chemical group 0.000 claims description 160
- 229910052736 halogen Inorganic materials 0.000 claims description 141
- 150000002367 halogens Chemical group 0.000 claims description 141
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 115
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 110
- 125000001072 heteroaryl group Chemical group 0.000 claims description 86
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 73
- 201000010536 head and neck cancer Diseases 0.000 claims description 67
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 64
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 125000003118 aryl group Chemical group 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 50
- 210000004027 cells Anatomy 0.000 claims description 49
- 125000002950 monocyclic group Chemical group 0.000 claims description 47
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 38
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 38
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 32
- 206010039491 Sarcoma Diseases 0.000 claims description 31
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 31
- 125000004429 atoms Chemical group 0.000 claims description 30
- 210000004602 germ cell Anatomy 0.000 claims description 30
- 125000003282 alkyl amino group Chemical group 0.000 claims description 29
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 28
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 26
- 201000005216 brain cancer Diseases 0.000 claims description 25
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 23
- 150000002431 hydrogen Chemical group 0.000 claims description 23
- 206010025323 Lymphomas Diseases 0.000 claims description 22
- 206010025310 Other lymphomas Diseases 0.000 claims description 22
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 22
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 21
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 20
- 125000004104 aryloxy group Chemical group 0.000 claims description 19
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 16
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 16
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 15
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 15
- 201000005962 mycosis fungoide Diseases 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 13
- 230000002730 additional Effects 0.000 claims description 12
- 229910052805 deuterium Inorganic materials 0.000 claims description 12
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 11
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 11
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 11
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 11
- 206010005949 Bone cancer Diseases 0.000 claims description 10
- 208000010027 Carcinoma, Intraductal, Noninfiltrating Diseases 0.000 claims description 10
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 10
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 10
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 10
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 10
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 10
- 206010028729 Nasal cavity cancer Diseases 0.000 claims description 10
- 206010028767 Nasal sinus cancer Diseases 0.000 claims description 10
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 10
- 201000009030 carcinoma Diseases 0.000 claims description 10
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 10
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 10
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 10
- 201000006721 lip cancer Diseases 0.000 claims description 10
- 230000001394 metastastic Effects 0.000 claims description 10
- 201000002575 ocular melanoma Diseases 0.000 claims description 10
- 201000005443 oral cavity cancer Diseases 0.000 claims description 10
- 201000006958 oropharynx cancer Diseases 0.000 claims description 10
- 201000008968 osteosarcoma Diseases 0.000 claims description 10
- 201000007052 paranasal sinus cancer Diseases 0.000 claims description 10
- 239000000546 pharmaceutic aid Substances 0.000 claims description 10
- 201000000849 skin cancer Diseases 0.000 claims description 10
- 201000011531 vascular cancer Diseases 0.000 claims description 10
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 9
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 9
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 230000001684 chronic Effects 0.000 claims description 8
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 8
- 206010024324 Leukaemias Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 201000010874 syndrome Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 206010035228 Plasma cell neoplasms Diseases 0.000 claims description 6
- 210000003491 Skin Anatomy 0.000 claims description 6
- 201000011231 colorectal cancer Diseases 0.000 claims description 6
- 230000002496 gastric Effects 0.000 claims description 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 6
- 201000009251 multiple myeloma Diseases 0.000 claims description 6
- 201000007224 myeloproliferative neoplasm Diseases 0.000 claims description 6
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 5
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 claims description 5
- 206010001433 Aesthesioneuroblastoma Diseases 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 208000001119 Benign Fibrous Histiocytoma Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 210000000988 Bone and Bones Anatomy 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims description 5
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 5
- 206010014967 Ependymoma Diseases 0.000 claims description 5
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 5
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 5
- 208000003884 Gestational Trophoblastic Disease Diseases 0.000 claims description 5
- 208000007890 Heart Neoplasms Diseases 0.000 claims description 5
- 206010020118 Histiocytosis Diseases 0.000 claims description 5
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 5
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 5
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims description 5
- 210000003734 Kidney Anatomy 0.000 claims description 5
- 201000005099 Langerhans-cell histiocytosis Diseases 0.000 claims description 5
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 5
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 5
- 210000004185 Liver Anatomy 0.000 claims description 5
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 5
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 5
- 208000006178 Malignant Mesothelioma Diseases 0.000 claims description 5
- 206010025650 Malignant melanoma Diseases 0.000 claims description 5
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims description 5
- 206010027406 Mesothelioma Diseases 0.000 claims description 5
- 206010051747 Multiple endocrine neoplasia Diseases 0.000 claims description 5
- 206010028193 Multiple endocrine neoplasia syndrome Diseases 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 5
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 claims description 5
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 5
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 claims description 5
- 208000003154 Papilloma Diseases 0.000 claims description 5
- 208000007312 Paraganglioma Diseases 0.000 claims description 5
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 5
- 206010034299 Penile cancer Diseases 0.000 claims description 5
- 206010034800 Phaeochromocytoma Diseases 0.000 claims description 5
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 5
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 5
- 206010038038 Rectal cancer Diseases 0.000 claims description 5
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 5
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 5
- 210000002784 Stomach Anatomy 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 206010043515 Throat cancer Diseases 0.000 claims description 5
- 208000008732 Thymoma Diseases 0.000 claims description 5
- 206010046766 Uterine cancer Diseases 0.000 claims description 5
- 206010046885 Vaginal cancer Diseases 0.000 claims description 5
- 206010047741 Vulval cancer Diseases 0.000 claims description 5
- 208000008383 Wilms Tumor Diseases 0.000 claims description 5
- 201000011165 anus cancer Diseases 0.000 claims description 5
- 201000008271 atypical teratoid rhabdoid tumor Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000009047 chordoma Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000001342 fallopian tube cancer Diseases 0.000 claims description 5
- 201000010175 gallbladder cancer Diseases 0.000 claims description 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 5
- 201000008298 histiocytosis Diseases 0.000 claims description 5
- 201000002529 islet cell tumor Diseases 0.000 claims description 5
- 201000003175 male breast cancer Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 5
- 201000008026 nephroblastoma Diseases 0.000 claims description 5
- 201000008859 olfactory neuroblastoma Diseases 0.000 claims description 5
- 201000008042 ovarian germ cell cancer Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 230000000849 parathyroid Effects 0.000 claims description 5
- 201000008006 pharynx cancer Diseases 0.000 claims description 5
- 201000008199 pleuropulmonary blastoma Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 201000000582 retinoblastoma Diseases 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 201000002314 small intestine cancer Diseases 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 210000003079 Salivary Glands Anatomy 0.000 claims description 4
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 4
- 201000010235 heart cancer Diseases 0.000 claims description 4
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 3
- 210000003128 Head Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 abstract description 51
- 239000003112 inhibitor Substances 0.000 abstract description 27
- 208000005980 beta-Thalassemia Diseases 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 3
- -1 but not limited to Substances 0.000 description 398
- 239000000203 mixture Substances 0.000 description 79
- 229910052757 nitrogen Inorganic materials 0.000 description 54
- 125000001309 chloro group Chemical group Cl* 0.000 description 44
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- 125000001153 fluoro group Chemical group F* 0.000 description 41
- 229910052760 oxygen Inorganic materials 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 33
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 33
- 239000001301 oxygen Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- 239000007787 solid Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 101700009373 EHMT2 Proteins 0.000 description 28
- 239000000543 intermediate Substances 0.000 description 28
- 150000002829 nitrogen Chemical group 0.000 description 28
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 27
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 27
- 230000002829 reduced Effects 0.000 description 27
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- 125000005842 heteroatoms Chemical group 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 23
- 229910052717 sulfur Inorganic materials 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 102100016355 EHMT1 Human genes 0.000 description 20
- 101700077246 EHMT1 Proteins 0.000 description 20
- 229940079593 drugs Drugs 0.000 description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 20
- 239000011593 sulfur Substances 0.000 description 20
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 19
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 19
- 101710004110 GLP Proteins 0.000 description 18
- 101710004985 GOLGA6A Proteins 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 18
- 101710038873 glc-1 Proteins 0.000 description 18
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 125000002947 alkylene group Chemical group 0.000 description 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 17
- 150000003254 radicals Chemical class 0.000 description 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 16
- FVSKHRXBFJPNKK-UHFFFAOYSA-N Propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 16
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 14
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 13
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 13
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 13
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 13
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increased Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
- 206010011401 Crohn's disease Diseases 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 125000004432 carbon atoms Chemical group C* 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 11
- 239000008079 hexane Substances 0.000 description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 10
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 10
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 10
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 9
- 206010003816 Autoimmune disease Diseases 0.000 description 9
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 9
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 9
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 9
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 200000000018 inflammatory disease Diseases 0.000 description 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- DIOQZVSQGTUSAI-UHFFFAOYSA-N Decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- BKIMMITUMNQMOS-UHFFFAOYSA-N Nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 8
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 206010018651 Graft versus host disease Diseases 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 125000003003 spiro group Chemical group 0.000 description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 7
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-Triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 6
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-Aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 description 6
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 230000001771 impaired Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 5
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 5
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 5
- JKFAIQOWCVVSKC-UHFFFAOYSA-N Furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 5
- 102100019126 HBB Human genes 0.000 description 5
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 5
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 5
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 5
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 5
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000003725 azepanyl group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000004305 biphenyl Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000001808 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 5
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 4
- HJVAVGOPTDJYOJ-UHFFFAOYSA-N 2-amino-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(N)=C(C(O)=O)C=C1OC HJVAVGOPTDJYOJ-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 206010003246 Arthritis Diseases 0.000 description 4
- 230000036912 Bioavailability Effects 0.000 description 4
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 4
- 206010008909 Chronic hepatitis Diseases 0.000 description 4
- 206010009839 Coeliac disease Diseases 0.000 description 4
- 206010009887 Colitis Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000008609 Collagenous Colitis Diseases 0.000 description 4
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 4
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 4
- 229960004679 Doxorubicin Drugs 0.000 description 4
- 208000006454 Hepatitis Diseases 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 229960004338 Leuprorelin Drugs 0.000 description 4
- 206010025135 Lupus erythematosus Diseases 0.000 description 4
- 210000004698 Lymphocytes Anatomy 0.000 description 4
- 208000005987 Polymyositis Diseases 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 206010040767 Sjogren's syndrome Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 150000001502 aryl halides Chemical class 0.000 description 4
- 201000001320 atherosclerosis Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 230000035514 bioavailability Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000051 modifying Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 235000014571 nuts Nutrition 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 201000004681 psoriasis Diseases 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 4
- IOZUOHZJVBPBLK-UHFFFAOYSA-N quinolin-6-ol Chemical compound N1=CC=CC2=CC(O)=CC=C21.N1=CC=CC2=CC(O)=CC=C21 IOZUOHZJVBPBLK-UHFFFAOYSA-N 0.000 description 4
- NIFLNJLWZZABMI-UHFFFAOYSA-N quinoline-6-carbonitrile Chemical compound N1=CC=CC2=CC(C#N)=CC=C21 NIFLNJLWZZABMI-UHFFFAOYSA-N 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 201000006704 ulcerative colitis Diseases 0.000 description 4
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 3
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- QRADKVYIJIAENZ-UHFFFAOYSA-N 1-[[bromo(difluoro)methyl]-ethoxyphosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)(F)Br)OCC QRADKVYIJIAENZ-UHFFFAOYSA-N 0.000 description 3
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 3
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 3
- 229960004630 Chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- BGTOWKSIORTVQH-UHFFFAOYSA-N Cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 3
- 229960004397 Cyclophosphamide Drugs 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229960000684 Cytarabine Drugs 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 210000004292 Cytoskeleton Anatomy 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229960005420 Etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108010000817 Leuprolide Proteins 0.000 description 3
- 210000004688 Microtubules Anatomy 0.000 description 3
- 102000028664 Microtubules Human genes 0.000 description 3
- 108091022031 Microtubules Proteins 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- 206010028417 Myasthenia gravis Diseases 0.000 description 3
- GCAFAXWKYLUKMD-UHFFFAOYSA-N NC=1C(=NC(=C(C=1)Br)OC)C(=O)O Chemical compound NC=1C(=NC(=C(C=1)Br)OC)C(=O)O GCAFAXWKYLUKMD-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- IXWNTLSTOZFSCM-YVACAVLKSA-N Ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 3
- 229960002340 Pentostatin Drugs 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- ADRDEXBBJTUCND-UHFFFAOYSA-N Pyrrolizidine Chemical compound C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- DZMVCVHATYROOS-ZBFGKEHZSA-N Soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 3
- 229950006050 Spiromustine Drugs 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 229960005454 Thioguanine Drugs 0.000 description 3
- 229960001727 Tretinoin Drugs 0.000 description 3
- 229960004528 Vincristine Drugs 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 3
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 229960001330 hydroxycarbamide Drugs 0.000 description 3
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 3
- 229940027318 hydroxyurea Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical compound NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 description 3
- 229960003440 semustine Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 201000009594 systemic scleroderma Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1S,3S,7S,10R,11S,12S,16R)-3-[(E)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N (2R,4R)-N,N-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2S)-N-tert-butyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 description 2
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CNTMOLDWXSVYKD-PSRNMDMQSA-N (E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound OC(=O)C(/C)=C/[C@H](C(C)C)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC)C(C)(C)C1=CC=CC=C1 CNTMOLDWXSVYKD-PSRNMDMQSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 2
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 2
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 2
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 2
- PSNDWZOXFDKLLH-UHFFFAOYSA-N 2-azaspiro[3.4]octane Chemical compound C1NCC11CCCC1 PSNDWZOXFDKLLH-UHFFFAOYSA-N 0.000 description 2
- IBODJKKYTBNWTD-UHFFFAOYSA-N 2-azaspiro[3.5]nonane Chemical compound C1NCC11CCCCC1 IBODJKKYTBNWTD-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- WXEUBFQJQVLQFA-UHFFFAOYSA-N 2-oxa-1-azaspiro[4.5]decane Chemical compound N1OCCC11CCCCC1 WXEUBFQJQVLQFA-UHFFFAOYSA-N 0.000 description 2
- SUSDYISRJSLTST-UHFFFAOYSA-N 2-oxaspiro[3.3]heptane Chemical compound C1CCC21COC2 SUSDYISRJSLTST-UHFFFAOYSA-N 0.000 description 2
- NTMUDPWGPGZGQW-UHFFFAOYSA-N 2-oxaspiro[3.4]octane Chemical compound C1OCC11CCCC1 NTMUDPWGPGZGQW-UHFFFAOYSA-N 0.000 description 2
- PNLURCRXZLVRJR-UHFFFAOYSA-N 2-oxaspiro[3.5]nonane Chemical compound C1OCC11CCCCC1 PNLURCRXZLVRJR-UHFFFAOYSA-N 0.000 description 2
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- HVFHYYCWZWCTMW-UHFFFAOYSA-N 4-azaspiro[2.5]octane Chemical compound C1CC11NCCCC1 HVFHYYCWZWCTMW-UHFFFAOYSA-N 0.000 description 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- YCBIWVHDKSQGFJ-UHFFFAOYSA-N 4-oxaspiro[2.5]octane Chemical compound C1CC11OCCCC1 YCBIWVHDKSQGFJ-UHFFFAOYSA-N 0.000 description 2
- 125000005986 4-piperidonyl group Chemical group 0.000 description 2
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N 5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-2-methylchromen-4-one Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- FOMNEVDLMZUAJY-UHFFFAOYSA-N 5-azaspiro[3.4]octane Chemical compound C1CCC21NCCC2 FOMNEVDLMZUAJY-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- OEYPKRLLTICJEO-UHFFFAOYSA-N 5-oxaspiro[3.4]octane Chemical compound C1CCC21OCCC2 OEYPKRLLTICJEO-UHFFFAOYSA-N 0.000 description 2
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5β,20-epoxy-1,7β,13α-trihydroxy-9-oxotax-11-ene-2α,4α,10β-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 2
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 2
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 2
- 229950004955 ADOZELESIN Drugs 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 229960004176 Aclarubicin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-UHFFFAOYSA-N Adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-UHFFFAOYSA-N 0.000 description 2
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229960001220 Amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N BEZ235 Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 229950006844 BIZELESIN Drugs 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 Batimastat Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- 229950009494 Bropirimine Drugs 0.000 description 2
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 2
- CDNRMUHNYMMJSF-UHFFFAOYSA-N C(OC(C)(C)C)(OC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)Cl)OC)=O Chemical compound C(OC(C)(C)C)(OC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)Cl)OC)=O CDNRMUHNYMMJSF-UHFFFAOYSA-N 0.000 description 2
- ZEIHBIFCRFTGJX-UHFFFAOYSA-N C1(CCC(N1C1C(NC(NC1=O)=O)=O)=O)=O Chemical compound C1(CCC(N1C1C(NC(NC1=O)=O)=O)=O)=O ZEIHBIFCRFTGJX-UHFFFAOYSA-N 0.000 description 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 2
- RUXRYQRFUQDUOR-UHFFFAOYSA-N C1=C(OC)C(OC)=CC(NC=2C=CC=CC=2)=C1C(O)=O Chemical compound C1=C(OC)C(OC)=CC(NC=2C=CC=CC=2)=C1C(O)=O RUXRYQRFUQDUOR-UHFFFAOYSA-N 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N CARZELESIN Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 102100006435 CSF3 Human genes 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
- 229950007509 Carzelesin Drugs 0.000 description 2
- BZXULYMZYPRZOG-UHFFFAOYSA-N Centaureidin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 BZXULYMZYPRZOG-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 210000003483 Chromatin Anatomy 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- CGZZMOTZOONQIA-UHFFFAOYSA-N Cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229950010621 Dezaguanine Drugs 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 229950004203 Droloxifene Drugs 0.000 description 2
- 102100016354 EHMT2 Human genes 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N Epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- KLEPCGBEXOCIGS-QPPBQGQZSA-N Erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 2
- 229950001426 Erbulozole Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N Etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 Etanidazole Drugs 0.000 description 2
- 229950011548 FADROZOLE Drugs 0.000 description 2
- 229950005096 FAZARABINE Drugs 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000961 Floxuridine Drugs 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 229950006905 ILMOFOSINE Drugs 0.000 description 2
- 229960003445 Idelalisib Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229940008250 Leuprolide Drugs 0.000 description 2
- 229950002676 MENOGARIL Drugs 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229960003951 Masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229960004296 Megestrol Acetate Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N Menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- 229960000350 Mitotane Drugs 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- 229960005343 Ondansetron Drugs 0.000 description 2
- 229950008017 Ormaplatin Drugs 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 229950009351 Perfosfamide Drugs 0.000 description 2
- 229960004293 Porfimer Sodium Drugs 0.000 description 2
- 229950004406 Porfiromycin Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- BBNQQADTFFCFGB-UHFFFAOYSA-N Purpurin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N Rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 Rogletimide Drugs 0.000 description 2
- 229950008902 SAFINGOL Drugs 0.000 description 2
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- HAOCRCFHEPRQOY-JKTUOYIXSA-N Spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960001052 Streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N Thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000036902 Thrombopoietin Human genes 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- 229950002376 Tirapazamine Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960001099 Trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 229960004824 Triptorelin Drugs 0.000 description 2
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 2
- 229960003895 Verteporfin Drugs 0.000 description 2
- 229960002110 Vincristine Sulfate Drugs 0.000 description 2
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- HJSSPYJVWLTYHG-UHFFFAOYSA-N XL765 Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(NC(=O)C=3C=C(OC)C(C)=CC=3)=CC=2)=C1 HJSSPYJVWLTYHG-UHFFFAOYSA-N 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229950003017 Zeniplatin Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 230000002280 anti-androgenic Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001833 anti-estrogenic Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 2
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 229930013357 epothilone A Natural products 0.000 description 2
- 229930013349 epothilone B Natural products 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N fijianolide B Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 125000006301 indolyl methyl group Chemical group 0.000 description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QQFHCCQSCQBKBG-UHFFFAOYSA-N methyl 2-amino-4,5-dimethoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(OC)C=C1N QQFHCCQSCQBKBG-UHFFFAOYSA-N 0.000 description 2
- PYMMKEZYPXHHHP-UHFFFAOYSA-N methyl 2-anilino-4,5-dimethoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(OC)C=C1NC1=CC=CC=C1 PYMMKEZYPXHHHP-UHFFFAOYSA-N 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 101700054071 myo1 Proteins 0.000 description 2
- 125000006606 n-butoxy group Chemical group 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 2
- 239000005445 natural product Substances 0.000 description 2
- 229930014626 natural products Natural products 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- TVYXNKUMLWUQPV-UHFFFAOYSA-N quinolin-6-yl trifluoromethanesulfonate Chemical compound N1=CC=CC2=CC(OS(=O)(=O)C(F)(F)F)=CC=C21 TVYXNKUMLWUQPV-UHFFFAOYSA-N 0.000 description 2
- CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 2
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 150000004654 triazenes Chemical class 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- NDTYTMIUWGWIMO-SNVBAGLBSA-N (-)-isocarveol Chemical compound CC(=C)[C@H]1CCC(CO)=CC1 NDTYTMIUWGWIMO-SNVBAGLBSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-β-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- FNEOHTTZLPHOSX-KZNAEPCWSA-N (1R)-1-[(2R,5R)-5-(hydroxymethyl)oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H](CO)O1 FNEOHTTZLPHOSX-KZNAEPCWSA-N 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N (1R,2R,3R,4S,5R)-4-amino-5-methylsulfanylcyclopentane-1,2,3-triol Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N (1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-5,7,9,9-tetramethyl-14-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N (1S,2Z,4E,8E,12E)-5,9,13-trimethyl-2-propan-2-ylcyclotetradeca-2,4,8,12-tetraen-1-ol Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- FXPSZLHFJDHOMI-DHZHZOJOSA-N (2E)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C/N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-DHZHZOJOSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2E,4E,6E)-7-[(1R,5R,6S)-3-[[(2E,4E)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2E,4E,6Z,8E,10E,14E)-13-hydroxy-N-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- NOENHWMKHNSHGX-FAZSUBJTSA-N (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@H](CCC1)C(=O)NC(C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-FAZSUBJTSA-N 0.000 description 1
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-FNQTVZJVSA-N (2R)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1C[C@@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-FNQTVZJVSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2R)-3,4-dihydroxy-2-[(4S)-2-phenyl-1,3-dioxolan-4-yl]-2H-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-YUHQQKLOSA-N (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@@H]1C)C(C)C)=C\C)C(C)C)[C@@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-YUHQQKLOSA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2R,3R,3aS,9aR)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2S)-2-[(3S,6S)-6-[2-[(1R,2R,4aS,8aS)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- XVOCEQLNJQGCQG-ACRSGXKRSA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl- Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 XVOCEQLNJQGCQG-ACRSGXKRSA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2S)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N (2S)-2-amino-3-(5-hydroxypyridin-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- RPEPXOHTYVXVMA-CIUDSAMLSA-N (2S)-2-amino-5-[[(2S)-1-[[(1S)-1-carboxy-4-(3H-diazirin-3-yl)-4-oxobutyl]amino]-5-(3H-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](CCC(=O)C1N=N1)C(O)=O)CC(=O)C1N=N1 RPEPXOHTYVXVMA-CIUDSAMLSA-N 0.000 description 1
- RYFOQDQDVYIEHN-ZETCQYMHSA-N (2S)-6-amino-2-(dimethylamino)hexanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCCN RYFOQDQDVYIEHN-ZETCQYMHSA-N 0.000 description 1
- UUSZLLQJYRSZIS-GHRWIAHFSA-N (2S)-N-[(2R)-1-[[(3S,6R,8S,12S,13R,16R,17S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4- Chemical compound CN([C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)C(CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-GHRWIAHFSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- BEHHCQFBLOARIX-APTPAJQOSA-N (2S,3S)-2-aminooctadecane-1,3-diol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO BEHHCQFBLOARIX-APTPAJQOSA-N 0.000 description 1
- FXPSZLHFJDHOMI-FLIBITNWSA-N (2Z)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C\N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-FLIBITNWSA-N 0.000 description 1
- JSUANXYBLFQZGI-HDFWGNLJSA-N (2Z,4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-5-methyl-2-(6-oxocyclohexa-2,4-dien-1-ylidene)-1,3-oxazolidine-4-carboxamide Chemical compound O=C([C@H]1NC(/O[C@@H]1C)=C\1C(C=CC=C/1)=O)N(CCCNC(=O)C=1C(=C(O)C=CC=1)O)CCCCNC(=O)C1=CC=CC(O)=C1O JSUANXYBLFQZGI-HDFWGNLJSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3S,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3S,6Z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1H-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 description 1
- UYRMXZIBPZVBNO-QPJJXVBHSA-N (4E)-4-[amino-(hydroxyamino)methylidene]-2-hydroxycyclohexa-2,5-dien-1-one Chemical compound ONC(/N)=C1\C=CC(=O)C(O)=C1 UYRMXZIBPZVBNO-QPJJXVBHSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- DLWOTOMWYCRPLK-UVTDQMKNSA-N (4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid Chemical compound C1=CC(OC)=C(OC)C(=O)\C1=C\1C(N)=C(C=2N=C3C(=O)C(N)=C(OC)C(=O)C3=CC=2)NC(C(O)=O)=C/1C DLWOTOMWYCRPLK-UVTDQMKNSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4aS,12bR)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'R)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- PTBPQBZWBIRISO-IAGVQPJWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(E)-N-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-C-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 PTBPQBZWBIRISO-IAGVQPJWSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7S,9S)-7-[(2S,4R,6S)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- JVHPTYWUBOQMBP-RVFAQHLVSA-N (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 JVHPTYWUBOQMBP-RVFAQHLVSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (Z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (Z,5S)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N 1,1-diphenylprop-2-ynyl N-cyclohexylcarbamate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2R)-oxiran-2-yl]methyl]-3-[[(2S)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N 1,9-Pyrazoloanthrone Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2R,3S,4R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1H-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N 1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 1
- RGJOJUGRHPQXGF-INIZCTEOSA-N 1-ethyl-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea Chemical compound C1=CC(NC(=O)NCC)=CC=C1C(N=C1N2[C@H](COCC2)C)=NC2=C1CCN(C1COC1)C2 RGJOJUGRHPQXGF-INIZCTEOSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- CHXUFRRQOZZSNV-UHFFFAOYSA-N 1-methylpiperidine Chemical group [CH2]N1CCCCC1 CHXUFRRQOZZSNV-UHFFFAOYSA-N 0.000 description 1
- KOFZWWMCDUHEEM-UHFFFAOYSA-N 1-methylpyrrolidine Chemical group [CH2]N1CCCC1 KOFZWWMCDUHEEM-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- NUXKIZBEPYVRKP-RWBWKAGLSA-N 1xa5 Chemical compound O([C@]12[C@@H]3N(C)C4=C([C@]53CCN3CC=C[C@@]([C@@H]53)(CC)C2)C=C(C(=C4)OC)[C@]2(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C2)C[C@@](C3)(O)CC)C(=O)N(CCCl)C1=O NUXKIZBEPYVRKP-RWBWKAGLSA-N 0.000 description 1
- LNELBQZKXVASLW-UHFFFAOYSA-N 2,2,2-trifluoro-N-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl)acetamide Chemical compound C1CC(NC(=O)C(F)(F)F)C2=CC(=O)C(SC)=CC=C2C2=C1C=C(OC)C(OC)=C2OC LNELBQZKXVASLW-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1H-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-N-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- JUNILAWHCDMYAE-HGJPKUQDSA-N 2-[(3E,7E,9E,17E)-14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxononadeca-3,7,9,17-tetraenyl]-2,3-dihydropyran-6-one Chemical compound OC/C=C(C)/CC(C)C(O)C(C)C(=O)C(C)/C=C(\C)/C=C/CC(C)\C=C(/C)CCC1CC=CC(=O)O1 JUNILAWHCDMYAE-HGJPKUQDSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N 2-[[2-[bis(2-hydroxyethyl)amino]-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-N-[(3S,6S,7R,10S,16S)-3-[(2S)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-N-[(3S,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XDLYKKIQACFMJG-UHFFFAOYSA-N 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1C1CCC(OCCO)CC1 XDLYKKIQACFMJG-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3H-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- KMLPEYHLAKSCGX-UHFFFAOYSA-N 2-aminocyclohexan-1-one Chemical compound NC1CCCCC1=O KMLPEYHLAKSCGX-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 1
- NKBWMBRPILTCRD-UHFFFAOYSA-M 2-methylheptanoate Chemical compound CCCCCC(C)C([O-])=O NKBWMBRPILTCRD-UHFFFAOYSA-M 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- JYVLIDXNZAXMDK-UHFFFAOYSA-N 2-pentanol Substances CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-PATWWPTKSA-N 3-[[2-[2-[2-[[(2R,3R)-2-[[(2R,3R,4S)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2R)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2S,3R,4R,5R,6R)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan- Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-PATWWPTKSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- XSCKKKKCZBNKQZ-UHFFFAOYSA-N 3-chloroquinoxaline-2-sulfonamide Chemical compound C1=CC=C2N=C(Cl)C(S(=O)(=O)N)=NC2=C1 XSCKKKKCZBNKQZ-UHFFFAOYSA-N 0.000 description 1
- HXZRMADPDYFMEB-MLTUFRGDSA-N 3-hydroxy-N-[3-[8-[(E)-6-hydroxy-3,5-dimethylhept-4-enyl]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]propyl]-2-methyl-4-[[2-[3-methyl-6-[(Z)-2-oxopent-3-enyl]oxan-2-yl]acetyl]amino]butanamide Chemical compound O1C(CC(=O)\C=C/C)CCC(C)C1CC(=O)NCC(O)C(C)C(=O)NCCCC1C(C)CCC2(OC(CCC(C)\C=C(/C)C(C)O)CCC2)O1 HXZRMADPDYFMEB-MLTUFRGDSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2H-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- YTXSYWAKVMZICI-PVCZSOGJSA-N 4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid Chemical compound N([C@@H](CC(C)C)B1OC(CC(O)=O)(CC(=O)O1)C(O)=O)C(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl YTXSYWAKVMZICI-PVCZSOGJSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-Hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- ZQUSFAUAYSEREK-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(O)CC2)=N1 ZQUSFAUAYSEREK-UHFFFAOYSA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N 5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-3-carboxamide Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(E)-5-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- AIHBRPSPSCCVPH-UHFFFAOYSA-N 5-bromo-6-methoxypyridine-2-carboxylic acid Chemical compound COC1=NC(C(O)=O)=CC=C1Br AIHBRPSPSCCVPH-UHFFFAOYSA-N 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- ZCJXQWYMBJYJNB-LRDBBFHQSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZCJXQWYMBJYJNB-LRDBBFHQSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N 5508-58-7 Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-Dimethoxy-Benzyl)-5-Methyl-Pyrido[2,3-D]Pyrimidine-2,4-Diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purin-2-amine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- GFYRZTLCYQQVHZ-UHFFFAOYSA-N 6-hydroxy-4-oxo-N-phenyl-2-sulfanylidene-1H-pyrimidine-5-carboxamide Chemical compound N1C(=S)NC(=O)C(C(=O)NC=2C=CC=CC=2)=C1O GFYRZTLCYQQVHZ-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78NZ2PMP25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N 9-[4-(methanesulfonamido)-2-methoxyanilino]-N,5-dimethylacridine-4-carboxamide Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- WDJQFWTUFXBNDF-UHFFFAOYSA-N 9-chloro-2,3-dimethoxyacridine Chemical compound C1=CC=C2C(Cl)=C(C=C(C(OC)=C3)OC)C3=NC2=C1 WDJQFWTUFXBNDF-UHFFFAOYSA-N 0.000 description 1
- ZUZXYJOSNSTJMU-UHFFFAOYSA-N 9-cyclohexyl-2-N,6-N-bis[(4-methoxyphenyl)methyl]purine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C3CCCCC3)C2=N1 ZUZXYJOSNSTJMU-UHFFFAOYSA-N 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N ACIVICIN Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 ACIVICIN Drugs 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 229950004810 ATAMESTANE Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- SMPZPKRDRQOOHT-UHFFFAOYSA-N Acronine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 1
- 229950000616 Acronine Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N Adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229960001686 Afatinib Drugs 0.000 description 1
- 229950010949 Ambamustine Drugs 0.000 description 1
- 229950004821 Ambomycin Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-QPSYGYIJSA-N Andrographolide Natural products C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1\[C@H](O)COC1=O BOJKULTULYSRAS-QPSYGYIJSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N Aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010075389 Aspergillus restrictus MITF protein Proteins 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950006933 Atrimustine Drugs 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N Axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N Axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 229950005951 Azasetron Drugs 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N Azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950004295 Azotomycin Drugs 0.000 description 1
- 229950005567 BENZODEPA Drugs 0.000 description 1
- 229950002370 BISNAFIDE Drugs 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N Balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N Betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- QGJZLNKBHJESQX-CASBDLHJSA-N Betulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2 QGJZLNKBHJESQX-CASBDLHJSA-N 0.000 description 1
- 229960004395 Bleomycin Sulfate Drugs 0.000 description 1
- ALFSIYVSZQJOHG-UHFFFAOYSA-N BrC1=C(N=C2C(=C3C(=NC2=C1)CCC3)Cl)OC Chemical compound BrC1=C(N=C2C(=C3C(=NC2=C1)CCC3)Cl)OC ALFSIYVSZQJOHG-UHFFFAOYSA-N 0.000 description 1
- KJTNPSKROATJFB-UHFFFAOYSA-N BrC=1C=C(C(=NC=1OC)C(=O)O)[N+](=O)[O-] Chemical compound BrC=1C=C(C(=NC=1OC)C(=O)O)[N+](=O)[O-] KJTNPSKROATJFB-UHFFFAOYSA-N 0.000 description 1
- 240000000772 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 229950002361 Budotitane Drugs 0.000 description 1
- 229950003628 Buparlisib Drugs 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N Buthionine sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- ZIWXKGQDQBLUMV-JUDXGUMMSA-N C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O Chemical compound C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O ZIWXKGQDQBLUMV-JUDXGUMMSA-N 0.000 description 1
- IJRCIVHWQBRUES-UHFFFAOYSA-N C(C)C=1C(=CC2=C(C3=CC=CC=C3N=C2C=1)NC1CCNCC1)OC Chemical compound C(C)C=1C(=CC2=C(C3=CC=CC=C3N=C2C=1)NC1CCNCC1)OC IJRCIVHWQBRUES-UHFFFAOYSA-N 0.000 description 1
- BITXWIYJCPUBBE-UHFFFAOYSA-N C(C)OC=1C(=CC2=C(C3=CC=CC=C3N=C2C=1)NC1CCN(CC1)CC)OC Chemical compound C(C)OC=1C(=CC2=C(C3=CC=CC=C3N=C2C=1)NC1CCN(CC1)CC)OC BITXWIYJCPUBBE-UHFFFAOYSA-N 0.000 description 1
- FGHWCEDONZUFFC-UHFFFAOYSA-N C(OC(C)(C)C)(OC1=CC=2C(=C3C(=NC=2C=C1OC)CCC3)Cl)=O Chemical compound C(OC(C)(C)C)(OC1=CC=2C(=C3C(=NC=2C=C1OC)CCC3)Cl)=O FGHWCEDONZUFFC-UHFFFAOYSA-N 0.000 description 1
- FLDWOQQWDVEAFS-UHFFFAOYSA-N C1(CC1)N1CCC(CC1)NC=1C2=CC=CC=C2N=C2C=C(C(=CC=12)OC)OCC Chemical compound C1(CC1)N1CCC(CC1)NC=1C2=CC=CC=C2N=C2C=C(C(=CC=12)OC)OCC FLDWOQQWDVEAFS-UHFFFAOYSA-N 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- AUNOHQICYZXXSG-ZDUSSCGKSA-N CC1(C[C@@H](CNC1)NC1=C2C(=NC=3C=C(C(=CC1=3)OC)OC)CCC2)C Chemical compound CC1(C[C@@H](CNC1)NC1=C2C(=NC=3C=C(C(=CC1=3)OC)OC)CCC2)C AUNOHQICYZXXSG-ZDUSSCGKSA-N 0.000 description 1
- 102000033243 CDKN2A Human genes 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N CHEMBL118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N CHEMBL2105109 Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- AEPCRURJWAULJL-UHFFFAOYSA-N COC1=CC2=C(C3=CC=CC=C3N=C2C=C1)NC1CCNCC1 Chemical compound COC1=CC2=C(C3=CC=CC=C3N=C2C=C1)NC1CCNCC1 AEPCRURJWAULJL-UHFFFAOYSA-N 0.000 description 1
- ABIKMOZFUMNHCJ-UHFFFAOYSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)NC1CCN(CC1)C(C)C)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)NC1CCN(CC1)C(C)C)OC ABIKMOZFUMNHCJ-UHFFFAOYSA-N 0.000 description 1
- ZABYSSOUDUWMPA-UHFFFAOYSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)NC1CCN(CC1)C1=CC=NC=C1)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)NC1CCN(CC1)C1=CC=NC=C1)OC ZABYSSOUDUWMPA-UHFFFAOYSA-N 0.000 description 1
- NDOLDOAAUXRZBR-UHFFFAOYSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)NC1CCN(CC1)C1CCOCC1)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)NC1CCN(CC1)C1CCOCC1)OC NDOLDOAAUXRZBR-UHFFFAOYSA-N 0.000 description 1
- RUGZKHYZERSOGH-ZDUSSCGKSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@@H]1CCNCCC1)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@@H]1CCNCCC1)OC RUGZKHYZERSOGH-ZDUSSCGKSA-N 0.000 description 1
- IRFDVXQXJCTBOO-OAHLLOKOSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@H]1CN(CCC1)C(=O)OC(C)(C)C)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@H]1CN(CCC1)C(=O)OC(C)(C)C)OC IRFDVXQXJCTBOO-OAHLLOKOSA-N 0.000 description 1
- IGUINZGCCXTHJC-GFCCVEGCSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@H]1CNCCC1)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@H]1CNCCC1)OC IGUINZGCCXTHJC-GFCCVEGCSA-N 0.000 description 1
- BRWFPHISLZWENR-NWDGAFQWSA-N COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@H]1CNC[C@H](C1)F)OC Chemical compound COC=1C(=CC=2C(=C3C(=NC=2C=1)CCC3)N[C@H]1CNC[C@H](C1)F)OC BRWFPHISLZWENR-NWDGAFQWSA-N 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N CURACIN-A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- 229950009908 Cactinomycin Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 Calusterone Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229950009338 Caracemide Drugs 0.000 description 1
- 229950005155 Carbetimer Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N Carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108050004290 Cecropins Proteins 0.000 description 1
- 229950010667 Cedefingol Drugs 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 229950009017 Cemadotin Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229950000634 Cicaprost Drugs 0.000 description 1
- 229950011359 Cirolemycin Drugs 0.000 description 1
- QNZNCHSYCHDTIJ-UHFFFAOYSA-N ClC1=C2C(=NC3=CC(=C(N=C13)OC)C1CC1)CCC2 Chemical compound ClC1=C2C(=NC3=CC(=C(N=C13)OC)C1CC1)CCC2 QNZNCHSYCHDTIJ-UHFFFAOYSA-N 0.000 description 1
- WKEQQNCNLCUAIK-UHFFFAOYSA-N ClC1=C2C(=NC3=CC(=C(N=C13)OC)O)CCC2 Chemical compound ClC1=C2C(=NC3=CC(=C(N=C13)OC)O)CCC2 WKEQQNCNLCUAIK-UHFFFAOYSA-N 0.000 description 1
- STAKOFPSXBMKHF-UHFFFAOYSA-N ClC1=C2C(=NC=3C=C(C(=CC1=3)OC)OCCO)CCC2 Chemical compound ClC1=C2C(=NC=3C=C(C(=CC1=3)OC)OCCO)CCC2 STAKOFPSXBMKHF-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N Cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- 229960002271 Cobimetinib Drugs 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N Conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- 201000002847 Cowden syndrome Diseases 0.000 description 1
- 206010051906 Cowden's disease Diseases 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N Cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- TYVRUMCYJWCOOO-TVEJMLEISA-N Cypemycin Chemical compound C1S\C=C/NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(C(C)CC)NC(=O)C(=C\C)/NC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(\NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)N(C)C)=C/C)=C/C)=C/C)C(C)C)CC1=CC=CC=C1 TYVRUMCYJWCOOO-TVEJMLEISA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010084740 Daclizumab Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 229960003109 Daunorubicin Hydrochloride Drugs 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N Decoquinate Chemical group N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 229950001466 Delanzomib Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 229960000605 Dexrazoxane Drugs 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- 229950005878 Dexverapamil Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- YKBUODYYSZSEIY-PLSHLZFXSA-N Diazonamide A Chemical compound N([C@H]([C@]12C=3O4)O5)C6=C2C=CC=C6C(C2=6)=CC=CC=6NC(Cl)=C2C(=C(N=2)Cl)OC=2C=3N=C4[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CC2=CC=C5C1=C2 YKBUODYYSZSEIY-PLSHLZFXSA-N 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N Dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950005133 Duazomycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229950011461 EDELFOSINE Drugs 0.000 description 1
- 229940121647 EGFR inhibitors Drugs 0.000 description 1
- 229950001022 ENPROMATE Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 229950010033 Ebselen Drugs 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselenum Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 229950005678 Ecomustine Drugs 0.000 description 1
- MHFRGQHAERHWKZ-UHFFFAOYSA-N Edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- 229950005450 Emitefur Drugs 0.000 description 1
- 229950010625 Enloplatin Drugs 0.000 description 1
- 229950004926 Epipropidine Drugs 0.000 description 1
- 229960003265 Epirubicin Hydrochloride Drugs 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N Epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N Epothilone E Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N Epothilone F Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 229950009537 Epristeride Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- 229960001766 Estramustine Phosphate Sodium Drugs 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N Etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229950010404 FOSTRIECIN Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 229950006000 Flezelastine Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- 229950005682 Flurocitabine Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229950008692 Foretinib Drugs 0.000 description 1
- 229950004217 Forfenimex Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N Fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 Fosquidone Drugs 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 229950004410 Galocitabine Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229960005144 Gemcitabine hydrochloride Drugs 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 102100004899 HBG2 Human genes 0.000 description 1
- 102100004109 HEY1 Human genes 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 108010072471 HTI-286 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- FXNFULJVOQMBCW-JWNPXFETSA-N Halichondrin B Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-JWNPXFETSA-N 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N Hexamethylene bisacetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N Hexanitrodiphenylamine Chemical class [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N Hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 102100014263 IGF1R Human genes 0.000 description 1
- 101700025802 IGF1R Proteins 0.000 description 1
- 229950007654 ITASETRON Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- 229960001176 Idarubicin Hydrochloride Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229950002248 Idoxifene Drugs 0.000 description 1
- 229950009926 Idramantone Drugs 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N Ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 1
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 229940109242 Interferon Alfa-n3 Drugs 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 229940028862 Interferon gamma-1b Drugs 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 208000008181 Intestinal Carcinoid Tumors Diseases 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N Iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 229950010897 Iproplatin Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229960000779 Irinotecan hydrochloride Drugs 0.000 description 1
- 229950000855 Iroplact Drugs 0.000 description 1
- 229950010984 Irsogladine Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- DWOIXRLFJBZDSB-MLLHTCFKSA-N Isoeleutherobin A Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](OC(C)=O)[C@@H]1O DWOIXRLFJBZDSB-MLLHTCFKSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- 229960003648 Ixazomib Drugs 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine dizwitterion Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- ZHTRILQJTPJGNK-FYBAATNNSA-N LEINAMYCIN Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
- 229950005634 LOXORIBINE Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- POCZBHBFCIWCCV-UHFFFAOYSA-N Lamellarin N Chemical compound C1=C(O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(O)C=C3C=CN2C2=C1C(C=C(OC)C(O)=C1)=C1OC2=O POCZBHBFCIWCCV-UHFFFAOYSA-N 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N Lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N Leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N Liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N Lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229950000909 Lometrexol Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 Losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N Losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 108091007472 MAP kinase family Proteins 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N METOPRINE, METHODICHLOROPHEN Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- 102100012644 MIF Human genes 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 229950010718 MOPIDAMOL Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 229950001474 Maitansine Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 102000001544 Maspin Human genes 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 229960002868 Mechlorethamine hydrochloride Drugs 0.000 description 1
- 229960003846 Melengestrol Acetate Drugs 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 229960003058 Methotrexate Sodium Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229950010895 Midostaurin Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950008541 Mirimostim Drugs 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N Mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 Mitindomide Drugs 0.000 description 1
- 229950002137 Mitocarcin Drugs 0.000 description 1
- 102000004331 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108090000823 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229950000911 Mitogillin Drugs 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229950007612 Mitomalcin Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229950001745 Mitonafide Drugs 0.000 description 1
- 229950005715 Mitosper Drugs 0.000 description 1
- 229960004169 Mitoxantrone Hydrochloride Drugs 0.000 description 1
- 229950008012 Mofarotene Drugs 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N Motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- ISYPMTHOLIXZHJ-UHFFFAOYSA-N Motexafin lutetium Chemical compound [Lu].CC(O)=O.CC(O)=O.C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 ISYPMTHOLIXZHJ-UHFFFAOYSA-N 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N N',N'-diethyl-N-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- OKXOENHAEFFQDT-UHFFFAOYSA-N N-(1-ethylpiperidin-4-yl)-2-methoxyacridin-9-amine Chemical compound C1CN(CC)CCC1NC1=C(C=CC=C2)C2=NC2=CC=C(OC)C=C12 OKXOENHAEFFQDT-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N N-[(2S,3S)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N N-[(E)-1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N N-[bis(aziridin-1-yl)phosphoryl]-N-ethyl-1,3,4-thiadiazol-2-amine Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N N-methyl-N-[(E)-(N-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N Napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- 229950010676 Nartograstim Drugs 0.000 description 1
- 229950007221 Nedaplatin Drugs 0.000 description 1
- 229950010159 Nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N Noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- 229960004708 Noscapine Drugs 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O(6)-benzylguanine; Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 229950000370 OXISURAN Drugs 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N Osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 Osaterone Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229950000039 PELDESINE Drugs 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 102100012884 PF4 Human genes 0.000 description 1
- 101710014074 PF4 Proteins 0.000 description 1
- 101700056724 PPIF Proteins 0.000 description 1
- HRWCSYMVAIWIDX-UHFFFAOYSA-N PS51OZG63Z Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCCN HRWCSYMVAIWIDX-UHFFFAOYSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N Palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N Palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N Panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- RDIMTXDFGHNINN-BRWVUGGUSA-N Panaxytriol Natural products CCCCCCC[C@@H](O)[C@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-BRWVUGGUSA-N 0.000 description 1
- 229950003440 Panomifene Drugs 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N Pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- 229950006361 Pazelliptine Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N Peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950006960 Peliomycin Drugs 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002139 Pilocarpine Hydrochloride Drugs 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229950001030 Piritrexim Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N Plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 Plomestane Drugs 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960001586 Procarbazine Hydrochloride Drugs 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 229960004356 RIBOPRINE Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229950002225 Retelliptine Drugs 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N Rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N Roquinimex Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- CGFVUVWMYIHGHS-UHFFFAOYSA-N SAINTOPIN Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 101700079896 SIPA1 Proteins 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 229950007841 SULOFENUR Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N Selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 241000854711 Shinkai Species 0.000 description 1
- 229950009089 Simtrazene Drugs 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- 229910002850 SnCl2 Inorganic materials 0.000 description 1
- 229950004296 Soblidotin Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 229950004225 Sonermin Drugs 0.000 description 1
- 229950004796 Sparfosic Acid Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N Sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- 229950009641 Sparsomycin Drugs 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 229950004330 Spiroplatin Drugs 0.000 description 1
- VGULLEUAAMBZTQ-YGHPZBLNSA-N Spongistatin 3 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](OC(C)=O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C VGULLEUAAMBZTQ-YGHPZBLNSA-N 0.000 description 1
- KRUKGDRIKMPUNX-JWFNSJLHSA-N Spongistatin 4 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C KRUKGDRIKMPUNX-JWFNSJLHSA-N 0.000 description 1
- JOEPUFOWFXWEDN-YBVGAWTPSA-N Spongistatin 5 Chemical compound C1C(=O)C(C)C(C2C)OC\C2=C\C(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)\C=C\C(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCC\C=C/C(O2)CC(O)CC22CC(OC)CC1O2 JOEPUFOWFXWEDN-YBVGAWTPSA-N 0.000 description 1
- GQOOASKKXHUNEJ-PYATXCCJSA-N Spongistatin 6 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C=C)OC1[C@@H]2C GQOOASKKXHUNEJ-PYATXCCJSA-N 0.000 description 1
- MUXXDGJMWHKJDJ-JCUQIGNJSA-N Spongistatin 7 Chemical compound C([C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@H](O)C1[C@H](C)[C@H]([C@@H]([C@@H](CC(=C)C[C@@H](O)\C=C\C=C)O1)O)OC(=O)CC1C[C@H](C[C@]2(C[C@](C)(O)C[C@H](O2)\C=C2/CCO[C@]2(C)[C@H](C)C(=O)C2)O1)OC(C)=O)CC\C=C/[C@@H](O1)C[C@@H](O)C[C@]11C[C@H](OC)CC2O1 MUXXDGJMWHKJDJ-JCUQIGNJSA-N 0.000 description 1
- GLMCWICCTJHQKE-BAVWCGNYSA-N Spongistatin 9 Chemical compound C1C(=O)C(C)C(C2C)OC\C2=C\C(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)\C=C/C(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCC\C=C\C(O2)CC(O)CC22CC(OC)CC1O2 GLMCWICCTJHQKE-BAVWCGNYSA-N 0.000 description 1
- RSHMLTSGIURLKH-SJMMKZBFSA-N Spongistatin-2 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C=C)O[C@@H]2[C@@H]1C RSHMLTSGIURLKH-SJMMKZBFSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N Swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N TCN-P Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- PTTJLTMUKRRHAT-VJAKQJMOSA-N Taccalonolide A Chemical compound C([C@@H]1C(=O)[C@@H]2O)[C@@H]3O[C@@H]3[C@H](OC(C)=O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2[C@@H](OC(C)=O)[C@H]3[C@@]4(C)[C@](C)(O)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]2(C)[C@@H](OC(C)=O)[C@H]1OC(C)=O PTTJLTMUKRRHAT-VJAKQJMOSA-N 0.000 description 1
- PTTJLTMUKRRHAT-KYDPQNDISA-N Taccalonolide A Natural products O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H]2[C@]3(C)[C@H](OC(=O)C)[C@H]4O[C@H]4C[C@@H]3C(=O)[C@H](O)[C@H]2[C@@H]2[C@@H](OC(=O)C)[C@H]3[C@@]4(C)[C@@](O)(C)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]12C)C PTTJLTMUKRRHAT-KYDPQNDISA-N 0.000 description 1
- 229950002687 Talisomycin Drugs 0.000 description 1
- 229950005667 Tallimustine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N Tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 Tanespimycin Drugs 0.000 description 1
- 229950010168 Tauromustine Drugs 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N Teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229950008703 Teroxirone Drugs 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 229960001712 Testosterone Propionate Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N Tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 229950010183 Thymotrinan Drugs 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229950011457 Tiamiprine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L Tin(II) chloride Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- TVPNFKRGOFJQOO-UHFFFAOYSA-N Topsentin B1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 1
- 229960004167 Toremifene Citrate Drugs 0.000 description 1
- 210000003014 Totipotent Stem Cells Anatomy 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229950003873 Triciribine Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N Turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 Turosteride Drugs 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 101700003320 VIP Proteins 0.000 description 1
- 102100015313 VIP Human genes 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950008261 Velaresol Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 Vindesine Sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N Vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- UNMODLJJNIJIBD-OTBVPMHJSA-N Vinglycinate sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 UNMODLJJNIJIBD-OTBVPMHJSA-N 0.000 description 1
- 229950009832 Vinleurosine Drugs 0.000 description 1
- 229960002166 Vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N VinorelbineTartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- UFOVYHGILLJGLP-UHFFFAOYSA-N Vitilevuamide Chemical compound N1C(=O)C(NC(=O)CCC(O)=O)CSCC(C(NC(C(=O)NC(=C)C(=O)NC(CC(C)CC)C(=O)NC(C(=O)N(C)C(C(O)COC)C(=O)NC(CO)C(=O)OC2C)C(C)C)C(C)CC)=O)NC(=O)C3CCCN3C(=O)C(CC=3C=CC=CC=3)NC(=O)C2NC(=O)C(CC(C)CC)NC(=O)C(C)NC(=O)C1CC1=CC=CC=C1 UFOVYHGILLJGLP-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N Wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- 229950005561 ZANOTERONE Drugs 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N Zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 Zinostatin stimalamer Drugs 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2S)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-BVTJJHQYSA-N [(1S,2Z,7S,10Z,12R,13R,15S)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C/C(=O)O[C@@H](C)CCC\C=C/[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-BVTJJHQYSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2R,3S)-2-[(2S,3R)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- VUPBDWQPEOWRQP-YDYCAPBPSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R)-3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino Chemical compound O([C@H]1[C@@H]([C@H](O)[C@H](N)[C@H](C)O1)O)C(C(O)C=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN)NC(=O)C(C(O)C)NC(=O)CC(O)C(C)NC(=O)C([C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C VUPBDWQPEOWRQP-YDYCAPBPSA-N 0.000 description 1
- ZHHIHQFAUZZMTG-BSVJBJGJSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C ZHHIHQFAUZZMTG-BSVJBJGJSA-N 0.000 description 1
- QTQAWLPCGQOSGP-DVKIRIBLSA-N [(3R,5R,6S,7R,8E,10R,11R,12E,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-DVKIRIBLSA-N 0.000 description 1
- VQSGYKUTGGRSPK-SIOACEIBSA-N [(3S,4S,7S)-2-[3-[(2S,5S,8S,11S,14R,17R,20S,23R,26R)-11,14-bis(2-amino-2-oxoethyl)-5,20-bis[(1R)-1-hydroxyethyl]-8-methyl-17,23-bis(2-methylpropyl)-26-octyl-3,6,9,12,15,18,21,24,27-nonaoxo-1,4,7,10,13,16,19,22,25-nonazacycloheptacos-2-yl]propyl]-5-chloro- Chemical compound N1C(=O)[C@@H](CCCCCCCC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1[C@@]2(OCCC2)[C@@H](O)C2=C(Cl)C(=O)[C@@](C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-SIOACEIBSA-N 0.000 description 1
- IVCRCPJOLWECJU-WJTCVZFGSA-N [(7R,8R,9S,13S,14S,17S)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CCC3[C@H]21 IVCRCPJOLWECJU-WJTCVZFGSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8E,10E,12E)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- XASGSSXPZXRXFL-UHFFFAOYSA-L [1-(aminomethyl)cyclohexyl]methanamine;platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O.NCC1(CN)CCCCC1 XASGSSXPZXRXFL-UHFFFAOYSA-L 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N [3-[4-(3-methylsulfonyloxypropanoyl)piperazin-1-yl]-3-oxopropyl] methanesulfonate Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- ASQRQYODAQUVBR-UHFFFAOYSA-L [4-(aminomethyl)oxan-4-yl]methanamine;cyclobutane-1,1-dicarboxylate;platinum(2+) Chemical compound [Pt+2].NCC1(CN)CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 ASQRQYODAQUVBR-UHFFFAOYSA-L 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- LNFBAYSBVQBKFR-UHFFFAOYSA-N [7-(6-aminopyridin-3-yl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone Chemical compound CC1=C(F)C(S(C)(=O)=O)=CC=C1C(=O)N1CC2=CC(C=3C=NC(N)=CC=3)=CC=C2OCC1 LNFBAYSBVQBKFR-UHFFFAOYSA-N 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] N-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 description 1
- IAGMBSXKAGFBJT-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC(O)=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO IAGMBSXKAGFBJT-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001780 adrenocortical Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 108060003434 alpha Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 102000025417 antigen binding proteins Human genes 0.000 description 1
- 108091000829 antigen binding proteins Proteins 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- WJUBYASTGWKFHK-UHFFFAOYSA-N azepan-3-amine Chemical compound NC1CCCCNC1 WJUBYASTGWKFHK-UHFFFAOYSA-N 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-M azetidine-1-carboxylate Chemical compound [O-]C(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-M 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 229930014667 baccatin III Natural products 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Inorganic materials [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 1
- 229960004649 calcipotriene Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229930016259 castanospermine Natural products 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010076060 chlorofusin Proteins 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- 108010083340 cryptophycin 52 Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004410 cyclooctyloxy group Chemical group C1(CCCCCCC1)O* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 125000004431 deuterium atoms Chemical group 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010870 diseases of metabolism Diseases 0.000 description 1
- SVJSWELRJWVPQD-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C1NC=2NC(N)=NC(=O)C=2CC1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940017743 dromostanolone propionate Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 230000001973 epigenetic Effects 0.000 description 1
- 229930013351 epothilone C Natural products 0.000 description 1
- 229930013353 epothilone D Natural products 0.000 description 1
- 229930013354 epothilone E Natural products 0.000 description 1
- 229930013311 epothilone F Natural products 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- 210000000267 erythroid cells Anatomy 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HWMJAPURZLIYQA-JPFZJSEDSA-L ethanolate;(Z)-3-oxo-1-phenylbut-1-en-1-olate;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)\C=C(/[O-])C1=CC=CC=C1.CC(=O)\C=C(/[O-])C1=CC=CC=C1 HWMJAPURZLIYQA-JPFZJSEDSA-L 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- AYYNUGSDPRDVCH-UHFFFAOYSA-N ethyl 3,4-dimethoxybenzoate Chemical compound CCOC(=O)C1=CC=C(OC)C(OC)=C1 AYYNUGSDPRDVCH-UHFFFAOYSA-N 0.000 description 1
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl N-[(2S)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl N-[4-[[(2R,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N ethyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N ethyl N-bis(2,2-dimethylaziridin-1-yl)phosphorylcarbamate Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 108010038853 gamma-Globins Proteins 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 102000018146 globin family Human genes 0.000 description 1
- 108060003196 globin family Proteins 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 description 1
- 125000005347 halocycloalkyl group Chemical group 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- HGCQWDFNEHWQDP-UHFFFAOYSA-N hexan-2-ol Chemical compound [CH2]C(O)CCCC HGCQWDFNEHWQDP-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;N-methyl-N-[4-[(7-methyl-3H-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003795 iobenguane (123I) Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- BIGQPYZPEWAPBG-UHFFFAOYSA-N methyl 3,4-dimethoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(OC)=C1 BIGQPYZPEWAPBG-UHFFFAOYSA-N 0.000 description 1
- SYYKLKHBZGFKOC-UHFFFAOYSA-N methyl 4,5-dimethoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(OC)=C(OC)C=C1[N+]([O-])=O SYYKLKHBZGFKOC-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- MAZYQGHSTXUZJF-ZBRHGPMOSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](O)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@]5(C)C[C@H](C[C@@H](O5)CC4=C3C3=O)N(C)C)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 MAZYQGHSTXUZJF-ZBRHGPMOSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N p-dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- SGIIQKAMTIJXBU-UHFFFAOYSA-N pentan-2-ol Chemical compound CC[CH]C(C)O SGIIQKAMTIJXBU-UHFFFAOYSA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 229930007643 perillyl alcohol Natural products 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- FXSKHQLAUMGYJK-UHFFFAOYSA-J platinum(4+);propan-2-amine;dichloride;dihydroxide Chemical compound [OH-].[OH-].[Cl-].[Cl-].[Pt+4].CC(C)N.CC(C)N FXSKHQLAUMGYJK-UHFFFAOYSA-J 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003881 protein kinase c inhibitor Substances 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- ZSJVRUWXJDVHQI-UHFFFAOYSA-N quinoline-6-sulfonamide Chemical compound N1=CC=CC2=CC(S(=O)(=O)N)=CC=C21 ZSJVRUWXJDVHQI-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 108010047846 soblidotin Proteins 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- HZOREEUASZHZBI-UHFFFAOYSA-M sodium;2-phenylacetate Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1 HZOREEUASZHZBI-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M sodium;6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylate Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2R)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
- NSFFYSQTVOCNLX-JKIHJDPOSA-M sodium;[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl phosphate;hydrate Chemical compound O.[Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 NSFFYSQTVOCNLX-JKIHJDPOSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108091007018 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 229930003522 swainsonine Natural products 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3R)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 108010013515 thymopoietin receptor Proteins 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- FQYFLFUZRJOLBC-UHFFFAOYSA-N titanocene Chemical compound C12C3C4C5C1[Ti]16782345C2C7C6C1C82 FQYFLFUZRJOLBC-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 108010061145 tubulysin A Proteins 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- GLOUOHCQKJMDFZ-UHFFFAOYSA-N vanadocene Chemical compound C12C3C4C5C1[V]16782345C2C7C6C1C82 GLOUOHCQKJMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 108010079700 vitilevuamide Proteins 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N δ-Valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
Abstract
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Description
Any and ail applications for which a foreign or domestic priority claim is identified, for 5 example, in the Application Data Sheet or Request as filed with the présent application, are hereby incorporated by reference under 37 CFR 1.57, and Rules 4.18 and 20.6, including U.S. Provisional Application No. 62/545936, filed August 15, 2017 and U.S. Provisional Application No. 62/712864, filed July 31,2018.
Field of the disclosure
The présent disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes 15 for preparing such compounds.
Background
Chromatin modification plays an essential rôle in transcriptional régulation. These modifications, including DNA méthylation, histone acétylation and histone méthylation, are important 20 in a variety of biological processes including protein production and cellular différentiation, and are emerging as attractive drug targets in various human diseases. Two particular enzymes associated with histone méthylation are G9a and GLP, also known as EHMT2 and EHMT1 (Euchromatic histone-lysine N-methyltransferase 2 and 1). G9a and GLP are the primary enzymes for mono- and dimethylation at Lys 9 of histone H3 (H3K9mel and H3K9me2), and exist predominantly as a G9a-GLP heteromeric 25 complex that appears to be a functional H3K9 methyltransferase in vivo. Structurally, either G9a or GLP is composed of a catalytic SET domain, a domain containing ankyrin repeats (involved in proteinprotein interactions) and nuclear localization signais on the N-terminal région. The SET domain is responsible for the addition of methyl groups on H3, whereas the ankyrin repeats hâve been observed to represent mono- and dimethyl lysine binding régions. The G9a-GLP complex is thus not only able 30 to both methylate histone tails but also able to recognize this modification, and can function as a scaffold for the recruitment of other target molécules on the chromatin. See Shinkai et aL, Genes Dev. 2011; 25(8):781-8 and Shankar et al., Epigenetics. 2013; 8(1):16-22.
Many studies hâve reported that G9a and GLP play critical rôles in various biological processes. Several reports hâve highlighted its link to a variety of cancers. See Cascielle et al., Front. Immunol. 2015; 6:487. It is upregulated in hepatocellular carcinoma, B cell acute lymphoblastic leukemia and lung cancers. In addition, elevated expression of G9a in aggressive lung cancer correlates with poor 5 prognosis, while its knockdown in highly invasive lung cancer cells suppressed metastasis in an in vivo mouse model. In prostate cancer cells (PC3), G9a knockdown caused significant morphological changes and inhibition of cell growth. See Liu et al., J. Med. Chem. 2013; 56(21):8931-42 and Sweis et al., ACS Med. Chem. Lett. 2014;5(2):205-9. Loss of G9a has been demonstrated to impair DNA damage repair and enhance the sensitivity of cancer cells to radiation and chemotherapeutics. See Yang 10 et al., Proc. Natl. Acad. Sci. USA, 2017, doi: 10.1073/pnas.l700694114.
Interestingly, recent studies hâve also shown that the inhibition of G9a and GLP by either genetic déplétion or pharmacological intervention increased fêtai hemoglobin (HbF) gene expression in erythroid cells. See Krivega et al., Blood, 2015;126(5):665-72 and Renneville et al., Blood 2015, 126(16):1930-9. Inducing fêtai globin gene would be potentially therapeutically bénéficiai for the 15 disease of hemoglobinopathies, including beta-thalassemia where the production of normal β-globm, a component of adult hemoglobin, is impaired. Similarly, induction of HbF would potentially be bénéficiai by diluting the concentration of hemoglobin S (HbS) molécules, thereby reducing polymerization of HbS. See Sankaran et al., Cold Spring Harb. Perspect. Med. 2013; 3(l):a011643. Moreover, G9a or GLP inhibitions may potentiate other clinically used thérapies, such as hydroxyurea 20 or HDAC inhibitors. These agents may act, at least in part, by increasing γ-globin gene expression through different mechanisms. See Charache et al., Blood, 1992; 79(10):2555-65. Thus, there is a need for the development of small molécules that are capable of inhibiting the activity of G9a and/or GLP. The compounds of the présent disclosure fulfill this and related needs.
Summary
In one aspect provided is a compound of Formula (I):
or a pharmaceutically acceptable sait thereof, wherein:
Ri and R2 can be independently hydrogen, halogen, cyano, alkyl, haloalkyl, hydroxy, 30 hydroxyalkyl, aryloxy, heteroaryloxy, cycloalkyl (optionally substituted with one or more hydroxy),
-3 cycloalkoxy, cyanoalkoxy, alkoxy (optionally substituted with one or more Ra, independently selected from deuterium, hydroxy, alkoxy or (hydroxy)alkoxy), haloalkoxy or aminosulfonyl (optionally substituted with one or more alkyl), provided that Ri and R2 are not each hydrogen; or Ri and R2, together with the atoms to which they are attached, form a monocyclic heterocyclyl group;
A can be CH or N;
Rsa can be (a) heterocyclyl;
(b) heterocyclylalkyl;
(c) spiroheterocycloamino (optionally substituted with one or more Rb, independently selected from alkyl, aryl (optionally substituted with one or more Rd, independently selected from halogen and alkyl) and alkoxycarbonyl);
(d) cycloalkylalkyl (optionally substituted with one or more Rc, independently selected from amino and alkylamino);
(e) heteroaralkyl (optionally substituted with alkyl);
(f) alkyl (optionally substituted with alkylamino); or (g) hydrogen;
wherein the heterocyclyl rings of (a) and (b) are independently optionally substituted with one or more Re, independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy);
Rsb can be hydrogen, alkyl or -(C=O)NH2;
Ring B can be wherein the asterisks indicate the points of attachments to the pyridinyl ring of Formula (I);
m and n are independently 1, 2, 3 or 4, wherein the sum of m + n can be 2, 3, 4 or 5,
X can be CR4aR4b, NR4c or O;
-4R4a, R4b and R4C can be independently hydrogen or alkyl; each Rs can be independently alkyl; and v can be 0, 1, 2, 3 or 4.
In another aspect provided is a compound of Formula (1):
or a pharmaceutically acceptable sait thereof, wherein:
Ri and R2 can be independently hydrogen, halogen, cyano, alkyl, haloalkyi, hydroxy, hydroxyalkyl, aryloxy, heteroaryloxy, cycloalkyl (optionally substituted with one or more hydroxy), cycloalkoxy, cyanoalkoxy, alkoxy (optionally substituted with one or more Ra, independently selected from hydroxy, alkoxy or (hydroxy)alkoxy), haloalkoxy or aminosulfonyl (optionally substituted with one or more alkyl), provided that Ri and R2 are not each hydrogen; or Ri and R2, together with the atoms to which they are attached, form a monocyclic heterocyclyl group;
A can be CH or N;
Rsa can be (a) heterocyclyl;
(b) heterocyclylalkyl;
(c) spiroheterocycloamino (optionally substituted with one or more Rb, independently selected from alkyl, aryl (optionally substituted with one or more Rd, independently selected from halogen and alkyl) and alkoxycarbonyl);
(d) cycloalkylalkyl (optionally substituted with one or more Rc, independently selected from amino and alkylamino);
(e) heteroaralkyl (optionally substituted with alkyl); or (f) alkyl;
wherein the heterocyclyl rings of (a) and (b) are independently optionally substituted with one or more Re, independently selected from hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted
-5with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy);
Rsb can be hydrogen, alkyl or -(C=O)NH2;
Ring B can be
wherein the asterisks indicate the points of attachments to the pyridinyl ring of Formula (I);
m and n are independently 1, 2, 3 or 4, wherein the sum of m + n can be 2, 3, 4 or 5;
X can be CR4AR4B, NRic or O;
R4A, R4B and R4C can be independently hydrogen or alkyl; each Rs can be independently alkyl; and v can be 0, 1, 2, 3 or 4.
For example, compounds of Formula (I), and pharmaceutically acceptable salts thereof, include compounds of Formula (1-1)
compounds of Formula (1-2)
Rsa^^-Rsb
TT XbTrs)v , and pharmaceutically acceptable salts of any of the foregoing.
In a second aspect, this disclosure is directed to a pharmaceutical composition comprising a compound of Formula (I) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable sait thereof; and a pharmaceutically acceptable excipient.
In a third aspect, this disclosure is directed to a method of treating a disease treatable by inhibition of G9a and/or GLP in a subject in need of such treatment, can include administering to the subject in need thereof, a compound of Formula (I) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable sait thereof, or a pharmaceutical composition comprising a compound of Formula (I) (or any of the embodiments thereof described herein), or a pharmaceutically acceptable sait thereof, in a therapeutically effective amount, and a pharmaceutically acceptable excipient. In one embodiment, the disease can be a hemoglobinopathy, such as beta- thalassemia and sickle cell disease. See Krivega et aL, Blood 2015; 126(5):665-72 and Renneville et al., Blood, 2015; 126(16):1930-9. In a second embodiment, the disease can be a cancer or tumor, for example, a cancer or tumor where G9a or GLP can be overexpressed. Examples of such cancers and tumors include, but are not limited to: Colorectal Cancer, Osteosarcoma Cancer, Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Adrenocortical Carcinoma, Kaposi Sarcoma (Soft Tissue Sarcoma); AIDS-Related Lymphoma (Lymphoma); Primary CNS Lymphoma; Anal Cancer; Gastrointestinal
Carcinoid Tumors; Astrocytomas; Atypical Teratoid/Rhabdoid Tumor; Basal Cell Carcinoma of the Skin; Bile Duct Cancer; Bladder Cancer; Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma); Brain Tumors; Breast Cancer; Bronchial Tumors - Burkitt Lymphoma; Cardiac Tumors; Embryonal Tumors (Brain Cancer); Germ Cell Tumor (Brain Cancer); Primary CNS Lymphoma; Cervical Cancer; Cholangiocarcinoma; Chordoma; Chronic Lymphocytic
Leukemia (CLL); Chronic Myelogenous Leukemia (CML); Chronic Myeloproliferative Neoplasms; Colorectal Cancer; Craniopharyngioma (Brain Cancer); Cutaneous T-Cell Lymphoma; Ductal Carcinoma In Situ (DCIS); Endométrial Cancer (Uterine Cancer); Ependymoma (Brain Cancer); Esophageal Cancer; Esthesioneuroblastoma; Ewing Sarcoma (Bone Cancer); Extracranial Germ Cell Tumor; Extragonadal Germ Cell Tumor; Eye Cancer; Intraocular Melanoma; Retinoblastoma;
Fallopian Tube Cancer; Fibrous Histiocytoma of Bone; Gallbladder Cancer; Gastric (Stomach) Gastrointestinal Stromal Tumors (GIST) (Soft Tissue Sarcoma); CNS Germ Cell Tumors (Brain Cancer); Extracranial Germ Cell Tumors; Extragonadal Germ Cell Tumors; Ovarian Germ Cell Tumors; Testicular Cancer; Gestational Trophoblastic Disease; Hairy Cell Leukemia, Head and Neck Cancer; Hepatocellular (Liver) Cancer; Histiocytosis, Langerhans Cell; Hodgkin Lymphoma;
Hypopharyngeal Cancer (Head and Neck Cancer); Intraocular Melanoma; Islet Cell Tumors, Pancreatic Neuroendocrine Tumors; Kidney (Rénal Cell) Cancer; Langerhans Cell Histiocytosis, Laryngeal Cancer (Head and Neck Cancer); Leukemia; Lip and Oral Cavity Cancer (Head and Neck Cancer); Lung Cancer (Non-Small Cell and Small Cell); Lymphoma; Male Breast Cancer; Melanoma; Merkel Cell Carcinoma (Skin Cancer); Mesothelioma, Malignant Mesothelioma; Metastatic Squamous Neck
Cancer with Occult Primary (Head and Neck Cancer); Midline Tract Carcinoma Involving NUT Gene; Mouth Cancer (Head and Neck Cancer); Multiple Endocrine Neoplasia Syndromes; Multiple Myeloma/Plasma Cell Neoplasms; Mycosis Fungoides (Lymphoma); Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms; Myelogenous Leukemia, Chronic (CML); Myeloproliferative Neoplasms, Chronic; Nasal Cavity and Paranasal Sinus Cancer (Head and Neck
Cancer); Nasopharyngeal Cancer (Head and Neck Cancer); Nasopharyngeal Cancer - Neuroblastoma; Non-Hodgkin Lymphoma; Oral Cancer; Lip and Oral Cavity Cancer and Oropharyngeal Cancer (Head and Neck Cancer); Ovarian Cancer; Pancreatic Cancer; Papillomatosis; Paraganglioma; Paranasal Sinus and Nasal Cavity Cancer (Head and Neck Cancer); Parathyroid Cancer; Penile Cancer;
Pharyngeal Cancer (Head and Neck Cancer); Pheochromocytoma; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Primary CNS Lymphoma; Primary Peritoneal Cancer; Prostate Cancer; Rectal Cancer; Récurrent Cancer;
Rhabdomyosarcoma (Soft Tissue Sarcoma); Salivary Gland Cancer (Head and Neck Cancer); Salivary
Gland Tumors; Vascular Tumors (Soft Tissue Sarcoma); Uterine Sarcoma; Sézary Syndrome (Lymphoma); Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma of the Skin;
Skin Cancer; Squamous Neck Cancer with Occult Primary, Metastatic (Head and Neck Cancer); T-Cell Lymphoma, Cutaneous; Lymphoma (Mycosis Fungoides and Sèzary Syndrome); Throat Cancer (Head and Neck Cancer); Nasopharyngeal Cancer; Oropharyngeal Cancer; Hypopharyngeal Cancer;
Thymoma and Thymie Carcinoma; Thyroid Cancer; Uréthral Cancer; Vaginal Cancer; Vascular Tumors (Soft Tissue Sarcoma); Vulvar Cancer; Myelodysplastic syndrome (MDS); and Wilms Tumor.
Thus, the terms “cancerous cell,” “cancer cell” or “tumor cell” as provided herein, includes a cell afflicted by any one of or related to the above identified conditions. See Cascielle et al., Front.
Immunol. 2015; 6:487, Agarwal et al., Cancer Letters 2016: 467 and Zhang et al., Oncotarget 2015, 15 6(5): 2917. In a second embodiment, treating a cancer and/or tumor comprises increasing tumor free survival and/or reducing tumor mass and/or slowing tumor growth. In a third embodiment, the disease can be a cancer prédisposition syndrome, such as Cowden syndrome. See You et al., Cancer Cell.
2012; 22(1):9-20. In a fourth embodiment, the disease can be an inflammatory and/or autoimmune disease, such as intestinal inflammation, arthritis, atherosclerosis, multiple sclerosis, myasthema gravis, 20 Crohn's disease, graft-versus-host disease, psoriasis, granulomatous colitis, lymphocyte colitis, collagenous colitis, ulcerative colitis, Coeliac Disease, subepidermal blistering disorders, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, primary biliaiy cirrhosis, active chronic hepatitis, chronic fatigue syndrome and vasculitis. See Antignano et al., J. Clin. Invest. 2014 4(5): 1945-55. In a fifth embodiment, the disease can be a metabolic disease, such as diabètes and/or obesity. See Wang et al., EMBO J. 201 j; 32(1).45-
59. In a sixth embodiment, the disease can be related to skeletal muscle development and régénération.
See Ling et al., Proc. Natl. Acad. Sci. USA, 2012; 109(3):841-6. In a seventh embodiment, the disease can be a viral disease, such as HIV-1 (human immunodeficiency virus 1) and HBV (Hepatitis B Virus).
See Imai et al., J. Biol. Chem. 2010; 285(22):16538-45 and Merkling et al., PLoSPathog. 2015; 11(4).
The compounds and compositions described herein can be administered with one or more additional therapeutic agents including, but not limited to, anticancer agents and antiviral agents. See, e.g., Front Immunol. 2015; 6:487.
- 8In a fourth aspect provided is the use of a compound of Formula (I) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable sait thereof, in the treatment of the diseases provided in the third aspect herein.
In a fifth aspect, this disclosure is directed to a method of inhibiting G9a and/or GLP, that can include contacting a cell that contains G9a with a therapeutically effective amount of a compound of Formula (I) (or any of the embodiments thereof described herein) or a pharmaceutically acceptable sait thereof, thereby inhibiting the activity of G9a. In some embodiments, the cell suffers from one or more of the diseases provided in the third aspect herein.
Detailed Description
Définitions:
Unless otherwise stated, the following terms used in the spécification and claims are defined for the purposes of this Application and hâve the following meaning:
“Alkyl” means a linear saturated monovalent hydrocarbon radical of one to ten carbon atoms or a branched saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., methyl, ethyl, n-propyl, 2-propyl (isopropyl), n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl (straight-chained or branched), hexyl (straight-chained or branched), heptyl (straight-chained or branched) and the like.
“Alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylène, pentylene and the like.
“Alkoxy” means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy and the like.
“Alkoxyalkyl” means alkyl as defined above which is substituted with one or two alkoxy groups as defined above, e.g., methoxyethyl, ethoxyethyl, methoxypropyl and the like.
“Alkylcarbonyl” or “Acyl” means a -COR radical where R is alkyl as defined above, e.g., methylcarbonyl, ethylcarbonyl and the like.
“Alkylsulfonyl” means a -SO2R radical where R is alkyl as defined above, e.g., methylsulfonyl or ethylsulfonyl.
“Alkoxycarbonyl” means a -(C=O)OR radical where R is alkyl as defined above, e.g., tertbutoxycarbonyl and the like.
“Alkoxycarbonylalkyl” means alkyl as defmed above which is substituted with one or two alkoxycarbonyl groups as defmed above, e.g., methoxycarbonylethyl, ethoxycarbonylethyl, methoxycarbonylpropyl and the like.
“Amino” means a -NH2 group.
“Aminoalkyl” means a -(alkylene)-NR’R” where R’ and R” are independently hydrogen or alkyl as defmed above.
“Aminosulfonyl” means a “-SO2NH2” group.
“Alkylamino” means a -NR’R” radical where R’ and R” are independently hydrogen or alkyl as defined above, and at least one of R’ and R” is alkyl, “Aminocarbonyl” means a —(C=O)-NH2 group, where one or each of the hydrogens in the
-NH2 can be independently replaced with an alkyl group, as defmed above.
“Aryl” means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyL “Aralkyl” means a -(alkylene)-R radical where R is aryl as defined above, e.g., benzyl, 15 phenethyl and the like.
“Aryloxy” means a -OR radical where R is aryl as defmed above, e.g., phenoxy, naphthyloxy and the like.
“Cyano” means a -CN group.
“Cyanoalkyl” means an alkyl group as defined above, substituted with one .or more cyano 20 groups, e.g., cyanomefhyl, cyanoethyl, 2-cyanopropyl, 2,3-dicyanobutyl and the like.
“Cyanoalkoxy” means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy and the like, where R is substituted with a cyano group. For example, cyanomethoxy, 2-cyanoethoxy, 2-cyanopropoxy and the like.
“Cycloalkyl” means a saturated monovalent monocyclic hydrocarbon radical of three to ten 25 carbon atoms, or a saturated monovalent bicyclic hydrocarbon radical of five to ten carbon atoms, unless stated otherwise. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion. As used herein, the term “fused” refers to two rings which hâve two atoms and one bond in common. As used herein, the term “bridged cycloalkyl refers to compounds wherein the cycloalkyl contains a linkage of one or more atoms connecting non-adjacent atoms. As 30 used herein, the term “spiro” refers to two rings which hâve one atom in common and the two rings are not linked by a bridge. Examples of monocyclic cycloalkyl groups includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. Examples of bicyclic cycloalkyl groups include, for example, decalinyl, norbomanyl, decahydronaphthalenyl, dodecahydro-lH-phenalenyl, adamantly, bicyclo[3.3.0]octanyl, spiro[3.3]heptanyl, spiro[3.4]octanyl, spiro[3.4]octanyl, spiro[3.5]nonanyl, spiro[4.4]nonanyl, spiro[3.6]decanyl, spiro[4.5]decanyl and the like.
“Cycloalkoxy” means a -OR radical where R is cycloalkyl as defïned above, e.g., forming a cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, cycloheptoxy, cyclooctoxy and the like.
“Cycloalkylalkyl” means a -(alkylene)-R radical where R is cycloalkyl as defïned above, e.g., cyclopropylmethyl, cyclohexylmethyl and the like.
“Cycloalkenyl” means a cyclic hydrocarbon radical of three to ten carbon atoms containing a double bond, unless stated otherwise, e.g., cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like.
“Carboxyalkyl” means a alkyl radical as defïned above that is substituted with a carboxy (-COOH) group.
“Deuterated alkoxy” means an alkoxy radical as defïned above, where one or more hydrogen atoms (up to the total number of hydrogen atoms in the alkoxy group) are replaced by deuterium, e.g., -OCHD2, -OCD3, -OCH2CD3, -OCD2CD3 and the like.
“Deuterated alkyl” means an alkyl radical as defïned above that is substituted with one, two or three deuterium atoms.
“Halo” or “halogen” means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
“Haloalkyl” means alkyl radical as defïned above, which is substituted with one or more halogen atoms, such as one to five halogen atoms, such as fluorine or chlorine, including those substituted with 20 different halogens, e.g., -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2 and the like. When the alkyl is substituted with only fluoro, it can be referred to in this Application as fluoroalkyl.
“Haloalkoxy” means a -OR radical where R is haloalkyl as defïned above e.g., -OCF3, -OCHF2, -OCH2F and the like. When R is haloalkyl where the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkoxy.
“Haloalkoxyalkyl” means alkyl as defïned above which is substituted with one or two haloalkoxy groups as defïned above, e.g., trifluormethoxyethyl, 3,3,3-trifluoroethoxyethyl and the like.
“Haloalkylcarbonyl” means a -COR radical where R is haloalkyl as defïned above, e.g., trifluoromethylcarbonyl, pentafluoroethylcarbonyl and the like.
“Hydroxyalkyl” means alkyl as defïned above which is substituted with one or two hydroxy 30 groups as defïned above, e.g., hydroxymethyl, hydroxyethyl, 1,3-dihydroxypropyl and the like.
“Halocycloalkyl” means cycloalkyl group as defïned above which is substituted with one, two or three halogen as defïned above, e.g., 2,2-difluorocyclopropyl and the like.
“Heterocyclyl” means a saturated or unsaturated monovalent group of 3 to 10 ring atoms in which one, two, or three ring atoms are heteroatom independently selected from N, O and S(O)n, where n is an integer from 0 to 2 and the remaining ring atoms are C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a — C(=O)- group. Heterocyclyl groups can be monocyclic or bicyclic. More specifically the term heterocyclyl includes, but is not Iimited to, pyiTolidino, piperidino, homopiperidino, 2oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, dihydropyranyl, thiomorpholino, 1,3dioxinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,2-dioxolanyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 2H-1,2oxazinyl, maleimido, succinimido, barbituric acid, thiobarbituric acid, dioxopiperazino, hydantoino, dihydrouracilyl, hexahydro-l,3,5-triazinyl, imidazolino, imidazolidino, isoxazolino, isoxazolidino, oxazolino, oxazolidino, oxazolidinono, thiazolino, thiazolidino, oxiranyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolino, pyrazolidino, 2-oxopyrrolidino, tetrahydropyranyl, 4H-pyranyl, tetrahydrothiopyranyl, azepanyl and the like. Heterocyclic groups can be monocyclic, for example, pyrrolidine, piperidine and piperazine, or bicyclic, for example, hexahydro-lH-pyrrolizine. Bicyclic heterocyclyl groups include bridged and fused ring Systems, for example, indoline, 7azabicyclo[2.2.1]heptane, hexahydro-lH-pyrrolizine, 8-azabicyclo[3.2.1]octane and the like. When the heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic. When the heterocyclyl ring has no double bond, it can be referred to herein as saturated heterocyclyl.
“Heterocyclylalkyl” or “heterocycloalkyl” means a -<alkylene)-R radical where R is heterocyclyl ring as defined above e.g., tetrahydrofuranylmethyl, piperazinyimethyl, morpholinylethyl and the like. When a heterocyclylalkyl group contains a secondary amino group (i.e., -NH-), the alkyl portion of the heterocyclylalkyl may replace the hydrogen on the nitrogen in the heterocyclyl ring, such that the heterocyclyl ring is linked to the alkyl potion of the heterocyclylalkyl group via the nitrogen atom.
“Heteroaryl” means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms, unless otherwise stated, where one or more, (in one embodiment, one, two, or three), ring atoms are heteroatom selected from N, O and S, the remaining ring atoms being carbon. Représentative examples include, but are not Iimited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl and the like. When the heteroaryl ring contains 5- or 6 ring atoms, it is also referred to herein as 5-or 6-membered heteroaryl.
“Heteroaralkyl” means a -(alkylene)-R radical where R is heteroaryl as defined above, e.g., pyridinylmethyl and the like. The heteroaryl ring in heteroaralkyl can contain from 5- to 10 ring atoms. When the heteroaryl ring in heteroaralkyl contains 5- or 6 ring atoms, it is also referred to herein as 5-or 6-membered heteroaralkyl. When a heteroaralkyl group contains a secondary amino 5 group (i.e., -NH-), the alkyl portion of the heteroaralkyl may replace the hydrogen on the nitrogen in the heteroaryl ring, such that the heteroaryl ring is linked to the alkyl potion ofthe heteroaralkyl group via the nitrogen atom.
“Heteroaryloxy” means a -OR radical where R is heteroaryl as defined above, e.g., pyridinoxy, pyrazinoxy, pyrimidinoxy, quinolinoxy and the like.
“Hydroxy” means-OH group.
“(Hydroxy )alkoxy” means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or /ert-butoxy and the like, where R is substituted with one or more hydroxy groups.
“Oxo” means a =(O) radical. As would be readily apparent to one of skill in the art, carbonyl refers to an oxo radical attached to a carbon atom, i.e., -C(O)-.
“Spiroheterocycloamino means a saturated bicyclic ring having 7 to 10 ring atoms in which one, two, or three ring atoms are heteroatom selected from N, N-oxide, O and S(O)n, where n is an integer from 0 to 2, the remaining ring atoms being C, provided that at least one ring atom is N and the rings are connected through only one atom. The connecting atom is also called the spiroatom and is 20 most often a quatemary carbon (spiro carbon). Représentative examples include, but are not limited to, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, l-azaspiro[3.3]heptane, l-oxaspiro[3.3]heptane, 5oxaspiro[3.4]octane, 5-azaspiro[3.4]octane, 2-oxaspiro[3.4]octane, 2-azaspiro[3.4]octane, l-oxa-4azaspiro[4.4]nonane, l,4-dioxaspiro[4.4]nonane, 2-azaspiro[3.5]nonane, 2-oxaspiro[3.5]nonane, 4azaspiro[2.5]octane, 4-oxaspiro[2.5]octane, l,4-dioxaspiro[4.5]decane, l-thiaspiro[4.5]decane 1,125 dioxide, 2-oxa-l-azaspiro[4.5]decane and the like.
It will be well recognized by a person skilled in the art that when Ring B is cycloalkyl, heterocyclyl, or a spirocycloalkyl, the carbon atoms in these rings that are shared with the adjacent ring (i.e., ring substituted with —NR3AR3B in Formula I) are sp_ carbons.
It will also be well recognized by a person skilled in the art that when a group containing carbon 30 atoms and NH groups is substituted, that the possible substituents may differ for the carbon atoms and the NH groups. Specifically, the skilled artisan would recognize that substitutions on an NH group are those that replace the hydrogen ofthe NH group with a carbon (i.e., forming a nitrogen-carbon bond).
- 13 The présent disclosure also includes protected dérivatives of compounds of the présent disclosure. For example, when compounds of the présent disclosure contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting group. A comprehensive list of suitable protective groups can be found in T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. (1999), the disclosure of which is incorporated herein by reference in its entirety. The protected dérivatives of compounds of the présent disclosure can be prepared by methods well known in the art.
It is to be understood that where compounds disclosed herein hâve unfilled valencies, then the valencies are to be filled with hydrogen.
The présent disclosure also includes deuterated forms of the compound of the présent disclosure, or a pharmaceutically acceptable sait thereof. Indeed, also provided herein are isotopologues (isotopically labeled analogues) of the compounds described herein. Substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements. In some embodiments, at any position of a compound described herein, or a pharmaceutically acceptable sait thereof, that has a hydrogen, the hydrogen atom can be replaced with hydrogen-2 (deuterium) or hydrogen-3 (tritium). For example, R1, R2, and/or Ring B can include one or more , D
Z Z-D 'VyD deuteriums (such as 1, 2, 3, 4, 5, or 6 deuteriums), such as when Ring B can be ,
An
I y F/ D D or D .
A “pharmaceutically acceptable sait” of a compound means a sait that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid,
- 14glucoheptonic acid, 4,4’-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like; or salts formed when an acidic proton présent in the parent compound either is replaced by a métal ion, e.g., an alkali métal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, Æ-methylglucamine and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference in its entirety.
The compounds of the présent disclosure may hâve asymmetric centers. Compounds of the présent disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to préparé optically active forms, such as by resolution of materials. Ail chiral, diastereomeric, ail mixtures of chiral or diastereomeric forms and racemic forms are within the scope of this disclosure, unless the spécifie stereochemistry or isomeric form is specifically indicated. It will also be well recognized by a person skilled in the art that when a bond is drawn from an optically active center, that a “fiat” bond ( ) represents and encompasses both the “wedge” bond (—) and the “dashed” bond (.........n) each representing the (R) or (S) stereoisomer. It will also be understood by a person of ordinary skill in the art that when a compound is denoted as (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity i.e., the (S) stereoisomer in less than about 5%, preferably 2% by wt. and then it is denoted as a mixture of R and S isomers, the amounts of R or S isomer in the mixture is greater than about 5%, preferably 2% w/w.
Certain compounds of the présent disclosure can exist as tautomers and/or géométrie isomers. Ail possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. Additionally, as used herein the term alkyl includes ail the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include ail the positional isomers albeit only a few examples are set forth. Furthermore, ail hydrates of a compound of the présent disclosure are within the scope of this disclosure.
“Optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heterocyclyl group optionally substituted with an alkyl group” means that the alkyl may but need not be présent, and the description includes situations
- 15 where the heterocyclyl group is substituted with an alkyl group and situations where the heterocyclyl group is not substituted with alkyl.
A “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable carrier/excipient” as used in the spécification and claims includes both one and more than one such excipient.
A “subject” refers to an animal that is the object of treatment, observation or experiment. “Animal” includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals. “Mammal” includes, without limitation, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, primates, such as monkeys, chimpanzees and apes, and, in particular, humans. In some embodiments, the subject can be human. In some embodiments, the subject can be a human child and/or a human infant, for example, a child or infant with a fever. In other embodiments, the subject can be a human adult.
“Treating” or “treatment” of a disease includes:
(1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet expérience or display symptoms of the disease;
(2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing régression of the disease or its clinical symptoms.
A “therapeutically effective amount” means the amount of a compound of the présent disclosure or a pharmaceutically acceptable sait thereof that, elicits the biological or médicinal response indicated. For example, when administered to a subject for treating a disease, the therapeutically effective amount of a compound is sufficient to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. This response may occur in a tissue, System, animal or human and includes alleviation of the signs or symptoms of the disease being treated. Détermination of an effective amount is well within the capability of those skilled in the art, in view of the disclosure provided herein. The “therapeutically effective amount” of the compounds disclosed herein will vary depending on the compound, the disease and its severily and the age, weight, etc., of the subject to be treated.
- 16Embodiments:
In further embodiments 1-235 below, the présent disclosure includes:
1. In embodiment 1, the compounds of Formula (I), or a pharmaceutically acceptable sait thereof, are as defined in the Summary.
2. In embodiment 2, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those wherein A can be CH.
3. In embodiment 3, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those wherein A can be N.
4. In embodiment 4, the compounds of any one of embodiments 1-3, or a pharmaceutically acceptable sait thereof, are those wherein R3B can be hydrogen.
5. In embodiment 5, the compounds of any one of embodiments 1-3, or a pharmaceutically acceptable sait thereof, are those wherein Rsb can be alkyl, for example, a Ci-Ce alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl (straight-chained or branched), or hexyl (straight-chained or branched).
6. In embodiment 6, the compounds of any one of embodiments 1-3, or a pharmaceutically acceptable sait thereof, are those wherein Rae can be -(C=O)NH2.
7. In embodiment 7, the compound of any one of embodiments 1-6, or a pharmaceutically acceptable sait thereof, are those wherein Ring B can be n . When Ring B is compound of Formula (I), or a pharmaceutically acceptable sait thereof, can hâve the structure:
R3A^N'R3B
8. In embodiment 8, the compounds of embodiment 7, or a pharmaceutically acceptable sait thereof, are those wherein X can be CR4AR4B.
9. In embodiment 9, the compounds of embodiment 8, or a pharmaceutically acceptable sait thereof, are those wherein R4A and R4b can each be hydrogen. For example, in some aspects of embodiment 9, Ring B can be a 5-8 membered monocyclic cycloalkyl group, such as:
- 17 When certain hydrogen atoms of Ring B are replaced with deuterium, Ring B can be, for example, + , D or u
10. In embodiment 10, the compounds of embodiment 8, or a pharmaceutically acceptable sait thereof, are those wherein R4a and R4b can each be alkyl, for example, a Ci-Ce alkyl such as methyl, ethyl, n-propyf isopropyi, n-butyl, tert-butyl, pentyl, or hexyL In some aspects of embodiment 10,
Ring B can be a monocyclic cycloalkyl group selected from:
11. In embodiment 11, the compounds of embodiment 8, or a pharmaceutically acceptable sait thereof, are those wherein one of R4a and R4b can be hydrogen and the other of R4a and R4b can be alkyl, for example, a C1-C7 alkyl such as methyl, ethyl, propyl, isopropyi, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl (straight-chained or branched), hexyl (straight-chained or branched), or heptyl (straight-chained or branched). In some aspects of embodiment 11, Ring B can be selected from:
12. In embodiment 12, the compounds of any one of embodiments 10-11, or a pharmaceutically acceptable sait thereof, are those wherein the alkyl can be methyl.
13. In embodiment 13, the compounds of embodiment 7, or a pharmaceutically acceptable sait thereof, are those wherein X can be O (oxygen). For example, in some aspects of embodiment 13, Ring B can be a 5-8 membered monocyclic heterocyclyl group containing one oxygen atom, such as:
In embodiment 14, the compounds of embodiment 7, or a pharmaceutically acceptable sait thereof, are those wherein X can be NR4C.
- 1815. In embodiment 15, the compounds of embodiment 14, or a pharmaceutically acceptable sait thereof, are those wherein R4c can be hydrogen. For example, in some aspects of embodiment 15, Ring B can be a 5-8 membered monocyclic heterocyclyl group containing one nitrogen atom, such as:
16. In embodiment 16, the compounds of embodiment 14, or a pharmaceutically acceptable sait thereof, are those wherein R4C can be alkyl, for example, a C1-C7 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl (straight-chained or branched), hexyl (straight-chained or branched), or heptyl (straight-chained or branched). For example, in some aspects of embodiment 16, Ring B can be a 5-8 membered monocyclic heterocyclyl group selected from:
and
17. In embodiment 17, the compounds of embodiment 16, or a pharmaceutically acceptable sait thereof, are those wherein R4C can be methyl.
18. In embodiment 18, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 1; and n can be 1.
19. In embodiment 19, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 2; and n can be 1.
20. In embodiment 20, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 1; and n can be 2.
21. In embodiment 21, the compounds of any one of embodiments 7-17, or a pharmaceutically 20 acceptable sait thereof, are those wherein m can be 2; and n can be 2.
22. In embodiment 22, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 3; and n can be 2.
23. In embodiment 23, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 2; and n can be 3.
24. In embodiment 24, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 1; and n can be 3.
25. In embodiment 25, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 3; and n can be 1.
26. In embodiment 26, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 1 ; and n can be 4.
27. In embodiment 27, the compounds of any one of embodiments 7-17, or a pharmaceutically acceptable sait thereof, are those wherein m can be 4; and n can be 1.
28. In embodiment 28, the compound of any one of embodiments 1-6, or a pharmaceutically ;θ(Β5)ν :θΜ)ν acceptable sait thereof, are those wherein Ring B can be . When Ring B is a compound of Formula (I), or a pharmaceutically acceptable sait thereof, can hâve the structure.
R3A^N'R3B
WW
Tl Î1(r5)v .
r2 N jn some aspects of embodiment 28, v can be 0 such that is unsubstituted. In other aspects of embodiment 28, v can be 1. When v is 1, the phenyl ring can be substituted at an ortho-, meta- or para-position. In still other aspects of embodiment 28, v can be 2. In yet still other aspects of embodiment 28, v can be 3. In some aspects of embodiment 28, v can be 4.
29. In embodiment 29, the compounds of any one of embodiments 1-6 or 28, or a pharmaceutically acceptable sait thereof, are those wherein each Rs can be independently a C1-C4 alkyl (such as those described herein).
30. In embodiment 30, the compounds of any one of embodiments 28-29, or a pharmaceutically acceptable sait thereof, are those wherein v can be 1, 2, or 3; and each R 5 can be independently a C1-C4 alkyl (such as those described herein).
31. In embodiment 31, the compounds of any one of embodiments 1-6 or 28, or a pharmaceutically acceptable sait thereof, are those wherein v can be 0.
32. In embodiment 32, the compounds of any one of embodiments 1-31, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be alkoxy, for example, a C1-C4 alkoxy (optionally substituted with one or more Ra, independently selected from deuterium, hydroxy, alkoxy, (hydroxy)alkoxy and cyano), such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, iso-butoxy or t-butoxy; and R2 can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, a Ci-Cô alkyl such as those described herein and including methyl or ethyl), haloalkyl (for example, a Ci-Cô haloalkyl such as -CF3 or -CHF2), hydroxyalkyl (for example, a Ci-Cô hydroxyalkyl such as those described herein and including hydroxymethyl or hydroxyethyl), aryloxy (for example a C6 aryloxy such as phenoxy), heteroaryloxy (for example a 5- to 6-membered heteroaryloxy such as pyridinoxy or thiazoloxy), cycloalkyl (for example a C3-C6 cycloalkyl such as
-20those described herein and including cyclopropyl)(optionally substituted with one or more hydroxy), cycloalkoxy for example a C3-C6 cycloalkoxy such as those described herein and including cyclopropoxy or cyclobutoxy), cyanoalkoxy (for example, a Ci-Ce cyanoalkoxy such as those described herein and including cyanomethoxy or cyanoethoxy), alkoxy (a C1-C4 alkoxy such as methoxy, ethoxy, 5 n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, iso-butoxy or t-butoxy)(optionally substituted with one or more Ra, independently selected from deuterium, hydroxy, alkoxy, (hydroxy)alkoxy and cyano), haloalkoxy (for example, a Ci-C6 haloalkoxy such as -OCF3 or -OCHF2) or aminosulfonyl (optionally substituted with one or more alkyl).
33. In embodiment 33, the compounds of any one of embodiments 1-32, or a pharmaceutically 10 acceptable sait thereof, are those wherein Ri can be methoxy optionally substituted with one or more deuterium.
34. In embodiment 34, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy.
35. In embodiment 35, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCD3.
36. In embodiment 36, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri and R2 can each be methoxy.
37. In embodiment 37, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri and R2 can each be -OCD3.
38. In embodiment 38, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be haloalkoxy.
39. In embodiment 39, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCD3; and R2 can be haloalkoxy.
40. In embodiment 40, the compounds of any one of embodiments 1-33 or 38-39, or a 25 pharmaceutically acceptable sait thereof, are those wherein R2 can be -OCH2F, -OCHF2 or -OCF3.
41. In embodiment 41, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be alkoxy (for example, a C1-C4 alkoxy such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, isobutoxy or t-butoxy) substituted with one or more Ra which can be alkoxy, for example, a C1-C4 alkoxy 30 such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, iso-butoxy or t-butoxy. In some aspects of embodiment 41, Ri can be methoxy. In some aspects of embodiment 41, Ri can be ko—(CH2)a— O—(CH2)z— CH3 , .
-OCD3. In some aspects of embodiment 41, R2 can be * » wherein q can
-21 be 1, 2, 3 or 4; and z can be 0, 1, 2, 3 or 4. In some aspects of embodiment 41, q can be 1; and z can be 0. In some aspects of embodiment 41, q can be 2; and z can be 0. In some aspects of embodiment 41, q can be 3; and z can be 0. In some aspects of embodiment 41, q can be 4; and z can be 0. In some aspects of embodiment 41, q can be 1; and z can be 1. In some aspects of embodiment 41, q can be 2; and z can be 1. In some aspects of embodiment 41, q can be 3; and z can be 1. In some aspects of embodiment 41, q can be 4; and z can be 1. In some aspects of embodiment 41, q can be 1; and z can be 2. In some aspects of embodiment 41, q can be 2; and z can be 2. In some aspects of embodiment 41, q can be 3; and z can be 2. In some aspects of embodiment 30, q can be 4; and z can be 2. In some aspects of embodiment 41, q can be 1; and z can be 3. In some aspects of embodiment 41, q can be 2; and z can be 3. In some aspects of embodiment 41, q can be 3; and z can be 3. In some aspects of embodiment 41, q can be 4; and z can be 3. In some aspects of embodiment 41, q can be 1; and z can be 4. In some aspects of embodiment 41, q can be 2; and z can be 4. In some aspects of embodiment 41, q can be 3; and z can be 4. In some aspects of embodiment 41, q can be 4; and z can be 4.
42. In embodiment 42, the compounds of embodiment 41, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be u , » or
43. In embodiment 43, the compounds of embodiment 41, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be alkoxy (for example, a C1-C4 alkoxy such as methoxy, ethoxy, npropoxy, iso-propoxy, n-butoxy, sec-butoxy, iso-butoxy or t-butoxy) substituted with one Ra- For example, R2 can be alkoxy substituted with a C1-C4 alkoxy such as those described herein and including methoxy and ethoxy.
44. In embodiment 44, the compounds of embodiment 41, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be alkoxy independently substituted with two Ra- For example, R2 can be a Ci-C8 alkoxy independently substituted with two C1-C4 alkoxys (for example, two methoxy groups or a methoxy and an ethoxy).
45. In embodiment 45, the compounds of embodiment 41, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be alkoxy independently substituted with three Ra. For example, R2 can be a Ci-C8 alkoxy independently substituted with three C1-C4 alkoxys (for example, three methoxy groups or two methoxy groups and one ethoxy group).
46. In embodiment 46, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be hydroxyalkyl. Exemplary hydroxyalkyl groups include, but are not limited to C1-C4 hydroxyalkyl groups such as hydroxymethyl,
-221-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxyisopropyl and 4hydroxybutyl.
47. In embodiment 47, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCD3; and R2 can be hydroxyalkyl. Exemplary hydroxyalkyl groups include, but are not iimited to C1-C4 hydroxyalkyl groups such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxyisopropyl and 4hydroxybutyL
48. In embodiment 48, the compounds of any one of embodiments 1-33 or 46-47, or a OH pharmaceutically acceptable sait thereof, are those wherein R2 can be V^oh ,
Loh
OH or
49. In embodiment 49, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be alkoxy (for example, a C1-C10 alkoxy such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, isobutoxy, t-butoxy, pentoxy (straight-chained or branched), hexoxy (straight-chained or branched), heptoxy (straight-chained or branched), octoxy (straight-chained or branched), nonoxy (straightchained or branched) or decoxy (straight-chained or branched)) mono-substituted with Ra which can be hydroxy. For example, in some aspects of embodiment 49, Ri can be methoxy or -OCD3. In other aspects of embodiment 49, Ri can be -OCD3. In some aspects of embodiment 49, R2 can be ^-0—(CH2)r—OH, wherein r is 2, 3, 4, 5, 6, 7, 8, 9 or 10. In some aspects of embodiment 49, r can be 1. In some aspects of embodiment 49, r can be 2. In some aspects of embodiment 49, r can be 3. In some aspects of embodiment 49, r can be 4. In some aspects of embodiment 49, r can be 5. In some aspects of embodiment 49, r can be 6. In some aspects of embodiment 49, r can be 7. In some aspects of embodiment 49, r can be 8. In some aspects of embodiment 49, r can be 9. In some aspects of embodiment 49, r can be 10.
50. In embodiment 50, the compounds of any one of embodiments 1-33 or 49, or a pharmaceutically
OH s O. 5 ,0, .OH a^O^ /L acceptable sait thereof, are those wherein R2 can be
-23 OH
OH .
51. In embodiment 51, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or —OCD3; and R2 can be alkoxy monosubstituted with RA which can be (hydroxy)alkoxy. In some aspects of embodiment 51, Ri can be methoxy. In other aspects of embodiment 51, Ri can be —OCD3. In some aspects of embodiment 51, R2 can be Ci-C8 alkoxy mono-substituted with Ra which can be hydroxy(Ci-C4)alkoxy. In some V-O—(CH.,)k—O—(CH2)D—OH , aspects of embodiment 51, R2 can be ' , wherein k and p can independently be 1, 2, 3 or 4. In some aspects of embodiment 51, k can be 1; and p can be 1. In some aspects of embodiment 51, k can be 2; and p can be 1. In some aspects of embodiment 51, k can be 3, and p can be 1. In some aspects of embodiment 51, k can be 4; and p can be 1. In some aspects of embodiment 51, k can be 1; and p can be 2. In some aspects of embodiment 51, k can be 2; and p can be 2. In some aspects of embodiment 51, k can be 3; and p can be 2. In some aspects of embodiment 51, k can be 4; and p can be 2. In some aspects of embodiment 51, k can be 1; and p can be 3. In some aspects of embodiment 51, k can be 2; and p can be 3. In some aspects of embodiment 51, k can be 3, and p can be 3. In some aspects of embodiment 51, k can be 4; and p can be 3. In some aspects of embodiment 51, k can be 1; and p can be 4. In some aspects of embodiment 51, k can be 2; and p can be 4. In some aspects of embodiment 51, k can be 3; and p can be 4. In some aspects of embodiment 51, k can be 4; and p can be 4.
52. In embodiment 52, the compounds of embodiment 51, or a pharmaceutically acceptable sait u ζχ/ΟΗ VO^^O^^OH thereof, are those wherein R2 can be or
53. In embodiment 53, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be halogen, for example, fluoro or chloro.
54. In embodiment 54, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCD3; and R2 can be halogen, for example, fluoro or chloro.
55. In embodiment 55, the compounds of any one of embodiments 53-54, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be fluoro.
56. In embodiment 56, the compounds of any one of embodiments 53-54, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be chloro.
57. In embodiment 57, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be cyano.
58. In embodiment 58, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCDa; and R2 can be cyano.
59. In embodiment 59, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or —OCD3; and R2 can be alkyl. In some aspects of embodiment 59, Ri can be methoxy. In other aspects of embodiment 59, Ri can be 10 -OCD3. In some aspects of embodiment 59, R2 can be a C1-C7 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl (straight-chained or branched), hexyl (straight-chained or branched) and heptyl (straight-chained or branched).
60. In embodiment 60, the compounds of embodiment 59, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be ethyl.
61. In embodiment 61, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be hydrogen.
62. In embodiment 62, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCD3; and R2 can be hydrogen.
63. In embodiment 63, the compounds of any one of embodiments 1-33, or a pharmaceutically 20 acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be haloalkyl. In some aspects of embodiment 63, Ri can be methoxy. In other aspects of embodiment 63, Ri can be — OCD3. In some aspects of embodiment 63, R2 can be a Ci-Ce haloalkyl group such as -CH2CI, -CF3, CHF2, -CH2F, -CH2CF3, -CF2CF3 and -CF(CH3)2.
64. In embodiment 64, the compounds of embodiment 63, or a pharmaceutically acceptable sait 25 thereof, are those wherein R2 can be -CF3.
65. In embodiment 65, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be aryloxy, for example, a Ce or Cio aryloxy such as phenoxy or naphthyloxy.
66. In embodiment 66, the compounds of any one of embodiments 1-33, or a pharmaceutically 30 acceptable sait thereof, are those wherein Ri can be -OCD3; and R2 can be aryloxy, for example, a Ce or Cio aryloxy such as phenoxy or naphthyloxy.
67. In embodiment 67, the compounds of any one of embodiments 65-66, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be phenoxy.
68. In embodiment 68, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or —OCD3; and R2 can be heteroaryloxy. In some aspects of embodiment 68, Ri can be methoxy. In other aspects of embodiment 68, Ri can be -OCD3. In some aspects ofembodiment 68, the heteroaryl group in heteroaryloxy can be a 5-membered heteroaryl group, a 6-membered heteroaryl group or a 10-membered heteroaryl group. In some aspects of embodiment 68, the heteroaryl group in heteroaryloxy can be a monocyclic heteroaryl. In some aspects of embodiment 68, the heteroaryl group in heteroaryloxy can be a 5- or 6-membered monocyclic heteroaryl group. In some aspects of embodiment 68, the heteroaryl group in heteroaryloxy can be a nitrogen-containing monocyclic 5- or 6-membered heteroaryl group. In some aspects of embodiment 68, the heteroaryl group in heteroaryloxy can be a 5- or 6-membered heteroaryl group containing nitrogen and oxygen. In some aspects of embodiment 68, the heteroaryl group in heteroaryloxy can be, for example, pyrrole, pyrazole, imidazole, 1,2,4-triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,3,4-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine or 1,3,5-triazine.
69. In embodiment 69, the compounds of embodiment 68, or a pharmaceutically acceptable sait thereof, are those wherein R2 can be
70. In embodiment 70, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be cyanoalkoxy, for example, a Ci-C6 cyanoalkoxy. In some aspects of embodiment 70, Ri can be methoxy. In other aspects of embodiment 70, Ri can be -OCD3. In some aspects of embodiment 70, the cyanoalkoxy group can be: wherein y can be 1, 2, 3, 4, 5 or 6, for example, cyanomethoxy, cyanoethoxy or cyanopropoxy.
71. In embodiment 71, the compounds of embodiment 70, or a pharmaceutically acceptable sait VO^CN thereof, are those wherein R2 can be
72. In embodiment 72, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or —OCD3; and R2 can be cycloalkoxy. In some aspects of embodiment 72, Ri can be methoxy. In other aspects of embodiment 72, Ri can be OCD3. In some aspects of embodiment 72, the cycloalkoxy group can be a monocyclic C3-C8 5 cycloalkoxy such as cyclopropoxy, cyclobutoxy, cyclopentoxy, cycloheptoxy or cyclooctoxy. In some aspects of embodiment 72, the cycloalkoxy group can be a Cô-Cio bicyclic cycloalkoxy, for example, a fused, spiro or bridged cycloalkoxy, for example, octahydropentalenoxy, bicyclo[3.1.1]heptanoxy, or bicyclo[2.2.1 ]heptanoxy.
73. In embodiment 73, the compounds of embodiment 72 or a pharmaceutically acceptable sait 10 thereof, are those wherein R2 can be cyclopropoxy, cyclobutoxy or cyclopentoxy.
74. In embodiment 74, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or —OCD3; and R2 can be cycloalkyl. In some aspects of embodiment 74, Ri can be methoxy. In other aspects of embodiment 74, Ri can be OCD3. In some aspects of embodiment 74, the cycloalkyl can be a monocyclic C3-C8 cycloalkyl such 15 as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cyclooctyl. In some aspects of embodiment 74, the cycloalkyl can be a C6-Cio bicyclic cycloalkyl, for example, a fused, spiro or bridged cycloalkyl, for example, octahydropentalenyl, bicyclo[3.1.1]heptanyl, or bicyclo[2.2.1]heptanyl.
75. In embodiment 75, the compounds of embodiment 74 or a pharmaceutically acceptable sait thereof, are those wherein R2 can be cyclopropyl, cyclobutyl or cyclopentyl.
76. In embodiment 76, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be cycloalkyl, which can be mono-substituted with hydroxy. In some aspects of embodiment 76, Ri can be methoxy. In other aspects of embodiment 76, Ri can be —OCD3. In some aspects of embodiment 76, the cycloalkyl can be a monocyclic C3-C8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, 25 cyclohexyl, or cyclooctyl. In some aspects of embodiment 76, the cycloalkyl can be a Cô-Cio bicyclic cycloalkyl, for example, a fused, spiro or bridged cycloalkyl, for example, octahydropentalenyl, bicyclo[3.1.1]heptanyl, or bicyclo[2.2.1]heptanyl. Exemplary cycloalkyl groups mono-substituted with hydroxy include, but are not limited to, 1-hydroxycyclopropyl, 2-hydroxycyclopropyl, 1hydroxycyclobutyl, 2-hydroxycyclobutyl, 3-hydroxycyclobutyl, l-hydroxycyclopentyl, 230 hydroxycyclopentyl, 3-hydroxycyclopentyl, 1-hydroxy cyclohexyl, 2-hydroxycyclohexyl, 3hydroxycyclohexyl and 4-hydroxycyclohexyl.
77. In embodiment 77, the compounds of embodiment 76 or a pharmaceutically acceptable sait
HO Z\ HO^>\ thereof, are those wherein R2 can be > , or > ' J.
78. In embodiment 78, the compounds of any one of embodiments l-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy; and R2 can be aminosulfonyl.
79. In embodiment 79, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be -OCD3; and R2 can be aminosulfonyl.
80. In embodiment 80, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be aminosulfonyl, which can be mono-substituted with alkyl, for example, a C1-C7 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, iso-butyl, pentyl (straight-chained or branched), hexyl (straight-chained or branched) or heptyl (straight-chained or branched). In some aspects of embodiment 80 Ri can be methoxy. In other aspects of embodiment 80, Ri can be
-OCD3.
81. In embodiment 81, the compounds of embodiment 80 or a pharmaceutically acceptable sait thereof, are those wherein R2 can be aminosulfonyl, which can be mono-substituted with methyl.
82. In embodiment 82, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri can be methoxy or -OCD3; and R2 can be hydroxy. In some aspects of embodiment 82, Ri can be methoxy. In other aspects of embodiment 82, Ri can be -OCD3.
83. In embodiment 83, the compounds of any one of embodiments 1-33, or a pharmaceutically acceptable sait thereof, are those wherein Ri and R2, together with the atoms to which they are attached, can form a monocyclic heterocyclyl group. In some aspects of embodiment 83, the heterocyclyl group can be a 5- or 6-membered monocyclic heterocyclyl. In some aspects of embodiment 83, the heterocyclyl group can be a 5- or 6-membered monocyclic heterocyclyl containing one or two oxygen atoms. In some aspects of embodiment 83, the heterocyclyl group can be a 5- or 6-membered monocyclic heterocyclyl containing one or two nitrogen atoms. Exemplary heterocyclyl groups include, but are not limited to: 1,3 dioxole, 2,3-dihydroimidazole, 2,3-dihydrofuran, pyrrolidine, 1,4 dioxine, 3,4-dihydro-l,4-oxazine, piperidine-2-one and tetrahydro-2H-pyranone.
84. In embodiment 84, the compounds of embodiment 83, or a pharmaceutically acceptable sait
O
O thereof, are those wherein the heterocyclyl group can be
85. In embodiment 85, the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heteroaralkyl (optionally substituted with alkyl). In some aspects of embodiment 85, the heteroaryl group in heteroaralkyl can be a 5-membered heteroaryl group, a 6-membered heteroaryl group or a 10-membered heteroaryl group. In some aspects 5 of embodiment 85, the heteroaryl group in heteroaralkyl can be a monocyclic heteroaryl. In some aspects of embodiment 85, the heteroaryl group in heteroaralkyl can be a 5- or 6-membered, monocyclic heteroaryl group. In some aspects of embodiment 85, the heteroaryl group in heteroaralkyl can be a nitrogen-containing 5- or 6-membered heteroaryl group. In some aspects of embodiment 85, the heteroaryl group in heteroaralkyl can be a 5- or 6-membered heteroaryl group containing nitrogen and 10 oxygen. In some aspects of embodiment 85, the heteroaryl group in heteroaralkyl can be, for example, pyrrole, pyrazole, imidazole, 1,2,4-triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,3,4-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine or 1,2,4-triazine, 1,3,5-triazine. In some aspects of embodiment 85, the alkylene in heteroaralkyl can be a Ci-Cô alkylene, such as -(CH2)i-6-. In some aspects of embodiment 85, the alkylene in heteroaralkyl can be a methylene (-CH2-).
86. In embodiment 86, the compounds of embodiment 85, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be an unsubstituted heteroaralkyl. In some aspects of embodiment 8686, the heteroaryl portion of the heteroaralkyl group can be pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, 20 isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl. In some aspects of embodiment 86, the alkylene portion of the heteroaralkyl group can be a C1-C4 alkylene such as -CH2, -CH2CH2-, -CH2CH2CH2- or -CH2CH2CH2CH2-. Exemplary heteroaralkyl groups include, but are not limited to: pyrrolylmethyl, thienylmethyl, thiazolylmethyl, imidazolylmethyl, furanylmethyl, indolylmethyl, isoindolylmethyl, oxazolylmethyl, isoxazolylmethyl, benzothiazolylmethyl, 25 benzoxazolylmethyl, quinolinylmethyl, isoquinolinylmethyl, pyridinylmethyl, pynmidinylmethyl, pyrazinylmethyl, pyridazinylmethyl, triazolylmethyl, tetrazolylmethyl, pyrrolylethyl, thienylethyl, thiazolylethyl, imidazolylethyl, furanylethyl, indolylethyl, isoindolylethyl, oxazolylethyl, isoxazolylethyl, benzothiazolylethyl, benzoxazolylethyl, quinolinylethyl, isoquinolinylethyl, pyridinylethyl, pyrimidinylethyl, pyrazinylethyl, pyridazinylethyl, triazolylethyl and tetrazolylethyL 30 87. In embodiment 87, the compounds of embodiment 86, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
88. In embodiment 88, the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heteroaralkyl substituted with alkyl. In some aspects of embodiment 88, the heteroaryl portion of the heteroaralkyl group can be pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl. In some aspects of embodiment 88, the alkyl portion of the heteroaralkyl group can be a C1-C4 alkyl such as CH2-, -CH2CH2-, -CH2CH2CH2- or -CH2CH2CH2CH2-. Exemplary heteroaralkyl groups include, but are not limited to: pyrrolylmethyl, thienylmethyl, thiazolylmethyl, imidazolylmethyl, furanylmethyl, indolylmethyl, isoindolylmethyl, oxazolylmethyl, isoxazolylmethyl, benzothiazolylmethyl, benzoxazolylmethyl, quinolinyl methyl, isoquinolinylmethyl, pyridinylmethyl, pyrimidinylmethyl, pyrazinylmethyl, pyridazinylmethyl, triazolylmethyl, tetrazolylmethyl, pyrrolylethyl, thienylethyl, thiazolylethyl, imidazolylelhyl, furanylethyl, indolylethyl, isoindolylethyl, oxazolylethyl, isoxazolylethyl, benzothiazolylethyl, benzoxazolylethyl, quinolinylethyl, isoquinolinylethyl, pyridinylethyl, pyrimidinylethyl, pyrazinylethyl, pyridazinylethyl, triazolylethyl and tetrazolylethyl. In some aspects of embodiment 88, the heteroaralkyl can be substituted with alkyl, for example, a C1-C4 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl or t butyl.
89. In embodiment 89, the compounds of embodiment 88, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
90. In embodiment 90, the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be cycloalkylalkyl (optionally substituted with one or more Rc, independently selected from amino and alkylamino, for example a mono-substituted amino or a di-substituted amino).
91. In embodiment 91, the compounds of embodiment 90, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be an unsubstituted cycloalkylalkyl. In some aspects of embodiment 91, the cycloalkyl can be a monocyclic C3-C8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl. In some aspects of embodiment 91, the cycloalkyl can be a Cô-Cio bicyclic cycloalkyl, for example, a fused, spiro or bridged cycloalkyl, for example, octahydropentalenyl, bicyclo[3.1.1]heptanyl, or bicyclo[2.2.1]heptanyl. In some aspects of embodiment 91, the alkylene in a cycloalkylalkyl group can be a Ci-C6 alkylene, for example,
-30-(CH2)i-6- In some aspects of embodiment 91, the alkylene in a cycloalkylalkyl group can be a methylene (-CH2-).
92. In embodiment 92, the compounds of embodiment 91, or a pharmaceutically acceptable sait thereof, are those wherein R3A can be or
93. In embodiment 93, the compounds of embodiment 90, or a pharmaceutically acceptable sait thereof, are those wherein R3A can be cycloalkylalkyl, which can be substituted with one or more Rc, independently selected from amino and alkylamino. In some aspects of embodiment 93, the alkylamino can be, for example, a C1-C3 alkylamino such as methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, diisopropylamino, n-propylamino or di-n-propylamino.
94. In embodiment 94, the compounds of embodiment 93, or a pharmaceutically acceptable sait ,nh2 thereof, are those wherein R3A can be or
95. In embodiment 95, the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein R3A can be spiroheterocycloamino (optionally substituted with one or more Rb, independently selected from alkyl, aryl (optionally substituted with one or more Rd, independently selected from halogen and alkyl) and alkoxycarbonyl). In some aspects of embodiment 95, the spiroheterocycloamino can be a nitrogen-containing 7-10 membered ring system. In some aspects of embodiment 95, the spiroheterocycloamino can be a 7-10 membered ring system containing nitrogen and oxygen. In some aspects of embodiment 95, the spiroheterocycloamino can be 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, l-azaspiro[3.3]heptane, l-oxaspiro[3.3]heptane, 5oxaspiro[3.4]octane, 5-azaspiro[3.4]octane, 2-oxaspiro[3.4]octane, 2-azaspiro[3.4]octane, l-oxa-4azaspiro[4.4]nonane, l,4-dioxaspiro[4.4]nonane, 2-azaspiro[3.5]nonane, 2-oxaspiro[3.5]nonane, 4azaspiro[2.5]octane, 4-oxaspiro[2.5]octane, l,4-dioxaspiro[4.5]decane, l-thiaspiro[4.5]decane 1,1dioxide or 2-oxa-l-azaspiro[4.5]decane.
96. In embodiment 96, the compounds of embodiment 95, or a pharmaceutically acceptable sait thereof, are those wherein R3A can be an unsubstituted spiroheterocycloamino. In some aspects of embodiment 96, the spiroheterocycloamino can be a nitrogen-containing 7-10 membered ring System. In some aspects of embodiment 96, the spiroheterocycloamino can be a 7-10 membered ring system containing nitrogen and oxygen.
97. In embodiment 97, the compounds of embodiment 96, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be
98. In embodiment 98, the compounds of embodiment 95, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be spiroheterocycloamino, which can be substituted with one or more Rb, independently selected from alkyl (for example, a C1-C4 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or t-butyl) and alkoxycarbonyl (for example, a C1-C4 alkoxy such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl, n-butoxycarbonyl or tbutoxycarbonyl).
99. In embodiment 99, the compounds of embodiment 98, or a pharmaceutically acceptable sait ! O | thereof, are those wherein R3a can be
100. In embodiment 100, the compounds of embodiment 95, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be spiroheterocycloamino, which can be substituted with one or more Rb, which can be aryl (optionally substituted with one or more Rd, independently selected from halogen and alkyl). In some aspects of embodiment 100, the aryl group is an unsubstituted Cô or Cio aryl group such as phenyl or naphthyl. In some aspects of embodiment 100, the aryl group is a Cô aryl group substituted with 1, 2, or 3 Rd, independently selected from halogen (such as chloro or fluoro) and Ci-Cô alkyl (such as those described herein). In some aspects of embodiment 100, the aryl group is a Cô aryl group substituted with one Rd, independently selected from halogen (such as chloro or fluoro) and Ci-Cô alkyl. In some aspects of embodiment 100, the aryl group is a Cô aryl group substituted with two Rd, independently selected from halogen (such as chloro or fluoro) and Ci-C3 alkyl (for example, methyl, ethyl, n-propyl or isopropyl).
101. In embodiment 101, the compounds of embodiment 100, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be
102. In embodiment 102, the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be heterocyclyl optionally substituted with one or more Re, independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl,
-32aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 102, the heterocyclyl of the heterocyclylalkyl can be a monocyclic 5- to 8-membered heterocyclyl. In some aspects of embodiment 102, the heterocyclyl of the heterocyclylalkyl can be a bicyclic 6- to 10-membered heterocyclyl. In some aspects of embodiment 102, the heterocyclyl can contain 1, 2 or 3 heteroatoms, which can be oxygen, nitrogen and/or sulfur. In some aspects of embodiment 102, the heterocyclyl of the heterocyclylalkyl can be a nitrogen-containing heterocyclyl. In some aspects of embodiment 102, the heterocyclyl of the heterocyclylalkyl can be an oxygen-containing heterocyclyl. In some aspects of embodiment 102, the heterocyclyl group of the heterocyclylalkyl can contain oxygen and nitrogen. In some aspects of embodiment 102, the heterocyclyl group of the heterocyclylalkyl can be a monocyclic 5- to 8membered heterocyclyl containing one nitrogen atom. In some aspects of embodiment 102, when the heterocyclyl group contains one or more -NH- groups in the ring, one or more Re may be bonded to the nitrogen atom (replacing the hydrogen). In some aspects of embodiment 102, Rsa can be heterocyclyl optionally substituted with one or more Re on one or more NH groups of the heterocyclyl, wherein the one or more Re independently selected from hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aiyl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In other aspects of embodiment 102, Rsa can be heterocyclyl optionally substituted with one or more Re on one or more carbons atoms of the heterocyclyl, wherein the one or more Re independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with
-33 hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy).
103. In embodiment 103, the compounds of embodiment 102, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be an unsubstituted heterocyclyl. In some aspects of embodiment 103, Rba can be an unsubstituted monocyclic 5 to 8 membered nitrogen-containing heterocyclyl. In some aspects of embodiment 103, Rsa can contain one nitrogen. In some aspects of embodiment 103, Rsa can contain two nitrogens. In some aspects of embodiment 103, Rsa can be selected from: pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, dihydropyranyl, thiomorpholino, 1,3-dioxinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,2-dioxolanyl, 1,3dioxolanyl, 1,4-dioxolanyl, 2H-l,2-oxazinyl, maleimido, succinimido, barbituric acid, thiobarbituric acid, dioxopiperazino, hydantoino, dihydrouracilyl, hexahydro-l,3,5-triazinyl, imidazolino, imidazolidino, isoxazolino, isoxazolidino, oxazolino, oxazolidino, oxazolidinono, thiazolino, thiazolidino, oxiranyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolino, pyrazolidino, 2oxopyrrolidino, tetrahydropyranyl, 4H-pyranyl, tetrahydrothiopyranyl and azepanyl.
104. In embodiment 104, the compounds of embodiment 103, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
105. In embodiment 105, the compounds of embodiment 102, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one or more Re, independently selected from hydroxy, alkoxy (for example a Ci-Cô alkoxy), hydroxyalkyl (for example, hydroxymethyl, hydroxyethyl or hydroxypropyl), cycloalkyl, cyanoalkyl (for example, cyanomethyl, cyanoethyl or cyanopropyl), aralkyl (for example, benzyl), alkoxycarbonyls (for example, a Ci-Cô alkoxycarbonyl), aminocarbonyl and cycloalkylalkyl. In some aspects of embodiment 105, the cycloalkyl groups can be monocyclic Cs-Cs cycloalkyls. In some aspects of embodiment 105, the cycloalkyl groups can be bicyclic Cô-Cio cycloalkyls.
106. In embodiment 106, the compounds of embodiment 105, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one or two Re, independently selected from hydroxy, alkoxy (for example a Ci-Cô alkoxy), hydroxyalkyl (for example, hydroxymethyl, hydroxyethyl or hydroxypropyl), cycloalkyl (for example a C3-C6 monocyclic 5 cycloalkyl), cyanoalkyl (for example, cyanomethyl, cyanoethyl or cyanopropyl), aralkyl (for example, benzyl), alkoxycarbonyls (for example, a Ci-Cô alkoxycarbonyl), aminocarbonyl and cycloalkylalkyl (for example, a C3-C6 monocyclic cycloalkyl(Ci-C3)alkyl). In some aspects of embodiment 106, the heterocyclyl can be a 5- to 8-membered nitrogen-containing heterocyclyl.
107. In embodiment 107, the compounds of any one of embodiments 105-106, or a pharmaceutically
108. In embodiment 108, the compounds of embodiment 102, or a pharmaceutically acceptable sait thereof, are those wherein R3A can be heterocyclyl independently substituted with one or more Re, which can be alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy). In some aspects of embodiment 108, the heterocyclyl is a 5- to 8-membered nitrogencontaining heterocyclyl.
109. In embodiment 109, the compounds of embodiment 108, or a pharmaceutically acceptable sait 10 thereof, are those wherein Rsa can be heterocyclyl independently substituted with one, two, three or four Re, which can each independently be an unsubstituted alkyl. In some aspects of embodiment 109, the unsubstituted alkyl can be a Ci-Cô alkyl group, such as, methyl, ethyl, n-propyl, isopropyi, n-butyl, isobutyl, t-butyl, pentyl (straight-chained or branched) or n-hexyl (straight-chained or branched).
110. In embodiment 110, the compounds of embodiment 109, or a pharmaceutically acceptable sait
111. In embodiment 111, the compounds of embodiment 108, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or two Re, which can be alkyl independently substituted with at least one halogen (such as chloro or fluoro) and at least one hydroxy.
112. In embodiment 112, the compounds of embodiment 111, or a pharmaceutically acceptable sait
113. In embodiment 113, the compounds of embodiment 108, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl indepdendently substituted with one or two Re, which can each independently be alkyl substituted with alkoxy. In some aspects of embodiment 116, each Re can independently be 2^s ( 3 . wherein s can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or
10; and t can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In some aspects of embodiment 116, each Re can independently be θ (CH2)t CH3 _ s can 2 or 3; and t can be 0, 1 or 2. In some aspects of embodiment 116, s can be 1; and t can be 0. In some aspects of embodiment 113, s can be 2; and t can be 0. In some aspects of embodiment 113, s can be 3; and t can be 0. In some aspects of embodiment 113, s can be 1; and t can be 1. In some aspects of embodiment 113, s can be 2; and t can be 1. In some aspects of embodiment 113, s can be 3; and t can be 1. In some aspects of
embodiment 113, s can be 1; and t can be 2. In some aspects of embodiment 113, s can be 2; and t can be 2. In some aspects of embodiment 113, s can be 3; and t can be 2.
114. In embodiment 114, the compounds of embodiment 113, or a pharmaceutically acceptable sait
thereof, are those wherein Rsa can be
115. In embodiment 115, the compounds of embodiment 108, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or two Re groups, which can each independently be halogen (for example, fluoro or chloro) or alkylsulfonyl.
116. In embodiment 116, the compounds of any one of embodiments 108 or 115, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one or two Re groups, which can be independently halogen. In some aspects of embodiment 116, Rsa can be substituted with one Re. In other aspects of embodiment 116, Rsa can be substituted with two Re groups. In some aspects of embodiment 116, each Re can be fluoro. In some aspects of embodiment
116, each Re can be chloro.
117. In embodiment 117, the compounds of any one of embodiments 108 or 115, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or two Re, which can be (Ci-Cô alkyl)sulfonyl, for example, methylsulfonyl, ethylsulfonyl, or isopropylsulfonyl.
118. In embodiment 118, the compounds of any one of embodiments 108 or 115, or a
pharmaceutically acceptable sait thereof, are those wherein Rsa can be
119. In embodiment 119, the compounds of embodiment 102, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re,
-38which can be alkylcarbonyl (optionally substituted with hydroxy or benzyloxy). In some aspects of embodiment 119, the heterocyclyl is a 5- to 8-membered nitrogen-containing heterocyclyl.
120. In embodiment 120, the compounds of embodiment 119, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Rd, 5 which can be an unsubstituted alkylcarbonyl.
121. In embodiment 121, the compounds of embodiment 120, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
122. In embodiment 122, the compounds of embodiment 119, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be alkylcarbonyl substituted with hydroxy or benzyloxy.
123. In embodiment 123, the compounds of embodiment 122, or a pharmaceutically acceptable sait
124. In embodiment 124, the compounds of embodiment 108, or a pharmaceutically acceptable sait 15 thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be heteroaryl (optionally substituted with one or more Rf independently selected from halogen, cyano and alkyl).
125. In embodiment 125, the compounds of embodiment 124, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, 20 which can be an unsubstituted heteroaryl.
126. In embodiment 126, the compounds of embodiment 125, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be an unsubstituted heteroaryl. In some aspects of embodiment 126, the heteroaryl group can be a 5membered heteroaryl group, a 6-membered heteroaryl group or a 10-membered heteroaryl group. In 25 some aspects of embodiment 126, the heteroaryl group can be a monocyclic 5- or 6-membered heteroaryl. In some aspects of embodiment 126, the heteroaryl group can be a nitrogen-containing 5
-39or 6-membered monocyclic heteroaryl group. In some aspects ofembodiment 126, the heteroaryl group can be a 5- or 6-membered heteroaryl group containing nitrogen and oxygen. In some aspects of embodiment 126, the heteroaryl group can be, for example, pyrrole, pyrazole, imidazole, 1,2,4-triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,3,4thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine or 1,3,5-triazine. In some aspects of embodiment 126, the heterocyclyl is a 5- to 8-membered nitrogen-containing heterocyclyL
127. In embodiment 127, the compounds of embodiments 125-126, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be azetidinyl, pyrrolidinyl, piperidinyl, 3azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, quinuclidinyl, azepanyl or 1,4-oxazepanyl, and Re can be pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl.
128. In embodiment 128, the compounds of embodiments 125-127, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
129. In embodiment 129, the compounds of embodiment 124, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be heteroaryl substituted with one or more Rf independently selected from halogen (such as fluoro or chloro), alkyl (for example, a Ci-C6 alkyl) and cyano. In some aspects of embodiment 132, the Ci-C6 alkyl of Rf can be methyl, ethyl, n-propyl or isopropyl.
130. In embodiment 130, the compounds of embodiment 124, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be heteroaryl substituted with one or two Rf independently selected from halogen and alkyl. In some aspects of embodiment 130, the heteroaryl group can be a 5-membered heteroaryl group, a 6-membered heteroaryl group or a 10-membered heteroaryl group. In some aspects of embodiment 130, the heteroaryl group can be a monocyclic 5- or 6-membered heteroaryl. In some aspects of embodiment 130, the heteroaryl group can be a nitrogen-containing 5- or 6-membered monocyclic heteroaryl group. In some aspects of embodiment 130, the heteroaryl group can be a 5- or 6-membered heteroaryl group containing
-40nitrogen and oxygen. In some aspects of embodiment 130, the heteroaryl group can be, for example, pyrrole, pyrazole, imidazole, 1,2,4-triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,3,4-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4triazine or 1,3,5-triazine. In some aspects of embodiment 130, the heteroaryl group can be substituted with one or two halogens, for example, fluoro or chloro. In some aspects of embodiment 130, the heteroaryl group can be substituted with one or two alkyl groups, for example, C1-C4 alkyl groups such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl and tert-butyl. In some aspects of embodiment 130, the heteroaryl group can be substituted with one halogen and one C1-C4 alkyl group, such as those described herein.
131. In embodiment 131, the compounds of embodiments 129-13 0, or a pharmaceutically acceptable
132. In embodiment 132, the compounds of embodiment 108, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl (optionally substituted with one or more Re, which can be heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy)).
133. In embodiment 133, the compounds of embodiment 132, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be an unsubstituted heteroaralkyl.
134. In embodiment 134, the compounds of embodiment 132, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be heteroaralkyl substituted with one or two Rg independently selected from halogen, alkyl, cyano and hydroxy. In some aspects of embodiment 134, the heteroaryl group in heteroaralkyl can be a 5-membered heteroaryl group, a 6-membered heteroaryl group or a 10-membered heteroaryl group. In some aspects of embodiment 134, the heteroaryl group in heteroaralkyl can be a monocyclic heteroaryl. In some aspects of embodiment 134, the heteroaryl group in heteroaryloxy can be a 5- or 6-membered heteroaryl group. In some aspects of embodiment 134, the heteroaryl group in heteroaralkyl can be a nitrogen-containing 5- or 6-membered heteroaryl group. In some aspects of embodiment 134, the heteroaryl group in
-41 heteroaralkyl can be a 5- or 6-membered heteroaryl group containing nitrogen and oxygen. In some aspects of embodiment 134, the heteroaryl group in heteroaralkyl can be, for example, pyrrole, pyrazole, imidazole, 1,2,4-triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,2,5oxadiazole, 1,2,3-oxadiazole, 1,3,4-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4triazine or 1,3,5-triazine. In some aspects of embodiment 137, the alkylene in heteroaralkyl can be a Ci-Cô alkylene. In some aspects of embodiment 134, the alkylene in heteroaralkyl can be a methylene (-CH2-).
135. In embodiment 135, the compounds of embodiment 108, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy). In some aspects of embodiment 135, Rsa and Re are each independently a 4- to 8-membered nitrogen-containing heterocyclyl.
136. In embodiment 136, the compounds of embodiment 135, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be an unsubstituted heterocyclyl. In some aspects of embodiment 136, the unsubstituted heterocyclyl can be a 5-membered heterocyclyl group, a 6-membered heterocyclyl group, a 7-membered heterocyclyl group or an 8-membered heterocyclyl group. In some aspects of embodiment 136, the heterocyclyl group can be a monocyclic heterocyclyl. In some aspects of embodiment 136, the heterocyclyl group can be a 5or 6-membered monocyclic heterocyclyl. In some aspects of embodiment 136, the heterocyclyl group can be a bicyclic heterocyclyl. In some aspects of embodiment 136, the heterocyclyl group can be a 7or 8-membered bicyclic heterocyclyl. In some aspects of embodiment 136, the heterocyclyl group can be a nitrogen-containing heterocyclyl. In some aspects of embodiment 136, the heterocyclyl group can be a nitrogen- and oxygen-containing heterocyclyl. In some aspects of embodiment 136, the heterocyclyl group can be, for example, pyrrolidino, piperidino, morpholino, piperazino, imidazolino, indoline, 7-azabicyclo[2.2.1]heptane, hexahydro-lH-pyrrolizine or 8-azabicyclo[3.2.1]octane. 1,3,5triazine.
137. In embodiment 137, the compounds of embodiment 136, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
NH
138. In embodiment 138, the compounds of embodiment 135, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be heterocyclyl substituted with one or more Rh independently selected from alkyl (for example, a Ci-Cô alkyl), cyano and hydroxy. In some aspects of embodiment 138, the Ci-Cô alkyl of Re can be methyl, ethyl, n-propyl or isopropyl.
139. In embodiment 139, the compounds of embodiment 108, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 139, the aryl group can be a Ce or a Cio aryl, such as phenyl or naphthyL
140. In embodiment 140, the compounds of embodiment 139, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl independently substituted with one or more Re, which can be an unsubstituted aryl. In some aspects of embodiment 140, Rsa can be heterocyclyl independently substituted with one or more Re, which can be an unsubstituted phenyl.
141. In embodiment 141, the compounds of embodiment 140, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
142. In embodiment 142, the compounds of embodiment 139, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be aryl substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy.
143. In embodiment 143, the compounds of embodiment 142, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclyl substituted with one Re, which can be aryl substituted with one or more Ri independently selected from halogen, alkyl, alkoxy and cyano.
144. In embodiment 144, the compounds of any one of embodiments 142-143, or a pharmaceutically
145. In embodiment 145, the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be heterocyclylalkyl optionally substituted with one or more Re, independently selected from hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl, alkylcarbonyl (optionally substituted 15 with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rp independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl
-44(optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 145, the heterocyclyl of the heterocyclylalkyl can be a 5- to 8-membered monocyclic heterocyclyl. In some aspects of embodiment 145, the heterocyclyl of the heterocyclylalkyl can be a 6- to 10-membered bicyclic heterocyclyl. In some aspects of embodiment 145, the heterocyclyl can contain 1, 2 or 3 heteroatoms, which can be oxygen, nitrogen or sulfur. In some aspects of embodiment 145, the heterocyclyl of the heterocyclylalkyl can be a nitrogencontaining heterocyclyl. In some aspects of embodiment 145, the heterocyclyl of the heterocyclylalkyl can be an oxygen-containing heterocyclyl. In some aspects of embodiment 145, the heterocyclyl group of the heterocyclylalkyl can contain oxygen and nitrogen. In some aspects of embodiment 145, the heterocyclyl group of the heterocyclylalkyl can be a 5- to 8-membered monocyclic heterocyclyl containing one nitrogen atom. In some aspects of embodiment 145, the alkylene of the heterocyclylalkyl can be a Ci-Cô alkylene, for example, -(CH2)i-6-. In some aspects of embodiment 145, the alkylene of the heterocyclylalkyl can be a methylene (-CH2-). In some aspects of embodiment 145, when the heterocyclylalkyl group contains one or more -NH- groups in the ring, one or more Re may be bonded to the nitrogen atom (replacing the hydrogen), or, the alkyl group of the heterocyclylalkyl may be bonded to the nitrogen atom of the heterocyclyl (replacing the hydrogen). In some aspects of embodiment 145, Rsa can be heterocyclylalkyl optionally substituted with one or more Re on one or more NH groups of the heterocyclylalkyl, wherein the one or more Re independently selected from hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In other aspects of embodiment 145, Rsa can be heterocyclyl optionally substituted with one or more Re on one or more carbons atoms of the heterocyclyl, wherein the one or more Re independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl,
- 45 cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy).
146. In embodiment 146, the compounds of embodiment 145, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be an unsubstituted heterocyclylalkyl. In some aspects of embodiment 146, the heterocyclyl of the heterocyclylalkyl can be a 5- to 8-membered monocyclic heterocyclyl containing one or two heteroatoms which can be nitrogen or oxygen. In some aspects of embodiment 146, the alkylene of the heterocyclylalkyl can be a methylene (-CH2-).
147. In embodiment 147, the compounds of embodiment 146, or a pharmaceutically acceptable sait
148. In embodiment 148, the compounds of any one of embodiments 145-147, or a pharmaceutically acceptable sait thereof, are those wherein R3a can be
In some aspects of embodiment 148, R3a can be
In other aspects of embodiment
148, R3a can be
In still other aspects of embodiment 148, Rsa can be
In still other aspects of embodiment 148, Rsa can be
149. In embodiment 149, the compounds of any one of embodiments 145-147, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl, azepanylmethyl or 1,4-oxazepanylmethyl.
150. In embodiment 150, the compounds of embodiment 145, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl independently substituted with one or more Re, independently selected from alkoxy (for example a Ci-Cô alkoxy), hydroxyalkyl (for example, hydroxymethyl, hydroxyethyl or hydroxypropyl), cyanoalkyl (for example, cyanomethyl, cyanoethyl or cyanopropyl), aralkyl (for example, benzyl), alkoxycarbonyl (for example, a Ci-Cô alkoxycarbonyl), aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy) or heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy). In some aspects of embodiment 150, the cycloalkyl groups can be monocyclic Cs-Cs cycloalkyls. In some aspects of embodiment 150, the cycloalkyl groups can be bicyclic Cô-Cio cycloalkyls.
151. In embodiment 151, the compounds of embodiment 150, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl substituted with one Re, which can be selected from hydroxyalkyl, alkoxy, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy) or heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy).
152. In embodiment 152, the compounds of embodiment 145, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl independently substituted with one or more Re, independently selected from halogen, hydroxy, alkoxy (for example a Ci-Cô alkoxy such as methoxy or ethoxy), alkyl (for example a Ci-Cô alkyl such as methyl, ethyl, n-propyl or isopropyl), cycloalkyl (for example a monocyclic Cs-Cs cycloalkyl), alkylsulfonyl, heteroaryl (for example, a monocyclic 5or 6-membered nitrogen-containing heteroaryl) (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy).
153. In embodiment 153, the compounds of any one of embodiments 145 or 152, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl independently substituted with one or two Re, independently selected from hydroxy, alkoxy, alkyl, cycloalkyl (for example a Cs-Cs cycloalkyl), heteroaryl (for example, a 5- or 6-membered nitrogen-containing heteroaryl) (optionally substituted with one or two Rf independently selected from halogen) and aryl (for example a Cô aryl) (optionally substituted with one or more Ri independently selected from halogen).
154. In embodiment 154 the compounds of any one of embodiments 145 or 152-153, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be selected from or OH
155. In embodiment 155, the compounds of any one of embodiments 145 or 152, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl independently substituted with one or two Re groups, which can independently be halogen (for example, fluoro or chloro) or alkylsulfonyL
156. In embodiment 156, the compounds of any one of embodiments 152 or 155, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl independently substituted with one or two Re groups, which can be independently halogen. In some aspects of embodiment 156, Rsa can be substituted with one Re. In other aspects of embodiment 156, Rsa can be substituted with two Re groups. In some aspects of embodiment 156, each Re can be fluoro. In some aspects of embodiment 156, each Re can be chloro.
157. In embodiment 157, the compounds of any one of embodiments 152 or 155, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be heterocyclylalkyl independently substituted with one or two Re, which can independently be alkylsulfonyl, for example, methylsulfonyl, ethylsulfonyl, or isopropylsulfonyL
158. In embodiment 158, the compounds of any one of embodiments 152 or 155, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be
159. In embodiment 159 the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be alkyl (optionally substituted with alkylamino), for example a Ci-Cs alkyl (optionally substituted with alkylamino). In some aspects of embodiment 159, the alkyl can be a Ci-Cs alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl (straight-chained or branched), hexyl (straight-chained or branched), heptyl (straight-chained or branched) or octyl (straight-chained or branched).
160. In embodiment 160, the compounds of embodiment 159, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be methyl or isopropyl.
161. In embodiment 161, the compounds of embodiment 159, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be ethyl, n-propyl, or n-butyl; each can be substituted with alkylamino.
162. In embodiment 162, the compounds of any one of embodiments 159 or 161, or a
163. In embodiment 163, the compounds of any one of embodiments 159-162, or a pharmaceutically acceptable sait thereof, are those wherein Rsb can be hydrogen. In some aspects of embodiment 163, Rsb can be hydrogen and Rsa is not hydrogen.
164. In embodiment 164 the compounds of any one of embodiments 1-84, or a pharmaceutically acceptable sait thereof, are those wherein Rsa can be hydrogen.
165. In embodiment 165, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (la), or a pharmaceutically acceptable sait thereof,
wherein: A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and Rei can be selected from hydrogen, hydroxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy), alkylsulfonyl and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 165, Rei can be hydrogen. In some aspects of embodiment 165, the aforementioned alkyl groups, including Rei, can be an unsubstituted Ci-Cô alkyl. In some aspects of embodiment 165, Rei can be a C1-C3 alkyl, such as methyl, ethyl, n-propyl and isopropyl. In some aspects of embodiment 165, Rei can be a CiCô alkyl substituted with a Ci-Cô alkoxy. In some aspects of embodiment 165, the aforementioned alkoxy groups can be Ci-Cô alkoxy groups such as those described herein and including methoxy or ethoxy. In some aspects of embodiment 165, Rei can be a C1-C3 alkyl substituted a C1-C3 alkoxy. In some aspects of embodiment 165, Rei can be Ci-Cô hydroxyalkyl groups such as those described herein and including hydroxymethyl, hydroxyethyl and 2-hydroxypropyL In some aspects of embodiment 165, Rei can be Ci-Cô cyanoalkyl groups such as those described herein and including cyanomethyl, cyanoethyl and 2-cyanopropyl. In some aspects of embodiment 165, the aforementioned halogens can be fluoro or chloro. In some aspects of embodiment 165, Rei can be C3-C8 monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some aspects of embodiment 165, Rei can be a C3-C6 monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some aspects of embodiment 165, the aforementioned alkylsulfonyl groups, including Rei, can be a (Ci-Cô alkyl)sulfonyl. Examples of (Ci-Cô alkyl)sulfonyls include, but are not limited to, methylsulfonyl, ethylsulfonyl and isopropylsulfonyl. In some aspects of embodiment 165, the aforementioned aryl groups, including Rei, can be a Cô aryl such as phenyl. In some aspects of embodiment 165, the aforementioned heteroaryl groups, including Rei, can be 5- or 619495
- 50membered heteroaryl groups containing one nitrogen atom, two mtrogen atoms, or one mtrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 165, the aforementioned heterocyclyl groups, including Rei, can be 5- to 8-membered monocyclic heterocyclyl groups containing one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 165, Rei can be 4- to 6-membered monocyclic heterocyclyl groups containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. In some aspects of embodiment 165, Rei can be a (Ci-Cô alkyl)carbonyl. In some aspects of embodiment 165, the structure of formula
embodiment 165, A can be CH. In other aspects of embodiment 165, A can be N.
166. In embodiment 166, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (Ib), or a pharmaceutically acceptable sait thereof,
wherein: A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and Rei can be selected from hydrogen, hydroxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy), alkylsulfonyl and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 166, Rei can be hydrogen. In some aspects of embodiment 166, the aforementioned alkyl groups, including Rei, can be an unsubstituted Ci-Cô alkyl. In some aspects of embodiment 166, Rei can be a C1-C3 alkyl, such as methyl, ethyl, n-propyl and isopropyl. In some
-51 aspects of embodiment 166, Rei can be a Ci-Cô alkyl substituted with a Ci-Cô alkoxy. In some aspects of embodiment 166, the aforementioned alkoxy groups can be Ci-Cô alkoxy groups such as those described herein and including methoxy and ethoxy. In some aspects of embodiment 166, Rei can be a C1-C3 alkyl substituted a C1-C3 alkoxy . In some aspects of embodiment 166, Rei can be Ci-Cô hydroxyalkyl groups such as those described herein and including hydroxymethyl, hydroxyethyl and 2-hydroxypropyL In some aspects of embodiment 166, Rei can be Ci-Cô cyanoalkyl groups such as those described herein and including cyanomethyl, cyanoethyl and 2-cyanopropyl. In some aspects of embodiment 166, the aforementioned halogens can be fluoro or chloro. In some aspects of embodiment 166, Rei can be C3-C8 monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some aspects of embodiment 166, Rei can be a C3-C6 monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some aspects of embodiment 166, the aforementioned alkylsulfonyl groups, including Rei, can be a (Ci-Cô alkyl)sulfonyl. Examples of (Ci-Cô alkyl)sulfonyls include, but are not limited to, methylsulfonyl, ethylsulfonyl and isopropylsulfonyL In some aspects of embodiment 166, the aforementioned aryl groups, including Rei, can be a Cô aryl such as phenyl. In some aspects of embodiment 166, the aforementioned heteroaryl groups, including Rei, can be 5- or 6-membered heteroaryl groups containing one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 166, the aforementioned heterocyclyl groups, including Rei, can be 5- to 8-membered monocyclic heterocyclyl groups containing one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 166, Rei can be 4- to 6-membered monocyclic heterocyclyl groups containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. In some aspects of embodiment 166, Rei can be a (Ci-Cô alkyl)carbonyl.
H3CO I I ('('A In some aspects of embodiment 166, the structure of formula (Ib) can be ^n'Re1
D3CO^ A
Χλ XJ or D3CO N In some aspects of embodiment 166, A can b of embodiment 166, A can be N.
HN'
CH. In other aspects
167. In embodiment 167, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (le), or a pharmaceutically acceptable sait thereof,
wherein: A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and Rei can be selected from hydroxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or-(C=O)N(Me)2), cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy), alkylsulfonyl and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 167, Rei can be hydrogen. In some aspects of embodiment 167, the aforementioned alkyl groups, including Rei, can be an unsubstituted CiCô alkyl. In some aspects of embodiment 167, Rei can be a C1-C3 alkyl, such as methyl, ethyl, n-propyl and isopropyl. In some aspects of embodiment 167, Rei can be a Ci-Cô alkyl substituted with a Ci-Cô alkoxy. In some aspects of embodiment 167, the aforementioned alkoxy groups can be Ci-Cô alkoxy groups such as those described herein and including methoxy and ethoxy. In some aspects of embodiment 167, Rei can be a C1-C3 alkyl substituted a C1-C3 alkoxy. In some aspects of embodiment 167, Rei can be Ci-Cô hydroxyalkyl groups such as those described herein and including hydroxymethyl, hydroxyethyl and 2hydroxypropyl. In some aspects of embodiment 167, Rei can be Ci-Cô cyanoalkyl groups such as those described herein and including cyanomethyl, cyanoethyl and 2-cyanopropyl. In some aspects of embodiment 167, the aforementioned halogens can be fluoro or chloro. In some aspects of embodiment 167, Rei can be C3-C8 monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some aspects
- 53 of embodiment 167, Rei can be a Cs-Cô monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyL In some aspects of embodiment 167, the aforementioned alkylsulfonyl groups, including Rei, can be a (Ci-Cô alkyl)sulfonyL Examples of (Ci-Cô alkyl)sulfonyls include, but are not limited to, methylsulfonyl, ethylsulfonyl and isopropylsulfonyl. In some aspects of embodiment 167, the aforementioned aryl groups, including Rei, can be a Ce aryl such as phenyl. In some aspects of embodiment 167, the aforementioned heteroaryl groups, including Rei, can be 5- or 6-membered heteroaryl groups containing one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 167, the aforementioned heterocyclyl groups, including Rei, can be 5- to 8-membered monocyclic heterocyclyl groups containing one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 167, Rei can be 4- to 6-membered monocyclic heterocyclyl groups containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. In some aspects of embodiment 167, Rei can be a (Ci-Cô alkyl)carbonyl. In some aspects of embodiment 167, A can be CH. In other aspects of embodiment 167, A can be N.
168. In embodiment 168, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (Id), or a pharmaceutically acceptable sait thereof,
REi N
wherein: A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and Rei can be selected from hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rp independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy), alkylsulfonyl and aryl (optionally substituted with one or more Ri independently
-54selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 168, Rei can be hydrogen. In some aspects of embodiment 168, the aforementioned alkyl groups, including Rei, can be an unsubstituted Ci-Cô alkyl. In some aspects of embodiment 168, Rei can be a C1-C3 alkyl, such as methyl, ethyl, n-propyl and isopropyl. In some aspects of embodiment 168, Rei can be a Ci5 Cô alkyl substituted with a Ci-Cô alkoxy. In some aspects of embodiment 168, the aforementioned alkoxy groups can be Ci-Cô alkoxy groups such as those described herein and including methoxy or ethoxy. In some aspects of embodiment 168, Rei can be a C1-C3 alkyl substituted a C1-C3 alkoxy. In some aspects of embodiment 168, Rei can be Ci-Cô hydroxyalkyl groups such as those described herein and including hydroxymethyl, hydroxyethyl and 2-hydroxypropyl. In some aspects of embodiment 10 168, Rei can be Ci-Cô cyanoalkyl groups such as those described herein and including cyanomethyl, cyanoethyl and 2-cyanopropyl. In some aspects of embodiment 168, the aforementioned halogens can be fluoro or chloro. In some aspects of embodiment 168, Rei can be C3-C8 monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some aspects of embodiment 168, Rei can be a C3-C6 monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, 15 cyclopentyl and cyclohexyl. In some aspects of embodiment 168, the aforementioned alkylsulfonyl groups, including Rei, can be a (Ci-Cô alkyl)sulfonyl. Examples of (Ci-Cô alkyl)sulfonyls include, but are not limited to, methylsulfonyl, ethylsulfonyl and isopropylsulfonyl. In some aspects of embodiment 168, the aforementioned aryl groups, including Rei, can be a Cô aryl such as phenyl. In some aspects of embodiment 168, the aforementioned heteroaryl groups, including Rei, can be 5- or 620 membered heteroaryl groups containing one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 168, the aforementioned heterocyclyl groups, including Rei, can be 5- to 8-membered monocyclic heterocyclyl groups containing one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 168, Rei can be 4- to 6-membered monocyclic heterocyclyl groups containing 25 one or more heteroatoms selected from nitrogen, oxygen and sulfur. In some aspects of embodiment
168, Rei can be a (Ci-Cô alkyl)carbonyL In some aspects of embodiment 168, A can be CH. In other aspects of embodiment 168, A can be N.
169. In embodiment 169, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (le), or a pharmaceutically acceptable sait thereof,
- 55 REi
wherein: A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and Rei can be selected from hydroxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkyl (optionally 5 substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and 10 hydroxy), alkylsulfonyl and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 169, Rei can be hydrogen. In some aspects of embodiment 169, the aforementioned alkyl groups, including Rei, can be an unsubstituted Ci-Cô alkyl. In some aspects of embodiment 169, Rei can be a C1-C3 alkyl, such as methyl, ethyl, n-propyl and isopropyl. In some aspects of embodiment 169, Rei can be a Ci-Cô alkyl 15 substituted with a Ci-Cô alkoxy. In some aspects of embodiment 169, the aforementioned alkoxy groups can be Ci-Cô alkoxy groups such as those described herein and including methoxy and ethoxy. In some aspects of embodiment 169, Rei can be a C1-C3 alkyl substituted a C1-C3 alkoxy. In some aspects of embodiment 169, Rei can be Ci-Cô hydroxyalkyl groups such as those described herein and including hydroxymethyl, hydroxyethyl and 2-hydroxypropyl. In some aspects of embodiment 169, 20 Rei can be Ci-Cô cyanoalkyl groups such as those described herein and including cyanomethyl, cyanoethyl and 2-cyanopropyl. In some aspects of embodiment 169, the aforementioned halogens can be fluoro or chloro. In some aspects of embodiment 169, Rei can be C3-C8 monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some aspects of embodiment 169, Rei can be aC3-Cô monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, 25 cyclopentyl and cyclohexyl. In some aspects of embodiment 169, the aforementioned alkylsulfonyl groups, including Rei, can be a (Ci-Cô alkyl)sulfonyl. Examples of (Ci-Cô alkyl)sulfonyls include, but are not limited to, methylsulfonyl, ethylsulfonyl and isopropylsulfonyl. In some aspects of embodiment
169, the aforementioned aryl groups, including Rei, can be a Ce aryl such as phenyL In some aspects of embodiment 169, the aforementioned heteroaryl groups, including Rei, can be 5- or 6-membered heteroaryl groups containing one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 169, the aforementioned heterocyclyl groups, including Rei, can be 5- to 8-membered monocyclic heterocyclyl groups containing one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 169, Rei can be 4- to 6-membered monocyclic heterocyclyl groups containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. In some aspects of embodiment 169, Rei can be a (Ci-Cô alkyl)carbonyl. In some aspects of embodiment 169, A can be CH. In other aspects of embodiment 169, A can beN.
170. In embodiment 170, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (If), or a pharmaceutically acceptable sait thereof,
wherein: A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and Rei can be selected from hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl (for example, -(C=O)NH2 or -(C=O)N(Me)2), cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy), alkylsulfonyl and aiyl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy). In some aspects of embodiment 170, Rei can be hydrogen. In some aspects of embodiment 170, the aforementioned alkyl groups, including Rei, can be an unsubstituted Ci-Cô alkyl. In some aspects of embodiment 170, Rei can be a C1-C3 alkyl, such as methyl, ethyl, n-propyl and isopropyl. In some aspects of embodiment 170, Rei can be a CiCô alkyl substituted with a Ci-Cô alkoxy. In some aspects of embodiment 170, the aforementioned alkoxy groups can be Ci-Cô alkoxy groups such as those described herein and including methoxy and ethoxy. In some aspects of embodiment 170, Rei can be a C1-C3 alkyl substituted a C1-C3 alkoxy. In
- 57 some aspects of embodiment 170, Rei can be Ci-Cô hydroxyalkyl groups such as those described herein and including hydroxymethyl, hydroxyethyl and 2-hydroxypropyl. In some aspects of embodiment 170, Rei can be Ci-Cô cyanoalkyl groups such as those described herein and including cyanomethyl, cyanoethyl or 2-cyanopropyL In some aspects of embodiment 170, the aforementioned halogens can be fluoro or chloro. In some aspects of embodiment 170, Rei can be C3-C8 monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some aspects of embodiment 170, Rei can be a C3-C6 monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some aspects of embodiment 170, the aforementioned alkylsulfonyl groups, including Rei, can be a (Ci-Cô alkyl)sulfonyl. Examples of (Ci-Cô alkyl)sulfonyls include, but are not limited to, methylsulfonyl, ethylsulfonyl and isopropylsulfonyL In some aspects of embodiment 170, the aforementioned aryl groups, including Rei, can be a Ce aryl such as phenyl. In some aspects of embodiment 170, the aforementioned heteroaryl groups, including Rei, can be 5- or 6membered heteroaryl groups containing one nitrogen atom, two nitrogen atoms, or one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 170, the aforementioned heterocyclyl groups, including Rei, can be 5- to 8-membered monocyclic heterocyclyl groups containing one nitrogen atom and one heteroatom selected from oxygen and sulfur. In some aspects of embodiment 170, Rei can be 4- to 6-membered monocyclic heterocyclyl groups containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. In some aspects of embodiment 170, Rei can be a (Ci-Cô alkyl)carbonyl. In some aspects of embodiment 170, the structure of formula
H3CO^A d3co^.a (If) can be Η3θθ or d3co
In some aspects of embodiment 170, A can be CH. In other aspects of embodiment 170, A can be N.
171. In embodiment 171 the compounds of any one of embodiments 165-170, or a pharmaceutically acceptable sait thereof, are those wherein Rei can be selected from an unsubstituted C1-C3 alkyl and a C1-C3 alkyl substituted with a C1-C3 alkoxy. In some aspects of embodiment 171, Rei can be methyl, ethyl or n-propyl. In other aspects of embodiment 171, Rei can be methyl, ethyl or n-propyl; each substituted with methoxy or ethoxy.
172. In embodiment 172 the compounds of any one of embodiments 165-170, or a pharmaceutically acceptable sait thereof, are those wherein Rei can be selected from an unsubstituted cyclopropyl, an
- 58 unsubstituted cyclobutyl, an unsubstituted cyclopentyl, an unsubstituted cyclohexyl and an unsubstituted phenyl.
173. In embodiment 173 the compounds of any one of embodiments 165-170, or a pharmaceutically acceptable sait thereof, are those wherein Rei can be selected from an unsubstituted 4-membered 5 heterocyclyl, an unsubstituted 5-membered heterocyclyl and an unsubstituted 6-membered heterocyclyl.
174. In embodiment 174 the compounds of any one of embodiments 165-170, or a pharmaceutically acceptable sait thereof, are those wherein Rei can be selected from an unsubstituted 5-membered heteroaryl and an unsubstituted 6-membered heteroaryl.
175. In embodiment 175 the compounds of any one of embodiments 165-170, or a pharmaceutically acceptable sait thereof, are those wherein Rei can be methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl or phenyl; each of which are unsubstituted.
176. In embodiment 176, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (Ig), or a pharmaceutically acceptable sait thereof, (Re) t
(Ig) wherein A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and each Re can be independently selected from halogen (such as fluoro or chloro), alkyl (including Ci-Cô alkyl) and alkoxy (including Ci-Cô alkoxy); and t can be 0, 1 or 2. In some aspects of embodiment 176, A can be CH. In other aspects of embodiment 176, A can be N. In some aspects of embodiment 176, 20 each Re can be a halogen. In some aspects of embodiment 176, each Re can be independently selected from fluoro, chloro, C1-C3 alkyl and C1-C3 alkoxy. In some aspects of embodiment 176, t can be 0. In other aspects of embodiment 176, t can be 1. In still other aspects of embodiment 176, t can be 2. In some aspects of embodiment 176, when t is 2, the Re groups can be the same. In other aspects of
-59embodiment 176, when t is 2, the Re groups can be the different. In some aspects of embodiment 176, (RE)t (Re)t
177. In embodiment 177, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (Ih), or a pharmaceutically acceptable sait thereof,
wherein A can be CH or N; Ri and R2 are independently selected from -OCH3 and -OCD3; and each Re can be independently selected from halogen (such as fluoro or chloro), alkyl (including Ci-Cô alkyl) and alkoxy (including Ci-Cô alkoxy); and t can be 0, 1 or 2. In some aspects of embodiment 177,
A can be CH. In some aspects of embodiment 177, A can be N. In some aspects of embodiment 177, 10 each Re can be a halogen. In some aspects of embodiment 177, each Re can be independently selected from fluoro, chloro, C1-C3 alkyl and C1-C3 alkoxy. In some aspects of embodiment 177, t can be 0. In other aspects of embodiment 177, t can be 1. In still other aspects of embodiment 177, t can be 2. In some aspects of embodiment 177, when t is 2, the Re groups can be the same. In other aspects of embodiment 177, when t is 2, the Re groups can be the different. In some aspects of embodiment 177,
178. In embodiment 178, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those having structural formula (Ij), or a pharmaceutically acceptable sait thereof,
wherein Ri can be alkoxy (optionally substituted with deuterium); R2 can be alkoxy (optionally substituted with deuterium); and R3A can be an optionally substituted heterocyclyl containing 1 or 2 nitrogens. In some aspects of embodiment 178, Ri can be an unsubstituted alkoxy. In some aspects of embodiment 178, Ri can be an unsubstituted Ci. C3 alkoxy. In some aspects of embodiment 178, Ri can be methoxy. In some aspects of embodiment 178, Ri can be a deuterated alkoxy. In some aspects of embodiment 178, Ri can be a deuterated Ci. C3 alkoxy. In some aspects of embodiment 178, Ri can be -OCD3. In some aspects of embodiment 178, R2 can be an unsubstituted alkoxy. In some aspects of embodiment 178, R2 can be an unsubstituted Ci- C3 alkoxy. In some aspects of embodiment 178, R2 can be methoxy. In some aspects of embodiment 178, R2 can be a deuterated alkoxy. In some aspects of embodiment 178, R2 can be a deuterated Ci- C3 alkoxy. In some aspects of embodiment 178, R2 can be -OCD3. In some aspects of embodiment 178, Rsa can be an optionally substituted monocyclic heterocyclyl containing 1 or 2 nitrogens. In some aspects of embodiment 178, Rsa can be an optionally substituted monocyclic 5- to 7-membered heterocyclyl containing 1 or 2 nitrogens. In some aspects of embodiment 178, R3A can be an optionally substituted monocyclic 5- to 7-membered heterocyclyl containing 1 nitrogen. In some aspects of embodiment 178, Rsa can be selected from an unsubstituted pyrrolidinyl, an unsubstituted piperidinyl and an unsubstituted azepanyl. In some aspects of embodiment 178, Rsa can be selected from a substituted pyrrolidinyl, a substituted piperidinyl and a substituted azepanyl. In some aspects of embodiment 178, Rsa can be substituted with one or more of the following groups independently selected from Ci- C3 alkyl (optionally substituted with Ci- C3 alkoxy), C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, phenyl, 5- to 6-membered heteroaryl, (Ci-ô alkyl)carbonyl and (Ci-Cô alkyl)sulfonyl.
179. In embodiment 179, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those compounds listed in Table 1.
180. In embodiment 180, the compounds of embodiment 1, or a pharmaceutically acceptable sait thereof, are those compounds listed in Table 2.
181. In embodiment 181, the compounds of embodiment 1, are those compounds selected from:
pharmaceutically acceptable sait of any of the foregoing.
182. Embodiment 182, provides a pharmaceutical composition comprising a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable excipient.
183. Embodiment 183, provides a method of inhibiting G9a, comprising contacting a cell that 10 contains G9a with a therapeutically effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, thereby inhibiting the activity of G9a.
184. In embodiment 184, the cell of embodiment 183 can be a cancer cell.
185. Embodiment 185, provides a method of ameliorating and/or treating a hemoglobinopathy, comprising administering a therapeutically effective amount of a compound of any one of embodiments
-621-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182 to a subject in need thereof.
186. In embodiment 186, the hemoglobinopathy of embodiment 185 can be sickle cell disease or beta-thalassemia.
187. Embodiment 187, provides a method of ameliorating and/or treating a cancer, comprising administering a therapeutically effective amount of a compound of any one of embodiments 1 -181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182 to a subject in need thereof.
J 88. In embodiment 188, the cancer of embodiment 187 can be selected from: a Colorectal Cancer;
a Osteosarcoma Cancer; an Acute Lymphoblastic Leukemia (ALL); an Acute Myeloid Leukemia (AML); an Adrenocortical Carcinoma; a Kaposi Sarcoma (Soft Tissue Sarcoma); an AIDS-Related Lymphoma (Lymphoma); a Primary CNS Lymphoma; an Anal Cancer; a Castro intestinal Carcinoid Tumor; an Astrocytoma; an Atypical Teratoid/Rhabdoid Tumor; a Basal Cell Carcinoma of the Skin; a Bile Duct Cancer; a Bladder Cancer; a Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and
Malignant Fibrous Histiocytoma); a Brain Tumor; a Breast Cancer; a Bronchial Tumor; a Burkitt Lymphoma; a Cardiac Tumor; an Embryonal Tumor (Brain Cancer); a Germ Cell Tumor (Brain Cancer); a Primary CNS Lymphoma; a Cervical Cancer; a Cholangiocarcinoma; a Chordoma; a Chronic Lymphocytic Leukemia (CLL); a Chronic Myelogenous Leukemia (CML); a Chronic Myeloproliferative Neoplasm; a Craniopharyngioma (Brain Cancer); a Cutaneous T-Cell Lymphoma;
a Ductal Carcinoma In Situ (DCIS); an Endométrial Cancer (Uterine Cancer); an Ependymoma (Brain Cancer); an Esophageal Cancer; an Esthesioneuroblastoma; an Ewing Sarcoma (Bone Cancer); Extracranial Germ Cell Tumor; Extragonadal Germ Cell Tumor; Eye Cancer; Intraocular Melanoma; a Retinoblastoma; a Fallopian Tube Cancer; a Fibrous Histiocytoma of Bone; a Gallbladder Cancer; a Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) (Soft Tissue Sarcoma); a CNS Germ Cell
Tumors (Brain Cancer); an Extracranial Germ Cell Tumor; an Extragonadal Germ Cell Tumor; an Ovarian Germ Cell Tumor; a Testicular Cancer; a Gestational Trophoblastic Disease; a Hairy Cell Leukemia; a Head and Neck Cancer; a Hepatocellular (Liver) Cancer; a Histiocytosis, a Langerhans Cell; Hodgkin Lymphoma; a Hypopharyngeal Cancer (Head and Neck Cancer); an Intraocular Melanoma; an Islet Cell Tumor; a Pancreatic Neuroendocrine Tumor; a Kidney (Rénal Cell) Cancer; a
Langerhans Cell Histiocytosis; a Laryngeal Cancer (Head and Neck Cancer); a Leukemia; a Lip and Oral Cavity Cancer (Head and Neck Cancer); a Lung Cancer (Non-Small Cell and Small Cell); a Lymphoma; a Male Breast Cancer; a Melanoma; a Merkel Cell Carcinoma (Skin Cancer); a Mesothelioma; a Malignant Mesothelioma; a Metastatic Squamous Neck Cancer with Occult Primary (Head and Neck Cancer); a Midline Tract Carcinoma involving NUT Gene; a Mouth Cancer (Head and Neck Cancer); Multiple Endocrine Neoplasia Syndromes; Multiple Myeloma/Plasma Cell Neoplasms; a Mycosis Fungoides (Lymphoma); a Myelodysplastic Syndrome, a Myelodysplastic/Myeloproliferative Neoplasm; a Nasal Cavity and Paranasal Sinus Cancer (Head and
Neck Cancer); a Nasopharyngeal Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer Neuroblastoma; a Non-Hodgkin Lymphoma; an Oral Cancer; Lip and Oral Cavity Cancer and Oropharyngeal Cancer (Head and Neck Cancer); an Ovarian Cancer; a Pancreatic Cancer, a Papillomatosis; a Paraganglioma; a Paranasal Sinus and Nasal Cavity Cancer (Head and Neck Cancer), a Parathyroid Cancer; a Penile Cancer; a Pharyngeal Cancer (Head and Neck Cancer); a
Pheochromocytoma; a Pituitary Tumor; a Pleuropulmonary Blastoma; a Primary CNS Lymphoma; a Primary Peritoneal Cancer; a Prostate Cancer; a Rectal Cancer; a Rhabdomyosarcoma (Soft Tissue Sarcoma); a Salivary Gland Cancer (Head and Neck Cancer); a Salivary Gland Tumor; a Vascular Tumor (Soft Tissue Sarcoma); an Uterine Sarcoma; a Sézary Syndrome (Lymphoma); a Small Intestine Cancer; a Squamous Cell Carcinoma; a Skin Cancer; a Squamous Neck Cancer with Occult Primary, 15 Metastatic (Head and Neck Cancer); a Cutaneous T-Cell Lymphoma; a Throat Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer; an Oropharyngeal Cancer; a Hypopharyngeal Cancer; a Thymoma and Thymie Carcinoma; a Thyroid Cancer; an Uréthral Cancer; a Vaginal Cancer; a Vascular Tumor (Soft Tissue Sarcoma); a Vulvar Cancer; a Myelodysplastic syndrome (MDS); and a Wilms Tumor.
189. In embodiment 189, the cancer of any one of embodiments 187-188 can be selected from: a
Myelodysplastic Syndrome (MDS); an Acute Myeloid Leukemia (AML); an Ovarian Cancer; a Colon Cancer; and a Non-Small Cell Lung Cancer (NSCLC).
190. Embodiment 190, provides a method of ameliorating and/or treating an autoimmune or inflammatory disease, comprising administering a therapeutically effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical 25 composition of embodiment 182 to a subject in need thereof.
191. In embodiment 191, the autoimmune or inflammatory disease of embodiment 190 can be selected from: arthritis, atherosclerosis, multiple sclerosis, myasthenia gravis, Crohn's disease, graftversus-host disease, psoriasis, granulomatous colitis, lymphocyte colitis, collagenous colitis, ulcerative colitis, Coeliac Disease, subepidermal blistering disorders, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, primary biliary cirrhosis, active chronic hepatitis, chronic fatigue syndrome and vasculitis.
192. In embodiment 192, the autoimmune or inflammatoiy disease of any one of embodiments 190191 can be selected from: Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary biliary cirrhosis and graft-versus-host disease.
193. Embodiment 193, provides for the use of an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for inhibiting the activity of G9a in a cell.
194. In embodiment 194, the cell of embodiment 193 can be a cancer cell.
195. Embodiment 195, provides an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, for inhibiting the activity of G9a in a cell.
196. In embodiment 196, the cell of embodiment 195 can be a cancer cell.
197. Embodiment 197, provides for the use of an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182, in the manufacture of a médicament for ameliorating and/or treating a hemoglobinopathy.
198. In embodiment 198, the hemoglobinopathy of embodiment 197 can be sickle cell disease or beta-thalassemia.
199. Embodiment 199, provides an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182, for ameliorating and/or treating a hemoglobinopathy.
200. In embodiment 200, the hemoglobinopathy of embodiment 199 can be sickle cell disease or beta-thalassemia.
201. Embodiment 201, provides for the use of an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182, in the manufacture of a médicament for ameliorating and/or treating a cancer.
202. In embodiment 202, the cancer of embodiment 201 can be selected from: a Colorectal Cancer; a Osteosarcoma Cancer; an Acute Lymphoblastic Leukemia (ALL); an Acute Myeloid Leukemia (AML); an Adrenocortical Carcinoma; a Kaposi Sarcoma (Soft Tissue Sarcoma); an AIDS-Related Lymphoma (Lymphoma); a Primary CNS Lymphoma; an Anal Cancer; a Gastrointestinal Carcinoid Tumor; an Astrocytoma; an Atypical Teratoid/Rhabdoid Tumor; a Basal Cell Carcinoma of the Skin; a Bile Duct Cancer; a Bladder Cancer; a Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma); a Brain Tumor; a Breast Cancer; a Bronchial Tumor; a Burkitt Lymphoma; a Cardiac Tumor; an Embryonal Tumor (Brain Cancer); a Germ Cell Tumor (Brain Cancer); a Primary CNS Lymphoma; a Cervical Cancer; a Cholangiocarcinoma; a Chordoma; a
- 65 Chronic Lymphocytic Leukemia (CLL); a Chronic Myelogenous Leukemia (CML); a Chronic Myeloproliferative Neoplasm; a Craniopharyngioma (Brain Cancer); a Cutaneous T-Cell Lymphoma; a Ductal Carcinoma In Situ (DCIS); an Endométrial Cancer (Uterine Cancer); an Ependymoma (Brain Cancer); an Esophageal Cancer; an Esthesioneuroblastoma; an Ewing Sarcoma (Bone Cancer); Extracranial Germ Cell Tumor; Extragonadal Germ Cell Tumor; Eye Cancer; Intraocular Melanoma; a Retinoblastoma; a Fallopian Tube Cancer; a Fibrous Histiocytoma of Bone; a Gallbladder Cancer; a Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) (Soft Tissue Sarcoma); a CNS Germ Cell Tumors (Brain Cancer); an Extracranial Germ Cell Tumor; an Extragonadal Germ Cell Tumor; an Ovarian Germ Cell Tumor; a Testicular Cancer; a Gestational Trophoblastic Disease; a Hairy Cell Leukemia; a Head and Neck Cancer; a Hepatocellular (Liver) Cancer; a Histiocytosis, a Langerhans Cell; Hodgkin Lymphoma; a Hypopharyngeal Cancer (Head and Neck Cancer); an Intraocular Melanoma; an Islet Cell Tumor; a Pancreatic Neuroendocrine Tumor; a Kidney (Rénal Cell) Cancer; a Langerhans Cell Histiocytosis; a Laryngeal Cancer (Head and Neck Cancer); a Leukemia; a Lip and Oral Cavity Cancer (Head and Neck Cancer); a Lung Cancer (Non-Small Cell and Small Cell); a Lymphoma; a Male Breast Cancer; a Melanoma; a Merkel Cell Carcinoma (Skin Cancer); a Mesothelioma; a Malignant Mesothelioma; a Metastatic Squamous Neck Cancer with Occult Primary (Head and Neck Cancer); a Midline Tract Carcinoma involving NUT Gene; a Mouth Cancer (Head and Neck Cancer); Multiple Endocrine Neoplasia Syndromes; Multiple Myeloma/Plasma Cell Neoplasms; a Mycosis Fungoides (Lymphoma); a Myelodysplastic Syndrome, a Myelodysplastic/Myeloproliferative Neoplasm; a Nasal Cavity and Paranasal Sinus Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer Neuroblastoma; a Non-Hodgkin Lymphoma; an Oral Cancer; Lip and Oral Cavity Cancer and Oropharyngeal Cancer (Head and Neck Cancer); an Ovarian Cancer; a Pancreatic Cancer; a Papillomatosis; a Paraganglioma; a Paranasal Sinus and Nasal Cavity Cancer (Head and Neck Cancer); a Parathyroid Cancer; a Penile Cancer; a Pharyngeal Cancer (Head and Neck Cancer); a Pheochromocytoma; a Pituitary Tumor; a Pleuropulmonary Blastoma; a Primary CNS Lymphoma; a Primary Peritoneal Cancer; a Prostate Cancer; a Rectal Cancer; a Rhabdomyosarcoma (Soft Tissue Sarcoma); a Salivary Gland Cancer (Head and Neck Cancer); a Salivary Gland Tumor; a Vascular Tumor (Soft Tissue Sarcoma); an Uterine Sarcoma; a Sézary Syndrome (Lymphoma); a Small Intestine Cancer; a Squamous Cell Carcinoma; a Skin Cancer; a Squamous Neck Cancer with Occult Primary, Metastatic (Head and Neck Cancer); a Cutaneous T-Cell Lymphoma; a Throat Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer; an Oropharyngeal Cancer; a Hypopharyngeal Cancer; a Thymoma
- 66and Thymie Carcinoma; a Thyroid Cancer; an Uréthral Cancer; a Vaginal Cancer; a Vascular Tumor (Soft Tissue Sarcoma); a Vulvar Cancer; a Myelodysplastic syndrome (MDS); and a Wilms Tumor.
203. In embodiment 203, the cancer of any one of embodiments 201-202 can be selected from: a Myelodysplastic Syndrome (MDS); an Acute Myeloid Leukemia (AML); an Ovarian Cancer; a Colon Cancer; and a Non-Small Cell Lung Cancer (NSCLC).
204. Embodiment 204, provides an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182, for ameliorating and/or treating a cancer.
205. In embodiment 205, the cancer of embodiment 204 can be selected from: a Colorectal Cancer; a Osteosarcoma Cancer; an Acute Lymphoblastic Leukemia (ALL); an Acute Myeloid Leukemia (AML); an Adrenocortical Carcinoma; a Kaposi Sarcoma (Soft Tissue Sarcoma); an AIDS-Related Lymphoma (Lymphoma); a Primary CNS Lymphoma; an Anal Cancer; a Gastrointestinal Carcinoid Tumor; an Astrocytoma; an Atypical Teratoid/Rhabdoid Tumor; a Basal Cell Carcinoma of the Skin; a Bile Duct Cancer; a Bladder Cancer; a Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma); a Brain Tumor; a Breast Cancer; a Bronchial Tumor; a Burkitt Lymphoma; a Cardiac Tumor; an Embryonal Tumor (Brain Cancer); a Germ Cell Tumor (Brain Cancer); a Primary CNS Lymphoma; a Cervical Cancer; a Cholangiocarcinoma; a Chordoma; a Chronic Lymphocytic Leukemia (CLL); a Chronic Myelogenous Leukemia (CML); a Chronic Myeloproliferative Neoplasm; a Craniopharyngioma (Brain Cancer); a Cutaneous T-Cell Lymphoma; a Ductal Carcinoma In Situ (DCIS); an Endométrial Cancer (Uterine Cancer); an Ependymoma (Brain Cancer); an Esophageal Cancer; an Esthesioneuroblastoma; an Ewing Sarcoma (Bone Cancer); Extracranial Germ Cell Tumor; Extragonadal Germ Cell Tumor; Eye Cancer; Intraocular Melanoma; a Retinoblastoma; a Fallopian Tube Cancer; a Fibrous Histiocytoma of Bone; a Gallbladder Cancer; a Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) (Soft Tissue Sarcoma); a CNS Germ Cell Tumors (Brain Cancer); an Extracranial Germ Cell Tumor; an Extragonadal Germ Cell Tumor; an Ovarian Germ Cell Tumor; a Testicular Cancer; a Gestational Trophoblastic Disease; a Hairy Cell Leukemia; a Head and Neck Cancer; a Hepatocellular (Liver) Cancer; a Histiocytosis, a Langerhans Cell; Hodgkin Lymphoma; a Hypopharyngeal Cancer (Head and Neck Cancer); an Intraocular Melanoma; an Islet Cell Tumor; a Pancreatic Neuroendocrine Tumor; a Kidney (Rénal Cell) Cancer; a Langerhans Cell Histiocytosis; a Laryngeal Cancer (Head and Neck Cancer); a Leukemia; a Lip and Oral Cavity Cancer (Head and Neck Cancer); a Lung Cancer (Non-Small Cell and Small Cell); a Lymphoma; a Male Breast Cancer; a Melanoma; a Merkel Cell Carcinoma (Skin Cancer); a Mesothelioma; a Malignant Mesothelioma; a Metastatic Squamous Neck Cancer with Occult Primary
-67 (Head and Neck Cancer); a Midline Tract Carcinoma involving NUT Gene; a Mouth Cancer (Head and Neck Cancer); Multiple Endocrine Neoplasia Syndromes; Multiple Myeloma/Plasma Cell Neoplasms; a Mycosis Fungoides (Lymphoma); a Myelodysplastic Syndrome, a Myelodysplastic/Myeloproliferative Neoplasm; a Nasal Cavity and Paranasal Sinus Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer Neuroblastoma; a Non-Hodgkin Lymphoma; an Oral Cancer; Lip and Oral Cavity Cancer and Oropharyngeal Cancer (Head and Neck Cancer); an Ovarian Cancer, a Pancreatic Cancer, a Papillomatosis; a Paraganglioma; a Paranasal Sinus and Nasal Cavity Cancer (Head and Neck Cancer), a Parathyroid Cancer; a Penile Cancer; a Pharyngeal Cancer (Head and Neck Cancer); a Pheochromocytoma; a Pituitary Tumor; a Pleuropulmonary Blastoma; a Primary CNS Lymphoma; a Primary Peritoneal Cancer; a Prostate Cancer; a Rectal Cancer; a Rhabdomyosarcoma (Soft Tissue Sarcoma); a Salivary Gland Cancer (Head and Neck Cancer); a Salivary Gland Tumor; a Vascular Tumor (Soft Tissue Sarcoma); an Uterine Sarcoma; a Sézary Syndrome (Lymphoma); a Small Intestine Cancer; a Squamous Cell Carcinoma; a Skin Cancer; a Squamous Neck Cancer with Occult Primary, Metastatic (Head and Neck Cancer); a Cutaneous T-Cell Lymphoma; a Throat Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer; an Oropharyngeal Cancer; a Hypopharyngeal Cancer; a Thymoma and Thymie Carcinoma; a Thyroid Cancer; an Uréthral Cancer; a Vaginal Cancer, a Vascular Tumor (Soft Tissue Sarcoma); a Vulvar Cancer; a Myelodysplastic syndrome (MDS); and a Wilms Tumor.
206. In embodiment 206, the cancer of any one of embodiments 204-205 can be selected from: a Myelodysplastic Syndrome (MDS); an Acute Myeloid Leukemia (AML); an Ovarian Cancer; a Colon Cancer; and aNon-Small Cell Lung Cancer (NSCLC).
207. Embodiment 207, provides for the use of an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182, in the manufacture of a médicament for ameliorating and/or treating an autoimmune or inflammatory disease.
208. In embodiment 208, the an autoimmune or inflammatory disease of embodiment 207 can be selected from: arthritis, atherosclerosis, multiple sclerosis, myasthenia gravis, Crohns disease, graftversus-host disease, psoriasis, granulomatous colitis, lymphocyte colitis, collagenous colitis, ulcerative colitis, Coeliac Disease, subepidermal blistering disorders, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, primary biliary cirrhosis, active chronic hepatitis, chronic fatigue syndrome and vasculitis.
209. In embodiment 209, the an autoimmune or inflammatory disease of any one of embodiments 207-208 can be selected from: Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary biliary cirrhosis and graft-versus-host disease.
210. Embodiment 210, provides an effective amount of a compound of any one embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182, for ameliorating and/or treating an autoimmune or inflammatory disease.
211. In embodiment 211, the an autoimmune or inflammatory disease of embodiment 210 can be selected from: arthritis, atherosclerosis, multiple sclerosis, myasthenia gravis, Crohn's disease, graftversus-host disease, psoriasis, granulomatous colitis, lymphocyte colitis, collagenous colitis, ulcerative colitis, Coeliac Disease, subepidermal blistering disorders, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, primary biliary cirrhosis, active chronic hepatitis, chronic fatigue syndrome and vasculitis.
212. In embodiment 212, the an autoimmune or inflammatory disease of any one of embodiments 210-211 can be selected from: Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary biliary cirrhosis and graft-versus-host disease.
213. Embodiment 213 provides a method of inhibiting the activity of GLP comprising contacting a cell that contains GLP with an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, and thereby inhibiting the activity of GLP.
214. Embodiment 214 provides a method of increasing fêtai hemoglobin (HbF) protein levels comprising contacting a cell characterized as having impaired production of β-globin with an effective amount of a compound of any one of embodiments 1 -181, or a pharmaceutically acceptable sait thereof, and thereby increasing fêtai hemoglobin (HbF) protein levels.
215. Embodiment 215 provides a method of inhibiting the polymerization of hemoglobin S molécules comprising contacting a cell characterized as having a hemoglobin S mutation with an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, and thereby inhibiting the polymerization of hemoglobin S molécules.
216. Embodiment 216 provides a method of inhibiting G9a activity in a subject comprising administering to the subject suffering from a disease that is treatable by fêtai hemoglobin an effective amount of a compound of any one of embodiments 1 -181, or a pharmaceutically acceptable sait thereof. 217. Embodiment 217 provides a method of inhibiting GLP activity in a subject comprising administering to the subject suffering from a disease that is treatable by fêtai hemoglobin an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof.
218. Embodiment 218 provides a method for treating a disease comprising administrating to a subject suffering from a disease treatable by fêtai hemoglobin an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182.
219. Embodiment 219 provides a method for treating a disease characterized by impaired production of β-globin comprising administrating to a subject suffering from the disease characterized by impaired production of β-globin an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 182.
220. In embodiment 220, the disease of embodiment 219 can be beta-thalassemia.
221. Embodiment 221 provides a method for treating a disease characterized by increased concentration of polymerized hemoglobin S molécules comprising administrating to a subject suffering from the disease characterized by increased concentration of polymerized hemoglobin S molécules an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof.
222. In embodiment 222, the disease of embodiment 221 can be sickle cell disease.
223. Embodiment 223 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for inhibiting the activity of G9a in a cell that contains G9a.
224. Embodiment 224 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for inhibiting the activity of GLP in a cell that contains GLP.
225. Embodiment 225 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for increasing fêtai hemoglobin (HbF) protein levels in a cell characterized as having impaired production of β-globin.
226. Embodiment 226 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for inhibiting the polymerization of hemoglobin S molécules in a cell characterized as having a hemoglobin S mutation.
227. Embodiment 227 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for treating a disease treatable by fêtai hemoglobin.
228. Embodiment 228 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for treating a disease treatable by fêtai hemoglobin.
229. Embodiment 229 provides for the use of an effective amount of a compound of any one of 5 embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for treating a disease characterized by impaired production of β-globin.
230. In embodiment 230, the disease of embodiment 229 can be beta-thalassemia.
231. Embodiment 231 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament 10 for treating a disease characterized by increased concentration of polymerized hemoglobin S molécules.
232. In embodiment 232, the disease of embodiment 231 can be sickle cell disease.
233. Embodiment 233 provides for the use of an effective amount of a compound of any one of embodiments 1-181, or a pharmaceutically acceptable sait thereof, in the préparation of a médicament for ameliorating or treating a hemoglobinopathy.
234. In embodiment 234, the hemoglobinopathy of embodiment 233 can be sickle cell disease.
235. In embodiment 235, the hemoglobinopathy of embodiment 233 can be beta-thalassemia.
Représentative compounds of Formula (I), or pharmaceutically acceptable salts thereof, are disclosed in Tables 1 and 2 below. Compounds in Table 1 were prepared either as a free base, or in sait form, for 20 example, with formic acid, HCl or trifluoroacetic acid.
Table 1
No | Structure | IUP AC Name | MS found |
1 | A H Z ~V Z t \ Γ °\ °_ | 6,7-dimethoxy-N-(propan-2-yl)lH,2H,3H-cyclopenta[b]quinolin-9amine | 287 |
2 | O — / \ ΣΕ Z λ— Z \\ \ | 7-methoxy-N-methyl-6-propoxylH,2H,3H-cyclopenta[b]quinoIin-9amine | 287.2 |
No | Structure | IUPAC Name | MS found |
3 | I HNX | 7-methoxy-6-(3-methoxypropoxy)-Nmethyl-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 317.3 |
4 | 1 HNX | 6-(2-ethoxyethoxy)-7-methoxy-Nmethyl-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 317.2 |
5 | HN O 1 | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 (propan-2-yl)piperidin-4-amine | 370.4 |
6 | HN^\ | 2- [2-( {7-methoxy-9- [(propan-2yl)amino]-1 H,2H,3Hcyclopenta[b]quinolin-6yl}oxy)ethoxy]ethan-1 -ol | 361.2 |
7 | — O ^o / \ z z λ— z /Ç z | N-[(azetidin-3-yl)methyl]-6,7dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 314.2 |
8 | H ___ N HN s 1 | N- [(azetidin-2-yl)methyl] -6,7dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-amine | 314.2 |
No | Structure | IUPAC Name | MS found |
9 | _o Y - >-\ | N- { 6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}-lmethylpiperidin-4-amine | 342.3 |
10 | — O \> / \ X Z λ— Z o b | N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yI}piperidin3-amine | 328.3 |
11 | / ! z ~x Z X \__Æ °\ °“ | 6,7-dimethoxy-N- [( 1 -methy lazetidin3-yl)methyl]-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 328.3 |
12 | O | HN ΤΎΥ) 1 | tert-butyl 3-({6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl} amino)azetidine-1 -carboxylate | 400.5 |
13 | [—NH HN 1 | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} azetidin3-amine | 300.2 |
No | Structure | IUPAC Name | MS found |
14 | HN 1 | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-y 1} -1 phenylpiperidin-4-amine | 404.4 |
15 | bp z —V z τ \ A °\ °“ | N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-lethylpiperidin-4-amine | 356.4 |
16 | HN^X 0 1XX> 1 | N- {6,7-dimethoxy-1 H, 2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(oxan4-yl)piperidin-4-amine | 412.5 |
17 | O 1 HN Xv/x/k^x xx?o □ ''xZ^X ' 1 | tert-butyl 6-({6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl}amino)-2-azaspiro[3.3]heptane-2carboxylate | 440.2 |
No | Structure | IUPAC Name | MS found |
18 | _o 'o 8- V o ô h 'o | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 (oxolan-3-yl)piperidin-4-amine | 398.4 |
19 | /•N H Z /J hn'a'-/ 1 | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-2azaspiro [3.3 ]heptan-6-amine | 340.2 |
20 | HN < J JL X> O-'^XÎzZ^X^/ | N- [ 1 -(propan-2-yl)piperidin-4-yl]12,14-dioxa-2azatetracyclo[7.7.0.03,7.011,15]hexade ca-1 (9),2,7,10,15-pentaen-8-amine | 354.3 |
21 | o j Xo / \ X Z λ— Z )— | 5-({7-methoxy-9-[(propan-2yl)amino]-lH,2H,3Hcyclopenta[b]quinolin-6yl} oxy)pentan-1 -ol | 359.2 |
22 | 1 | N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl} -1 (pyridin-4-yl)piperidin-4-amine | 405.3 |
No | Structure | IUP AC Name | MS found |
23 | p-'W HN I | N- { 6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-y 1} -1 (pyridin-3 -y l)piperidin-4-am ine | 405.3 |
24 | o I | N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-y 1} -1 (pyridin-2-yl)piperidin-4-amine | 405.2 |
25 | F O I | N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-l-(3fluorophenyl)piperidin-4-amine | 422.2 |
26 | JL J F G ,-^-L^ τχχ> I | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(2fluoropheny l)piperidin-4-am ine | 422.4 |
No | Structure | IUPAC Name | MS found |
27 | -O Xo / \ z λ— z o T / | N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinol in-9-y 1} -1 ethylazetidin-3-amine | 328.4 |
28 | — O V Z />— Z o b -L | (3 S)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}piperidin3-amine | 328.3 |
29 | T z X x \ A °\ °“ | (3 R)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}piperidin3-amine | 328.3 |
30 | HN \ 1 | (3 S)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} -1 methylpiperidin-3 -amine | 342.4 |
31 | HN OH | 5-({7-methoxy-9-[(propan-2yl)amino]-lH,2H,3Hcyclopenta[b]quinolin-6yl} oxy)pentan-2-ol | 359.2 |
No | Structure | IUPAC Name | MS found |
32 | HN I | 6,7-dimethoxy-N-[l-(propan-2yl)piperidin-4-y I]-1,2,3,4tetrahydroacridin-9-amine | 384.3 |
33 | i J HN7^/ O YXY > N''\--' I | N-{2,3-dimethoxy- 6H,7H,8H,9H,10Hcyclohepta[b]quinolin-l 1 -yl} -1(propan-2-yl)piperidin-4-amine | 398.2 |
34 | — O \> /”\ T Z Λ— Z o b _1_ | N- { 6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}piperidin4-amine | 328.2 |
35 | À J HN ^°xxbo | 7-methoxy-9- {[ 1 -(propan-2yl)piperidin-4-yl]amino} - 1H,2H,3Hcyclopenta[b]quinolin-6-ol | 356.4 |
36 | C Ή X J HN O F | N-[6-(difluoromethoxy)-7-methoxylH,2H,3H-cyclopenta[b]quinolin-9y I] -1 -(propan-2-yl)piperidin-4-amine | 406.3 |
No | Structure | IUP AC Name | MS found |
37 | H T \_Ç °\ °~ | N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(4fluorophenyl)piperidin-4-amine | 422.4 |
38 | o ^>3^ xÏXx> 1 1 | N-{[3(dimethylamino)cyclobutyl]methyl}6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-amine | 356.2 |
39 | H HN ^°xxbo 1 | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-2,2,6,6tetramethylpiperidin-4-amine | 384.1 |
40 | % N °XXbo 1 | N- {[ 1 -(2-fluorophenyl)azetidin-3yl]methyl}-6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9amine | 408.2 |
No | Structure | IUPAC Name | MS found |
41 | / HN T XX/ 1 | N- {[ 1 -(2-fluorophenyl)azetidin-3 yl]methyl}-6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9amine | 339.1 |
42 | H N ^xxbo 1 | (3 R)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} -1 methylpiperidin-3-amine | 342.2 |
43 | — O V &b -(-0 | l-(2-chlorophenyl)-N-{6,7dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin4-amine | 438.2 |
44 | /0H ox'Jx<i;:>ro ' 1 | 3-chioro-2- [4-( {6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9y 1} amino)piperidin-1 -yl]propan-1 -ol | 420.3 |
No | Structure | IUPAC Name | MS found |
45 | H N I | 1 -benzyl-N- {6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl}piperidin-4-amine | 418.4 |
46 | HN ΎΎ1O I | 2,3 -dimethoxy-N- [ 1 -(propan-2yl)piperidin-4-yl]acridin-9-amine | 380.2 |
47 | 1 J HN ' 1 | 2,3-dimethoxy-N- [l-(propan-2yl)piperidin-4-yl]acridin-9-amine | 380.2 |
48 | c HN> >--N 1 | (3R)-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-y 1} azepan-3 amine | 342.3 |
No | Structure | IUP AC Name | MS found |
49 | _ jO JL J O. TXX) 1 | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(2methoxyphenyl)piperidin-4-amine | 434.3 |
50 | jQl XO 1 | l-(3-chlorophenyl)-N-{6,7dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}piperidin4-amine | 438.2, 440.3 |
51 | A /θ^^ΖΪ^Α^Λ HO^— | 3- [(7-methoxy-9- {[ 1 -(propan-2y l)piperidin-4-yl]amino} -1 H,2H,3 Hcyclopenta[b]quinolin-6yl)oxy]propan-1 -ol | 414.2 |
52 | 0 X° 1 | 2-(benzyloxy)-l-[4-({6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl} amino)piperidin-1 -yl] ethan-1 -one | 476.9 |
No | Structure | IUP AC Name | MS found |
53 | ^,0 HO —/ | 2-[(7-methoxy-9- {[ 1 -(propan-2yl)piperidin-4-yl]amino} -1 H,2H,3Hcyclopenta[b]quinolin-6yl)oxy]ethan-l-ol | 400.2 |
54 | R -^\χΟΗ I | 1 - [4-( { 6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9yl} amino)piperidin-1 -y l]-2hydroxyethan-1 -one | 386.1 |
55 | J^jj A U F HN ^0 O I | N-{6,7-dimethoxy-lH,2H,3Hcyc lopenta[b]quinolin-9-y 1} -1 -(3fluoropyridin-4-yl)piperidin-4-amine | 423.2 |
56 | T Qn cm Z “\ z X / \ / z A ° \ / O O — | 1 - {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-y 1} -1 (piperidin-4-yl)urea | 370.8 |
No | Structure | IUP AC Name | MS found |
57 | HN | N-{6-cyclopropyl-7-methoxylH,2H,3H-cyclopenta[b]quinolin-9y 1} -1 -(propan-2-y l)piperidin-4-amine | 380.2 |
58 | — O V / \ x Z Λ— Z Ub I to | 4-( {6,7-dimethoxy-1 H, 2H,3Hcyclopenta[b]quinolin-9yl}amino)piperidine-l-carboxamide | 370.9 |
59 | / \ O O tb | l-(2,3-difluorophenyl)-N-{6,7dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin4-amine | 440.3 |
60 | Z λ—Z bo b | 1 -cyclopentyl-N - { 6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl}piperidin-4-amine | 396.2 |
61 | / O ris \7 O O \ / | N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(2methoxyethyl)piperidin-4-amine | 386.1 |
No | Structure | IUPAC Name | MS found |
62 | f NH HN'' /O^Z^z^z^ JT X) | (4R)-N- {6,7-dimethoxy- 1H,2H, 3Hcyclopenta[b]quinolin-9-yl}azepan-4amine | 342.2 |
63 | Γ N— HN''' | (4R)-N-{6,7-ditnethoxy-lH,2H,3Hcyclopenta[b] quinolin-9-y l} -1 methylazepan-4-amine | 356.1 |
64 | l n-n, I H N >' Οχ/^^ζχ 0>kXÎi^';y^/ I | (4R)-N- { 6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}-lethylazepan-4-amine | 370.3 |
65 | HN^\ / MeO^zTJ, NH TJ T) MeCT^^ | 6,7-dimethoxy-N-[(pyrrolidin-3yl)methyl]-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 328.1 |
66 | HN^\ / ΜθΟ'^^ΤΤΧχ* XJ X/ MeO^^^N | 6,7-dimethoxy-N - [(pyrrolidin-2yl)methyl]-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 328.1 |
No | Structure | IUP AC Naine | MS found |
67 | Htf Τ'ΊΗ MeCT^^N^ | 6,7-dimethoxy-N-[(piperidin-4yl)methyl]-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 342.1 |
68 | 2 2 ro œ O O mA X Z /)— Z - xzjj | 6,7-dimethoxy-N-{[(3R)-piperidin-3yl]methyl}-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 342.0 |
69 | g g Φ <0 O O /=% I z />—z T | 6,7-dimethoxy-N- {[(3 S)-piperidin-3yl]methyl}-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 342.0 |
134 | 1 X QV Z—<z Z X \__/ z p O /° | N-[2,3-dimethoxy-6H,7H,8Hcyclopenta[b] 1,5-naphthyridin-9-yI]l-(propan-2-yl)piperidin-4-amine | 371.2 |
149 | %H HN' ï T T) ^Cr^^N^7 | (3R)-N-[2, 3-dimethoxy-6H, 7H, 8Hcyclopenta [b] 1,5 naphthyridin9-yl] piperidin-3-amine | 329.2 |
No | Structure | IUP AC Name | MS found |
163 | Γ N— H N'' ^0^,0- | (4R)-N-[2, 3-dimethoxy-6H, 7H, 8Hcyclopenta[b] 1, 5-naphthyridin-9-yl] azepan-4-amine | 343.2 |
164 | O \) O / \ 1 z /)—z \\ // G ο O / | (3R)-N-[2, 3-dimethoxy-6H, 7H, 8Hcyclopenta[b] 1, 5-naphthyridin-9yl]-l-methylpiperidin-3-amine | 343.2 |
165 | / \ O O O T\ | (4R)-N-{2,3-dimethoxy-6H,7H,8Hcyclopenta[b] 1,5-naphthyridin-9-yl}l-methylazepan-4-amine | 357.2 |
286 | O 'o z0- 5 o O..... T | (3R,5S)-N-{6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl}-5-methyIpiperidin-3-amine | 342.2 |
402 | (3R)-N-[2, 3-dimethoxy-6H, 7H, 8Hcyclopentafb] 1, 5-naphthyridin-9-yl] azepan-3-amine | 343.2 |
No | Structure | IUPAC Name | MS found |
403 | O \ / \ 1 Z Λ—z ZI | 6,7-dimethoxy-N-{2-[(propan-2yl)amino]ethyl}-lH,2H,3Hcyclopenta[b]quinolin-9-amine | 330.1 |
404 | 0% T \__/ zQ O O \ / | (3R)-N-[2, 3-dimethoxy-6H, 7H, 8Hcyclopenta[b] 1, 5-naphthyridin-9-yl]l-methyIazepan-3-amine | 357.5 |
405 | c σ σ0- ο ο—(-ο σ \=0 σ 4/ / \ ζ ζ /)—ζ y ο 0 | (3 R)-N-[6,7-di(2H3 )methoxylH,2H,3H-cyclopenta[b]quinolin9-yl]piperidin-3-amine | 334 |
406 | τ ο η 3 Z/V Z—C Ζ τ \__/ 0° χ°0 | (3R)-N-[6,7-di(2H3)ethoxy- 1 H,2 H,3 H-cyclopenta[b]quinolin-9yl]piperidin-3-amine | 356.1 |
407 | ) X ο ο Υ0 ο 0 Ζ | (3 R)-N-{6-ethoxy-7-methoxylH,2H,3H-cyclopenta[b]quinolin-9yl}piperidin-3-amine | 341.9 |
No | Structure | IUP AC Name | MS found |
408 | O / \ 1 z /)— z À # \__ Z—' ZL 1 | (3S,5R)-N-{6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl}-5-methylpiperidin-3-amine | 342.2 |
409 | _NH HN | (3R,5R)-N-{6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl}-5-methylpiperidin-3-amine | 342.2 |
410 | Ο 'b / \ \r··. O ex: T ____ | (3R)-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-5,5difluoropiperidin-3-amine | 364.2 |
411 | Λ\Λ * O O o \ / | N- {| (2S,4S)-4-fluoropyrrolidin-2yl]methyl}-6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9amine | 346.1 |
412 | F _NH HN' | (3R,5S)-N-{6,7-dimethoxy- 1 H,2H,3 H-cyclopenta[b]quinolin-9yl}-5-fluoropiperidin-3-amine | 346.1 |
No | Structure | IUP AC Name | MS found |
413 | / \ O O NX I | (3 S)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}-5,5difluoropiperidin-3-amine | 364.1 |
414 | _NH HN' J T T) | (3 R)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yI}-5,5dimethylpiperidin-3-amine | 356.2 |
415 | c/ Xo / \ T Va Fa Z—/ I ___ | (3 S)-N- { 6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-5,5dimethylpiperidin-3-amine | 356.3 |
416 | F VX ,NH HN' XX X) 0 N | (3R,5R)-N-{6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9yl} -5-fluoropiperidin-3-amine | 346.3 |
Table 2
No. | Structure | IUP AC Name |
70 | T T U ‘o O O | 1 -cyclopropyl-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
71 | Qû z—G z T f/ O O O O CO CO T T | 1-cyclobutyl-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
72 | çh3 x^ .ô < N O xs. h3c Yf ΥΛ H3C. xk xk^Z O N | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin- 9-yl}-l-(2-methoxyethyl)piperidin-4-amine |
73 | Qû z -Z z 1 y // >4 O O O O o co T X | 3-[4-( {6,7-dimethoxy- 1H, 2H,3Hcyclopenta[b]quinolin-9-yl}amino)piperidin-lyl]propanenitrile |
74 | τ’ O 0 QA h O O O τ’ τ’ | N-{6,7-dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin9-yl} -1 -(2-methylpyridin-4-yl)piperidin-4-amine |
75 | T T ω ω Ο Ο ο* ο Κ7 Ο \ X ζ 7— ζ οο 0 Ο JE | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinoIin9-yl}-l-(6-methylpyridin-3-yl)piperidin-4-amine |
76 | ΗΝ' ^N^ CH3 O JL H3C κΎύ\ h.c . J^ JL> >L/ 3 Ό N | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl}-l-[(6-methylpyridm-3-yl)methyl]piperidin-4amine |
77 | δ b Qû z—Λ Z T Y ❖ >4 o o R R | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-y 1} -1 -(3-methoxypropy l)piperidin-4-amine |
78 | X Qû z —G z x 'X tj o o b < - b CO T | N-{6-ethoxy-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
79 | rX3 4L J F HN o JL H,C ><> 7r\ > h3c. «As. ><. 3 o N | l-(2,6-difluorophenyl)-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
80 | JL J f HN ____ Y- - h3c p Yr (TA H3Cfc xUn ^zL JL^Z 3 0 N | 1 -(2,4-difluorophenyl)-N - { 6,7-dimethoxy-1 H,2H,3 Hcyc lopenta[b] quino lin-9-y 1} piperidin-4-amine |
81 | qq z—4 z T Y // V? o o * * o o en m T I | l-(2,5-difluorophenyl)-N-{6,7-dimethoxy-lH,2H,3H- cyclopenta[b]quinolin-9-yl}piperidin-4-amine |
82 | r-9 HN^J I 1 N O JL _ h3c 7t^\ 2 H3C. 4 *O N | 2- [4-( { 6,7-dimethoxy-1 Η,2Η,3 Ηcyclopenta[b]quinolin-9-yl} amino)piperidin-1 yl]benzonitrile |
83 | T T ω ω Ο ο ο ο Χ7 0C ο I ω | N- {6,7-dimethoxy- 1H,2H, 3H-cyclopenta[b]quinolin9-y 1} -1 -propylpiperidin-4-amine |
84 | I I ω ω Ο Ο ο’ ο XX oc Ο X | 2- [4-( {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-y 1} amino)piperidin-1 yl]ethan-l-ol |
85 | C0 T Ο Où 7-ί ο ο ο / X ' χ ο CO r | N- {6-ethoxy-7-methoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -methylpiperidin-4amine |
86 | ι-^Ν' CH3 ,ο. ___JL h3c β βΥΑ h3c ο | N-{6-ethoxy-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-y 1} -1 -ethylpiperidin-4amine |
87 | Μ τ ο-ο Λ-Ζ >-< ο ο Ο < nf | N-{6-ethoxy-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-1-(2methoxyethyl)piperidin-4-amine |
88 | T Ο A O O O O « CO X X | 2-{4-[(6,7-dimethoxy-l,2,3,4-tetrahydroacridin-9yl)amino]piperidin-1 -yl} ethan-1 -ol |
89 | QQ Z—G z T y— O O O O co co T T | N-(l-cyclopropylpiperidin-4-yl)-6,7-dimethoxy- l,2,3,4-tetrahydroacridin-9-amine |
90 | X X ω ω Ο ο « « ο ο \7 οΟ 0-0 X ω | 6,7-dimethoxy-N-[l-(2-methoxyethyl)piperidin-4y 1] -1,2,3,4-tetrahydroacridin-9-amine |
91 | ζ QQ Ζ —G Ζ Χ Ο Ο ο ο eo to X X | 3-{4-[(6,7-dimethoxy-l,2,3,4-tetrahydroacridin-9yl)amino]piperidin-1 -y 1} propanenitrile |
92 | CO δ % QQ ζ —G ζ 1 y 9 O O O O CO CO T T | 6,7-dimethoxy-N-(l-methylpiperidin-4-yl)-l,2,3,4tetrahydroacridin-9-amine |
93 | CO T υ < QQ z —G z 1 Y 9 >-< o o O o CO CO X X | N-(l-ethylpiperidin-4-yl)-6,7-dimethoxy-l,2,3,4tetrahydroacridin-9-amine |
94 | I^^NH ---Z\ h 3c ppif] H3C 0 N | 6-ethoxy-7-methoxy-N-(piperidin-4-yl)-l,2,3,4tetrahydroacridin-9-amine |
95 | I^^NH HN^— O JL H3C KT|f] h,c . JL^. JL. JL J 3 ’o N ^z*' | 6 Adimethoxy-N-(piperidin-4-yl)-1,2,3,4tetrahydroacridin-9-amine |
96 | -CH, [ N 3 n JL z\ h3c Il I h3c ' o '^z^· N 'N— | 6-ethoxy-7-methoxy-N-(l-methylpiperidin-4-yl)l,2,3,4-tetrahydroacridin-9-amine |
97 | z^n^ch3 HN^^ .cr xL___. H3C JOljO H3C 0 ^XZ^ N Άζ | 6-ethoxy-N-(l-ethylpiperidin-4-yl)-7-methoxyl,2,3,4-tetrahydroacridin-9-amine |
98 | O X~^ JL Zk H,C' iT 1 k AA AJ H3C O ^z N | N-(l-cyclopropylpiperidin-4-yl)-6-ethoxy-7methoxy-l,2,3,4-tetrahydroacridin-9-amine |
99 | _____ --s. ^OH g N HN*^^ O JL >z~^ h3c +rz γζ 7r \ / H,C. -As x+> X J J O N ----! | 2-[4-({2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -y 1} amino)piperidin-1 yl]ethan-l-ol |
100 | Qp χ Λ/ ο ο ο ο fo η Τ Τ | l-cyclopropyl-N-{2,3-dimethoxy6H,7H,8H,9H, 10H-cyclohepta[b]quinolin-11 yl}piperidin-4-amine |
101 | çh3 ζ->. Χ^ ζό Ζ Ν Ην'Χ' ,Ο^ Z-S. PL H3e f βΥ Λ h3c. P^-zxk JL 7 Ο— n X—7 | N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -y 1} -1 -(2methoxyethyl)piperidin-4-amine |
102 | ^,Ν . C) ____ JL X--ν h3c Pf|] Λ h3c. JL / 0 N X-—' | 3-[4-( {2,3 -dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b]quinolin-11 -yl} amino)piperidin-1 yl]propanenitrile |
103 | -CH, f N 3 hn'NZ .G) ^z^. JL X--y h3c f YY Λ h3c. z-Ls Po Jx j O XZ N ---' | N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -yl} -1 -methy lpiperidin-4amine |
104 | Z^N' CH3 HN^Z . ο ζχ^ PL y—x h3c 7t \ ) h3c . χλ^, zl«. X J 0 *0 — N X-J | N- { 2,3 -dimethoxy-6H,7H, 8H,9H, 10Hcyclohepta[b]quinolin-l l-yl}-l-ethylpiperidin-4amine |
105 | <? O O K7 x do I | N- {3 -ethoxy-2-methoxy-6H,7H, 8H,9H, 10Hcyclohepta[b]quinolin-l l-yl}piperidin-4-amine |
106 | τ χ*-.. QO z z 1 \ // O O O O CO CO I T | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b]quinolin-l l-yl}piperidin-4-amine |
107 | ,CH3 p N 3 O xX ./-χ H3C Il \ H3C O 'N/'^ N A—I | N- {3-ethoxy-2-methoxy-6H,7H,8H,9H, 10Hcyclohepta[b] quinolin-11 -y 1} -1 -methylpiperidin-4amine |
108 | x». -CH3 p N 3 hn^x^ O X^ XX /^x X AA -θ’ H3C 0 X*^ N X— | N- {8-ethoxy-9-methoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11 -yl} -1 -methylpiperidin-4-amine |
109 | zx ^OH Ç N hnAx ,C) ____ zL y—> H3C X^ 1K 7Γ ' ° H3C zks xk· / 0 X^ N X-^ | 2-[4-( {8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-l l-yl}amino)piperidin-l-yl]ethan-l-ol |
110 | z- A1 K N hn^^A O XK JL h3c X^ il ' ο h3c . xks. ><· xk j 3 *O X*^ N X---' | 1 -cyclopropyl-N- {8,9-dimethoxy-1 H,2H,4H,5 Hoxepino[4,5-b]quinolin-l l-yl}piperidin-4-amine |
111 | <? So o O O \7 v \ I z ')— z oo ° o-o ω | N- {8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11-yl} -1-(2-methoxyethyl)piperidin-4amine |
112 | n Π X^ JL .X-> h3c ' 0 h3c. >1^. JL / 0 N X--' | 3-[4-({8,9-dimethoxy-lH,2H,4H,5H-oxepino[4,5b]quinolin-l l-yl}amino)piperidin-l-yl]propanenitrile |
113 | ,CH, p N o x-^ JL y—i H,C γί^ TT ' ° h3c. xks. xQ> JL / J *o N X---' | N- {8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinoiin-11 -y 1} -1 -methylpiperidin-4-amine |
114 | I I ω ω Ο Ο Ο ο Χ7 Ο A I ζ y-z Ο0 ° > ο ώ“ | N- {8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11-yl} -1-ethy lpiperidin-4-amine |
115 | I I ω ω Ο ο ο ο 00 00 | N-{ 8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11 -yl} piperidin-4-amine |
116 | ,ΟΗ ρ Ν ΗΝ'Ζ .0/-Κ h3c >r^ π ι h3c . ><s xQ- JL 7 O N X 7 | 2-[4-({2,3-dimethoxy-6H,7H,8H,9H,10H,l 1Hcycloocta[b]quinolin-12-yl} amino)piperidin-1 yl]ethan-l-ol |
117 | qQ H O O O O CO CO T T | l-cyclopropyl-N-{2,3-dimethoxy6H,7H,8H,9H, 1 OH, 1 lH-cycloocta[b]quinolin-12yl} piperidin-4-am ine |
118 | çh3 X«^ -ô p N h3c i H3C, xks. -¼ A J J O ----- N X X | N- {2,3-dimethoxy-6H,7H,8H,9H, 1 OH, 11Ηcycloocta[b]quinolin-12-yl} -1 -(2methoxyethyl)piperidin-4-amine |
119 | I JE <o o O O K7 VA i z y-z o$ Z | 3-[4- ({2,3-dimethoxy-6H,7H,8H,9H, 1 OH, 11Hcycloocta[b]quinolin-12-yl} amino )piperidin-1 yl]propanenitrile |
120 | I I ω ω Ο ο ο ο \7 z y-ζ 0$ ο τ ω | N- {2,3-dimethoxy-6H,7H,8H,9H, 1 OH, 11Hcycloocta[b]quinolin-12-yl}-l-methylpiperidin-4amine |
121 | Ζ Τ ω ω Ο Ο Ο ο κζ ζΜ-§ οο > ο τ ω | N- {2,3-dimethoxy-6H,7H,8H,9H, 1 OH, 11Hcycloocta[b]quinolin-12-yl} -1 -ethylpiperidin-4amine |
122 | qQ ζ —G ζ I'W Ο Ο « « ο ο en en Τ Τ | N- {2,3-dimethoxy-6H,7H,8H,9H, 1 OH, 11Hcycloocta[b]quinolin-12-yl}piperidin-4-amine |
123 | /X. -CH3 β Ν 3 ΗΝ^--- . C) _ η3ο ρ |Γ> H3C. χ*·^ Χ0Ζ 3 Ό Ν | N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-y 1} -1 -methy lpiperidin-4-amine |
124 | AQû H o o « t o o n T r | l-cyclopropyl-N-{2,3-dimethoxy-6H,7H,8Hcyclopenta[b] 1,5-naphthyridin-9-yl}piperidin-4amine |
125 | HN^— .0^ .N. A. HoC Ύ?· > H3C Aïs Aï AsZ 3 O —N | l-cyclobutyl-N-{2,3-dimethoxy-6H,7H,8Hcyclopenta[b]l,5-naphthyridin-9-yl}piperidin-4amine |
126 | T T ω ω Ο ο ο ο ce b | 1 -cyclopenty 1-N - {2,3 -dimethoxy-6H,7H, 8Hcyclopenta[b]l,5-naphthyridin-9-yl}piperidin-4amine |
127 | ΗΝ'^ΑΑ η JL _ h3c FA τ\ > h3c. As. Α> ΑΆ 3 'O N | N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl}-l-(oxan-4-yl)piperidin-4-amine |
128 | °Q Qû i -yy yy o o o o CO CO T T | N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl}-l-(oxolan-3-yl)piperidin-4-amine |
129 | çh3 —____ A N hn'^^ .cr A. h3c 7r\ ✓ H3C. x^z J O N | N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl}-l-(2-methoxyethyl)piperidin-4amine |
- 100-
130 | I X ω w Ω Ω Ο* Ο où ζ | 3-[4-({2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-y 1} amino)piperidin-1 yl]propanenitrile |
131 | r-^'NH Ο JL _ H 3 C ψ” |Τ^\ H,C . Jks S--J 3 Ο N | N- {2,3 -dimethoxy-6H,7H, 8H-cyclopenta[b] 1,5naphthyridin-9-yl} piperidin-4-amine |
132 | T X ω ω Ο ο ο ο /Λ-ί οθ > ο X ω | N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl} -1 -ethy lpiperidin-4-amine |
133 | ^ch3 -—·Ν·**χ ην'*^ Ο JL h3c —X H3C. xUs χθ· JL^Z | N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl} -1 -propy lpiperidin-4-am ine |
135 | -OH K N ,O^ JL h3c ψ· Y|I—k H,C. xLÿ. O N | 2-[4-({2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl}amino)piperidin-l-yl]ethan-l-ol |
136 | «CH, Ç N 3 HN^--- ,C> .N- X\ h,c >^· >T^ 7Γ 1 H3c. xks xL> x< J 3 *o — N | N-{2,3-dimethoxy-6H,7H,8H,9H-cyclohexa[b]l,5naphthyridin-10-yl} -1 -methylpiperidin-4-amine |
- 101 -
137 | QQ 1 yy o o o o co co X X | l-cyclopropyl-N-{2,3-dimethoxy-6H,7H,8H,9Hcyclohexa[b] 1,5 -naphthyridin-10-y 1} piperidin-4amine |
138 | q QQ x yy o o ο ω co co T X | l-cyclobutyl-N-{2,3-dimethoxy-6H,7H,8H,9Hcyclohexa[b] 1,5 -naphthyridin-10-yl} piperidin-4amine |
139 | ,0^ JL h3c 7i i h3c. xQs Jo J | l-cyclopentyl-N-{2,3-dimethoxy-6H,7H,8H,9Hcyclohexa[b] 1,5-naphthyridin-10-yl} piperidin-4amine |
140 | T X ω ω Ο ο • « ο ο ^ζ Ο0 0 | N-{2,3-dimethoxy-6H,7H,8H,9H-cyclohexa[b]l,5naphthyridin-10-yl} -1 -(oxan-4-yl)piperidin-4-amine |
141 | X X ο ο ο ο λ^ζ ζΜοΟ ! | N- {2,3 -dimethoxy-6H,7H, 8H,9H-cyclohexa[b] 1,5naphthyridin-10-yl} -1 -(oxolan-3 -y l)piperidin-4amine |
142 | çh3 < Ν ^-Χ Ο JL H3C ψ- Y|f] h3c. ><>.><· Jk J 0 N ^x | N-{2,3-dimethoxy-6H,7H,8H,9H-cyclohexa[b]l,5naphthyridin-10-yl} -1 -(2-methoxyethy l)piperidin-4amine |
- 102-
143 | Χ>Ν ΗΝ^'Χ^ Ο -N. Α. χ^ h3c ψ· Υ|ΐ—Ί H3C. JL. JL JL J O ^X^N | 3-[4-({2,3-dimethoxy-6H,7H,8H,9Hcyclohexafb] 1,5 -naphthyridin-10yl}amino)piperidin-l-yl]propanenitrile |
144 | I I ω ω Ο Ο « * Ο ο /7^ \ Ζ zVi U0 τ ..... | N- {2,3 -dimethoxy-6H,7H,8H,9H-cyclohexa[b] 1,5naphthyridin-10-yl} piperidin-4-amine |
145 | X I ω ω Ο Ο Ο ο λ^ζ zM-i 00 > ο τ ω | N-{2,3-dimethoxy-6H,7H,8H,9H-cyclohexa[b]l,5naphthyridin-10-yl} -1 -ethylpiperidin-4-amine |
146 | χ. Χ^ ^CH, r----Ν ,C> -N. χ. h3c' ψ· Ίτ |[ ] h3c . JL. xk xL > ο—N | N-{2,3-dimethoxy-6H,7H,8H,9H-cyclohexa[b]l,5naphthyridin-10-y 1} -1 -propylpiperidin-4-am ine |
147 | CO r CO O $-< QQ i yjF ZM O O » · O O to CO X X | N-{2,3-dimethoxy-6H,7H,8H,9H-cyclohexa[b]l,5naphthyridin-10-y 1} -1 -(propan-2-yl)piperidin-4amine |
148 | X T ω ω Ο ο θ' ο A zM-i ΟΟ ο X | 2-[4-({2,3-dimethoxy-6H,7H,8H,9Hcyclohexa[b] 1,5 -naphthyridin-10y 1} amino)piperidin-1 -y l]ethan-1 -ol |
- 103 -
150 | T T ω ω Ο ο ο ο λ^ζ 00 Ο I ω | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b] 1,5-naphthyridin-11 -yl} -1 methylpiperidin-4-amine |
151 | .ΟΝ J^X--ν h3c ύ> τγ \ ) H3C. χΟ>χ^<· xk / 3 Ο N X--' | l-cyclopropyl-N-{2,3-dimethoxy6H,7H,8H,9H,10H-cyclohepta[b]l,5-naphthyridin1 l-yl}piperidin-4-amine |
152 | I I ω ω Ο Ο Ο ο λ^ζ ζ^Λ-i οο | l-cyclobutyl-N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b] 1,5-naphthyridin-11 -yl} piperidin-4amine |
153 | Λ* ,Ο^ h3c Or^ 7τ \ ) H3C. xksx^ xk J 3 *Ο N X—J | 1 -cyclopentyl-N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcycloheptafb] 1,5-naphthyridin-11 -yl} piperidin-4amine |
154 | Γ° hn'n'^ MeO^. N | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b] 1,5-naphthyridin-11 -yl} -4-(oxolan-3yl)piperazin-l-amine |
155 | ro a'X/ h3c y γν A H3C. xjxk- xk / 3 '0 N X—J | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b] 1,5-naphthyridin-11 -yl} -1 -(oxolan-3yl)piperidin-4-amine |
- 104-
156 | çh3 ZK F K N hn''^ O JL ---- h3c ψ· y \ H,C. JL. Js> JL J Ό XZ N X^ | N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b] 1,5-naphthyridin-11 -yl} -1 -(2methoxyethyl)piperidin-4-amine |
157 | [•'Z\ZNZ HN^^Z o ^n. JL y-—. h 3c V· V|[ Λ h3c. xL JL JL / J 0 N X—7 | 3-[4-( {2,3 -dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b] 1,5-naphthyridin-11 y 1} am ino)p iperidin-1 -y 1] propanenitrile |
158 | OQ s -yy z λ A IJ O O O Q CO CO T X | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b] 1,5-naphthyridin-l l-yl}piperidin-4amine |
159 | .°x Jx z—-x h3c V· p II \ h3c. zL-P< JL J 3 0 N X--, | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b] 1,5-naphthyridin-l 1 -yl} -1ethylpiperidin-4-amine |
160 | X T ω ω Ο ο t * ο ο ζ^-ί 00 ο X W | N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcycloheptafb] 1,5-naphthyridin-11 -yl} -1 propylpiperidin-4-amine |
161 | ch3 <ΧΛοη3 ΗΝ^^Ζ . Ο . X Jx. Ζ---ν h3c Ν> ϊτ \ / h3c. Z<s><· JL. J 0 N X—-7 | N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b] 1,5-naphthyridin-11 -yl} -1 -(propan-2yl)piperidin-4-amine |
- 105 -
162 | X T ω ω Ο Ο Ο* ο οο ο 1 I | 2-[4-({2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b] 1,5-naphthyridin-11 yl} amino)piperidin- l-yl]ethan-1 -ol |
166 | X X ω ω Ο ο ο ο Μ ο 0 < ο X ω | (3R)-N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl}-l-ethylpiperidin-3-amine |
167 | ( Ν—\ 7 ch3 .N. A. h3c >< h3c. -9—/ 3 '0 — N | (4R)-N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-y 1} -1 -ethy lazepan-4-am ine |
168 | HN XZ Ch3 O -N. JL _ h3c |1—\ h3c. xL JL- O ^z n | (3R)-N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl} -1 -propylpiperidin-3 -amine |
169 | X X ω ω Ο ο ο’ ο λ^ζ zVi ? ο X ω ί | (4R)-N-{2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl} -1 -propy lazepan-4-am ine |
170 | ΧχΑ ΗΝ ^r-y ,Ο^ χΝ^ xL _ V H,C r τ\ 2 h3c. zQs Jo 3 ο | (3 R)-1 -cyclopropyl-N- {2,3 -dimethoxy-6H,7H, 8Hcyclopenta[b] 1,5-naphthyridin-9-y 1} piperidin-3 amine |
- 106-
171 | T I ω ω Ο ο ο ο Y k | (4R)-l-cyclopropyl-N-{2,3-dimethoxy-6H,7H,8Hcyclopenta[b]l,5-naphthyridin-9-yl}azepan-4-amine |
172 | λ ΖΚ ζ°Η Ζ Ν ^-ζ ην'ΝΖ 0 PL χ~^ h,c χί' ΟΖ ηΖ X H3C. χΐ^. xQ- χΚ^ J Ο Ν | 2- {4- [(2,3-dimethoxyacridin-9-yl)amino]piperidin-1 yl}ethan-l-ol |
173 | I I ω ω Ο Ω Ο Ο \7 ζΜ0 0 | N-( 1 -cyclopropylpiperidin-4-yl)-2,3dimethoxyacridin-9-amine |
174 | ch3 χ\ ___. 0 Z Ν ΗΝ^--- , Ο. χ\ PL Χ^ h 3c Υρ Ύ η H3C. xk. χ-L xL.p 0 N | 2,3 -d imethoxy-N- [ 1 -(2-methoxyethy l)piperidin-4yl]acridin-9-amine |
175 | Z z ω ω Ο Ο ο’ ο XX Ο Σ ζ ')— ζ Ot) ζ | 3 - {4-[( 2,3-dimethoxyacridin-9-yl)amino]piperidin-1 yl}propanenitrile |
176 | Τ I ω ω Ω Ω Ο Ο \7 ι ζ y- ζ ο 0 Ω I ω | 2,3-dimethoxy-N-(l-methylpiperidin-4-yl)acridin-9amine |
- 107-
177 | I^^NH ^x^ -A -x^ h3c |^ || J H3C O | 3-ethoxy-2-methoxy-N-(piperidin-4-yl)acridin-9amine |
178 | QQ z —G z 1 O o o o co co T X | 2,3-dimethoxy-N-(piperidin-4-yl)acridin-9-amine |
179 | -CH3 p N 3 HNZSx' O _Z< JL ✓X h,c τι 1 1 H J H3C O N '^x^ | 3 -ethoxy-2-methoxy-N-( 1 -methy lpiperidin-4yl)acridin-9-amine |
180 | JE ° T \ ω > °. o o \7 Ayi où > o T ω | 3-ethoxy-N-(l-ethylpiperidin-4-yl)-2methoxyacridin-9-amine |
181 | HN^^x o JL . h3c il J H3C O N | N-(l-cyclopropylpiperidin-4-yl)-3-ethoxy-2methoxyacridin-9-amine |
182 | T z^ *z -4 z 1 O O o o CO CO T I | (3 R)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}piperidin-3-amine |
- 108-
183 | CO T O » Qfi - \ à O O O O CO CO r x | (3 R)-N- {6,7-dimethoxy-1 Η,2Η,3Ηcyclopenta[b]quinolin-9-yl} -1 -methylpiperidin-3amine |
184 | I T ω ω Ο ο ο ο 4-\ τ ζ ζ οθ I | (4S)-N- {6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl}azepan-4-amine |
185 | I I ω ω Ο ο « * ο ο \7 ζ / ζ 0 b ζ I ω | (3R)-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b] quino lin-9-yl} -1 -ethy lpyrrolidin-3 amine |
186 | ΓΛ ch3 jl Ν—ζ ΗΝ ch3 CL χ^ χΧ h3c ρ |Γ> H3C. χΧ>/Χ χΧν 3 0 Ν | (3 S)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} -1-(propan-2yl)pyrrolidin-3-amine |
187 | Τ I ω ω ο ο ο ο Κ7 I ζ y— ζ ο 0 Ο —/ I ω | (3R)-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -ethylpiperidin-3amine |
188 | Λ .Ν___,CH3 ΗΝ ζ f 0 χ^ JX CH3 h3c' H3C. χΐ^. Λ--/ 3 ο --------Ν | (3R)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-l-(propan-2yl)piperidin-3-amine |
- 109-
189 | Js___ HN Vy 0 x^ JL - * h3c 7ir\ > h3c. xks. Jxy 3 O N | (3 R)-1 -cyclopropy 1-Ν- {6,7-dimethoxy-1 Η,2Η,3 Ηcyclopenta[b]quinolin-9-yl}piperidin-3-aniine |
190 | Λ___N.___, HN O X^. X0 h3c p |T> H3C. 00 X0/ 3 N | (3 R)-1 -cyclobuty 1-Ν- { 6,7-dimethoxy-1 Η,2Η,3 Ηcyclopenta[b]quinolin-9-yl}piperidin-3-amine |
191 | X I ω ω Ο ο ο ο Χ7 ζ / ζ »0 1 ο I | (4R)-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-l-methylazepan-4-amme |
192 | I I ω ω Ο Ο Ο Ο <00 00 ι ζ /”Ζ 1 ο τ ω | (4S)-N- {6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -methylazepan-4-amine |
193 | <ο X °Ί Qq Ζ—Ζ Ζ ι 'Χ Λ 0# ο ο υ ο CO Λ X X | (4R)-N-{6,7-dimethoxy-lH,2H,3H- cyclopenta[b]quinolin-9-yl}-l-ethylazepan-4-amine |
194 | Τ X ω ω Ο Ο ο ο X/ 00 ι ζ ζ $0 | (4S)-N- {6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl}-l-ethylazepan-4-amine |
- 110-
195 | Γ N— M HN ---- O JL _ h3c 2 h3c. Aïs Aï· A^/ O ----- N | (4R)-1 -cyclopropyl-N- {6,7-dimethoxy-1 Η,2Η,3Ηcyc lopenta[b]quinolin-9-yl} azepan-4-am ine |
196 | I I ω ω Ο ο ο ο Κ7 Ο ' 9 | (4S)-l-cyclopropyl-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}azepan-4-amine |
197 | r\ ch3 ην'^ ch3 h3c γγ\\\ h3c. J<sAï- JL^/ 0 N | (3 R)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-l-(propan-2yl)pyrrolidin-3-amine |
198 | CO T O 1 0 Q 1 yy >-< o o o o CO CO I X | (3 R)-N- { 6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}-l-methylpyrrolidin-3amine |
199 | I I ω ω Ο Ο « » Ο ο Χ7 νΆι ζ '>-ζ Ο Ô | (3R)-1 -cyclobutyl-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}pyrrolidin-3-amine |
200 | Ζ Λ Q Q ζ —Λ ζ 1 γ 9 Ο ο ο ο CO CO X X | (3 S)-1 -cyclobutyl-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}pyrrolidin-3-amine |
201 | X T ω ω ο ο * * ο ο ΟΟ Λ | (3R)-l-cyclopropyl-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}pyrrolidin-3-amine |
202 | X X ω ω Ο ο ο ο Μ ον À | (3S)-l-cyclopropyl-N-{6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}pyrrolidin-3-amine |
203 | X X ω ω Ο Ο Ο ο \7 Ο 1 ζ y-z οβ ο X ω | (3R)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-y 1} -1 -propy lpiperidin-3 amine |
204 | ΗΝ > χ^ JL _ k H3C ΤΓ'Χ ΟΗ > H3C. xksxki χ·^/ 3 *Ο Ν | 2-[(3R)-3-({6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}amino)piperidin-lyl]ethan-l-ol |
205 | vk ΗΝ > ,Ο^ χ-κ JL k .CH3 h3c ?ι^\ ° / h3c. xk- -k- P—/ Ο ----- N | (3R)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(2methoxyethyl)piperidin-3-amine |
206 | HN > O Xk xk k H3C iT*\ λδ· h3c. xks-xk· x1—/ O N | 3-[(3R)-3-({6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}amino)piperidin-lyl]propanenitrile |
- 112-
207 | hn'* χ—7 --s^ A. H3C f f |Γλ h3c. JLx. JL. JL0 Ο XX N | 2-[(4R)-4-( {6,7-dimethoxy-1 H, 2H,3Hcyclopenta[b]quinolin-9-yl}amino)azepan-lyl]ethan-l-ol |
208 | I z ω ω Ο Ω Ο Ο Χ7 zKi $0 ζ | 3-[(4R)-4-({6,7-dimethoxy-lH,2H,3Hcyclopeiita[b]quinolin-9-yl}amino)azepan-lyl]propanenitrile |
209 | ζ ζ Ω Ω Ο Ο \7 zKi 0> ο Ζ | 2-[(3 S)-3-( {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} amino)piperidin-1 yl]ethan-l-ol |
210 | JL HN XX > <Ί ___JL _ L ,CH, h3c Νχ τχ îUx ° / h3c. Ass-As- Av Ο XX N | (3 S)-N- {6,7-d imethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} -1 -(2methoxyethyl)piperidin-3-amine |
211 | z Qû Z—ά z X II y-\ O O O O CO CO Z Z | 3 - [(3 S)-3 -( {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b] quinolin-9-y 1} amino)piperidin-1 yl]propanenitrile |
212 | VL -NH HN xs JL ---- h 3c II 1 H,C. JLxs χ-L J 3 O — N ----- | 6,7-dimethoxy-N-[(3R)-piperidin-3-yl]-l,2,3,4tetrahydroacridin-9-amine |
- 113 -
213 | .N. HN CH3 .O^ xx. Xx. h3c JK || ] H3C. xLs. xL- JL J 3 0 N | 6,7-dimethoxy-N-[(3R)-l-methylpiperidin-3-yl]1,2,3,4-tetrahydroacridin-9-amine |
214 | HN N Ow /x JL xx. CH3 h3c Y5- ït i h3c . xk? A. J 3 ο N | N-[(3R)-l-ethylpiperidin-3-yI]-6,7-dimethoxy- 1,2,3,4-tetrahydroacridin-9-amine |
215 | ok ^CH, HN--- γ 3 ,C> x^ JL _____ CH3 h3c Ντ^τ^Ττι h3c. xksxk >_____J O N | 6,7-dimethoxy-N-[(3R)-l-(propan-2-yl)piperidin-3yl]-1,2,3,4-tetrahydroacridin-9-amine |
216 | QQ O O * » Q O CO CO T r | N-[(3R)-l-cyclopropylpiperidin-3-yl]-6,7-dimethoxy- l,2,3,4-tetrahydroacridin-9-amine |
217 | □: i ω ω Ο Ο Ο* ο \Ί ζ /“ζ ο_0 ο I ω | 6,7-dimethoxy-N-[(3R)-l-propylpiperidin-3-yl]- l,2,3,4-tetrahydroacridin-9-amine |
218 | ν< .Ν ΗΝ Ν 0 χ^. xL. χ^ L h3c 7γ ί οη h3c. xksxk- Α^χΐ 3 *o N' | 2- [(3 R)-3 - [(6,7-dimethoxy-1,2,3,4-tetrahydroacridin9-yl)amino]piperidm-1 -yl]ethan-1 -ol |
- 114-
219 | « ο ο ορ ζ—G Ζ V/ Ο Ο * « ο ο CO CO I T | 6,7-dimethoxy-N-[(3R)-l-(2-methoxyethyl)piperidin3-y 1]-1,2,3,4-tetrahydroacridin-9-amine |
220 | HN > 0 x^ Jk XK k h>c τππΓΐ x» | 3 - [(3 R)-3 - [(6,7-dimethoxy-1,2,3,4-tetrahydroacridin9-yl)amino]piperidin-l-yl]propanenitrile |
221 | JL .NH HN . 0 x\ A. X— h3c rYY λ H.C. xLs J^· jk J | (3R)-N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-ll-yl}piperidin-3-amine |
222 | JL P. HN CH3 h3c ' ° \ / h3c , xks ^k X J 3 ‘o N X—J | (3R)-N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-ll-yl}-l-methylpiperidin-3amine |
223 | Λ ^N. HN o x^ JL y—y ch3 h3c' \ / H3C. x^xk· xk / 3 O N -----' | (3 R)-N- {2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b]quinolin-11 -y 1} -1 -ethylpiperidin-3amine |
224 | J^N___,CH3 HN Ύ* 0 x— xk ----1 CH3 h3c* \ ) H3C. X^xk· xk / 3 ’O — N ----' | (3R)-N-{2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -yl} -1 -(propan-2yl)piperidin-3-amine |
- 115 -
225 | HN V7 ,O. -___. ζ'^-χ V H3C Yz γζΧζ \ > h3c. zL- JL / 3 ’o \-z | (3R)-1 -cyclopropyl-N- {2,3-dimethoxy6H,7H,8H,9H, 1 OH-cyclohepta[b]quinolin-11 y 1} piperidin-3 -am ine |
226 | T I ω ω Ο Ο Ο* ο X/ dp ο I ω | (3 R)-N- {2,3 -dimethoxy-6H,7H, 8H,9H, 10Hcyclohepta[b]quinolin-11 -yl} -1 -propy lpiperidin-3 amine |
228 | vk^N^ ΗΝ X .C) Ζ\ zk Ζ--1 k H3C ν' ν'Y \ ΟΗ h3c. zLxJo JL J | 2-[(3R)-3-({2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -y 1} amino)piperidin-1 yl]ethan-l-ol |
229 | Â-N. HN ^Z \ -O^Z^xLz—\ k .CH3 h3c V γζ y \ O H3c. As. A / 0 N | (3 R)-N-{2,3-dimethoxy-6H,7H,8H,9H, 10Hcyclohepta[b]quinolin-11 -yl} -1 -(2methoxyethyl)piperidin-3-amine |
230 | vk NHN N . ο ~ ZK zk Z--1 k H3C Vz \ h3c . zV< -A / O ^*z N v7 | 3-[(3R)-3-({2,3-dimethoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -yl} amino)piperidin-1 yl]propanenitrile |
231 | I r— *“0 O O O O CO CO T X | 2,3-dimethoxy-N-[(3R)-piperidin-3-yl]acridin-9amine |
232
233
234
235
236
- 1162,3-dimethoxy-N-[(3R)-l-methylpiperidin-3yl]acridin-9-amine
N-[(3R)-l-ethylpiperidin-3-yl]-2,3-dimethoxyacridin9-amine
2,3-dirnethoxy-N-[(3R)-l-(propan-2-yl)piperidin-3yl]acridin-9-amine
N-[(3R)-l-cyclopropylpiperidin-3-yl]-2,3dimethoxyacridin-9-amine
2,3 -dimethoxy-N- [(3 R)-1 -propy lpiperidin-3 yl]acridin-9-amine
237
2-[(3R)-3-[(2,3-dimethoxyacridin-9yl)amino]piperidin-1 -yl]ethan-1 -ol
- 117-
238 | T X ω ω Ο ο * * ο ο /ϊ~\ ι ζ /—ζ ορ ο ο X ω | 2,3-dimethoxy-N-[(3R)-l-(2-methoxyethyl)piperidin3 -y 1] acridin-9-amine |
239 | ΗΝ Ν ο χχ JL χ~χ L H,C Χ> Th X 3 H3C. χ^χΛζ. xlL^J | 3 - [(3 R)-3 - [(2,3 -dimethoxyacridin-9yl)amino]piperidin-1 -yl]propanenitrile |
240 | ν< χΝΗ ΗΝ Χ^ 0 JL >---ν H,C Y7 χζ 7τ ' ο H3C. As PL / 3 Ο Ν X---' | (3 R)-N- { 8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-l l-yl}piperidin-3-amine |
241 | ΤχΝ ΗΝ CH3 . ο X ----\ h3c χ^ κΥ ' ° H3C. xkx. χ*<- W j 3 Ο Χ*^ Ν X--' | (3R)-N- {8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11 -yl} -1 -methylpiperidin-3-amine |
242 | X X ω ω Ο Ο f · ο ο \7 ζ y—ζ V J ° / ο —' I ω | (3R)-N- { 8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11 -yl} -1 -ethy lpiperidin-3-amine |
243 | s'L χΝ^ ^CH3 ΗΝ'^ζ Ύ 3 . Ο χ>. JL , CH3 h3c ' ° h3c. X<s xkj. A / O N N-—J | (3 R)-N-{ 8,9-dimethoxy- 1H,2H,4H, 5H-oxepino[4,5b]quinolin-11 -yl} -1 -(propan-2-y l)piperidin-3-amine |
- 118-
244 | I T ω ω Ο Ο ο ο OÔ | (3R)-1 -cyclopropyl-N- {8,9-dimethoxylH,2H,4H,5H-oxepino[4,5-b]quinolin-l 1yl}piperidin-3-amme |
245 | Λ___ ΗΝ > .ο JL /—, L h3c ît ' ch3 ο h3c. ζΑ.Α W / 3 ο — N X—-7 | (3R)-N- {8,9-dimethoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-l l-yl}-l-propylpiperidin-3-amine |
246 | Â X HN X ,ο^ _____ JL L H3C ν' KJ ' OH θ h3c . z-ks A j 3 *o >< n'\—' | 2-[(3R)-3-( {8,9-dimethoxy-1 H,2H,4H,5Hoxepino[4,5-b]quinolin-11 -yl} amino)piperidin-1 yl]ethan-l-ol |
247 | A-X HN ,<D ^x. zL z-~~, Q ,CH3 h3c k k Y ' 0 ° H3c. zAs. X / 0 N ---' | (3R)-N-{8,9-dimethoxy-lH,2H,4H,5H-oxepino[4,5b]quinolin-l l-yl}-l-(2-methoxyethyl)piperidin-3amine |
248 | I I ω ω Ο Ο Ο* ο \7 οο Ο __( fi 1 | 3 - [(3 R)-3-( { 8,9-dimethoxy-1 H,2H,4H,5Hoxepino[4,5-b]quinolin-11 -yl} amino)piperidin-1 yl]propanenitrile |
249 | 3 Χ^ ΝΗ ΗΝ^Χ^ ______ JL h 3 c ^Y\F\ HqC . As β·--- 3 Ο — N | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl} -3-methylpiperidin-4-amine |
- 119-
250 | CH3 H3C< Jx .Οχ JL h3c X^ 7t^\ 2 H3C. ζΑχ^Ο JLx/ 3 0 N | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl}-2,3-dimethylpiperidin-4-amine |
251 | H3C ^Zx. 3 Y NH HN 0 zX JL CH3 H3C * X^ Χ^ >—\ 7 H.C. JLx JL JJkx/ 3 O X^ N | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl}-3,5-dimethylpiperidin-4-amine |
252 | H3Cx 3 NH HN^ '^CHa .Οχ PP h3c X^ îT^N 2 h3c. O X^ N | N- {6,7- dimethoxy-1 H,2H,3H-cyclopenta[b]quinolm9-yl}-2,5-dimethylpiperidin-4-amine |
253 | CH3 HN J h3c '0 X^X^rr^v ch3 2 h3c . AsA O N | 6,7-dimethoxy-N-{[l-(propan-2-yl)azetidin-3yl]methyl}-lH,2H,3H-cyclopenta[b]quinolin-9amine |
254 | HN .<3 z. JL _ \__1 h3c Ύ^Ρτ|]—\ h3c . JL JL JL/ O — N | N-[(l-cyclopentylazetidin-3-yl)methyl]-6,7dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-amine |
255 | HN' VjNxy^ .Ox^Z*xjL^- jL J H3C TYlîO h3c . .As A> JA^/ 0 — N | N- {[ 1 -(2-fluorophenyl)azetidin-3-yl]methyl}-6,7dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-amine |
- 120-
256 | H N \ N -Z ιΓ> n XC. J^Z | 6,7-dimethoxy-N- {[ 1 -(pyridin-3-yl)azetidin-3yl]methyl} -1 H,2H,3H-cyclopenta[b]quinolin-9amine |
257 | UM *—CH, HN A N^Z 3 h,c * ° z h,c. As Aï AJ 3 *O N | N-[(l-ethylazetidin-3-yl)methyl]-6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9-amine |
258 | OH CH, UN Λ N^Z 13 .o^ x—As. h,c >r^ JiTx z h3c. x^Aï A^Z 3 O N | 3-[({6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}amino)methyl]-lethylazetidin-3-ol |
259 | OH hn' ^^nh o JL h3c f f||—\ h,c. xLs JX· 3 *0 N | 3-[( {6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl}amino)methyl]azetidm-3ol |
260 | I I ω ω Ο Ο ο’ ο \7 ν \ = ζ / ζ Ο ζ | N- {[ 1 -(3-fluoropyridin-4-yl)azetidin-3-yl]methyl}6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9amine |
261 | ην' ο xs^ JL _ V ζ,Ν h3c' τι—\ A-x Z Cl H,C . xls. Aï β—Z 3 *0 N | N-{ [ 1 -(3-chloropyridin-4-yl)azetidin-3-yl]methyl}6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9amine |
- 121 -
262 | T -Π ‘ο 0 ο ο Π ) ( Χ7 00 χ ζ ζ Ο 0 > ο I ω | N-[6-(difluoromethoxy)-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-1 -ethylpiperidin-4-amine |
263 | <Ώ X Ο < QQ Ζ—(. ζ 'λ h V? ο ο —\ b U- C0 X | 1 -ethy 1-N - [6-(fluoromethoxy )- 7-methoxy-1 H,2H, 3 Hcyclopenta[b]quinolm-9-yl]piperidin-4-amine |
264 | I -Π ‘ο Π0 Ο Ο a\ ζ ζ Ζ 0 0 ο ω JE | N- [7-methoxy-6-(trifluoromethoxy)-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl]-1 -(propan-2yl)piperidin-4-amine |
265 | I Ο \ τ / w° ο ο Μ ι ζ ζ οο > ο -1 | 3-({9-[(l-ethylpiperidin-4-yl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinoIin-6-yl}oxy)propan-lol |
266 | X X ω ω Ο ο * * ο ο Χ7 zM-i 0^ τι / Ο | 3-[({6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}amino)methyl]-l-(2fluorophenyl)azetidin-3-ol |
267 | ΟΗ ΗΝ' ο JL ν > Ν h3c' H3C. >L%. Χ0/ 0 N | 3-[({6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}amino)methyl]-l(pyridin-4-yl)azetidin-3-ol |
- 122-
268 | OH 0 XK JL Y Z A h3c' k Z^ / F h3c. AA 3 *O XX N | 3-[({6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}amino)methyl]-1-(3fluoropyridin-4-yl)azetidin-3-ol |
269 | I T ω ω Ο ο 1 * ο ο I ζ /“ ζ ο Ζ / ι ^'Χ | (6S)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b] quinolin-9-y 1} -1,4-oxazepan-6-amine |
270 | I I ω ω Ο ο « * ο ο Οι ζ y- ζ ° ζ -χ I | (6R)-N - {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-l,4-oxazepan-6-amine |
271 | ο—, ΗΝ''\χΝ. 1 CH, h,c ν' γχ 7γ\ 7 H3C. Χ*^><· Χ*Χ^Ζ 3 ο ^Χ Ν | (6S)-N- {6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-y 1} -4-methyl-1,4-oxazepan6-amine |
272 | I I ω ω Ο ο ο ο Χ7 zM-i of,· Ο I ω | (6R)-N - {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-y 1} -4-methyl-1,4-oxazepan6-amine |
273 | I I ω ω Ο ο ο ο Χ7 ο \-ο Ζ / I ω Q ω Ζ ω | 7-methoxy-N-methyl-9-[(l-methylpiperidin-4yl)amino]-lH,2H,3H-cyclopenta[b]quinoline-6sulfonamide |
- 123 -
274 | I I ω w Ο Ο ο ο XX Ζ Ζ ου ο X—ο χ / ι ο ζ | Ν- {6,7-dimethoxy-2-methy 1-1 Η,2Η,3 H-pyrrolo [3,4b]quinolin-9-yl}-l-(propan-2-yI)piperidin-4-amine |
275 | ch3 ηνΆΑ ο Χ^ χΧ χ'--\ H,C Χ^ 7τ ' 3 N-CH, H3C. χΧ^χΧ χΧ / 3 ’Ο Ν ----' | N-{7,8-dimethoxy-2-methyl-lH,2H,3H,4Hbenzo [b] 1,7-naphthyridin-5 -yl} -1 -(propan-2yl)piperidin-4-amine |
276 | r*cN Ην 'Χ'^ Ο χ\ χΧ h3c ρ II ο ch3 | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-y 1} -1 -azabicyclo [2.2.2]octan-4-amine |
277 | I ω Ο 0-0 ο Τ \ / ω \7 >< V. ζ I Ο I | N- {6,7-dimethoxy-1 H,2H,3H-cyclopenta[b]quinolm9-yl} -6-methy 1-6-azabicyclo [3.1.1] heptan-3 -amine |
278 | C0 Τ Ο I Ζ h -b Ο 0-0 ο ω Τ | N- {6,7-dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin9-yI}-3-methyl-3-azabicyclo[3.1. l]heptan-6-amine |
279 | τ ‘ο ο · ο ο X ν / ω \7 * \ I k Ο I X ω ω | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl}-2-(propan-2-yl)-2-azaspiro[3.3]heptan-6-amine |
- 124-
280 | F HN .0. XX xk - h3c Y|| ch3 | N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl}-2-(2-fluorophenyl)-2-azaspiro[3.3]heptan-6amine |
281 | I O O \ | 3-({9-[(cyclopropylmethyl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinolin-6-yl}oxy)propan-lol |
282 | y HN \x 0 N | 2-({9-[(cyclopropylmethyl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinolin-6-yl}oxy)ethan-lol |
283 | 'Ml Y O O \ O T | 4-({9-[(cyclopropylmethyl)amino]-7-methoxy1 H,2H,3 H-cyclopenta[b] quinol in-6-y 1} oxy)butan-1 ol |
284 | ch3 CÇCP σσ | 1 -cyclobuty 1-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}azetidin-3-amine |
285 | ch3 JL λ N CÎ yv VykA0-CH3 ,NH MU | l-(cyclopropylmethyl)-N-{6,7-dimethoxy1 H,2H,3 H-cyclopenta[b]quinolin-9-y 1} azetidin-3 amine |
287 | ch3 rxzN>/Xx° (i ï i \xVAA0-CH3 σΗ '-N ch3 | (3 R)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} -1 -methylazepan-3-amine |
- 125-
288 | /=( 2 yj O 0*0 » Z O X | N-[(l-ethylazetidin-3-yl)methyl]-6,7-dimethoxylH,2H,3H-cyclopenta[b]quinolin-9-amine |
289 | O 0-0 O JC | 6,7-dimethoxy-N-[(piperidin-4-yl)methyl]lH,2H,3H-cyclopenta[b]quinolin-9-amine |
290 | Z^' Z 1 \ ! O 0 o-o O w ____ | (3R)-N-{6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl}-7-methylazepan-3-amine |
291 | ch3 _ -N -x^ Ô Ίηί nh HN JL· | (3 S,4R)-N- {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}-3-methylpiperidin-4amine |
292 | ch3 _ x\ ^0 CCÏÏ CH 1 ch3 HN . 3 0 ch3 | N- {6,7-dimethoxy- 1H,2H, 3H-cyclopenta[b]quinolin9-yl} -1,4-dimethylpiperidin-4-amine |
293 | 1 \=N HN 1 Y- NH s—f o-ch3 | N-{6,7-dimethoxy-1H,2H,3H-cyclopenta[b]quinolin9-yl}-6-azabicyclo[3.1.1 ]heptan-3-amine |
294 | ch3 _ X\ F cxsOc CH V- 3 Xxv**NH HN -J h3c ch3 | N-{6,7-dimethoxy-1H,2H,3H-cyclopenta[b]quinolin9-yl}-2,2-dimethylpiperidin-4-amine |
295 | ch3 .N'X'X-Ô V--U*JL^L ,CH, 3 ï h3c*<> NH | 6,7-dimethoxy-N-{[(2S)-2-methylazetidin-3yl]methyl}-lH,2H,3H-cyclopenta[b]quinolin-9amine |
- 126-
296 | ch3 CXJQt ch NH CH? | 6,7-dimethoxy-N-{[(2R)-2-(pyridin-2-yl)azetidin-3y l]methyl} -1 H,2H,3 H-cyclopenta[b]quinolin-9amine |
297 | ο ο·ο g * | (3R)-N- {6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinoIin-9-yl}-l-ethylazepan-3-amine |
298 | to I « θ υ·ο ο \7 f \ Z ζ /½2 | (3 R)- 1-cyclopropyl-N- {6,7-dimethoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl}azepan-3-amine |
299 | ch3 /^->N θ \J^ JL .JL . CH, x-*\anh N OH | 2- [(3R)-3 -( {6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}amino)azepan-lyl]ethan-l-ol |
300 | ch3 _ _N 0 HJ ,^Χ^ΝΗ '-n' N | 3-[(3R)-3-({6,7-dimethoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}amino)azepan-lyl]propanenitrile |
301 | o o y-u. | 6-((9-((cyclopropylmethyl)amino)-7-methoxy-2,3dihydro-lH-cyclopenta[b]quinolin-6-yl)oxy)hexan-2ol |
302 | Υ^ΝΗ HN^--O >K JL h,c X^ 7i^\ XI Kz F N | N-{6-fluoro-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
- 127-
303 | HN'*''·' .o^ Zx. xk _ H 3 C z^z^z^ N z*^Z N Z | 7-methoxy-9-[(piperidin-4-yl)amino]-lH,2H,3Hcyclopenta[b]quinoline-6-carbonitrile |
304 | f^^NH HN O zk zk — h3c Pf|l—\ H- zL.zL Jk^Z 3 --------- Z | N- {6-ethyl-7-methoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
305 | X ω O Q O \7 oO X | N-{6-chloro-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
306 | f ’NH hn‘a—' ,0^ Z\ zk η3% TfXjO Vz^zsn'z^/ F F | N-[7-methoxy-6-(trifluoromethyl)-lH,2H,3Hcyclopenta[b]quinolin-9-yl]piperidin-4-amine |
307 | o? O O ^7 Mi ο b | N-{7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-9y 1} piperidin-4-am ine |
308 | [Z^NH Hn''' .0^ zs. xk h3c t<\ JL X JLy ç y—o ^z^Nz^z | N-[7-methoxy-6-(pyridin-2-yloxy)-lH,2H,3Hcyclopenta[b]quinolin-9-yl]piperidin-4-amine |
309 | I ω O -Π O \Z σ 0 O ω | N- { 6-fluoro-7-methoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}-l-methylpiperidin-4amine |
- 128-
310 | ,ch3 3 JL h3c- rYY\ N x | 7-methoxy-9-[(l-methylpiperidin-4-yl)amino]lH,2H,3H-cyclopenta[b]quinoline-6-carbonitrile |
311 | λ .ch3 Z^N 3 h ri — .0. xx Js. - H3C K K T\ H,C^ χΧχ χ1-^ P-y 3 Xz^X^^N^^ | N- {6-ethyI-7-methoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}-l-methylpiperidin-4amine |
312 | I ω O Q O M vA_i z '>— z oü O I ω | N-{6-chloro-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-l-methylpiperidin-4amine |
313 | ,CH3 X ‘N* 3 HN^— JL h3c Y^ iTA F JL. JL Jj/ F F | N-[7-methoxy-6-(trifluoromethyl)-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-l-methylpiperidin-4amine |
314 | z ω O b Tz z^A-i σ 0 O z ω | N-{7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-9y 1} -1 -methylpiperidin-4-amine |
315 | 0I ° o b KZ z^A-i o 0 O z | N- [7-methoxy-6-(pyridin-2-yloxy )-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl]-l-methylpiperidin-4amine |
316 | T O LL Ο> T | 1 -ethyl-N- {6-fluoro-7-methoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
- 129-
317 | δ < Qû Z-Z Z x 'X h Q /¼ O Z tn I | 9-[(l-ethylpiperidin-4-yl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinoline-6-carbonitrile |
318 | ^Ν^Η3 h3c Y^ il—\ h3c b<s | 1 -ethyl-N- {6-ethyl-7-methoxy- 1H,2H,3Hcyclopenta[b]quinolin-9-yl}piperidin-4-amine |
319 | τ’ Q < Qû z—G Z h ° ü o □F | N-{6-chloro-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-l-ethylpiperidin-4amine |
320 | HnX7 .0, λ Λ h3c rrYA F JL JL IL/ | 1 -ethy 1-N-[7-methoxy-6-(trifluoromethy 1)lH,2H,3H-cyclopenta[b]quinolin-9-yl]piperidin-4amine |
321 | δ < Qû ^aj o o, X5 | 1 -ethyl-N- {7-methoxy-1 H,2H,3Hcyclopenta[b]qumolin-9-yl}piperidin-4-amine |
322 | CL Pp o o b ib > o <? | l-ethyl-N-[7-methoxy-6-(pyridin-2-yloxy)lH,2H,3H-cyclopenta[b]quinolin-9-yl]piperidin-4amine |
323 | ch3 < N HN*X*^ ________ JL h3c nb | N- {6-fluoro-7-methoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-yl} -1 -(2methoxyethyl)piperidin-4-amine |
- 130-
324 | ......“Ί co X 0-0 A z—G Z // o z CO X | 7-methoxy-9- {[1 -(2-methoxyethyl)piperidin-4y 1] amino} -1 H,2H,3 H-cyclopenta[b]quinoline-6carbonitrile |
325 | <o 0-0 A o ) o o co co X X | N-{6-ethyl-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl} -1 -(2methoxyethyl)piperidin-4-amine |
326 | çh3 -x -O p N HN^X^ h3c Y fVA οι^^'Άι^'' | N- {6-chloro-7-methoxy-1 H,2H,3 Hcyclopenta[b]quinolin-9-y 1} -1 -(2methoxyethyl)piperidin-4-amine |
327 | X ω -π Ο Ο XX Ο 0 0-0 X ω | N-[7-methoxy-6-(trifluoromethyl)-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-l-(2methoxyethyl)piperidin-4-amine |
328 | ch3 ^χ ζ— A f Ν ΗΝ^Χ^ .c> .A __ h3c Υκ χκ Χ<Χ EL JL? | N-{7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-9yl}-l-(2-methoxyethyl)piperidin-4-amine |
329 | ch3 ✓N ό .0^ H3C Υ^τίΤΛ /“V AA Α2 Æ Λ— 0 — Ν | N-[7-methoxy-6-(pyridin-2-yloxy)-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-1 -(2methoxyethyl)piperidin-4-amine |
- 131 -
330 | X^NH O ____ xL H,c V V IT 1 AàaJ X>xxx N XX N“x | 2-methoxy-9-[(piperidin-4-yl)amino]-5,6,7,8tetrahydroacridine-3-carbonitrile |
331 | Ί X QQ z —4 z y? O ) O Q CO CO T X | 6-ethy 1-7-methoxy-N-(piperidin-4-yl)-1,2,3,4tetrahydroacridin-9-amine |
332 | T QQ * -yy yy O O O CO X | 6-chloro-7-methoxy-N-(piperidin-4-yl)-l,2,3,4tetrahydroacridin-9-amine |
333 | y^NH HN^xx o JL_____ h3c Yf||| | 7-methoxy-N-(piperidin-4-yl)-1,2,3,4tetrahydroacridin-9-amine |
334 | ,ch3 h3c p p|| ] N^ | 2-methoxy-9-[(l-methylpiperidin-4-yl)amino]5,6,7,8-tetrahydroacridine-3-carbonitrile |
335 | CO I O QQ H y_# O ) O O CO CO I X | 6-ethyl-7-methoxy-N-(l-methyIpiperidin-4-yl)l,2,3,4-tetrahydroacridin-9-amine |
336 | /X. -CH, z----N 3 HN*xx xL ____ H,C >x γχ 7Γ Ί KL IJ Cl XX N XX | 6-chloro-7-methoxy-N-(l-methylpiperidin-4-yl)l,2,3,4-tetrahydroacridin-9-amine |
- 132-
337 | ,CH3 Ç N 3 HN*^— O JL h,c X^ X^Nr i LÀ KJ — N | 7-methoxy-N-(l-methylpiperidin-4-yl)-l, 2,3,4tetrahydroacridin-9-amine |
338 | T ω Z O b X7 VA z z y-z OÙ > O ω | 9-[(l-ethylpiperidin-4-yl)ammo]-2-methoxy-5,6,7,8tetrahydroacridine-3-carbonitrile |
339 | Z Z ω ω Ο Ο / ο X/ yyg οο > ο ζ ω __ | 6-ethyl-N-( 1 -ethy lpiperidin-4-yl)-7-methoxy-1,2,3,4tetrahydroacridin-9-amine |
340 | [---N^CHj Η Ν ,c> _____JL h3c γΥΥ । | 6-chloro-N-(l-ethylpiperidin-4-yl)-7-methoxyl,2,3,4-tetrahydroacridin-9-amine |
341 | <X^CH3 hn'X^ O ZK J^ X\ h3c μ Or II | | N-( 1 -ethylpiperidin-4-y l)-7-methoxy-1,2,3,4tetrahydroacridin-9-amine |
342 | hn'x^ .O^^Xs. A.____ H3C Y^ TF 1 LL IJ N | 9-[(l-cyclopropylpiperidin-4-yl)amino]-2-methoxy- 5,6,7,8-tetrahydroacridine-3-carbonitrile |
- 133 343
N-( 1 -cyclopropylpiperidin-4-yl)-6-ethyl-7-methoxyl,2,3,4-tetrahydroacridin-9-amine
344
6-chloro-N-(l-cyclopropylpiperidin-4-yl)-7methoxy-1,2,3,4-tetrahydroacridin-9-amine
345
346
N-( 1 -cyclopropylpiperidin-4-y l)-7-methoxy-1,2,3,4tetrahydroacridin-9-amine
2-methoxy-11 - [(piperidin-4-yl)amino]6H,7H,8H,9H, 10H-cyclohepta[b]quinoline-3carbonitrile
347
N-{3-ethyl-2-methoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-l l-yl}piperidin-4-amine
348
349
N-{3-chloro-2-methoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-l l-yl}piperidin-4-amine
N- {2-methoxy-6H,7H,8H,9H, 10Hcyclohepta[b]quinolin-l l-yl}piperidin-4-amine
- 134-
350 | co I ο QQ °Γ\ ζ τ’ | 2-methoxy-11 -[( 1 -methylpiperidin-4-yl)amino]6H, 7H, 8H, 9H, 1 OH-cy cio heptafb] quinoline-3 carbonitrile |
351 | xs. -CH, ρ^Ν 3 , ο JL /**> h3c γγ\\ \ H3C xk J | N-{3-ethyl-2-methoxy-6H,7H,8H,9H,10Hcyclohepta[b]quinolin-11 -yl} -1 -methylpiperidin-4amine |
352 | ,CH3 < N 3 ,0^ x^ xJ^ h3c p 1^ || ) Cl | N- {3-chloro-2-methoxy-6H,7H,8H,9H, 1 OHcy clohepta[b] quinolin-11 -y 1} -1 -methy lpiperidin-4amine |
353 | ^x. .CH, p N 3 HN^^^ O X^ JL X^^x h3c ît \ LL Jk j | N- {2-methoxy-6H,7H,8H,9H, 10Hcyclohepta[b]quinolin-l l-yl}-l-methylpiperidin-4amine |
354 | ,ch3 p N 3 HN^— ,0^ ___JL /—> H3c 7r ' XA X ? N X-—7 N^ | 9-methoxy-ll-[(l-methylpiperidin-4-yl)amino]lH,2H,4H,5H-oxepino[4,5-b]quinoline-8-carbonitrile |
355 | « T O Qp x ~yy O > b o CO CO T T | N-{8-ethyl-9-methoxy-lH,2H,4H,5H-oxepino[4,5b]quinolin-11 -y 1} -1 -methy lpiperidin-4-amine |
356 | I ‘o o b K/ zKi oo O ' O X ω | N- {8-chloro-9-methoxy-1 H,2H,4H,5H-oxepino[4,5b]quinolin-11 -yl} -1 -methy lpiperidm-4-amine |
- 135 -
357 | .K .CH, K N 3 HN ,C> _____ Jk H,C T ' 3 Γ 1 II o ΧαΉ# | N- {9-methoxy-1 H,2H,4H,5H-oxepino [4,5 bjquinolin-11 -yl} -1 -methylpiperidin-4-amine |
358 | r^N^CHa Jx /—\ LL 1 j N | ll-[(l-ethylpiperidin-4-yl)amino]-9-methoxylH,2H,4H,5H-oxepino[4,5-b]quinoline-8-carbonitrile |
359 | M 1 O < Zx Qp z—Λ z x \ // Y-< O ) o o CO CO T I | 1 -ethy 1-N- { 8-ethyl-9-methoxy-1 H,2H,4H,5Hoxepino[4,5-b]quinolin-l l-yl}piperidin-4-amine |
360 | Z^n'^CHj H FL O xk X^\ H,C TT ' AAA / | N-{8-chloro-9-methoxy-lH,2H,4H,5H-oxepino[4,5b]quinolin-11-y 1} -1-ethylpiperidin-4-amine |
361 | HN*^— .C) xk JL χ<~~> h,c t^· il ' LA A T N X—-' | 1-ethyl-N-{9-methoxy-1H,2H,4H,5H-oxepino[4,5b]quinolin-l l-yl}piperidin-4-amine |
362 | Z^NH HN^KZ ,C> ____ Jk /--\ ΗΑ Pfi] | _/ | 2-methoxy-12-[(piperidin-4-yl)amino]6H,7H,8H,9H,10H,l lH-cycloocta[b]quinoline-3carbonitrile |
- 136-
363 | X ω Ο Ο Ο L > X X X | N- {2-methoxy-6H,7H,8H,9H, 1 OH, 11Ηcycloocta[b]quinolin-12-yl}piperidin-4-amine |
364 | ___. . CH, f N 3 ΗΝ^— . ο. χ— χΑ y κ h3c ρ Ίρ II | ζχΑ^'/χ / Ν ' | 2-methoxy-12-[(l-methylpiperidin-4-yl)amino]6Η,7Η,8Η,9Η,10Η,1 lH-cycloocta[b]quinoline-3carbonitrile |
365 | η X ο __ qQ Ζ—ό ζ χ ο ϋ « X | N- {2-methoxy-6H,7H,8H,9H, 1 OH, 11Hcycloocta[b]quinolin-12-yl} -1 -methylpiperidin-4amine |
366 | ΧΑη ην·^>Ά -χόο | 2-methoxy-9-[(piperidin-4-yl)amino]acridine-3carbonitrile |
367 | X ζ —ν / Λ gyV y-< ο ) ο ο CO (Ό X X | 3-ethyl-2-methoxy-N-(piperidin-4-yl)acridin-9-amine |
368 | Χ^ΝΗ C) χκ JL _____ H-C >Τ^Τ^Ίη^Ί 1 CI | 3-chloro-2-methoxy-N-(piperidin-4-yl)acridin-9amine |
369 | X ω Ο « ο ^7 Ζ '>— ζ et) X | 2-methoxy-N-(piperidin-4-yl)acridin-9-amine |
- 138-
376 | X w Ο Ο ο ν \ χ ζ ζ ot} > ο X ω | 3-chloro-N-( 1 -ethylpiperid in-4-y 1)-2methoxyacridin-9-amine |
377 | I ω Ο Ο ζ 7“ ζ οΟ > ο ζ ω .. | N-(l-ethylpiperidin-4-yl)-2-methoxyacridin-9-amine |
378 | ρζ ΗΝ^— 0 ζ\ zk ζΧ h3 c ρι || η N Z | 9-[(l-cyclopropylpiperidin-4-yl)amino]-2methoxyacridine-3-carbonitrile |
379 | Z Z ω ω Ο ο / ο \7 ζΗ-ι | N-(l-cyclopropylpiperidin-4-yl)-3-ethyl-2methoxyacridin-9-amine |
380 | Z ω Ο ο Ο \7 zM-i OÙ | 3 -ch loro-N-( 1 -cyclopropy lpiperidin-4-yl)-2methoxyacridin-9-amine |
381 | ρ^ ηιψ— ,0^ ζκ À ζχ h3c fl· Il 1 | N-(l-cyclopropylpiperidin-4-yl)-2-methoxyacridin-9amine |
382 | îz^n^ch3 2£°)θΛθ> | N-{6-cycIopropoxy-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-y 1} -1 -ethylpiperidin-4amine |
- 139-
383 | Ν' 'CH3 ΗΝ*^^ Ο JL - h3c |f\ | N-{6-cyclopropyl-7-methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl}-l-ethylpiperidin-4amine |
384 | 7 I ΗΝ L 1 1 τ χ> | N-(cyclopropylmethyl)-7-rnethoxy-6-phenoxylH,2H,3H-cyclopenta[b]quinolin-9-amine |
385 | Ρ ο ο— | N-(cyclopropylmethyl)-7-methoxy-6-(pyridin-2yloxy)-lH,2H,3H-cyclopenta[b]quinolin-9-amme |
386 | X \__/ —ο Ο /ΖΡ | N-(cyclopropylmethyl)-7-methoxy-6-(pyrimidin-2yloxy)-lH,2H,3H-cyclopenta[b]quinolin-9-amine |
387 | Q ο ο— | N-(cyclopropylmethyI)-7-methoxy-6-(pyridazin-3yloxy)-lH,2H,3H-cyclopenta[b]quinolin-9-amine |
388 | 0 ο ο— β- | N-(cyclopropylmethyl)-7-methoxy-6-(pyrimidin-4yloxy)-lH,2H,3H-cyclopenta[b]quinolin-9-amine |
389 | 0 Ο ο— | N-(cyclopropylmethyl)-7-methoxy-6-(pyridin-4yloxy)-lH,2H,3H-cyclopenta[b]quinolin-9-amme |
390 | y I ΗΝ | N-(cyclopropylmethyl)-7-methoxy-6-(pyridin-3yloxy)-1 H,2H,3H-cyclopenta[b]quinolin-9-amine |
- 140-
391 | y 1 HN Οχ/Χ Λ /= n Υγγλ s J II J X) | N-(cyclopropylmethyl)-7-methoxy-6-(l,3-thiazol-4yloxy)-lH,2H,3H-cyclopenta[b]quinolin-9-amine |
392 | y HN ηοΧ6ΛνΧ> | {9-[(cyclopropylmethyl)ammo]-7-methoxylH,2H,3H-cyclopenta[b]quinolin-6-yI}methanol |
393 | y HN J T X> OH | 1 - {9- [(cyclopropylmethyl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinolin-6-yl}ethan-l-ol |
394 | y HN HO 1 | 2-{9-[(cyclopropylmethyl)amino]-7-methoxy- 1 H,2H,3 H-cyclopenta[b] quinolin-6-y 1} propan-2-ol |
395 | y HN ^χ/Χ/L^ | 6-cyclopropyl-N-(cyclopropylmethyl)-7-methoxylH,2H,3H-cyclopenta[b]quinolin-9-amine |
396 | 7 HN /θν^Α/κ·/ . J T χ> \Z OH | l-{9-[(cyclopropylmethyl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinolin-6-yl}cyclobutan- Ιοί |
397 | f^N^^CHa hn'x' 0 As. h3c >τ*Λ 3 1 £ |l 2 | 3-({9-[(l-ethylpiperidin-4-yl)amino]-7-methoxylH,2H,3H-cyclopenta[b]quinolin-6y 1} oxy)propanenitrile |
- 141 -
398 | -CH, |^ N 3 O JL ν rrO H3C .S. N o’ '0 | 9-((cyclopropylmethyl)amino)-7-methoxy-N-methyl2,3 -dihydro-1 H-cyclopenta[b]quinoline-6sulfonamide |
399 | V O O / \ T Z /)—Z \\ \____ | 2-({9-[(cyclopropylmethyl)amino]-7-methoxy1 H,2H,3 H-cyclopenta[b]quinolin-6y 1} oxy )acetonitrile |
400 | X X ω ω Ο Ο Ο ο Ζ 7~ ζ Ot) > ο X ω | N-( 1 -ethy lpiperidin-4-y 1)-2,3 -dimethoxy acridin-9amine |
401 | J ΗΝ οη | 6-( {9- [(cyclopropy Imethy l)amino] -7-methoxylH,2H,3H-cyclopenta[b]quinolin-6-yl}oxy)hexan-2ol |
General Synthetic Schemes
Compounds of this disclosure can be made by the methods depicted in the reaction schemes shown below.
The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Sigma-Aldrich Chemical Co., (Milwaukee, Wis.), Acros Organics, Oakwood Chemicals, Matrix Chemicals, and Bachem (Torrance, Calif.), or are prepared by methods 10 known to those skilled in the art following procedures set forth in references such as Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and Supplémentais (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March’s Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock’s Comprehensive Organic Transformations (VCH Publishers 15 Inc., 1989). Generic schemes 1-6 are merely illustrative of some methods by which the compounds of
- 142this disciosure, and pharmaceutically acceptable salts thereof, can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art reading this disciosure. The starting materials, the intermediates, and the final products of the reaction(s) may be isolated and purified if desired using conventional techniques, including but not limited to filtration, 5 distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a température range from about —78 °C to about 200 °C, such as from about 0 °C to about 125 °C and further such as at about room (or ambient) température, e.g., about 20 °C. The routes shown 10 and described herein are illustrative only and are not intended, nor are they to be construed, to limit the scope of the claims in any manner whatsoever. Those skilled in the art will be able to recognize modifications of the disclosed synthèses and to devise alternate routes based on the disclosures herein; ail such modifications and alternate routes are within the scope of the claims.
Compounds of described herein such as compounds of Formula (1-1), and pharmaceutically 15 acceptable salts thereof, are defïned herein, and can be prepared as illustrated and described in Scheme below.
Scheme 1 ci
11-1 m, n, = 1,2, 3 or 4 h2nrx1 or
RX1NH3CI
BrettPhos Pd G1
I-2 m, n, = 1, 2, 3 or 4
I-3 m, n, = 1, 2, 3 or4 ^3B j^3A
Formula (1-1) m, n, = 1, 2, 3 or 4
Reacting compounds of formula II-1 wherein A can be N or CH; X can be CH2 or O; and m, n 20 can independently be 1, 2, 3 or 4; R1 can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, npropoxy, or iso-propoxy), deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCD7CD3), haloalkoxy (for example, -OCH2F, -OCHF2, -OCF3, or -OCH2CF3), alkylamino (for example, -NHMe, -NMe2, or-NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for 25 example, phenoxy), or heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy); R2 can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or isopropoxy), deuterated alkoxy (for example, -OCD3, -OCH7CD3, or -OCD2CD3), cycloalkoxy (for
- 143 - example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or -NHEt), haloalkyl (for example, -CHF2 or -CF3), or haloalkoxy (for example, -OCHF2 or -OCF3), with appropriate commercially available amines H2NRX1, or the corresponding HCl salts, under Buchwald coupling conditions using catalysts such as BrettPhos Pd Gl, methyl t-butyl ether adduct, provides 5 compounds of formula 1-2. Some compounds of formula 1-2 are compounds of Formula (1-1). Some compounds of formula 1-2 are further converted into compounds of formula 1-3 by methods well known in the art, such as TFA mediated removal of the Boc group from nitrogen atom(s) within NRX1, or palladium catalyzed hydrogenative cleavage of benzyl group from nitrogen atom(s) within NRX1. Some compounds of formula 1-3 are compounds of Formula (I-1 ). Some compounds of formula 1-3 are 10 converted to compounds of Formula (1-1) by methods well known in the art, such as N-acylations with appropriate acyl chlorides or acyl anhydride followed with Chemical reactions well known in the art, or N-alkylation with appropriate halides or tosylate, reductive aminations with appropriate aldéhydes or ketones, or Buchwald coupling with appropriate aryl halides or triflates. This conversion may be carried out once (i.e., wherein R3B can be hydrogen), or twice (i.e., where R3B can be alkyl or -(C=O)-NH2).
The acyl chlorides, halides, tosylates, aldéhydes, ketones, aryl halides or aryl triflates are available from commercial resources, or easily accessible by synthetic methods well known in the art.
Some of compounds of formula II-1 where A can be CH; X can be CH2 or O; and m, n can independently be 1, 2, 3 or 4; R1 can be alkoxy (for example, methoxy), deuterated alkoxy (for example, -OCD3), haloalkoxy (for example, -OCH2F, -OCHF2, -OCF3, or -OCH2CF3), hydrogen, halogen (for 20 example fluoro or chloro), haloalkyl (for example, -CHF2 or -CF3), alkylamino (for example, -NHMe, -NMe2, or -NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for example, phenoxy), or heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy); R2 can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, methyl, ethyl, npropyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated 25 alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), cycloalkoxy (for example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or -NHEt), haloalkyl (for example, -CHF2 or -CF3), or haloalkoxy (for example, -OCH2F, -OCHF2, -OCF3, or -OCH2CF3), as defined in the summary can be prepared as illustrated and described in Scheme 2 below.
- 144Scheme 2
Reaction of amino carboxylate compounds of formula III-l where A can be CH; Rla can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, methyl, ethyl, n-propyl, 5 or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), haloalkoxy (for example, -OCH2F, -OCHF2, -OCF3, or -OCH2CF3), alkylamino (for example, -NHMe, -NMe2, or -NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for example, phenoxy), or heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy); R2a can be hydrogen, halogen (for example, fluoro or chloro), 10 cyano, alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), cycloalkoxy (for example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or -NHEt2), haloalkyl (for example, -CHF2 or -CF3), or haloalkoxy (for example, -OCHF2 or -OCF3), with an appropriate cyclic ketones IV where X can be CH2 or O; and m, n can 15 independently be 1, 2, 3 or 4, in the presence of POCI3 provides compounds of formula 11-11. Some compounds of formula 11-11 are compounds of Formula (1-1). Some compounds of formula II-l 1 are converted to compounds of formula II-l by methods well known in the art. Some compounds of formula III-l are commercially available. Some compounds of formula III-l can be prepared by methods well known in the art. Compounds of formula IV such as cyclopentanone, cyclohexanone, and cycloheptanone are commercially available.
Some of compounds of formula of II-l where A can be CH or N; X can be CH2 or O; m, n can independently be 1,2,3 or 4; R1 can be alkoxy (for example, methoxy), deuterated alkoxy (for example, -OCD3), haloalkoxy (for example, -OCH2F, -OCHF2, -OCF3, or -OCH2CF3), hydrogen, halogen (for example fluoro or chloro), haloalkyl (for example, -CHF2 or -CF3), alkylamino (for example, -NHMe, 25 -NMe2, or -NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for example, phenoxy), or heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy); and R2 can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, methyl, ethyl, npropyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated
- 145 alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), cycloalkoxy (for example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or —NHEt), haloalkyl (for example, -CHF2 or -CF3), or haloalkoxy (for example, -OCHF2 or -OCF3), can be prepared as illustrated and described in Scheme 3 below.
Scheme 3
H-2 11-3 11-4 11-1 m, n, = 1, 2, 3 or 4
De-methylation of compounds of formula II-2 under conditions well known in the art, such as reacting Π-2 with AlCb, provides hydroxy compounds of formula II-3. Compounds of formula II-3 can also be converted to compounds of formula II-l (R1= aryloxy (for example, phenoxy) or 10 heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy)) by reaction with appropriate commercially available aryl halides or heteroaryl halides under conditions well known in the art. Compounds of formula II-3 can be converted to compounds of formula Π-4 (L = OCHF2) by reaction with diethyl bromo(difluoro)methyl- phosphonate in the presence of a base, for example, KOH. Compounds of formula II-3 can also be converted to compounds of formula II-4 (L = alkoxy, for 15 example, methoxy, ethoxy, n-propoxy, or iso-propoxy) by either alkylation with appropriate commercially available alkyl halides or Mitsunobu reaction with appropriate commercially available alcohols under conditions well known in the art. Compounds of formula II-3 can also be converted to compounds of formula II-4 (L = Cl or Br) by reaction with POCI3, or POBn, or to compounds of formula II-4 (L = OTf) by reaction with Tf2Û in the presence of a base, for example, trimethylamine. 20 Some compounds of formula II-4 are compounds in formula II-l. Some compounds of formula II-4 (for example L = Br or OTf) can be converted to compounds of formula II-l via Chemical transformations well known in the art, including, for example, métal catalyzed hydrogénation or, via Suzuki, Stille, Nigishi or Buchwald coupling reactions with appropriate commercially available reagents. Compounds of formula II-2 can be made from commercially available materials via well25 known methods well known in the art as illustrated in scheme 2.
Some compounds of formula II-l where A can be CH or N; X can be CH2 or O; m, n can independently be 1, 2, 3 or 4; R1 can be hydrogen, cyano, halogen (for example fluoro or chloro), alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkylamino (for example, -NHMe, -N Me?, or -NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for example, phenoxy), or
- 146heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy); and R2 can be hydrogen, cyano, alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), cycloalkoxy (for example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or -NHEt), haloalkyl (for example, -CHF2 or -CF3), or haloalkoxy (for example,
-OCHF2 or -OCF3) can be prepared as illustrated and described in Scheme 4 below.
De-methylation of compounds of formula Π-5 under reaction conditions well known in the art, such as reacting compounds of formula Π-5 with AICI3, provides hydroxy compounds of formula II-6. Compounds of formula II-6 can be converted to compounds of formula II-l (R2 = aryloxy (for example, phenoxy) or heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy)) by reaction with appropriate commercially available aryl halides or heteroaryl halides. Compounds of formula Π-6 can also be converted to compounds of formula II-l (R2 = OCHF2) by reaction with diethyl bromo(difluoro)methyl- phosphonate in the presence of a base, such as KOH. Compounds of formula II-6 can also be converted to compounds of formula II-l (R2 = alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy) or cycloalkoxy (for example, cyclopropoxy or cyclobutoxy)) by alkylation with appropriate commercially available alkyl halides. Some compounds of formula II-6 can also be converted to compounds of formula II-7 (R2 = alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), or cycloalkoxy (for example, cyclopropoxy or cyclobutoxy)) either by alkylation with appropriate commercially available alkyl halides or by Mitsunobu reactions with appropriate commercially available alcohols under conditions well known in the art. Compounds of formula II-6 can also be converted to compounds of formula II-7 (Y = Cl or Br) by reaction with POCI3, or POBrs, or to compounds of formula II-7 (Y= OTf) by reaction with Tf2O in the presence of a base, such as trimethylamine. Some compounds of formula II-7 are compounds of formula II-l. Some compounds of formula II-7 can be converted to compounds of formula II-l by appropriate Chemical transformation of the Y group via methods well known in the art including, for example, desilyation, alkylation, acylation, and sulfonylation. Some
- 147 compounds of formula II-7 (for examples Y = Br or OTf) can be converted to compounds of formula II-1 by appropriate Chemical transformation of Y group via methods well known in the art, for example, via métal catalyzed hydrogénation, or via métal-catalyzed coupling reactions such as Suzuki, Stille, Nigishi or Buchwald reactions with appropriate commercially available reagents. Compounds of formula II-5 can be made from commercially available materials via well-known methods as illustrated in scheme 2.
Some compounds of formula II-1 where A can be N; X can be CH2 or O; m, n can independently be 1, 2, 3 or 4; R1 can be hydrogen, cyano, halogen (for example fluoro or chloro), alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkylamino (for example, -NHMe, -NMe2, or-NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for example, phenoxy), heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy), haloalkoxy (for example, -OCHF2 or -OCF3), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), or deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCDÆD3); and R2 can be hydrogen, cyano, halogen (for example fluoro or chloro), alkyl (for example, methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), cycloalkoxy (for example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or -NHEt), haloalkoxy (for example, -OCHF2 or -OCF3), haloalkoxy (for example, -OCHF2 or -OCF3); can be prepared as illustrated and described in Scheme 5 below.
Scheme 5
Nitration of compounds of formula V-l followed by réduction of the resulting product by methods well known in the art, including treatment with SnCl2, or treatment with iron in the presence of NH4CI, provides the amino-carboxylate compounds of formula ΠΙ-2. Compounds of formula IH-2 are converted to compounds of formula II-8 upon reaction with appropriate cyclic ketone compounds of formula IV in the presence of POCI3. Some compounds of formula 11-8 are compounds of formula
- 148Π-l. Reacting some compounds of formula Π-8 with 4,4,5,5-tetramethyl-2-(propan-2-yloxy)-l,3,2dioxaborolane in the presence of nBuLi, followed by reaction of the resulting product with hydrogen peroxide provides compounds of formula Π-9, which after Chemical transformations well known in the art, including, for example, O-alkylation, or Mitsunobu reactions with appropriate reagents, lead to compounds of formula II-l (R1 = MeO; R2 = alkoxy, for example, methoxy, ethoxy, n-propoxy, or isopropoxy). Some compounds of formula II-8 can also be converted to compounds of formula II-l via métal catalyzed coupling reactions well known in the arts, including, for example, Suzuki, Stille, Nigishi and Buchwald reactions.
Some compounds of formula II-l where A can be CH; X can be CH2 or O; m, n can independently be 1, 2, 3 or 4; R1 and R2 together form -OCH2O- linkage, can be prepared as illustrated and described in Scheme 6 below.
Scheme 6
11-6 11-10 11-1 m, n, = 1, 2, 3 or 4
De-methylation of compounds of formula II-6 (R1 = OMe) with BBn provides the di-hydroxy compounds of formula H-10, which upon treatment with dibromoethane in the presence of CsF leads to compounds of formula II-l (A can be CH; X can be CH2 or O; m, n can be 1, 2, 3 or 4; R1 and R2 together form a -OCH2O- linkage.
Compounds of described herein such as compounds of Formula (1-2), and pharmaceutically acceptable salts thereof, are defined herein, and can be prepared as illustrated and described in Scheme 7 below.
R3B1 r3A1
IX-1
Reacting compounds of formula ΠΙ-3 wherein A can be N or CH; RIbb can be H, alky, for example, methyl, ethyl; Rlb can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for 5 example, methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or iso-propoxy), deuterated alkoxy (for example, -OCD3, -OCH2CD3, or -OCD2CD3), alkylamino (for example, -NHMe, -NMe2, or-NHEt), cycloalkyl (for example, cyclopropyl or cyclobutyl), aryloxy (for example, phenoxy), or heteroaryloxy (for example, pyridinoxy, pyrimidinoxy, thiazoloxy, or pyrroloxy); R2b can be hydrogen, halogen (for example, fluoro or chloro), cyano, alkyl (for example, 10 methyl, ethyl, n-propyl, or isopropyl), alkoxy (for example, methoxy, ethoxy, n-propoxy, or isopropoxy), cycloalkoxy (for example, cyclopropoxy or cyclobutoxy), alkylamino (for example, -NHMe, -NMe2, or -NHEt), haloalkyl (for example, -CHF2 or -CF3), or haloalkoxy (for example, -OCHF2 or -OCF3), with appropriate aryl or heteroaryl halides (for example, phenyl or naphthyl halides, or 5 to 10 membered nitrogen containing heteroaryl halides) compounds of formula VI-1 (D = Cl, Br or I;), or an 15 aryl or heteroaryl trifluoromethanesulfonate (for example, phenyl or naphthyl triflates, or 5 to 10 membered nitrogen containing heteroaryl triflates) compounds of formula VI-1 (D = OTf), under appropriate conditions, for example, Buchwald coupling condition using catalysts such as BrettPhos Pd Gl, methyl t-butyl ether adduct, provides compounds of formula VII-1. Some compounds of formula VII-1 (Rlbb= H) are further converted into compounds of formula VIII-1 by methods well known in 20 the art, such as reaction with POCI3. Some compounds of formula VII-1 (for example, Rlbb = Ci-Cô alkyl as described herein, such as methyl or ethyl) are further converted into compounds of formula VIII-1 through saponification followed by treatment with POCI3. Some compounds of formula VIII1 can further react with appropriate commercially available amines HNR3B1R3A1, or the corresponding HCl salts, under Buchwald coupling condition using catalysts such as BrettPhos Pd Gl, methyl t-butyl 25 ether adduct, to provide compounds of formula IX-1. Some compounds of IX-1 are compounds in
- 150formula of 1-2. Some compounds of formula IX-1 are converted to compounds of Formula (1-2) via appropriate Chemical modifications of the Rlb, and/or the R2b, and/or R3B1, and/or R3 A1group(s) under conditions well known in the art. Some compounds of formula VHI-1 can also be converted to compounds of formula IX-2 under appropriate conditions well known in the art. Compounds of formula IX-2 can be further converted to compounds of Formula (1-2) by reaction with appropriate commercially available amines HNR3B1R3A1, or the corresponding HCl salts, under conditions well known in the art, for example, Buchwald coupling conditions using catalysts such as BrettPhos Pd Gl, methyl t-butyl ether adduct, optionally followed by further Chemical transformations of the R3B1 and or R3A1 groups under conditions well known in the art. Some compounds of formula III-3, for example, 2-amino-4,5-dimethoxybenzoic acid, are commercially available. Some compounds of formula III-3 can be readily accessible from commercially available material (for example, methyl 3,4dimethoxybenzoate, ethyl 3,4-dimethoxybenzoate) through conditions well known in the art.
Testing
The G9a inhibitory activity of the compounds of the présent disclosure can be tested using the in vitro assay described in Biological Examples 1 below.
Administration and Pharmaceutical Composition
In general, the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds this disclosure may range from about 0.01 to about 500 mg per kg subject body weight per day, which can be administered in single or multiple doses. A suitable dosage level may be from about 0.1 to about 250 mg/kg per day or about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day. For oral administration, the compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams ofthe active ingrédient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, or 1000 milligrams of the active ingrédient. The actual amount ofthe compound ofthis disclosure, i.e., the active ingrédient, will dépend upon numerous factors such as the severity of the disease to be treated, the âge and relative health of the subject, the potency of the compound being utilized, the route and form of administration, and other factors.
- 151 In general, compounds of this disclosure will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parentéral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the 5 degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, élixirs, aérosols, or any other appropriate compositions.
The choice of formulation dépends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules, including enteric 10 coated or delayed release tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations hâve been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active 15 material is supported on a cross-linked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
The compositions are comprised of in general, a compound of this disclosure in combination 20 with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of this disclosure. Such excipient may be any solid, liquid, semi-solid or, in the case of an aérosol composition, gaseous excipient that is generally available to one of skill in the art.
Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, 25 malt, rice, flour, chalk, silica gel, magnésium stéarate, sodium stéarate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, éthanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, minerai oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose and glycols.
Compressed gases may be used to disperse a compound of this disclosure in aérosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
- 152The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt. %) basis, from about 0.01-99.99 wt. % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. For example, the compound is présent at a level of about 1-80 wt. %.
The compounds of this disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of this disclosure or the other drugs may hâve utility. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the présent disclosure. When a compound of this disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the présent disclosure is preferred. However, the combination therapy may also include thérapies in which the compound of this disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingrédients, the compounds of the présent disclosure and the other active ingrédients may be used in lower doses than when each is used singly.
Accordingly, the pharmaceutical compositions of the présent disclosure also include those that contain one or more other drugs, in addition to a compound of the présent disclosure.
The above combinations include combinations of a compound of this disclosure not only with one other drug, but also with two or more other active drugs. Likewise, a compound of this disclosure may be used in combination with other drugs that are used in the prévention, treatment, control, amelioration, or réduction of risk of the diseases or conditions for which a compound of this disclosure is useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the présent disclosure. When a compound of this disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of this disclosure can be used. Accordingly, the pharmaceutical compositions of the présent disclosure also include those that also contain one or more other active ingrédients, in addition to a compound of this disclosure. The weight ratio of the compound of this disclosure to the second active ingrédient may be varied and will dépend upon the effective dose of each ingrédient. Generally, an effective dose of each will be used.
Where the subject in need is suffering from or at risk of suffering from cancer, the subject can be treated with a compound of this disclosure in any combination with one or more other anti-cancer agents and/or anti-cancer thérapies. In some embodiments, the anti-cancer thérapies can be surgery
- 153 and/or radiation therapy. In some embodiments, one or more of the anti-cancer agents are proapoptotic agents. Examples of anti-cancer agents include, but are not limited to, any of the following: gossyphol, genasense, polyphenol E, Chlorofusin, ail trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2’-deoxycytidine, ail trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec™), geldanamycin, 17-NAllylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD 184352, Taxol™, also referred to as “paclitaxel”, which is a well-known anti-cancer drug which acts by enhancing and stabilizing microtubule formation and analogs of paclitaxel (Taxol™), such as docetaxel (Taxotere™). Compounds that hâve the basic taxane skeleton as a common structure feature, hâve also been shown to hâve the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.
Further examples of anti-cancer agents for use in combination with a compound of this disclosure include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; antibodies (e.g., rituxan); MET inhibitor such as foretinib, carbozantinib, or crizotinib; VEGFR inhibitor such as sunitinib, sorafenib, regorafinib, lenvatinib, vandetanib, carbozantinib, or axitinib; EGFR inhibitor such as afatinib, brivanib, carbozatinib, erlotinib, gefitinib, neratinib, or lapatinib; PI3K inhibitor such as XL147, XL765, BKM120 (buparlisib), GDC-0941, BYL719, IPI145, BAY80-6946. BEX235 (dactolisib), CAL101 (idelalisib), GSK2636771, or TG100115; MTOR inhibitor such as rapamycin (sirolimus), temsirolimus, everolimus, XL388, XL765, AZD2013, PF04691502, PKI-587, BEZ235, or GDC0349; MEK inhibitor such as AZD6244, trametinib, PD 184352, pimasertinib, GDC-0973, or AZD8330; and protéasome inhibitor such as carfilzomib, MLN9708, delanzomib, or bortezomib.
Other anti-cancer agents that can be employed in combination with a compound of this disclosure include adriamycin; dactinomycin; bleomycin; Vinblastine; cisplatin; acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutéthimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine
- 154mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or Ril2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-la; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfïn; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; and zorubicin hydrochloride.
Other anti-cancer agents that can be employed in combination with a compound of the disciosure including 20-epi-analogues of 1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid;
- 155 ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axmastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III dérivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam dérivatives; beta-alethine; betaclamycin B; betulinic acid; Bfgf inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin dérivatives; canarypox IL-2; capecitabine; carboxamideamino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A dérivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gélatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilie disaccharide peptide; lipophilie platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fïbroblast
- 156growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+, diethylstibestrol; mopidamol; multiple drug résistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinumtriamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; protéasome inhibitors; protein A-based immune modulator; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugale; raf antagonists; raltitrexed; ramosetron; ras famesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhénium Re 186 étidronate; rhizoxin; ribozymes; Ru retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogénital sinus-derived
- 157growth inhibitory factor; urokinase receptor antagonists; vapreotide; vanohn B; vector System, érythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
Yet other anticancer agents that can be employed in combination with a compound of this disclosure include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan, etc.), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include but are not limited to folie acid analog (e.g., methotrexate), pyrimidine analogs (e.g., cytarabine, etc.), or purine analogs (e.g., mercaptopurine, thioguanine, pentostatin, etc.).
Examples of natural products useful in combination with a compound of this disclosure include but are not limited to vinca alkaloids (e.g., vincristine, etc.), epipodophyllotoxins (e.g., etoposide, etc.), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin, etc.), enzymes (e.g., L-asparaginase, etc.), or biological response modifiers (e.g., interferon alpha, etc.).
Examples of alkylating agents that can be employed in combination a compound of this disclosure include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa, etc.), alkyl sulfonates (e.g., busulfan, etc.), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include, but are not limited to folie acid analog (e.g., methotrexate, etc.), pyrimidine analogs (e.g., fluorouracil, floxuridine, cytarabine, etc.), or purine analogs (e.g., mercaptopurine, thioguanine, pentostatin, etc.).
Examples of hormones and antagonists useful in combination a compound of this disclosure include, but are not limited to, adrenocorticosteroids (e.g., prednisone, etc.), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate and medroxyprogesterone acetate, etc.), estrogens (e.g., diethylstilbestrol and ethinyl estradiol, etc.), antiestrogen (e.g., tamoxifen, etc.), androgens (e.g., testosterone propionate, fluoxymesterone, etc.), antiandrogen (e.g., flutamide, etc.) and gonadotropin releasing hormone analog (e.g., leuprolide, etc.). Other agents that can be used in the methods and compositions described herein for the treatment or prévention of cancer include platinum coordination complexes (e.g., cisplatin, carboplatin, etc.), anthracenedione (e.g., mitoxantrone, etc.), substituted urea (e.g., hydroxyurea, etc.), methyl hydrazine dérivative (e.g., procarbazine, etc.) and adrenocortical suppressant (e.g., mitotane, aminoglutéthimide, etc.).
- 158Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with an irréversible Btk inhibitor compound include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8 and Spongistatin 9), Cemadotin hydrochloride (also known as LU-103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B,
Epothilone C (also known as desoxyepothilone A or dEpoA)), Epothilone D (also referred to as KOS862, dEpoB and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21hydroxyepothilone D (also known as Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad),
AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (also known as LY-355703),
AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL138067 and TI-13 8067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261),
H10 (Kansas State University), H16 (Kansas State University), Oncocidin Al (also known as BTO956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B. Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR-115781 (Aventis), Eleutherobins (such as
- 159Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta 5 Medica), Myoseverin B, D-43411 (Zéntaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate sait) (Wyeth), D-82317 (Zéntaris), D82318 (Zéntaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes) and SSR-250411 (Sanofi).
Examples
The following préparations of compounds of Formula (I) (Examples) and intermediates (References) are given to enable those skilled in the art to more clearly understand and to practice the présent disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and représentative thereof.
Common intermediates that had been made for the synthèses of the described examples are listed in Table A below:
Table A
Intermediate No. | Structure | Intermediate No. | Structure | |
1 | / \ O O Z λ—o + // - | 1-b | z: \ O O | |
2 | O O \ / | 6 | Cl f3cs°2 | |
3 | O O \ / | 7 | Cl | |
4 | O O \ / | 8 | Cl f\ XX XX F_________________________ |
- 160-
Reference 1
9-chloro-6,7-dimethoxy- lH,2H,3H-cyclopenta[b]quinolone (Intermediate 1)
Cl
Into a 3-L 4-necked round-bottom flask, was placed 2-amino-4,5-dimethoxybenzoic acid (80 g, 405.70 mmol, 1 eq), POCh (2.5 L) and cyclopentanone (37.8 g, 449.38 mmol, 1.10 eq). The solution was stirred at 110 °C for 16 h. After removal of the volatiles under reduced pressure, the remaining residue was treated with ice/water (1.0 L), basifïed with 1 N NaOH (aq) to pH=7~8 and extracted with a mixed solution of CILCh/methanol (MeOH) (7/7=10/1, 5 x 1.0 L). The organic layers were dried 10 over anhydrous Na2SÛ4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel column with ethyl acetate (EtOAc)/petroleum ether (1:1 ) to provide the title compound as a white solid (25.7 g, 24%). LCMS (ES) [M+l]+ m/z 264.0.
Reference 2
9-chloro-6,7-dimethoxy-l,2,3,4-tetrahydroacridine (Intermediate 2)
Cl
The title compound was made from 2-amino-4, 5-dimethoxybenzoic acid and cyclohexanone following a synthetic method similar as described for Intermediate 1 (reference 1). LCMS (ES) [M+l]+ m/z 278.1.
- 161 Reference 3
9-chloro-2,3-dimethoxyacridine (Intermediate 3)
Cl
Step 1
To a solution of methyl 4,5-dimethoxy-2-nitrobenzoate (10.0 g, 41.46 mmol, 1 eq) in MeOH (200 mL) was added 10% Pd/C (50% water moistened, 2.0 g). The mixture was degassed and purged with hydrogen gas three times. The mixture was stirred under H2 atmosphère at room température (rt) for 16 h. The solids were filtered off through a pad of celite. The filtrate was concentrated under reduced pressure to provide methyl 2-amino-4,5-dimethoxybenzoate as a yellow solid (7.6 g, 87%). LCMS (ES) [M+l]+ m/z 212.2.
Step 2
Into a 500-mL round-bottom flask, was placed methyl 2-amino-4,5-dimethoxybenzoate (7.5 g, 35.51 mmol, 1 eq), iodobenzene (8.7 g, 42.65 mmol, 1.20 eq), 1,4-dioxane (150 mL), CS2CO3 (23.2 g, 71.20 mmol, 2 eq), XantPhos (2.1 g, 3.63 mmol, 0.10 eq) and Pd2(dba)s (1.8 g, 1.97 mmol, 0.05 eq). The mixture was stirred for 16 h at 100 °C under N2. The mixture was filtered and the filter cake was washed with EtOAc (2 x 100 mL). The filtrate was concentrated under reduced pressure and the residue was purified by chromatography on silica gel column with EtOAc/Hexanes troleum (1:2) to provide methyl 4,5-dimethoxy-2-(phenylamino)benzoate as a light yellow solid (4.55 g, 45%). LCMS (ES) [M+l]+ m/z 288.1.
Step 3
Into a 100-mL round-bottom flask, was placed methyl 4,5-dimethoxy-2-(phenylamino)benzoate (4.5 g, 15.66 mmol, 1 eq), MeOH (40 mL), water (10 mL) NaOH (1.3 g, 31.32 mmol, 2 eq). The solution was stirred for 4 h at 80 °C. The solution was concentrated under reduced pressure. To the residue was added water (20 mL) and acidified with HCl (1 mol/L) (pH ~4). The mixture was extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (30 mL), dried over anhydrous Na2SÛ4 and concentrated under reduced pressure to provide 4,5-dimethoxy-2(phenylamino)benzoic acid as a light yellow solid (3.58 g, 84%). LCMS (ES) [M+l]+ m/z 274.2. Step 4
Into a 100-mL round-bottom flask, was placed a solution of 4,5-dimethoxy-2(phenylamino)benzoic acid (2.0 g, 7.32 mmol, 1 eq) and POCI3 (40 mL). The solution was stirred for
- 162 16 h at 110 °C. The mixture was concentrated under reduced pressure and ice water (50 mL) was added, basified with 10% NaHCCL (aq) to pH 7~8 and extracted with EtOAc (200 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel with EtOAc/Hexanes (1:1) as eluents to provide the title compound as a light yellow solid (1.54 g, 77%). LCMS (ES) [M+l]+ m/z 274.1.
Reference 4 l-chloro-2,3-dimethoxy-6H,7H,8H,9H,10H-cyclohepta[b]quinolone (Intermediate 4)
Cl
-λ
The title compound was made from 2-amino-4, 5-dimethoxybenzoic acid and cycloheptanone following a synthetic method similar as described for Intermediate 1 (reference 1), except that the final crude product was purified by flash chromatography on silica gel with EtOAc/Hexanes (1:1) as eluents to provide the title compound as ayellow solid 1.7 g (21%). LCMS (ES) [M+l] m/z 292.0.
Reference 5
9-chloro-2,3-dimethoxy-6H,7H,8H-cyclopenta[b] 1,5-naphthyridine(Intermediate 5)
To a solution of 5-bromo-6-methoxypyridine-2-carboxylic acid (500 mg, 2.15 mmol, 1 eq) in sulfuric acid (10 mL) in ice bath was added HNO3 (5 mL) dropwise. The solution was stirred at 60 °C for 16 h. After cooling to rt, the solution was poured into ice/water (20 mL). The solids were collected by filtration to provide 3-amino-5-bromo-6-methoxypyridine-2-carboxylic acid as a light yellow solid (260 mg, 44%). LCMS (ES) [M-l]' m/z 275.0.
Step 2
To 5-bromo-6-methoxy-3-nitropyridine-2-carboxylic acid (2.6 g, 9.39 mmol, 1 eq) in EtOH (25 mL) and water (25 mL) was added NH4CI (1.49 g, 28.17 mmol, 3 eq) and Fe (dust) (2.63 g, 46.95 mmol, 5 eq). The mixture was stirred at 70 °C for 3 h. The mixture was basified with 2.0 N NaOH (aq) to pH ~10. The precipitate was filtered. The filter cake was washed with MeOH/H2O (V/V=\l\, 2 x 50 mL). The filtrate was concentrated under reduced pressure. The residue was redissolved in DMF (20 mL), filtered and subjected to reverse phase préparative HPLC (Prep-C18, 20-45 μΜ, 120 g, Tianjin
- 163 Bonna-Agela Technologies-, gradient elution of 0% MeCN in water to 5% MeCN in water over a 7 min period, 100% MeCN to 100% MeCN over a 4 min period, where both solvents contain 0.05% FA) to provide 3-amino-5-bromo-6-methoxypyridine-2-carboxylic acid as a light yellow solid (1.0 g, 43%). LCMS (ES) [M-l]- m/z 245.0.
Step 3
To a solution of 3-amino-5-bromo-6-methoxypyridine-2-carboxylic acid (1.0 g, 4.05 mmol, 1 eq) in POCh (30 mL) was added cyclopentanone (680 mg, 8.10 mmol, 2 eq). The solution was stirred at 90 °C for 16 h. The mixture was concentrated under reduced pressure. To the residue was added CH2 Ch(25 mL) and the mixture was slowly added into ice/water ( 100 mL) dropwise. The mixture was then basified with 2.0 N NaOH (aq.) to pH = 10 and extracted with EtOAc thrice. The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel column with EtOAc/Hexanes (1/2) as eluents to provide 3bromo-9-chloro-2-methoxy-6H, 7H, 8H-cyclopenta[b] 1, 5-naphthyridine as a light yellow solid (700 mg, 55%). LCMS (ES) [M+l]+ m/z 315.1.
Step 4
To a solution of 3-bromo-9-chloro-2-methoxy-6H,7H,8H-cyclopenta[b]l,5-naphthyridine (700 mg, 2.23 mmol, 1 eq) and 4,4,5,5-tetramethyl-2-(propan-2-yloxy)-l,3,2-dioxaborolane (1.24 g, 6.69 mmol, 3 eq) in dry THF (15 mL) at -78 °C under N2 atmosphère was added nBuLi (2.7 mL, 2.5 M in hexane, 6.69 mmol, 3 eq) dropwise. The solution was stirred at -78 °C for 1 h before being quenched with H2O (2 mL) followed with H2O2 (30% aq., 2 mL). The mixture was stirred at rt for additional 1 h. To the solution was added saturated aq.Na2SO3 (30 mL) and the mixture was stirred at rt for 30 min. The crude mixture was extracted with EtOAc (5 x 50 mL). The organic layers were combined, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel column with EtOAc/Hexanes (2/1) as eluents to provide 9-chloro-2methoxy-6H, 7H, 8H-cyclopenta[b] 1, 5-naphthyridin-3-ol as a light yellow solid (301 mg, 54%). LCMS (ES) [M+l]+ m/z 251.2.
Step 5
To a solution of 9-chloro-2-methoxy-6H,7H,8H-cyclopenta[b]l,5-naphthyridin-3-ol (301 mg, 3.99 mmol, 1.2 eq) in MeCN (10 mL) was added K2CO3 (490 mg g, 3.02 mmol, 3 eq) and Mel (256 mg, 1.8 mmol, 1.50 eq). The mixture was stirred for 1 h at rt. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel column with EtOAc/Hexanes (2:1) as eluents to provide 204 mg (65%) of the title compound as an off-white solid. LCMS (ES) [M+l]+ m/z 265.0.
- 164-
Reference 6
9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6-ol (Intermediate 1-b)
Cl
Step 1
Into a 2-L 4-necked round-bottom flask was placed 9-chloro-6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolone (Intermediate 1) (31.6 g, 0.12 mol, 1 eq), CH2CI2 (1.0 L) followed by AICI3 (47.88 g, 0.36 mol 3 eq). The solution was stirred at 40 °C for 16 h. This reaction was repeated in this same scale for 4 batches. The reaction mixtures were combined, treated with ice/water (2.0 L) and basified with aq. NaOH (1.0 N) to pH 7~8. The mixture were combined and directly used in the next 10 step without purification.
Step 2
To the above mixture was added CH2CI2 (2.0 L), BOC2O (314 g, 1.44 mol, 3 eq) and 4dimethylaminopyridine (6.1 g, 0.05 mol, 0.10 eq). The mixture was stirred at rt for 16 h. The organic layer was separated. The water layer was back extracted with a mixed solution of CH2C12/MeOH j5 (FÆ=10/l, 3.0 L) thrice. Ail the organic layers were combined and dried over anhydrousNa2SO4. After removal of the organic solvents under reduced pressure, the residue was purified by chromatography on silica gel column with EtOAc/Hexanes (5:1 to 1:1) as eluents to provide tert-butyl 9-chloro-7methoxy-2,3-dihydro-lH-cyclopenta[b]quinolin-6-yl carbonate as white solid (48 g, 20%), LCMS (ES) [M+l]+ m/z 350.1; and tert-butyl 9-chloro-6-methoxy-2,3-dihydro-lH-cyclopenta [b]quinolin-7-yl 20 carbonate as a white solid (50 g, 21%), LCMS (ES) [M+l]+ m/z 350.1.
Step 3
Into a rt solution of tert-butyl 9-chloro-7-methoxy-2,3-dihydro-lH-cyclopenta[b]quinolin-6-yl carbonate (48.0 g, 0.14 mol, 1 eq) in CH2CI2 (500 mL) was added a sat. HCl solution in 1,4-dioxane (175 mL) dropwise. The solution was stirred at rt for 16 h. After removal of volatiles under reduced 25 pressure, the residue was triturated with EtOAc (2 x 200 mL) to provide of the title compound as a light brown solid (25.26 g, 74%). LCMS (ES) [M+l]+ m/z 250.0.
- 165Reference 7
9-chloro-6-methoxy-1 H,2H,3H-cyclopenta[b]quinol in-7-ol (Intermediate 1-a)
Cl
T T)
To a solution of tert-butyl 9-chloro-6-methoxy-2,3-dihydro-lH-cyclopenta[b]quinolin-7-yl carbonate (Reference 6, step 2) ( 1.2 g, 3.43 mmol, 1 eq) in CH2CI2 (20 mL) was added a sat. HCl solution in 1,4-dioxane (10 mL) sat. HCl (gas) dropwise. The solution was stirred at rt for 16 h. After removal of organic volatiles under reduced pressure, the remaining residue was triturated with EtOAc (2x10 mL) to provide the title compound as an off-white solid (769.1 mg, 90 %). LCMS (ES) [M+l]+ m/z 250.0.
Reference 8
9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6-yl trifluoromethanesulfonate (Intermediate 6)
Cl
To 9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6-ol (Intermediate 1-b, reference 6) (450 mg; 1.80 mmol; 1 eq.) in CH2CI2 (7 mL) and Et3N (3 mL) in ice bath under N2 atmosphère was added trifluoromethanesulfonyl trifluoromethanesulfonate (762.71 mg; 2.70 mmol; 1.50 eq.) dropwise. The mixture was allowed to warm with the ice bath to rt and stir at rt for 6 hr. The mixture was concentrated under reduced pressure and the remaining residue was purified by flash chromatography on silica gel column with 0-5% MeOH/CIECh as eluent to provide the title compounds as an off-white solid (350 mg, 51%), LCMS (ES) [M+l]+ m/z 382.1.
Reference 9
9-chloro-3-cyclopropyl-2-methoxy-6H,7H,8H-cyclopenta[b] 1,5-naphthyridine (Intermediate 7)
A mixture of 9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6-yl trifluoromethane sulfonate (Intermediate 6) (50 mg; 0.13 mmol; 1 eq.), cyclopropylboronic acid (13.50 mg; 0.16 mmol;
1.20 eq.), Pd(dppf)2Cl2.CH2C12 (10.70 mg; 0.01 mmol; 0.10 eq.) and K2CO3 (54.22 mg; 0.39 mmol; 3
- 166eq.) in toluene (1.5 mL) and water (0.2 mL) was purged with N2 for 2 mm. The reaction vessel was sealed and the mixture was stirred at 80 °C for 90 min. The mixture was cooled to rt, diluted with water and extracted with EtOAc thrice. The combined organic layers were concentrated under reduced pressure. The remaining residue was purified by flash chromatography on silica gel column with ΟΙ 00% EtOAc/Hexanes as eluent to provide the title compound as a white solid (22 mg, 62%). LCMS (ES) [M+l]+ m/z 274.0.
Reference 10
9-chloro-6-(difluoromethoxy)-7-methoxy-lH,2H,3H-cyclopenta[b]quinolone (Intermediate 8)
Into 9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6-ol (Intermediate 1-b) (491 mg; 1.97 mmol; 1 eq.) and KOH (3309.81 mg; 58.99 mmol; 30 eq.) in MeCN (2 mL) and water (2 mL) in an ice bath was added diethyl bromo(difluoro)methylphosphonate (2*100.2 mg; 7.87 mmol; 4 eq.). After 5 min, the mixture was removed from ice bath and was stirred at rt for 60 min and then at 50 °C for 60 min subsequently. The mixture was cooled to rt, diluted with water and extracted with EtOAc thrice. The organic layers were combined. After removal of the organic volatiles under reduced pressure, the remaining residue was purified by chromatography on silica gel column with 0-50% EtOAc/Hexanes to provide the title compound as an off white solid (385 mg, 65%). LCMS (ES) [M+l]+ m/z 300.1.
Reference 11
2-( {9-chloro-7-methoxy-1 H,2H,3H-cyclopenta[b]quinolin-6-yl}oxy)ethan-1 -ol (Intermediate 9)
To a vial charged with a solution of 9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6-ol (Intermediate 1-b) (315 mg; 1.26 mmol; 1 eq.) in toluene (1.0 mL ) was added a solution of (tributylphosphoranylidene)acetonitrile (761.20 mg; 3.15 mmol; 2.50 eq.) in toluene (0.4 mL). The mixture was stirred at 130 °C for 15 min whileN2was used to blow off most solvent. To the résidé was added ethane-l,2-diol (1 174.53 mg; 18.92 mmol; 15 eq.) in toluene (0.8 mL). The mixture was stirred at 130 °C for 30 min while N2 was used to blow off most of the solvents. The vial was cooled to rt and
- 167the residue was subjected to purification by chromatography silica gel column with 0-100% EtOAc/Hexanes as eluents to provide 2-({9-chloro-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-6yl}oxy)ethan-l-ol (354 mg, 96%). LCMS (ES) [M+l]+ m/z m/z 294.2.
Example 1
6,7-dimethoxy-N-(propan-2-yl)-lH,2H,3H-cyclopenta[b]quinolin-9-amine formate
To Intermediate 1 (200 mg, 0.76 mmol, 1 eq), toluene (5 mL), propan-2-amine (448 mg, 7.60 mmol, 10 eq), t-BuONa (146 mg, 1.52 mmol, 2 eq) was added chloro[2-(dicyclohexylphosphino)-3,6dimethoxy-2',4', 6'-triisopropyl-l,T-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) (BrettPhos Pd Gl, Methyl t-Butyl Ether Adduct) (34 mg, 0.04 mmol, 0.05 eq). The mixture was purged with N2 for 5 min, and stirred at 90 °C under N2 for 2 h, cooled to rt and concentrated under reduced pressure. The residue was dissolved in DMF (5 mL) and the solution was filtered and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ SunFire column, 19 x 150 mm, Waters; gradient elution of 21 % MeCN in water to 36 % MeCN in water over a 6 min period, where both solvents contain 0.1% FA) to provide the title compound as a white solid (71.8 mg, 28 %). LCMS (ES) [M-FA+1]+ m/z 287.2.
Example 2
N- {6,7-dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin-9-yl} -1 -(propan-2-yl)piperidin-4-amine;
bis(formic acid)
A mixture of Intermediate 1 (200 mg, 0.75 mmol) in 1,4-dioxane (6 ml) in a 20 mL microwave reaction vial was purged with Ar gas for 5 min. To the mixture was added l-isopropylpiperidin-4-amine (130 mg, 1.15 mmol), chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4', 6'-triisopropyl-l,Tbiphenyl][2-(2-aminoethyl)phenyl]palladium(II) (BrettPhos Pd Gl, Methyl t-Butyl Ether Adduct, 60 mg) followed by ‘BuONa (293 mg, 3.03 mmol). The reaction vial was sealed and subjected to a microwave reactor at 115 °C for 45 min. The mixture was cooled to rt, treated with water and extracted with 10%MeOH/CH2C2 thrice. The combined organic layers were concentrated under reduced pressure.
- 168The remaining residue was redissolved in DMSO, filtered and subjected to purification on reverse phase préparative HPLC (Prep-C18, 5 μΜ SunFire column, 19 x 150 mm, Waters; gradient elution of 5 % MeCN in water to 25 % MeCN in water over a 6 min period, where both solvents contain 0.1% FA) to provide the title compound as an off- white solid. LCMS (ES) [M-2FA+1]+ m/z 370.4.
Example 3
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinoIin-9-yl}-l-methylpiperidin-4-amine -2HC1
A mixture of Intermediate 1 (80 mg, 0.3 mmol) in 1,4-dioxane (2 ml) in a 10 mL microwave reaction vial was purged with Ar gas for 5 min. To the mixture was added l-methyl-4-piperidine (52 mg, 0.46 mmol), chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4', 6'-triisopropyl-l,l'biphenyl][2-(2-aminoethyl)phenyl] palladium(II) (BrettPhos Pd Gl, Methyl t-Butyl Ether Adduct, 24 mg) followed by ‘BuONa (117 mg, 1.21 mmol). The reaction vial was sealed and subjected to a microwave reactor at 115 °C for 45 min. The mixture was cooled to rt, diluted with water and acetonitrile and filtered through a small pad of celite. The solution was subjected to purification on reverse phase préparative HPLC (Waters XSelect CSH C18 colümn, gradient elution of 10% MeCN in water to 40% MeCN in water over 13 min, where both solvents contain 0.1% HCl) to provide the title compound as an off- white solid (95 mg, 75%). LCMS (ES) [M-2HC1+1]+ m/z 342.4.
Example 4
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}piperidin-4-amine; bis(formic acid)
C^NH
Step 1
A mixture of Intermediate 1 (320 mg, 1.2 mmol) in 1,4-dioxane (6 ml) in a microwave reaction vial was purged with Ar gas for 5 min. To the mixture was added tert-butyl 4-aminopiperidine-l-carboxylate (320 mg, 1.6 mmol), chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4', 6'-triisopropyl-l,l'biphenyl][2-(2-aminoethyl)phenyl]palIadium(II) (BrettPhos Pd Gl, Methyl t-Butyl Ether Adduct, 96 mg) followed by ‘BuONa (468 mg, 4.85 mmol). The reaction vial was sealed and subjected to a
- 169microwave reactor at 115 °C for 45 min. The mixture was cooled to rt, diluted with water and extracted with 10%MeOH/CH2Ch thrice. The organic layers were combined. After removal of the organic solvents under reduced pressure, the residue purified by chromatography on silica gel column with 010% MeOH/CH2C12 as eluents to provide tert-butyl 4-({ 6,7-dimethoxy-1 H,2H,3Hcyclopenta[b]quinolin-9-yl}amino)piperidine-l-carboxylate as white solid (390 mg, 77%).
Step 2
To a rt solution of tert-butyl 4-({6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9yl}amino)piperidine-l-carboxylate as white solid (190 mg, 0.44 mmol) in CH2CI2 (5mL) was added trifluoroacetic acid (TFA, 2 mL). The mixture was stirred at 45 °C for 30 min. After removal of the organic volatiles under reduced pressure, the remaining residue was redissolved in DMF and subjected to purification on reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, PLaters; gradient elution of 11 MeCN in water to 39% MeCN in water over a 6 min period, where both solvents contain 0.1% FA) to provide the title compound as an off- white solid as a white solid (120.8, 75%). LCMS (ES) [M-2FA+1]+ m/z 328.2.
Example 5 (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}piperidin-3-amine-2HCl
Step 1
To a rt solution of Intermediate 1 (300 mg; 1.14 mmol; 1 eq.) in 1,4-dioxane (4 mL) was added tert-butyl (3R)-3-aminopiperidine-l-carboxylate (341.75 mg; 1.71 mmol; 1.50 eq.) and chloro[2(dicyclohexylphosphino)-3,6-dimethoxy-2',4', 6'-triisopropyl-l,l'-biphenyl][2-(2-aminoethyl)phenyl] palladium(II) (BrettPhos Pd Gl, Methyl t-Butyl Ether Adduct, 45.44 mg) followed by 'BuONa (218.65 mg; 2.28 mmol; 2 eq.). The mixture was purged with N2 for 5 min and was stirred at 125 °C for 25 min. The mixture was cooled to rt, diluted with MeCN and the insoluble components were filtered off. The filtrate was concentrated under reduced pressure and the remaining residue was subjected purification by préparative HPLC (Waters XSelect CSH Cl8 column, gradient elution of 5% MeCN in water to 95% MeCN in water over a 13 min period, where both solvents contain 0.1% HCl) to give tert-butyl (R)-3-((6,7-dimethoxy-2,3-dihydro-lH-cyclopenta[b]quinolin-9-yl)amino)piperidine-l-carboxylate in HCl sait form as off-white solid.
- 170Step 2
To a solution of the above tert-butyl (R)-3-((6,7-dimethoxy-2,3-dihydro-lHcyclopenta[b]quinolin-9-yl)amino)piperidine-l-carboxylate HCl sait in CH2CI2 (2 mL) was added TFA (2 mL). The mixture was stirred at rt for 1 h. The mixture was concentrated under reduced pressure and the remaining residue was subjected to purification by préparative HPLC (Waters XSelect CSH Cl8 column, gradient elution of 5% MeCN in water to 40% MeCN in water over a 13 min period), where both solvents contain 0.1% HCl) to give the title compounds as a white solid. (344 mg, 75%). LCMS (ES) [M-2HC1+1]+ m/z 328.3.
Example 6 (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-methylpiperidin-3-amine -2HC1
A rt solution of (3R)-N-{6,7-dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin-9-yl}piperidin-3amine -2HC1 (Example 5) (0.20 g; 0.61 mmol; 1 eq.) and formaldéhyde (0.18 mL; 2.44 mmol; 4 eq.) in MeOH (2 mL) was stirred at rt for 10 min followed by sodium cyanoborohydride (0.12 g; 1.83 mmol; 3 eq.). The mixture was stirred at rt for 15 h, after which the crude solution was concentrated under reduced pressure. The remaining residue was diluted with water and MeCN and subjected to purification préparative HPLC (Waters XSelect CSH C18 column, gradient elution of 5% MeCN in water to 95% MeCN in water over a 13 min period, where both solvents contain 0.1% HCl) to give the title compound as white solid (93 mg, 45%). LCMS (ES) [M-2HC1+1 ] m/z 342.2.
Example 7
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-ethylpiperidin-4-amine -2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-ethyl-4-piperidine was used in the place of l-methyl-4piperidine. The title compound was obtained as an off-white solid. LCMS (ES) [M-2HC1+1]+ m/z 356.3.
- 171 -
Example 8
N-[(azetidin-3-yl)methyl]-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-amine -2HC1
The title compound was made from Intermediate 1 and following a 2-step synthetic method similar as described for Example 5, except that tert-butyl 3-(aminomethyl)azetidine-l-carboxylate was used in the place of tert-butyl 3-aminopiperidine-l-carboxylate. The title compounds was obtained as an off-white solid. LCMS (ES) [M-2HC1+1]+ m/z 314.2.
Example 9
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}azetidin-3-amine -2HC1
The title compound was made from Intermediate 1 and following a 2-step synthetic method similar as described for Example 5, except that tert-butyl 3-amino- 1-azetidinecarboxylate was used in the place of tert-butyl 3-aminopiperidine-l-carboxylate. The title compounds was obtained as an offwhite solid. LCMS (ES) [M-2HC1+1]+ m/z 300.4.
Example 10
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(oxan-4-yl)piperidin-4-amine 2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-tetrahydro-2H-pyran-4-yl-4-piperidinamine -2HC1 was used in place of l-methyI-4-piperidine. The title compounds was obtained as an off-white solid. LCMS (ES) [M-2HC1+1]+ m/z 412.5.
- 172-
Example 11
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(oxolan-3-yl)piperidin-4-amine -2HC1
L p
The title compound was made from Intermediate 1 foilowing a synthetic method similar as described for Example 3, except that l-(tetrahydrofuran-3-yl)piperidin-4-amine was used in place of l-methyl-4-piperidine. The title compounds was obtained as an off-white solid. LCMS (ES) [M2HC1+1]+ m/z 398.4.
Example 12
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-2-azaspiro[3.3]heptan-6-amine -2HC1
The title compound was made from Intermediate 1 foilowing a 2-step synthetic method similar as described for Example 5, except that tert-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate was used in place of tert-butyl (3R)-3-aminopiperidine-l-carboxylate. The title compounds was obtained as a colorless solid. LCMS (ES) [M-2HC1+1]+ m/z 340.2.
Example 13 N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(pyridin-4-yl)piperidin-4-amine 2HC1
The title compound was made from Intermediate 1 foilowing a synthetic method similar as described for Example 3, except that l-(4-pyridinyl)-4-piperidinamine -2HC1 was used in place of 1methyl-4-piperidine. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]” m/z 405.3.
- 173 -
Example 14
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(pyridin-3-yl)piperidin-4-amine -2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-(Pyridin-3-yl)piperidin-4-aminewas used in place of 1-methyl4-piperidine. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 405.2.
Example 15
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(pyridin-2-yl)piperidin-4-amine -2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-(2-Pyridinyl)-4-piperidinylamine was used in place of 1methyl-4-piperidine. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 405.2.
Example 16
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(2-fluorophenyl)piperidin-4-amine hydrochloride
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-(2-fluorophenyl)piperidin-4-amine was used in place of 1methyl-4-piperidine. The final crude product was purified by reverse phase préparative HPLC
- 174 (Phenomenex Luna Cl8 column, gradient elution of 10% MeCN m water to 40% MeCN in water over a 13 min period, where both solvents contain 0.1% HCl) to give the title compound as white a yellow solid. LCMS (ES) [M-2HC1+1]+ m/z 422.3.
Example 17
N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-ethylazetidin-3-amine -2HC1
To N- {6,7-dimethoxy- lH,2H,3H-cyclopenta[b]quinolin-9-yl}azetidin-3-amine (HCl)? (Example 9; 40 mg; 0.13 mmol; 1 eq.) and Hunig's base (0.23 mL; 1.34 mmol; 10 eq.) in N,Ndimethylformamide (1.34 mL) at ambient température was added iodoethane (0.01 mL; 0.13 mmol; 1 eq.) drop-wise. The mixture was stirred at ambient température ovemight (17 h) then it was diluted with 1:1 PhMe/EtOAc, washed with brine, dried over MgSO4, fïltered and concentrated. The residue was taken up in 1.0 N HCl (1.5 mL) and subjected to purification by reverse phase préparative HPLC (Waters XSelect CSH C18 column, gradient elution of 0% MeCN in water to 70% MeCN ;n water over a 13 min period, where both solvents contain 0.1% HCl) to provide the title product as a colorless powder (4.6 mg; 11%). LCMS (ES) [M-2HC1+1]+ m/z 328.4.
Example 18
6,7- dimethoxy-N-[l-(propan-2-yl)piperidin-4-yl]-l,2,3,4-tetrahydroacridin-9-amine; bis (formic acid)
The title compound was made from Intermediate 2 and l-isopropylpiperidin-4-amine following a synthetic method similar as described for Example 2. The crude final compound was purified by reverse phase préparative HPLC (Prep-C18, 5 μΜ SunFire column, 19 x 150 mm, Waters; gradient elution of 2 % MeCN in water to 11 % MeCN in water over a 6 min period, where both solvents contain 0.1% FA) to provide the title compound as a white solid (71.8 mg, 21%). LCMS (ES) [M2FA+1]+m/z 384.3.
- 175 -
Example 19
N- {2,3-dimethoxy-6H,7H,8H,9H, 1 OH-cyclohepta[b]quinolin-11 -yl}-1 -(propan-2-yl)piperidin-4amine; bis(formic acid)
Into a 40-mL vial was placed Intermediate 4 (300 mg, 1.03 mmol, 1 eq), 1,4-dioxane (20 mL), l-(propan-2-yl)piperidin-4-amine (438.8 mg, 3.09 mmol, 3 eq), ‘BuONa (296.6 mg, 3.09 mmol, 3 eq) and 3rd BrettPhos precatalyst (45 mg, 0.05 mmol, 0.05 eq). The mixture was purged with N2 for 5 min and then stirred 90 °C under N2 for 2 h. The mixture was filtered and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, Waters; gradient elution of 2% MeCN in water to 17% MeCN in water over a 6 min period, where both solvents contain 0.1% FA) to provide the title compound as an off- white solid (216.4 mg, 47%). LCMS (ES) [M-2FA+1]+ m/z 398.2.
Example 20
6,7-dimethoxy-N-{[l-(propan-2-yl)azetidin-3-yl]methyl}-lH,2H,3H-cyclopenta[b]quinolin-9amine -2HC1
O
The title compound was made from Intermediate 1 foilowing a synthetic method similar as described for Example 3, except that (l-isopropylazetidin-3-yl)methanamine was used in place of 1methyl-4-piperidine. The title compounds was obtained as an off white solid. LCMS (ES) [M-2HC1+1]+ m/z 356.2
- 176-
Example 21
6,7-dimethoxy-N-[(l-methyl-lH-imidazol-4-yl)methyl]-lH,2H,3H-cyclopenta[b]quinolin-9amine -2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-(4-pyridinyl)-4-piperidinamine -2HC1 was used in place of 1methyl-4-piperidine. The title compound was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 339.1.
Example 22
3-chloro-2-[4-({6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}amino)piperidin-l-yl]propanl-ol -2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-(oxetan-3-yl)piperidin-4-amine oxalate was used in place of 115 methyl-4-piperidine. The title compounds was obtained as a tan solid. LCMS (ES) [M-2HC1+1]+ m/z 420.3.
Example 23
-benzyl-N-{6,7-dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin-9-yl}piperidin-4-amine -2HC1
- 177The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-benzyl-4-piperidinamine was used in place of l-methyl-4piperidine. The title compounds was obtained as an off white solid. LCMS (ES) [M-2HC1+1]+ m/z 418.4.
Example 24 (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}azepan-3-amine -2HC1 hn+Oh
T X>
The title compound was made from Intermediate 1 following a 2-step synthetic method similar as described for Example 5, except that tert-butyl (R)-3-aminoazepane-l-carboxylate was used in place of tert-butyl (3R)-3-aminopiperidine-l-carboxylate. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 342.1.
Example 25
2-[(7-methoxy-9-{[l-(propan-2-yl)piperidin-4-yi]amino}-lH,2H,3H-cyclopenta[b]quinolin-6yl)oxy]ethan-l-ol -2HC1
Step 1
To a solution of Intermediate 9 (354 mg; 1.21 mmol; 1 eq) and diisopropylethyl amine(1.0 mL) in CH2CI2 (3 mL) and DMF (1.5 mL) under N2 atmosphère in ice bath was added tertbutyl(chloro)dimethylsilane (272.46 mg; 1.81 mmol; 1.50 eq.). The mixture was allowed to warm with ice bath to rt and stir at rt for 1.5 h. The mixture was concentrated under reduced pressure and the remaining residue was dissolved in EtOAc, washed with water and brine. After removal of the organic volatiles under reduced pressure, the residue was purified by chromatography on silica gel column with 0-30% EtOAc/Hexanes as eluents to provide 6-{2-[(tert-butyldimethylsilyl)oxy]ethoxy}-9-chloro-7methoxy-lH,2H,3H-cyclopenta[b]quinoline as white solid (360 mg, 73%) LCMS (ES) [M+l]+m/z 408.8.
- 178 Step 2
A mixture of 6-{2-[(tert-butyldimethylsilyl)oxy]ethoxy}-9-chloro-7-methoxy-lH,2H,3Hcyclopenta[b]quinoline (90 mg, 0.22 mmol) in 1,4-dioxane (2 ml) in a 10 mL microwave reaction vial was purged with Ar gas for 5 min. To the mixture was added l-methyl-4-piperidine (52 mg, 0.46 mmol), 5 chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4', 6'-triisopropyl-l,l'-biphenyl][2-(2aminoethyl)phenyl]palladium(II) (BrettPhos Pd Gl, Methyl t-Butyl Ether Adduct, 18 mg; 0.023 mol; 0.10 eq) followed by ‘BuONa (99 mg, 0.88 mmol, 4.0 eq). The reaction vial was sealed and subjected to a microwave reactor at 120 °C for 30 min. The mixture was cooled to rt, diluted with water and extracted with EtOAc thrice. After removal of organic solvents under reduced pressure, the residue was 10 purified by chromatography on silica gel column with 0-100% EtOAc/Hexanes as eluents to provide N-(6-{2-[(tert-butyldimethylsilyl)oxy]ethoxy}-7-methoxy-lH,2H,3H-cyclopenta[b]quinoIin-9-yl)-l(propan-2-yl)piperidin-4-amine as a white solid (75mg, 66%). LCMS (ES) [M+l]‘ m/z 513.8.
Step 3
To a solution N-(6-{2-[(tert-butyldimethylsiIyl)oxy]ethoxy}-7-methoxy-lH,2H,3H15 cyclopenta[b]quinolin-9-yl)-l-(propan-2-yl)piperidin-4-amine (75 mg, 0.15 mmol) in CH2CI2 (0.5 mL) was added tetrabutylammonium fluoride (1.5 mL, 1.0 N in THF) and water (0.4 mL). The mixture was stirred 50 °C for 25 min. The organic solvents were removed under reduced pressure, the remaining mixture was treated with water and extracted with 25% ‘PrOH/chloroform thrice. After removal of organic volatiles under reduced pressure, the residue was redissolved in DMSO, filtered and subjected 20 to purification on reverse phase préparative HPLC (Waters XSelect CSH C18 column, gradient elution of 0% MeCN in water to 20% MeCN in water over a 20 min period, where both solvents contain 0.1% HCl) to provide the title compound as an off- white solid. LCMS (ES) [M-2HC1+1]’ m/z 400.2
Example 26
N-{6-cyclopropyl-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-(propan-2-yl)piperidin-425 amine -2HC1
- 179The title compound was made from Intermediate 7 following a synthetic method similar as described for Example 3, except that l-isopropylpiperidin-4-amine was used in place of l-methyl-4piperidine. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 380.2.
Example 27
1-cyclopentyl-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}piperidin-4-amine -2HC1
The title compound was made from Intermediate 1 following a synthetic method similar as described for Example 3, except that l-Cyclopentyl-4-piperidinylamine was used in place of 1-methyl4-piperidine and N-Methyl-2-pyrrolidinone was used as solvent. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1F m/z 396.2.
Example 28 (4R)-N-{6,7-dimethoxy-lH,2H,3EI-cyclopenta[b]quinolin-9-yl}azepan-4-amine -2HC1
The title compound was made from Intermediate 1 following a 2-step synthetic method similar as described for Example 5, except that tert-butyl (R)-4-aminoazepane- 1-carboxylate was used in place of tert-butyl (3 R)-3-aminopiperidine-1-carboxylate. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 342.2.
Example 29 (4R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-methylazepan-4-amine -2HCI
- 180The title compound was made from (4R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinohn9-yl}azepan-4-amine 2HC1 (Example 28) following a synthetic method similar as described for Example 6. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 356.1.
Example 30
N- { 6,7-dimethoxy-1 H,2H,3 H-cyclopenta[b]quinolin-9-y 1} -1 -(propan-2-yl)azetidin-3 -am ine · 2HC1
The title compound was made from N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9yl}azetidin-3-amine -2HC1 (Example 9) (50 mg; 0.17 mmol; 1 eq.), following a synthetic method similar as described for Example 6, except that propan-2-one was used in place of formaldéhyde. The title compounds was obtained as colorless powder. LCMS (ES) [M-2HC1+1]1 m/z 342.4
Example 31 (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-l-methylazepan-3-amine -2HC1
The title compound was made from (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin9-yl}azepan-3-amine -2HC1 (Example 24) following a synthetic method similar as described for Example 6. The title compounds was obtained as a white solid. LCMS (ES) [M-2HC1+1]+ m/z 356.3.
Example 32
N-[2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5-naphthyridin-9-yl]-l-(propan-2-yl)piperidin-4amine (bis formic acid sait)
- 181 Into a 40-mL vial, was placed Intermediate 5 (150 mg, 0.57 mmol, 1 eq.), dioxane (10 mL), 1(propan-2-yl)piperidin-4-amine (243 mg, 1.71 mmol, 3 eq.), t-BuONa (164 mg, 1.71 mmol, 3 eq.) and 3rd BrettPhos precatalyst (27 mg, 0.03 mmol, 0.05 eq.). The mixture was stirred for 2 h at 90°C under N2 and concentrated under vacuum. The residue was diluted with DMF (5 mL), filtered and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, Waters; gradient elution of 2% MeCN in water to 20 % MeCN in water over a 6-min period, where both solvents contain 0.1% FA) to provide the title compound as a white solid (82.9 mg, 32%). 'H NMR (300 MHz, DMSOdô) δ 10.53 (br, 1H), 7.54 (s, 1H), 7.20 (br, 1H), 4.63-4.43 (m, 1H), 4.15 (s, 3H), 3.97 (s, 3H), 3.60-3.32 (m, 3H), 3.19-3.08 (m, 6H), 2.27-2.03 (m, 6H), 1.32 (d, .7=7.2 Hz, 6H). LCMS (ES) [M+l]+ m/z 371.2.
Example 33 (3R)-N-[2, 3-dimethoxy-6H, 7H, 8Hcyclopenta [b] 1,5 naphthyridin-9-yl] piperidin-3-amine-HCl
Into a 40-mL vial, was placed a mixture of Intermediate 5 (120 mg, 0.45 mmol, 1 eq.), dioxane (10 mL), tert-butyl (3R)-3-aminopiperidine-l-carboxylate (270 mg, 1.35 mmol, 3 eq.), 3rd BrettPhos precatalyst (18 mg, 0.02 mmol, 0.05 eq.) and t-BuONa (130 mg, 1.35 mmol, 3 eq.). The mixture was stirred for 2 h at 90°C under N2 and then concentrated under vacuum. The residue was purified by a silica gel column eluted with dichloromethane (CHaChj/MeOH (10/1) to provide (7R)-l-tert-butyl-7([2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5-naphthyridin-9-yl]amino)-lA[3],3-oxazocan-2-one an off-white solid (132 mg, 68%). LCMS (ES) [M+l]+m/z 429.2.
To a solution of tert-butyl (R)-3-((2,3-dimethoxy-7,8-dihydro-6Hcyclopenta[b][l,5]naphthyridin-9-yl)amino)piperidine-l-carboxylate (132 mg, 0.31 mmol, 1 eq.) in CH2CI2 (5 mL) was added HCl/dioxane (0.4 mL, 4M in dioxane, 1.55 mmol, 5 eq.). The solution was stirred for 2 h at rt. The mixture was concentrated under vacuum, diluted ±with DMF (5 mL), filtered and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, Waters; gradient elution of 2% MeCN in water to 12 % MeCN in water over a 6 min period, where both solvents contain 0.1% FA). To the eluent was added 1 M HCl (aq., 10 mL) and the solution was lyophilized to provide the title compound as brown solid (81.1 mg, 66%). 'H NMR (300 MHz, DMSOd6) δ 14.62 (br, 1H), 9.50 (br, 2H), 7.57 (br, 1H), 4.15 (s, 3H), 4.07 (s, 3H), 3.48-3.14 (m, 8H), 2.802.74 (m, 1H), 2.28-2.20 (m, 2H), 2.17-2.02 (m, 1H), 2.00-1.83 (m, 3H). LCMS (ES) [M+l]+ m/z 329.2.
- 182-
Example 34 (3R)-N-[2, 3-dimethoxy-6H, 7H, 8H-cyclopenta[b] 1, 5-naphthyridin-9-yl]-l-methylpiperidin-3amine-HCl
The title compound was made from Intermediate 5 foilowing a synthetic method similar as described for Example 32, except that (3 R)-1 -methylpiperidin-3 -amine was used in place of 1 -(propan2-yl)piperidin-4-amine. The title compound was obtained as a lyophilized off-white solid (44.2 mg, 23%). ’H NMR (300 MHz, DMSO-#6) δ 14.57 (br, 1H), 11.30 (br, 1H), 7.55 (s, 1H), 7.50 (br, 1H), 4.15 (s, 3H), 4.10 (s, 3H), 3.57-3.43 (m, 4H), 3.33-3.12 (m, 4H), 2.85-2.78 (m, 4H), 2.28-2.20 (m, 2H), 2.18-2.10 (m, 1H), 2.06-1.80 (m, 3H). LCMS (ES) [M+l]+m/z 343.2.
Example 35 (3R)-N-[2, 3-dimethoxy-6H, 7H, 8H-cyclopenta[b] 1, 5-naphthyridin-9-yl] azepan-3-amine HCl
The title compound was made from Intermediate 5 foilowing a synthetic method similar as described for Example 33, except that tert-butyl (3R)-3-aminoazepane-l-carboxylate was used in place of tert-butyl (3R)-3-aminopiperidine-l-carboxylate. The title compound was obtained as a lyophilized light brown solid (42.8 mg, 31%). ‘H NMR (300 MHz, MeOD) δ 7.38 (s, 1H), 4.21 (s, 3H), 4.06 (s, 3H), 3.75-3.60 (m, 4H), 3.56-3.40 (m, 3H), 3.28-3.20 (m, 2H), 2.44-2.33 (m, 3H), 2.11-2.00 (m, 4H), 1.85-1.76 (m, 1H). LCMS (ES) [M+l]+ m/z 343.2.
Example 36 (4R)-N-[2, 3-dimethoxy-6H, 7H, 8H-cyclopenta[b] 1, 5-naphthyridin-9-yl] azepan-4-amineHCl
- 183 The title compound was made from Intermediate 5 foilowing a synthetic method similar as described for Example 33, except that tert-butyl (4R)-4-aminoazepane-1 -carboxylate was used in place of tert-butyl (3R)-3-aminopiperidine-l-carboxylate. The title compound was obtained as a lyophilized light yellow solid (36 mg, 43%). ’H NMR (300 MHz, CD3OD) δ 7.36 (s, 1H), 4.18 (s, 3H), 4.05 (s, 3H), 3.69-3.65 (m, 2H), 3.61-3.57 (m, 3H), 3.40-3.34 (m, 2H) 3.24-3.21 (m, 2H), 2.39-1.95 (m, 8H). LCMS (ES) [M+l]+ m/z 343.2.
Example 37 (3R,5S)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5-methylpiperidin-3-amine
Tert-butyl N-[(3R,5S)-5-methylpiperidin-3-yl]carbamate (0.14 g; 0.64 mmol; 1 eq.) (Synthonix) was dissolved in CH2CI2 (dry, 2 ml). Triethylamine (0.11 mL; 0.77 mmol; 1.20 eq.) was added and the reaction was cooled in an ice bath. Benzyl chloroformate (0.10 mL; 0.74 mmol; 1.15 eq.) dissolved in 0.5 ml of CH2CI2 was then added dropwise. After 1.3 h, the reaction was quenched with 1 M HCl solution (2 ml) and partitioned into CH2CI2 (25 ml) and water (10 ml). The phases were separated and the aqueous phase was extracted once more with CH2CI2 (20 ml) The combined organics were dried overNa2SO4, evaporated and purified by silica gel chromatography (0-40% EtOAc/ CH2CI2) to give a film of benzyl (3R,5S)-3-{[(tert-butoxy)carbonyl]amino}-5-methylpiperidine-l-carboxylate (0.114 g, 51%). Ή NMR (400 MHz, Chloroform-J) δ 7.40 - 7.28 (m, 5H), 5.11 (s, 2H), 4.45 - 3.98 (m, 4H), 3.61-3.41 (m, 1H), 2.39-2.16 (m, 2H), 1.76-1.61 (m, 1H), 1.43 (s, 12H), 0.90 (d, J=6.6 Hz, 3H). MS (ES): (M+Na)+ = 371.3.
Benzyl (3R,5S)-3-{[(tert-butoxy)carbonyl]amino}-5-methylpiperidine-l-carboxyIate (114 mg; 0.33 mmol; 1 eq.) was dissolved in CH2CI2 (dry, 3 ml). The solution was cooled in an ice bath and trifluoracetic acid (1.10 mL; 0.30 mol/L; 0.33 mmol; 1.01 eq.) was added. The reaction was stirred at 25 0 C for 2 h and then evaporated. The residue was suspended with toluene (20 ml) and evaporated again to a residue which was used as-is in the next step.
Benzyl (3R,5S)-3-amino-5-methylpiperidine-l-carboxylate; trifluoroacetic acid (118.7 mg; 0.33 mmol; 1.20 eq.) and 9-chloro-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinoline (72 mg; 0.27 mmol; 1 eq.) were suspended in 1,4-dioxane (dry, 3 ml). The mixture was purged with Ar. BrettPhos Pd G1 (21.8 mg; 0.03 mmol; 0.10 eq.) (Aldrich) andNaO‘Bu (157.4 mg; 1.64 mmol; 6 eq.) were added,
- 184 the reaction vessel sealed and heated in a microwave reactor at 110 C for 50 m. After coolmg, the mixture was filtered through Celite, and then rinsed through with EtOAc and 5-10% MeOH/ CH2CI2. The filtrate was evaporated and purified by silica gel chromatography (0-10% MeOH/ CH2CI2) to give benzyl (3R,5S)-3-( {6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}amino)-5methylpiperidine-l-carboxylate (76 mg, 58% for Cbz-protected product). MS (ES): (M+HL = 476.4.
Benzyl (3R,5S)-3-({6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}amino)-5-methyl piperidine-l-carboxylate (76 mg; 0.16 mmol; 1 eq.) was dissolved in warm éthanol (absolute, 4 ml). 10% palladium on carbon (Aldrich, wet, ~90 mg) in éthanol (~ 1 ml) was then added and the reaction vessel was charged with an H2-filled balloon. After 3 h, the mixture was purged with nitrogen gas, filtered through celite and rinsed through with MeOH. After évaporation the crude residue was combined with deprotected product collected from the preceding step and purified by reverse phase chromatography (Waters XSelect CSH C18 column, 0.1% aqueous HCl/acetonitrile gradient). Lyophilization gave a white solid of (3R,5S)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9yl}-5-methylpiperidin-3-amine -2HC1 (66 mg, 64 % (two steps). *H NMR (400 MHz, DMSO-<76) δ 14.36 (s, 1H), 9.82 - 9.32 (m, 2H), 8.29 (d, J= 9.3 Hz, 1H), 8.01 (s, 1H), 7.30 (s, 1H), 4.66 (s, 1H), 4.05 - 3.85 (m, 6H), 3.31-3.03 (m, 8H), 2.43 - 2.29 (m, 1H), 2.18 - 2.03 (m, 3H), 1.81-1.62 (m, 1H), 0.96 (d, J= 6.5 Hz, 3H). MS (ES): (M+H)+ = 342.2.
Example 38
6,7-dimethoxy-N-{2-[(propan-2-yl)ammo]ethyl}-lH,2H,3H-cyclopenta[b]quinolin-9-amine
The title compound was made from Intermediate 1 following a 2-step synthetic method similar as described for Example 5, except that tert-butyl N-(2-aminoethyl)-N-(propan-2-yl)carbamate was used in place of tert-butyl (3R)-3-aminopiperidine-l-carboxylate. LCMS (ES) [M+H]^ m/z 330.1. 'H NMR (400 MHz, Methanol-À) δ 7.78 (s, 1H), 7.09 (s, 1H), 4.17 (t, J = 6.5 Hz, 2H), 4.01 (d, J= 19.8 Hz, 6H), 3.46 (p, J= 6.6 Hz, 1H), 3.40 (dt, J = 11.1, 7.0 Hz, 4H), 3.16 (t, J = 7.9 Hz, 2H), 2.36 - 2.24 (m, 2H), 1.39 (d, J= 6.5 Hz, 6H).
Example 39 (3R)-N-[2, 3-dimethoxy-6H, 7H, 8H-cyclopenta[b]l, 5-naphthyridin-9-yl]-l-methylazepan-3amine-HCl
- 185 -
Into a 8-mL vial, was placed a solution of (3R)-N-[2,3-dimethoxy-6H,7H,8H-cyclopenta[b]l,5naphthyridin-9-yl]azepan-3-amine hydrogen chloride (80 mg, 0.23 mmol, 1 eq.), MeOH (5 mL), CH2O (aq.) (1 mL), TEA (70 mg, 0.69 mmol, 3 eq.) and NaBH(OAc)3 (244 mg, 1.15 mmol, 5 eq.). The solution was stirred for 16 h at rt and concentrated under vacuum. The residue was diluted with MeOH (5 mL), fïltered and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, Waters; gradient elution of 2% MeCN in water to 18 % MeCN in water over a 6 min period, where both solvents contain 0.1% FA). The eluents were concentrated under vacuum and H2O (10 mL) and 1 M HCl (aq. 1 mL) were added. The solution was lyophilized to provide the title compound as a dark green solid (15.5 mg, 17%). *H NMR (300 MHz, CD3OD) δ 7.40 (s, 1H), 5.085.00 (m, 1H ), 4.22 (s, 3H), 4.06 (s, 3H), 3.89-3.68 (m, 2H), 3.60-3.52 (m, 3H), 3.40-3.33 (m, 1H), 3.32-3.21 (m, 2H), 3.03-2.98 (m, 3H), 2.47-2.30 (m, 4H), 2.25-1.70 (m, 4H). LCMS (ES) [M+l]+ m/z 357.5.
Example 40 (4R)-N- { 2,3 -dimethoxy-6H,7H, 8H-cyclopenta[b] 1,5-naphthyridin-9-yl} -1 -methy lazepan-4amineHCI
Into a 40-mL vial, was placed a mixture of (R)-N-(azepan-4-yl)-2,3-dimethoxy-7,8-dihydro6H-cyclopenta[b][l,5]naphthyridin-9-amine HCl (100 mg, 0.26 mmol, 1 eq.) in MeOH (10 mL), and TEA (78.8 mg, 0.78 mmol, 3 eq.), the mixture was stirred for 15 minutes at rt, HCHO ( 30% aqueous, 3 mL) and NaBH(OAc)3 (276 mg, 1.3 mmol, 5 eq.) were added subsequently. The mixture was stirred for 16 h at 50°C and then concentrated under vacuum. The residue was diluted with DMF (5 mL), fïltered and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, Waters-, gradient elution of 4% MeCN in water to 20 % MeCN in water over a 6 min period, where both solvents contain 0.1% TFA). The eluents were concentrated under vacuum, and H2O (10 mL) and IM HCl (aq., 1 mL) were added. The solution was lyophilized to provide the title compound as a light
- 186 yellow solid (54 mg, 50%).Ή NMR (300 MHz, Methanol-d4) δ 7.38 (s, 1H), 4.19 (d, J= 2.8 Hz, 3H), 4.06 (s, 3H), 3.67-3.55 (m, 3H), 3.51-3.32 (m, 3H), 3.32-3.12 (m, 3H), 2.97 (d, J= 2.5 Hz, 3H), 2.512.27 (m, 5H), 2.19-1.94 (m, 3H). LCMS (ES) [M+l]+m/z 357.2.
Example 41 (3R)-N-[6,7-di(2H3)methoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]piperidin-3-amine
To a solution of Intermediate 1 (650 mg; 2.46 mmol; 1 eq.) in CH2CI2 (6 mL) at 0 °C was added BBn (6.16 mL; 1 mol/L; 6.16 mmol; 2.50 eq.). The solution was warmed to rt, concentrated, and diluted with water and sat. NaHCCh followed by 4N NaOH. The aqueous layer was extracted with EtOAc, acidified with concentrated HCl to pH=5, and filtered to give 9-chloro-lH,2H,3Hcyclopenta[b]quinoline-6,7-diol as yellow solid (299 mg, 52%). LCMS (ES) [M+l]+m/z 235.4, 237.6.
To a suspension of 9-chloro-4-(chlorohydrogenio)-lH,2H,3H-4<34-cyclopenta[b]quinoline-6,7diol (600e mg; 2.20 mmol; 1 eq.) and césium fluoride (2 002.14 mg; 13.18 mmol; 6 eq.) in DMF (18 mL) was added iodo(2H3)methane (0.55 mL; 8.79 mmol; 4 eq.). After 4 h at rt, the mixture was heated at 55 °C for 2 h, and cooled to rt. Water and EtOAc were added, the solution was filtered, and the organic layer was separated, the aqueous layer was extracted with EtOAc and the organic layers were combined, dried and concentrated to give 9-chloro-6,7-bis(2H3)methoxy-lH,2H,3Hcyclopenta[b]quinoline (160 mg, 27%). LCMS (ES) [M+l]+m/z 269.4, 271.8.
To a solution of 9-chloro-6,7-bis(2H3)methoxy-lH,2H,3H-cyclopenta[b]quinoline (160 mg; 0.59 mmol; 1 eq.) in Dioxane (5 mL) was added tert-butyl (3R)-3-aminopiperidine-l-carboxylate (178.19 mg; 0.89 mmol; 1.50 eq.) followed by BrettPhos G1 precatalyst (47.38 mg; 0.06 mmol; 0.10 eq.) and NaOtBu (171.01 mg; 1.78 mmol; 3 eq.). The mixture was degassed with N2 for 5 min, sealed and heated at 100 °C for 1 h. The mixture was cooled and diluted with water and EtOAc, organic layer was separated and concentrated to give tert-butyl (3R)-3-{[6,7-bis(2H3)methoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl]amino}piperidine-l-carboxylate, which was used without purification (250 mg, 97%). LCMS (ES) [M+l]+m/z 433.8.
To a solution of tert-butyl (3R)-3-{[6,7-bis(2H3)methoxy-lH,2H,3H-cyclopenta[b]quinolin-9yl]amino}piperidine-l-carboxylate (250 mg; 0.58 mmol; 1 eq.) in CH2CI2 (2 mL) was added TFA (2 mL). The mixture was stirred for 1 hr at ambient température, and was concentrated to remove TFA,
- 187the residue was diluted with AcCN/lN HCl and subjected to reverse phase préparative HPLC (Waters XSelect CSH C18 column, 0.1% aqueous HCl/acetonitrile gradient) to provide title compound as off white solid. (165 mg, 86%). Ή NMR (400 MHz, DMSO-A) δ 9.33 (s, 2H), 8.17 (d, J = 8 Hz, 1H), 7.96 (s, 1H), 7.21 (s, 1H), 4.60 - 4.53 (m, 1H), 3.40 - 3.29 (m, 1H), 3.27 - 3.05 (m, 5H), 2.74 (s, 1H), 2.14 (p, J = 7.5 Hz, 2H), 2.01 (d, J= 10.2 Hz, 1H), 1.97 - 1.84 (m, 2H), 1.79 (d, J = 13.3 Hz, 1H). LCMS (ES) [M+l]+m/z 334.02.
Example 42 (3R)-N-[6,7-di(2H3)ethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]piperidin-3-amine
To a solution of 9-chloro-lH,2H,3H-cyclopenta[b]quinoline-6,7-diol (125 mg; 0.53 mmol; 1 eq.) in DMF (2 mL) was added K2CO3 (365.98 mg; 2.65 mmol; 5 eq.) and iodoethane (0.17 mL; 2.12 mmol; 4 eq.). The mixture was stirred at rt for 2 h, and was heated at 55 °C for 55 h, the dark solution was diluted with water and extracted with EtOAc, organic layers was concentrated and subjected to column purification (CH2Ch/EtOAc = 100:0 to 50:50) to give 9-chloro-6,7-diethoxy-lH,2H,3Hcyclopenta[b]quinoline (25 mg, 16%). LCMS (ES) [M+l]+m/z 291.5, 293.8.
To a solution of 9-chloro-6,7-diethoxy-lH,2H,3H-cyclopenta[b]quinoline (25 mg; 0.09 mmol; 1 eq.) and tert-butyl (3R)-3-aminopiperidine-l-carboxylate (25.74 mg; 0.13 mmol; 1.50 eq.) in dioxane (1.5 mL) was added Brettphos precatalyst (6.84 mg; 0.01 mmol; 0.10 eq.) andNaOtBu (24.70 mg; 0.26 mmol; 3 eq.). The mixture was heated at 100 °C for 1 h, cooled and diluted with water and EtOAc, organic layer was separated and the aqueous layer was extracted with additional EtOAc. The organic layers were combined, washed with brine, dried and concentrated to give tert-butyl (3R)-3-{[6,7di(2H3)ethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]amino}piperidine-l-carboxylate as crude product, which was diluted with CH2CI2 (1 mL) and TFA (1.5 mL), stirred for 1.5 h, concentrated, and purified by préparative HPLC to give the title compound (11 mg, 36%). ’H NMR (400 MHz, DMSOdd) δ 9.50 (s, 2H), 8.20 (s, 1H), 7.99 (s, 1H), 7.28 (s, 1H), 4.63 - 4.54 (m, 1H), 4.26 (q, J= 6.9 Hz, 2H), 4.13 (q,J= 6.9 Hz, 2H), 3.41 - 3.32 (m, lH),3.32(s, 1H), 3.21 (d, J= 12.6 Hz, 1H), 3.10 (dt, J= 19.5, 7.7 Hz, 3H), 2.72 (d, J= 10.9 Hz, 1H), 2.13 (p, J= 7.5 Hz, 2H), 2.04 - 1.76 (m, 4H), 1.38 (dt, J= 12.8, 6.9 Hz, 6H). LCMS (ES) [M+l]+ m/z 356.1.
- 188-
Example 43 (3R)-N-{6-ethoxy-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}piperidin-3-amine
Intermediate 1-b (500 mg; 2 mmol; 1 eq.) was suspended in N,N-dimethylformamide (20 ml).
lodoethane (0.32 mL; 4 mmol; 2 eq.) and potassium carbonate (829.02 mg; 6.01 mmol; 3 eq.) were added and the reaction was stirred at 100 °C. After 3 h, the mixture was partit!oned into EtOAc and water. The phases were separated, the aqueous phase was extracted with EtOAc, and the combined organic phases were then washed with water and NaCl (aq.). After drying over Na2SO4 and évaporation, the residue was purified by silica gel chromatography (0-50% EtOAc/CH2C12) to give an off-white 10 solid of9-chloro-6-ethoxy-7-methoxy-lH,2H,3H-cyclopenta[b]quinoline (0.38 g, 68%).1 HNMR(400 MHz, Chloroform-d) δ 7.38 - 7.33 (m, 2H), 4.25 (q, J= 7.0 Hz, 2H), 4.03 (s, 3H), 3.15(dt, J= 18.4, 7.6 Hz, 4H), 2.22 (p, J= 7.6 Hz, 2H), 1.55 (t, J= 7.0 Hz, 3H). LCMS (ES) [M+l]+m/z 277.5.
9-chloro-6-ethoxy-7-methoxy-lH,2H,3H-cyclopenta[b]quinoline (0.38 g; 1.37 mmol; 1 eq.) was partly dissolved in 1,4-dioxane (9 ml) and the mixture was purged with argon gas. Tert-butyl (3R)15 3-aminopiperidine-l-carboxylate (0.33 g; 1.64 mmol; 1.20 eq.), BrettPhos Pd Gl (32.79 mg; 0.04 mmol; 0.03 eq.) and then NaOtBu (0.53 g; 5.47 mmol; 4 eq.) were added. The reaction was stirred in a heat block at 110 °C. After 2 h, the reaction was cooled and filtered through Celite, rinsing with warm EtOAc. The filtrate was evaporated and purified by silica gel chromatography (0-10% MeOH/ CH2CI2) to give a glassy residue of tert-butyl (3R)-3-({6-ethoxy-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin20 9-yI}amino)piperidine-l-carboxylate (0.6 g, 99%). NMR (400 MHz, Chloroform-<7) δ 7.32 (s, 1H), 6.96 (s, 1H), 4.23 (q, J = 7.0 Hz, 3H), 3.98 (s, 3H), 3.91 - 3.75 (m, 2H), 3.56 - 3.49 (m, 1H), 3.37 3.29 (m, 1H), 3.27-3.20 (m, 1H), 3.14 - 2.99 (m, 4H), 2.16 (p,J= 7.5 Hz, 2H), 2.02 - 1.95 (m, 1H), 1.53 (t, J= 7.0 Hz, 4H), 1.43 (d, J= 20.8 Hz, 9H). LCMS (ES) [M+l]+m/z 442.0.
tert-butyl (3R)-3-({6-ethoxy-7-methoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}amino) piperidine-l-carboxylate (0.60 g; 1.36 mmol; 1 eq.) was dissolved in CH2CI2 (6 ml). Trifluoroacetic acid (3.40 mL; 0.40 mol/L; 1.36 mmol; 1 eq.) was added slowly. After 2 h, the reaction solution was evaporated to dryness. It was resuspended in toluene (20 ml) and evaporated to dryness again. The residue was purified by reverse phase chromatography (Waters XSelect CSH C18 column, 0.1% aqueous HCl/acetonitrile gradient) to give a white solid of (3R)-N-{6-ethoxy-7-methoxy-lH,2H,3H19495
- 189 cyclopenta[b]quinolin-9-yl}piperidin-3-amine -2HC1 (0.56 g, 62%). 1 H NMR (400 MHz, DMSO-<76) δ 9.51 (s, 2H), 8.31 (s, 1H), 8.04 (s, 1H), 7.30 (s, 1H), 4.62 (s, 1H), 4.16 (s, 2H), 4.01 (s, 3H), 3.30 3.03 (m, 7H), 2.76 (s, 1H), 2.17 (s, 2H), 2.09 - 1.76 (m, 4H), 1.43 (s, 3H). LCMS (ES) [M+l]+m/z 341.9.
Example 44 (3S,5R)-N- {6,7-dimethoxy- lH,2H,3H-cyclopenta[b]quinoIin-9-yl}-5-methylpiperidin-3-amine
Into a 40-mL vial purged and maintained under N2, was placed a mixture of (cis)-tert-butyl -3amino-5-methylpiperidine-1-carboxylate (1 g, 4.67 mmol, 1 eq.), dioxane (20 mL), 9-chloro-6,710 dimethoxy-lH,2H,3H-cyclopenta[b]quinoline (1.2 g, 4.67 mmol, 1 eq.), t-BuONa (1.3 g, 14 mmol, 3.0 eq.) and 3rd Génération BrettPhos precatalyst (211.5 mg, 0.23 mmol, 0.05 eq.). The solution was stirred for 2 hr at 90°C. The mixtures were combined and concentrated under vacuum. The residue was purified by column chromatography on silica gel eluted with EtOAc to provide (±)-tert-butyl (3S,5R)-3-([6,7dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin-9-yl]amino)-5-methylpiperidine- 1-carboxylate as yellow 15 oil (1.2 g, 58 %). LCMS (ES) [M+l]+ m/z 442.3.
Into a 50-mL round-bottom flask, was placed a mixture of (±)-tert-butyl (3S,5R)-3-([6,7dimethoxy-1 H,2H,3H-cyclopenta[b]quinolin-9-yl]amino)-5-methylpiperidine-1-carboxylate (1.2 g, 2.72 mmol, 1 eq.), CH2CI2 (20 mL), 4 M HCl/dioxane (10.2 mL, 40.8 mmol, 15 eq.). The solution was stirred for 5 h at rt. The solids were filtered out to provide a racemic mixture of N-{6,7-dimethoxy20 lH,2H,3H-cycIopenta[b]quinolin-9-yl}-5-methylpiperidin-3-amine as white solid 780mg (75.95%). LCMS (ES) [M-2HC1+1]+ m/z 342.2.
The mixture was separated by Pre-Chair-HPLC with the following conditions: Column, CHIRALCEL OD-3, 4.6*50 mm, 3.0 um; mobile phase, A: n-Hexane (0.2%MIPA); B: EtOH/MeOH=l/l; Detector, 190 nm to 500 nm to provide 273.8 mg (49.29 %) of (3R, 5S)-N-[6, 725 dimethoxy-lH, 2H, 3H-cyclopenta[b]quinolin-9-yl]-5methylpiperidin-3-amine as off-white solid and 279.2 mg (36%) of (3S,5R)-N-[6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]-5methylpiperidin-3-amine as off-white solid. 'H NMR (300 MHz, DMSO-tZd): 10.0-9.50 (br, 1H), 7.66 (s, 1H), 7.19 (s, 1H), 6.70 (br, 1H), 4.29-4.29 (m, 1H), 3.94 (s, 3H), 3.88 (s, 3H), 3.33-3.30 (m, 1H),
- 190-
3.22- 3.19 (m, 2H), 3.08-3.06 (m, 1H), 3.03-2.94 (m, 3H), 2.41-2.28 (m, 1H), 2.14-2.01 (m, 4H), 1.531.41 (m, 1H), 0.89 (m, 3H). LCMS (ES) [M+l]+ m/z 342.2.
Example 45 (3R,5R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5-methylpiperidin-3amine
Into a 250-mL round-bottom flask, was placed a solution of 1,5-dimethyl (2R)-2aminopentanedioate (9.8 g, 55.94 mmol, 1 eq.) in MeOH (100 mL), TEA (17.0 g, 167.82 mmol, 3 eq.), BOC2O (14.7 g, 67.13 mmol, 1.2 eq.). The solution was stirred for 16 hr at rt. The mixture was concentrated, diluted with 200 mL of CH2CI2, andwashed with brine. The mixture was dried over anhydrous Na2SO4, concentrated, and applied onto a silica gel column with CH2CI2 /MeOH (30:1) to provide 1,5-dimethyl (2R)-2-[[(tert-butoxy)carbonyl]amino]pentanedioate 10 g (64.9%) as colorless oil. LCMS (ES) [M+l]+ m/z 276.1.
Into a 500-mL 3-necked round-bottom flask, was placed a solution of 1,5-dimethyl (2R)-2[[(tert-butoxy)carbonyl]amino]pentanedioate (10 g, 36.32 mmol, 1 eq.) in THF (100 mL). This was followed with LiHMDS (36.3 mL, 72.6 mmol, 2 eq.) dropwise with stirring at -78°C. The solution was stirred for 0.5 hr at -78°C. To this Mel (7.7 g, 54.49 mmol, 1.5 eq.) was added. The solution was stirred for 2 hr at -78 °C. The reaction was then quenched with 100 mL of NH4CL The solution was extracted with EtOAc and the organic layers combined and dried over anhydrous Na2SÛ4, concentrated, and applied onto a silica gel column with CH2C12/MeOH (100:1) to provide the 1,5-dimethyl (2R)-2-[[(tertbutoxy)carbonyl]amino]-4-methylpentanedioate 6.7 g (63.75%) as white solid. LCMS (ES) [M+l]+ m/z 290.2.
Into a 100-mL round-bottom flask, was placed a solution of 1,5-dimethyl (2R)-2-[[(tertbutoxy)carbonyl]amino]-4-methylpentanedioate (3 g, 10.37 mmol, 1 eq.) in EtOH (15 mL), a solution of CaCE (4.6 g, 41.48 mmol, 4 eq.) in H2O (15 mL). This was followed with NaBH4 (3.1 g, 82.95 mmol, 8 eq.) at 0°C. The solution was stirred for 16 hr at rt. The reaction was then quenched with 50 mL of 10% Na2CO3. The solution was extracted with EtOAc and the organic layers combined. The mixture was washed with brine. The mixture was dried over anhydrous Na2SÜ4 and concentrated to
- 191 - provide the crude tert-butyl N-[(2R)-l,5-dihydroxy-4-methylpentan-2-yl]carbamate 2.1 g (86.81%) as colorless oil without further purification. LCMS (ES) [M+l]+ m/z 234.2.
Into a 100-mL 3-necked round-bottom flask, was placed a solution of tert-butyl N-[(2R)-1,5dihydroxy-4-methylpentan-2-yl]carbamate (2.1 g, 9 mmol, 1 eq.) in CH2CI2 (25 mL), TEA (3.6 g, 36 5 mmol, 4 eq.). This was followed with MsCl (3.1 g, 27 mmol, 3 eq.) dropwise with stirring at 0°C. The solution was stirred for 1 hr at 0°C. The solution was diluted with 30 mL of CH2CI2. The mixture was washed with brine. The mixture was dried over anhydrous Na2SO4 and concentrated to provide the crudeN-[(2R)-l,5-bis(methanesulfonyloxy)-4-methylpentan-2-yl]carbamate 2.9 g (82.7%) as colorless oil. LCMS (ES) [M+l]+ m/z 390.1.
Into a 100-mL round-bottom flask, was placed tert-butyl N-[(2R)-1,5-bis(methanesulfonyloxy)4-methylpentan-2-yl]carbamate (2.9 g, 7.46 mmol, 1 eq.), 1-phenylmethanamine (30 mL). The solution was stirred for 16 hr at 70 °C. The solution was cooled to rt and diluted with 100 mL of EA. The mixture was washed with 2 xlOO ml of IN NaOH and 2 xlOO mL of brine. The mixture was dried over anhydrous Na2SO4, and applied onto a silica gel column with EtOAc/petroleum ether (1:50) to provide 15 the tert-butyl N-[(3R,5R)-l-benzyl-5-methylpiperidin-3-yl]carbamate 1.4 g (61.7%) as colorless oil. LCMS (ES) [M+l]+ m/z 305.2.
Into a 100-mL round-bottom flask, was placed a solution of tert-butyl N-[(3R,5R)-l-benzyl-5methylpiperidin-3-yl]carbamate (1.4 g, 4.60 mmol, 1 eq.) in dioxane (10 mL), HCl in 1,4-dioxane (10 mL, 4mol/L). The solution was stirred for 1 hr at rt. The solution was diluted with 20 mL of H2O. The 20 pH value of the solution was adjusted to 7-8 with Na2COs (10 %). The mixture was concentrated and applied onto a silica gel column with CH2CI2 /MeOH (4:1) to provide (3R,5R)-l-benzyl-5methylpiperidin-3-amine 540 mg (57.5%) as colorless oil. LCMS (ES) [M+l]+ m/z 205.2.
Into a 100-mL round-bottom flask purged and maintained under N2, was placed a solution of (3R,5R)-l-benzyl-5-methylpiperidin-3-amine (464.8 mg, 2.28 mmol, 1.2 eq.) in dioxane (5 mL), 925 chloro-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinoline (500 mg, 1.90 mmol, 1 eq.), t-BuONa (728.8 mg, 7.58 mmol, 4 eq.), BrettPhos Pd G3 (85.9 mg, 0.09 mmol, 0.05 eq.). The solution was stirred for 4 hr at 90°C under N2 atmosphère. The mixture was filtered, concentrated, and applied onto a silica gel column with EtOAc to provide (3R,5R)-l-benzyl-N-[6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-5-methylpiperidin-3-amine 400 mg (48.9%) as light yellow solid. LCMS 30 (ES) [M+l]+m/z 432.3.
Into a 50-mL pressure tank reactor, was placed a solution of (3R,5R)-l-benzyl-N-[6,7dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]-5-methylpiperidin-3-amine (400 mg, 0.93 mmol, 1 eq.) in MeOH (10 mL), 10% Pd/C (40 mg, 10% w/w), HCl (67.6 mg, 1.85 mmol, 2 eq.) . The solution
- 192- was stirred for 16 hr at rt under H2 atmosphère (20 atm). The solution was fïltered and diluted with 10 mL of H2O. The pH value of the solution was adjusted to 7-8 with Na2CO3 (10 %). The crude product was purified by Flash-Prep-HPLC with the following conditions (IntelFlash-1): Column, silica gel; mobile phase, H2O:MeCN=10:l increasing to H2O:MeCN=l:l with 10 min; Detector, UV. to provide the title compound product 78 mg (24.6%) as off-white solid. ’H NMR (300 MHz, DMSO-A) δ 7.28 (s, 1H), 7.14 (s, 1H), 5.84 - 5.64 (m, 1H), 3.86 (d, J= 7.1 Hz, 7H), 3.03 - 2.93 (m, 2H), 2.90 2.71 (m, 5H), 2.46 (s, 1H), 2.20 (dd, J= 11.8, 8.3 Hz, 1H), 2.02 (p, J= 7.4 Hz, 2H), 1.75 (d, J= 12.6 Hz, 2H), 1.39 - 1.19 (m, 1H), 0.79 (d, J= 6.3 Hz, 3H). LCMS (ES) [M+l]+ m/z 342.2.
Example 46 and Example 47 (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-difluoropiperidin-3-amine
(3S)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-difluoropiperidin-3-amine
Into a 50-mL round-bottom flask, was placed tert-butyl N-(5,5-difluoropiperidin-3yl)carbamate (1.2 g, 5.08 mmol, 1 eq.), CH2CI2 (20 mL), benzaldehyde (646.8 mg, 6.09 mmol, 1.20 eq.), AcOH (2 mL) and NaBH(OAc)3 (2.2 g, 10.16 mmol, 2 eq.). The solution was stirred for 16 h at rt. The mixture was concentrated and purified by column chromatography on silica gel eluted with EtOAc/petroleum ether (1/10) to provide the title compound as yellow oil (965 mg, 58%). LCMS (ES) [M+l]+ m/z 327.3.
Into a 25-mL round-bottom flask, was placed a mixture of tert-butyl N-(l-benzyl-5,5difluoropiperidin-3-yl)carbamate (965 mg, 2.96 mmol, 1 eeq.), CH2CI2 (10 mL) and 4M HCl/dioxane (3.7 mL, 14.8 mmol, 5 eq.). The solution was stirred for 6 h at rt. The mixture was concentrated and water was added (5.0 ml), basified with 2 N Na2CCh aqueous solution (pH 7~8). The residue was
- 193 purified by column chromatography on silica gel eluted with EtOAc/petroleum ether (1/1) to provide the title compound as yellow oil (654 mg, 97.7%). LCMS (ES) [M+l]+ m/z 227.3.
Into a 40-mL vial purged and maintained under N2, was placed a mixture of l-benzyl-5,5difluoropiperidin-3-amine (653.8 mg, 2.89 mmol, 2 eq.), 9-chloro-6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinoline (381 mg, 1.44 mmol, 1 eq.), dioxane (20 mL), t-BuONa (416.5 mg, 4.33 mmol, 3.0 eq.) and 3rd Génération BrettPhos precatalyst (65.5 mg, 0.07 mmol, 0.05 eq.). The solution was stirred for 2 h at 90°C. The residue was purified by column chromatography on silica gel eluted with EtOAc provide the title compound as yellow solid (507 mg 77%). LCMS (ES) [M+l]+ m/z 454.1.
Into a 50-mL sealed tube, was placed a mixture of l-benzyl-N-[6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-5,5-difluoropiperidin-3-amine (507 mg, 1.12 mmol, 1 eq.), MeOH (10 mL),10% Pd/C (50 mg, 0.42 eq.), HCl (122.3 mg, 3.35 mmol, 3 eq.) . The mixture was degassed and purged with H2 for several time and then stirred for 8 h at rt under H2. The solids were fîltered out. The mixture was concentrated to provide the title compound as off-white solid 350mg (78.30%). LCMS (ES) [M-HC1+1]+ m/z 364.4.
The mixture was separated by Pre-Chair-HPLC with the following conditions: Column, CHIRALCEL OD-3, 4.6*50 mm, 3.0 um; mobile phase, A: n-Hexane (0.2% MIPA); B: EtOH; Detector, 190 nm to 500 nm to provide 56.3 mg (14.28 %) of (3R)-N-[6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-yl]-5,5-difluoropiperidin-3-amine as white solid and 23.62 mg (6.7%) of (3S)N-[6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]-5,5-difluoropiperidin-3-amine (3R)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-difluoropiperidin-3amine: ‘HNMR (300 MHz, DMSO-A): 8.18 (br, 1H), 7.44 (s, 1H), 7.15 (s, 1H) , 6.03-6.00 (br, 1H), 4.03-3.97 (m, 1H), 3.90 (s, 1H), 3.86 (s, 1H), 3.14-2.96 (m , 4H), 2.91-2.83 (m, 2H), 2.79-2.73 (m,lH), 2.58-2.51(m, 1H), 2.41-2.21(m, 1H), 2.18-2.15 (m, 1), 2.12-2.09 (m, 3H). LCMS (ES) [M+l]+ m/z 364.2.
(3S)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-difluoropiperidin-3amine: Ή NMR (300 MHz, DMSO-î/6): 8.25-8.20 (br, 1H), 7.42 (s, 1H), 7.15 (s, 1H), 5.93-5.87 (br, 1H), 4.01-3.98 (m, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.18-2.96 (m, 4H), 2.90-2.80 (m, 2H), 2.78-2.73 (m, 1H), 2.69-2.58 (m, 1H), 2.43-2.27 (m, 1H), 2.22-2.12 (m, 3H). LCMS (ES) [M+l]+ m/z 364.2.
- 194 -
Example 48 Onh HNZ 'O
N-{[(2S,4S)-4-fluoropyrrolidin-2-yl]methyl}-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9amine
Into a 40-mL vial purged and maintained under N2, was placed a mixture of 1-[(2S,4S)-1benzyl-4-fluoropyrrolidin-2-yl]methanamine (200 mg, 0.48 mmol, 0.5 eq., 50%w/w), dioxane (5.0 mL), 9-chloro-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinoline (278.6 mg, 1.06 mmol, 1.1 eq.), tBuONa (276.8 mg, 2.88 mmol, 3 eq.) and 3rd Génération BrettPhos precatalyst (43.5 mg, 0.05 mmol, 0.05 eq.). The solution was stirred for 2 hours at 90 °C in an oil bath. The reactions were conducted for 10 2 batches (200 mg x 2, total 400 mg) in parallel. The mixure was concentrated and purified by flash column eluted with CH2CI2 /MeOH (10/1) to provide 342 mg (82%) of N-[[(2S,4S)-l-benzyl-4fluoropyrrolidin-2-yl]methyl]-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-amine as yellow solid. LCMS (ES) [M+l]+ m/z 436.3.
Into a 30-mL pressure tank reactor, was placed a mixture of N-[[(2S,4S)-l-benzyl-415 fluoropyrrolidin-2-yl]methyl]-6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-amine (300 mg, 0.69 mmol, 1 eq.), MeOH (4.0 mL), Pd/C (60 mg, 10%w/w), Conc. HCl (0.20 mL). The solution was stirred for 24 hours at rt under H2. The mixture was filtered, concentrated, and subjected to reverse phase préparative HPLC (Prep-C18, SunFire column, 19x150 mm, Waters; gradient elution of 11% MeCN in water to 21% MeCN in water over a 5 min period, where water phase contain 0.05% TFA) 20 to provide 187.8 mg (48%) ofN-[[(2S,4S)-4-fluoropynOlidin-2-yl]methyI]-6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinolin-9-amine (TFA)2 as white solid. *HNMR(300 MHz, DMSO-ô/ô, ppm}: 14.20 (br, 1H), 10.15 (br, 1H), 9.75 (br, 1H), 8.43 (s, 1H), 7.71 (s, 1H), 7.29 (s, 1H), 5.48 (d, J=52.8 Hz, 1H), 4.08 (d, J=2.7Hz, 3H), 3.95 (s, 6H), 3.74-3.63 (m, 1H), 3.52-3.20 (m, 3H), 3.18-3.11 (m, 2H), 2.632.55 (m, 1H), 2.32-2.08 (m, 3H). LCMS (ES) [M+l]+ m/z 346.1.
- 195 Example 49 (3R,5S)-N- {6,7-dimethoxy- lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5-fluoropiperidin-3-amine
Into a 500-mL round-bottom flask, was placed a mixture of ethyl (2S,4R)-4hydroxypyrrolidine-2-carboxylate hydrochloride (10.0 g, 51.11 mmol, 1 eq.), BnBr (9.6 g, 0.06 mmol, 1.1 eq.), DIEA (16.5 g, 0.13 mmol, 2.5 eq.) and toluene (150 mL). The solution was stirred for 6 hours at 110 °C in an oil bath. The reaction was then quenched with 200 mL of saturated aqueous NaHCO3, extracted with EtOAc, the combined organic layers were washed with brine, dried over anhydrous Na?SO4 and concentrated to provide 14.3 g of ethyl (2S,4R)-l-benzyl-4-hydroxypyrrolidine-2carboxylate as crude brown oil. LCMS (ES) [M+l]+ m/z 250.2.
Into a 500-mL 3-necked round-bottom flask purged and maintained under N2, was placed a solution of ethyl (2S,4R)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate (13.0 g, 52.14 mmol, 1 eq.) in CH2CI2 (300 mL). This was followed with DAST (21.0 g, 130 mmol, 2.5 eq.) dropwise with stirring at -78 °C. The solution was stirred for 16 hours at rt. The reaction was then quenched with 200 mL of saturated aqueous Na2CO3 solution, extracted with CH2CI2, the combined organic layers were dried over anhydrous Na2SO4, concentrated, and purifïed by flash column eluted with EtOAc/petroleum ether (1/4) to provide 7.45 g (57%) of ethyl (2S,4S)-l-benzyl-4-fluoropyrrolidine-2-carboxylate as yellow oil. LCMS (ES) [M+l]+ m/z 252.2.
Into a 500-mL 3-necked round-bottom flask purged and maintained under N2, was placed a solution of ethyl (2S,4S)-l-benzyl-4-fluoropyrrolidine-2-carboxylate (7.45 g, 29.65 mmol, 1 eq.) in THF (200 mL), DIBAL-H (90 mL, 89.1 mmol, 3.0 eq., IM in hexane) was added dropwise at 0 °C. The solution was stirred for 45 minutes at 0 °C in a water/ice bath. The reaction was quenched with 150 mL saturated aqueous potassium sodium tartrate solution and stirred for 1 hour at rt. The mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na3SO4, concentrated, and purifïed by flash column eluted with EtOAc/petroleum ether (1/2) to provide 4.70 g (76%) of [(2S,4S)-l-benzyl-4-fluoropyrrolidin-2-yl] as light yellow oil. LCMS (ES) [M+l]+ m/z 210.2.
-196Into a 250-mL 3-necked round-bottom flask purged and maintained under N2, was placed a solution of [(2S,4S)-l-benzyl-4-fluoropyrrolidin-2-yl]methanol (2 g, 9.56 mmol, 1 eq.) in CH2CI2 (160 mL), to which were added BU4NN3 (2.98 g, 10.48 mmol, 1.10 eq.) and XtalFluor-E (2.40 g, 10.48 mmol, 1.10 eq.) at -78 °C. The solution was stirred for 4 hours at -78 °C in a liquid nitrogen bath. The 5 reaction was then quenched with 100 mL of 3.75M aqueous NaOH solution at -78 °C. The solution was extracted with CH2CI2, the combined organic layers were dried over anhydrous Na2SO4, concentrated, and purified by flash column eluted with EtOAc/petroleum ether (1/4) to provide 1.21 g crude mixture of (3R,5S)-3-azido-l-benzyl-5-fluoropiperidine and (2S,4S)-2-(azidomethyl)-l-benzyl-4fluoropyrrolidine as yellow oil. LCMS (ES) [M+l]+ m/z 235.2.
Into a 40-mL vial purged and maintained under N2, was placed a mixture of (3R,5S)-3-azidol-benzyl-5-fluoropiperidine (0.50 g, 2.13 mmol, 0.5 eq.) and (2S,4S)-2-(azidomethyl)-l-benzyl-4fluoropyrrolidine (0.50 g, 2.13 mmol, 0.5 eq.) in THF (20 mL), to which were added PPI13 (1.7 g, 0.01 mmol, 1.5 eq.) and H2O (0.538 g, 29.86 mmol, 7.0 eq.). The solution was stirred for 4 hours at 80 °C in an oil bath. The mixture was concentrated and purified by flash column eluted with CH2CI2 /MeOH 15 (10/1) to provide 582 mg (66%) mixture of (3R,5S)-l-benzyl-5-fluoropiperidin-3-amine and 1[(2S,4S)-l-benzyl-4-fluoropyrrolidin-2-yl]methanamine as light yellow oil. LCMS (ES) [M+l]+ m/z 209.2.
Into a 40-mL vial purged and maintained under N2, was placed a mixture (3R,5S)-l-benzyl-5fluoropiperidin-3-amine (200 mg, 0.48 mmol, 0.5 eq., 50%w/w), dioxane (5.0 mL), 9-chloro-6,720 dimethoxy-lH,2H,3H-cyclopenta[b]quinoline (278.6 mg, 1.06 mmol, 1.1 eq.), t-BuONa (276.8 mg, 2.88 mmol, 3.0 eq.) and 3rd Génération BrettPhos precatalyst (43.5 mg, 0.05 mmol, 0.05 eq.). The solution was stirred for 2 hours at 90 °C in an oil bath. The reactions were conducted for 2 batches (200 mg x 2, total 400 mg) in parallel. The mixtures were concentrated and purified by flash column eluted with CH2CI2 /MeOH (10/1) to provide 258 mg (62%) of (3R,5S)-l-benzyl-N-[6,7-dimethoxy25 lH,2H,3H-cyclopenta[b]quinolin-9-yl]-5-fluoropiperidin-3-amine as yellow solid. LCMS (ES) [M+l]+ m/z 436.3.
Into a 30-mL pressure tank reactor, was placed a mixture of (3R,5S)-l-benzyl-N-[6,7dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]-5-fluoropiperidin-3-amine (200 mg, 0.46 mmol, 1 eq.), MeOH (4.0 mL), Pd/C (50 mg, 10% w/w) and Conc. HCl (0.2 mL, 0.01 mmol, 0.01 eq.). The 30 solution was stirred for 48 hours at rt under H2 atmosphère. The mixture was fïltered through a pad of celite, the fîlter cake was washed with MeOH (2x10 mL). The filtrate was concentrated and subjected to reverse phase préparative HPLC (Prep-C18, SunFire column, 19x150 mm, Waters; gradient elution of 2% MeCN in water to 18% MeCN in water over a 7-min period, where water phase contain 0.05%
- 197-
TFA) to provide 89.9 mg (34%) of (3R,5S)-N-[6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]5-fluoropiperidin-3-amine (TFA)2 as white solid. ’H NMR (300 MHz, DMSO-#6, ppmf. 14.16 (br, 1H), 9.57 (br, 2H), 7.75 (d, d, ./=9.0 Hz, 1H), 7.68 (s, 1H), 7.24 (s, 1H), 5.14-4.96 (m, 1H), 4.68-4.62 (m, 1H), 3.95 (s, 6H), 3.69-3.62 (m, 1H), 3.53-3.48 (m, 1H), 3.30-3.03 (m, 6H), 2.60-2.55 (m, 1H), 2.242.10 (m, 3H). LCMS (ES) [M+l]+ m/z 346.1.
Example 50 and Example 51 (3R)-N- {6,7-dimethoxy- lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-dimethylpiperidin-3-amine
(3S)-N-{6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-dimethylpiperidin-3-amine
Into a 500-mL 3-necked round-bottom flask purged and maintained under N2, was placed a solution of 2-methylpropanenitrile (10 g, 144.70 mmol, 1 eq.) in THF (300 mL). This was followed with LDA (79.6 mL, 159.20 mmol, 1.1 eq.) dropwise with stirring at -78 °C. The solution was stirred for 30 min. To this was added 3-bromoprop-l-ene (21.0 g, 173.64 mmol, 1.2 eq.) at -78 °C. The solution was stirred for 16 hr at rt, then quenched with 200 mL of NH4CI. The solution was extracted with Et2Û and the organic layers combined. The mixture was washed with x200 mL of brine. The mixture was dried over anhydrous Na2SÛ4 and concentrated to provide the title compound 5.1 g (32.3%) as light yellow oil.
Into a 250-mL 3-necked round-bottom flask, was placed a solution of 2,2-dimethylpent-4enenitrile (5.1 g, 46.72 mmol, 1 eq.) in Et2O (100 mL). This was followed with L1AIH4 (4.4 g, 116.79 mmol, 2.5 eq.) in several batches at 0 °C. The solution was stirred for 4 hr at rt, quenched with 4.4 mL H2O, 13.2 mL 10% NaOH, and then 4.4 mL H2O. The solids were filtered out. The solution was extracted with Et2O and the organic layers combined and dried over anhydrous Na2SO4and concentrated to provide the title compound 2.6 g (49.2%) as yellow oil.
- 198-
Into a 100-mL round-bottom flask, was placed a solution of 2,2-dimethylpent-4-en-1-amine (2.5 g, 22.08 mmol, 1 eq.) in MeOH (30 mL), benzaldehyde (2.6 g, 24.29 mmol, 1.1 eq.), NaBH4 (1.3 g, 33.13 mmol, 1.5 eq.). The solution was stirred for 16 hr at rt. The reaction was then quenched with 20 mL of 10% NaOH. The solution was diluted with 100 mL of H2O. The solution was extracted with EtOAc and the organic layers combined and dried over anhydrous Na2SO4, concentrated, and applied onto a silica gel column with EtOAc/petroleum ether (1:4) to provide the title compound 2.6 g (57.9%) as colorless oil. LCMS (ES) [M+l]+ m/z 204.2.
Into a 100-mL round-bottom flask, was placed a solution of benzyl(2,2-dimethylpent-4-en-lyl)amine (2.3 g, 11.31 mmol, i eq.) in MeCN (30 mL), NCS (1.5 g, 11.31 mmol, 1 eq.).The solution was stirred for 2 hr at rt. To this was added NaNa (0.9 g, 13.57 mmol, 1.2 eq.), Nal (1.8 g, 11.88 mmol, 1.05 eq.). The solution was stirred for 16 hr at 60 °C. The reaction was then quenched with 100 mL of 10% NaOH. The solution was extracted with Et2O and the organic layers combined. The mixture was washed with brine. The solid was dried in an oven under reduced pressure to provide the crude title compound 2.8 g as colorless oil. LCMS (ES) [M+l]+ m/z 245.2.
Into a 100-mL round-bottom flask, was placed a solution of 5-azido-l-benzyl-3,3dimethylpiperidine (2.8 g, 11.46 mmol, 1 eq.) in THF (30 mL), PPha (4.5 g, 17.19 mmol, 1.5 eq.), H2O (1.4 g, 80.22 mmol, 7 eq.). The solution was stirred for 3 hr at 80 °C. The mixture was concentrated and applied onto a silica gel column with ClLCh/MeOH (10:1) to provide the title compound 2.1 g (83.9%) as light-yellow oil. LCMS (ES) [M+l]+ m/z 219.2.
Into a 100-mL round-bottom flask purged and maintained under N2, was placed a solution of 1 benzyl-5,5-dimethylpiperidin-3-amine (1.7 g, 7.96 mmol, 1.50 eq.) in dioxane (15 mL), 9-chloro-6,7dimethoxy-lH,2H,3H-cyclopenta[b]quinoline (1.4 g, 5.31 mmol, 1 eq.), t-BuONa (2.0 g, 21.23 mmol, 4 eq.), BrettPhos Pd G3 (0.2 g, 0.27 mmol, 0.05 eq..The solution was stirred for 3 hr at 90 °C under N2 atmosphère. The mixture was cooled to rt and filtered. The mixture was concentrated and applied onto a silica gel column with EtOAc/petroleum ether (9:1) to provide the title compound 2.1 g (88.77%) as a light yellow solid. LCMS (ES) [M+l]+ m/z 446.3.
Into a 50-mL sealed tube, was placed a solution of l-benzyl-N-[6,7-dimethoxy-lH,2H,3Hcyclopenta[b]quinoIin-9-yl]-5,5-dimethylpiperidm-3-amine (1 g, 2.24 mmol, 1 eq.) in MeOH (20 mL), Pd/C (100 mg, 10% w/w), HCl (163.6 mg, 4.49 mmol, 2 eq.). The solution was stirred for 16 min at rt under H2 atmosphère (20 atm).The solids were filtered out. The solution was diluted with 10 mL of H2O. NaOH (10 %) was employed to adjust the pH to 7-8. The crude product was purified by FlashPrep-HPLC with the following conditions (IntelFlash-1): Column, C18 silica gel; mobile phase, H2O:
- 199MeCN=10:l increasing to H2O: MeCN=2:l within 10 min; Detector, UV, provided a mixture of the title compounds 400 mg (50.1%) as white solid. LCMS (ES) [M+l]+ m/z 356.2.
The mixture was sepratrated by Pre-Chair-HPLC with the following conditions: Column, CHIRALCEL OD-3, 4.6*50 mm, 3.0 um; mobile phase, A: n-Hexane (0.2%MIPA); B: 5 EtOH/MeOH=l/l; Detector, 190 nm to 500 nm to provide.91.6 mg (22.9 %) of (R)-N-(5,5dimethylpiperidin-3-yl)-6,7-dimethoxy-2,3-dihydro-lH-cyclopenta[b]quinolin-9-amine(CO2H)2 as off-white solid and 86.6 mg (21.6 %) of (S)-N-(5,5-dimethylpiperidin-3-yl)-6,7-dimethoxy-2,3dihydro-lH-cyclopenta[b]quinolin-9-amine as off-white solid.
(3 R)-N-{6,7-dimethoxy-1E1,2H,3H-cyclopenta[b]quinolin-9-yl}-5,5-dimethylpiperidin-3- amine: Ή NMR (300 MHz, DMSO-cfe) δ 8.27 (d, J= 2.7 Hz, 2H), 7 Al (s, IH), 7.26 - 7.08 (m, 1H), 5.98 (d, J = 12.9 Hz, 1H), 4.11 (d, J= 21.8 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.26 - 3.10 (m, 2H), 3.02 (dt, J= 14.7, 7.1 Hz, 1H), 2.96 - 2.82 (m, 2H), 2.73 (s, 1H), 2.59 (s, 1H), 2.43 (s, 1H), 2.05 (p, J = 7.3 Hz, 2H), 1.76 (d, J = 12.5 Hz, 1H), 1.49 (t, J = 12.2 Hz, 1H), 1.08 (s, 3H), 0.95 (d, J = 1.6 Hz, 3H). LCMS (ES) [M-2HCOOH+1]+ m/z 356.2 (3 S)-N- {6,7-dimethoxy- 1H,2H, 3H-cyclopenta[b]quinolin-9-yl}-5,5-dimethylpiperidin-3amine: Ή NMR (300 MHz, DMSO-À) δ 7.43 (s, 1H), 7.11 (s, 1H), 5.63 (d, J = 9.7 Hz, 1H), 3.90 (s, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.21 - 2.92 (m, 3H), 2.84 (t, J= 7.7 Hz, 2H), 2.50 (s, 1H), 2.38 (t, J= 11.2 Hz, 1H), 2.27 (d, J= 12.3 Hz, 1H), 2.03 (p, 4 = 7.3 Hz, 2H), 1.71 (d, J= 12.8 Hz, 1H), 1.40 (t, J = 12.1 Hz, 1H), 1.04 (s, 3H), 0.89 (s, 3H). LCMS (ES) [M+l]+ m/z 356.3.
Example 52 (3R,5R)-N-{6,7-dimethoxy-lH,2H,3H-cycIopenta[b]quinoIin-9-yl}-5-fluoropiperidin-3-amine
F
Into a 250-mL round-bottom flask, was placed a mixture of methyl (2S,4S)-4hydroxypyrrolidine-2-carboxylate hydrochloride (10.9 g, 60.0 mmol, 1 eq.), toluene (60 mL), N-ethyl25 N-isopropylpropan-2-amine (15.5 g, 120 mmol, 2 eq.), (bromomethyl)benzene (11.3 g, 66.1 mmol, 1.10 eq.). The solution was stirred for 6 hours at 110 °C, concentrated, and applied onto a silica gel column with EtOAc/petroleum ether (1:3) to provide 11.0 g (78%) of methyl (2S,4S)-l-benzyl-4hydroxypyrrolidine-2-carboxylate as light yellow oiL LCMS (ES) [M+l]+ m/z 236.1.
-200Into a 250-mL 3-necked round-bottom flask, was placed a mixture of methyl (2S,4S)-l-benzyL 4-hydroxypyrrolidine-2-carboxylate (10.0 g, 42.5 mmol, 1 eq.), CH2CI2 (85 mL), N,N-diethyl-l,l,ltrifluoro-sulfanamine (17.1 g, 106 mmol, 2.50 eq.). The solution was stirred for hr at -78 °C. The reaction was then quenched with saturated aq. Na2COs. The pH value of the solution was adjusted to 9 5 with saturated Na2CÛ3 aqueous. The mixture was washed with brine, the organic layer dried over Na2SÜ4, fïltered, concentrated, and applied onto a silica gel column with EtOAc/petroleum ether (1:5) to provide 5.50 g (55%) of methyl (2S,4R)-l-benzyl-4-fluoropyrrolidine-2-carboxylate as light yellow oil. LCMS (ES) [M+l]+ m/z 238.1.
Into a 250-mL round-bottom flask, was placed a mixture of methyl (2S,4R)-l-benzyl-410 fluoropyrrolidine-2-carboxylate (5.50 g, 23.2 mmol, 1 eq.), tetrahydrofiiran (47 mL), lithium aluminium tetrahydride (1.30 g, 34.8 mmol, 1.50 eq.). The solution was stirred for 2 hr at 0 °C. The reaction was then quenched with water (1.25 mL) and 3.75 M NaOH aqueous (1.25 mL). The mixture was dried over anhydrous Na2SÛ4, fdtered, and concentrated to provide 3.89 g (80%) of [(2S,4R)-1benzyl-4-fluoropyrrolidin-2-yl]MeOH as colorless oil. LCMS (ES) [M+l]+ m/z 210.2.
Into a 1000-mL 3-necked round-bottom flask, was placed a mixture of [(2S,4R)-l-benzyl-4fluoropyrrolidin-2-yl]MeOH (3.90 g, 18.6 mmol, 1 eq.), CH2CI2 (373 mL), tetrabutylammoniumn azide (5.80 g, 20.4 mmol, 1.10 eq.), XtalFluor-E (4.70 g, 20.4 mmol, 1.10 eq.). The solution was stirred for 30 minutes at -78 °C and then allowed the température warm to rt. The solution was diluted with 20 mL of 3.75 M NaOH. The mixture was washed with 5 x40 ml of brine. The mixture was dried over 20 anhydrous Na2SO4., fïltered, and concentrated to provide 2.20 g (50%) of (3R,5R)-3-azido-l-benzyl5-fluoropiperidine as light yellow oil. LCMS (ES) [M+l]+ m/z 235.1.
Into a 50-mL round-bottom flask, was placed a mixture of (3R,5R)-3-azido-l-benzyl-5fluoropiperidine (2 g, 8.54 mmol, 1 eq.), tetrahydrofuran (17 mL), triphenylphosphane (3.40 g, 13.0 mmol, 1.50 eq.), water (1.10 g, 59.9 mmol, 7 eq.). The solution was stirred for 5 hr at 70 °C. The 25 mixture was dried over anhydrous Na2SÜ4, concentrated, and applied onto a silica gel column with EtOAc/petroleum ether (1:1) to provide 1.30 g (73%) of (3R,5R)-l-benzyl-5-fluoropiperidin-3-amine as grey solid. LCMS (ES) [M+l]+ m/z 209.1.
Into a 50-mL round-bottom flask, was placed a mixture of (3R,5R)-l-benzyl-5-fluoropiperidin3-amine (200 mg, 0.96 mmol, 1 eq.), dioxane (10 mL), 9-chloro-6,7-dimethoxy-lH,2H,3H30 cyclopenta[b] quinoline (279 mg, 1.06 mmol, 1.10 eq.), sodium 2-methylpropan-2-olate (185 mg, 1.92 mmol, 2 eq.), 3G Brettphos Precatalyst (44 mg, 0.05 mmol, 0.05 eq.). The solution was stirred for 2 hr at 90 °C, fïltered, concentrated, and applied onto a silica gel column with EtOAc/petroleum ether (1:1)
-201 to provide 235 mg (56%) of (5R)-l-benzyl-N-[6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]5-fluoropiperidin-3-amine as white solid. LCMS (ES) [M+l]+ m/z 436.3.
Into a 50-mL vial, was placed a mixture of (3R,5R)-l-benzyl-N-[6,7-dimethoxy-lH,2H,3Hcyclopenta [b]quinolin-9-yl]-5-fluoropiperidin-3-amine (200 mg, 0.46 mmol, 1 eq.), MeOH (10 mL), 5 2M hydrogen chloride aqueous (1.15 mL, 4.60 mmol, 5 eq.), Pd/C (20 mg). The solution was stirred for 6 hr at rt, filtered, concentrated, filtered again, and subjected to reverse phase préparative HPLC (Prep-C18, 5 μΜ XBridge column, 19 x 150 mm, Waters; gradient elution of 2% MeCN in water to 18% MeCN in water over a 6 min period, where the aqueous phase contains 0.1% FA) to provide 119.7 mg (60%) of (3R,5R)-N-[6,7-dimethoxy-lH,2H,3H-cyclopenta[b]quinolin-9-yl]-5-fluoropiperidin-310 amine bis(formic acid) as a light green solid. ’H NMR (300 MHz, DMSO-ώ): δ 8.27 (s, 2H), 7.46 (s, 1H), 7.19 (s, 1H), 6.01 (d, J= 10.2 Hz, 1H), 4.97-4.81 (m, 1H), 4.16-4.07 (m, 1H), 3.90-3.86 (m, 6H), 3.19-2.99 (m, 4H), 2.91-2.86 (m, 2H), 2.79-2.60 (m, 2H), 2.27-2.21 (m, 1H), 2.15-1.80 (m, 3H), 1.251.20 (m, 1H). LCMS (ES) [M+l]+ m/z 346.3.
Biological Examples
Example 1
Détermination of G9a enzymatic activity assay
The G9a AlphaLISA assay was used to detect the methyl modifications of a biotinylated histone 20 H3 peptide by the compounds. These modifications are done by the histone methyl transferase activity of the G9a enzyme. The assay consists of reading a chemiluminescent signal at 615nm; this signal is generated by a laser excitation at 680nm that transfers a reactive singlet oxygen between the donor beads and acceptor beads. Donor beads are streptavidin conjugated and bind to the biotin on the peptide. Accepter beads are conjugated with an antibody that recognizes the spécifie G9a methyl mark on the 25 peptide. If there is a methyl mark on the peptide, the acceptor beads will bind to the peptide. Upon binding, the acceptor beads will be in close proximity (<200nm) of the donor beads and when the donor beads are excited, the transfer of the oxygen can occur and a strong signal will be generated. If there is no methyl mark, the interaction between beads will not occur and signal will be at background levels.
For the assay, the following buffer was used to set up reactions: 50mM Tris-HCl pH9, 50mM 30 NaCl, 0.01% Tween-20 and ImM DTT (added fresh prior to starting the reactions). The assay is set up by adding a final concentration of 0.15nM G9a, 15uM S-adenosyl-methionine and lOOnM biotinylated histone 3 peptide (1-21). The reaction is incubated at rt for 1 hour and subsequently quenched with the acceptor beads (anti-H3k9me2 AlphaLISA acceptor beads, PerkinElmer #AL117) at a final concentration of 20ug/mL. The acceptor beads are incubated for 1 hour. After 1 hour, the
-202donor beads are added at a final concentration of 20ug/mL (Alpha Streptavidin donor beads, PerkinElmer #6760002). Donor beads are incubated for 0.5 hours. Both donor and acceptor beads are resuspended in AlphaLISA 5X Epigenetics Buffer 1 Kit (PerkinElmer # AL008) prior to addition to the reaction. Ail manipulations and incubations with the donor and acceptor beads are done in subdued light. Signal is detected in an EnVision plate reader in Alpha mode. See ACS Med. Chem. Lett. 2014; 5(2):205-9.
Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated. This value is presented as the pICso, which is the négative log of the ICso value in molar. The pICso values for a représentative number of compounds of the disclosure are provided in Table B below.
Table B
No | pICso |
1 | 5.97 |
2 | 5 |
3 | 5.53 |
4 | 5.57 |
5 | 7.44 |
6 | 5 |
7 | 7.52 |
8 | 7.27 |
9 | 7.31 |
10 | 7.66 |
11 | 7.49 |
12 | 5.5 |
13 | 7.22 |
14 | 5.55 |
15 | 7.67 |
16 | 7.27 |
17 | 5.5 |
18 | 6.21 |
19 | 5 |
20 | 7.53 |
21 | 5.3 |
22 | 6.21 |
23 | 7.05 |
24 | 6.11 |
25 | 5.87 |
26 | 7.53 |
27 | 8.08 |
28 | 6.66 |
29 | 6.81 |
30 | 7.83 |
31 | 6.23 |
32 | 5 |
33 | 5.78 |
34 | 5.7 |
35 | 7.94 |
36 | 5.42 |
37 | 6.85 |
38 | 5.24 |
39 | 7.27 |
40 | 5.76 |
41 | 5.32 |
42 | 5.48 |
43 | 6.72 |
44 | 5.49 |
45 | 7.07 |
46 | 6.75 |
47 | 7.1 |
48 | 7.58 |
49 | 5.63 |
50 | 5.53 |
51 | 6.45 |
52 | 6.39 |
53 | 6.54 |
54 | 6.24 |
55 | 6.05 |
56 | 6.45 |
57 | 6.72 |
58 | 6.12 |
59 | 5.3 |
60 | 7.4 |
61 | 6.7 |
62 | 7.5 |
63 | 7.5 |
64 | 7.6 |
65 | 7.4 |
66 | 7.3 |
67 | 7 |
68 | 6.9 |
69 | 7.1 |
134 | 6.8 |
149 | 7.2 |
163 | 6.8 |
164 | 6.2 |
402 | 7.1 |
286 | 8 |
403 | 7.5 |
404 | 6.6 |
165 | 7 |
405 | 7.9 |
406 | <5 |
407 | 7 |
408 | 6.9 |
409 | 7.9 |
410 | <5 |
-203 -
411 | 6.3 |
412 | 6.5 |
413 | <5 |
414 | 7.2 |
415 | <5 |
416 | 6.9 |
Example 2
Safety Pharmacological Profiling
Certain compounds were screened in a safety pharmacological profiling against a panel of receptors, enzymes and transporters. The compounds were each evaluated at ΙΟμΜ (in duplicate) for ligand binding to membranes of cells expressing different G protein coupled receptors (GPCRs) such as adrenergic alA, muscarinic M2, mu (μ) opiate (OP3) and serotonin 5HT2A receptors. See, e.g., Michel et al., Br. J. Pharmacol. 1998, 98(3):883/ Buckley et al., Mol. Pharmacol. 1989, 35(4):469;
Wang et al., FEBSLett. 1994, 338:217; and Saucier et al., J. Neurochem. 1997,68:1998. Inhibition of acetylcholinesterase was determined spectrophotometrically in cells expressing human recombinant acetylcholinesterase. See Nadarajah, J. Anal. Toxicol. 1992, 16:192. Norepinephrine transporter inhibition was determined in membranes from cells expressing the norepinephrine transporter. See Galli et al., J. Exp. Biol. 1995, 198(Pt 10):2197. Reference compounds were used as positive Controls in ail assays. Specifically, prazosin, 4-DAMF ((l,l-dimethyl-4-diphenylacetoxypiperidinium iodide), DAMGO (Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol) and ketanserin were used for the adrenergic al A, muscarinic M2, μ opiate and 5HT2A receptor binding assays, respectively. Physostigmine was used in the acetylcholinesterase assay and desipramine was used in the norepinephrine transporter assay. The percent inhibition values for certain compounds are provided in Tables C and D below.
-204Table C
Compound | Acetylcholinesterase | Adrenergic alA | Muscarinic M2 |
Ynh ' ÏIY | — | 104 | 51 |
Q \ 0 0 ^5 Z )— Z Y 1/ t | 86 | 97 | 62 |
XkL JO O M 1 | 31 | 86 | 78 |
hn^Vjnh | 19 | 88 | 65 |
\ -o o / \ I z\ # z i___ | 23 | 76 | 76 |
\ — o o / \ T Z /)— Z üb T | 32 | 87 | 62 |
T ..,......~y .....O Q q o o \ / | 23 | 72 | 75 |
- 205 -
Compound | Acetylcholinesterase | Adrenergic alA | Muscarinic M2 |
/ \ O o y) O Q •y ’·χ/ | 13 | 83 | 80 |
Table D
Compound | Mu Opiate | Serotonin 5HT2A | Norepinephrine Transporter (NET) |
Anh n AA- N Æ | 92 | 98 | 84 |
I 'NH ' ïïl) | 92 | 101 | 84 |
\ —o o 0 / \ T Z />—z 0 b | 26 | 21 | 38 |
ηιΆΑ o'^^hr'·' I | 12 | 54 | 57 |
A ^mh HN' I | 44 | 40 | 72 |
-206-
Compound | Mu Opiate | Serotonin 5HT2A | Norepinephrine Transporter (NET) |
\ — O O &b T | 48 | 38 | 57 |
T N fi z—e z 1 \_/ w O O \ / | 23 | 27 | 33 |
/ \ O O y} b O 0 | 73 | 30 | 65 |
Example 2
Fêtai Hemoglobin Induction Assay
Cryopreserved bone marrow CD34+ hematopoietic cells obtained from healthy adult human 5 donors were used for ail studies. A 21 day ex vivo sérum free culture System was utilized that consists of two phases. In culture phase I (culture days 1-7), CD34+ cells were placed in media containing StemPro-34 complété media (1-glutamine, pen-strep and StemPro-34 nutrient supplément) (Invitrogen, Carlsbad, CA) supplemented with 50 ng/mL SCF (HumanZyme, Chicago, IL), 50 ng/mL FLT3-Ligand (HumanZyme) and 10 ng/mL IL-3 (HumanZyme). During the first phase of culture (days 0-7), the 10 CD34+ cells differentiate into progenitor cell populations that include erythroblasts. After 7 days, the cells were transferred to erythropoietin (EPO; Stemcell) supplemented medium (phase 2; culture days 7-21) which is comprised of the following: StemPro-34 complété medium, 4 U/mL EPO, 3 μΜ mifepristone (Sigma Aldrich, St. Louis, MO), 10 pg/mL insulin (Sigma Aldrich), 3 U/mL heparin (Sigma Aldrich) and 0.8 mg/mL holo transferrin (Sigma Aldrich). The Compounds are added during 15 phase 2; days 7-21 to test fêtai hemoglobin production (See Blood. 2015 Jul 30;126(5):665-72).
Expression levels of α-, β- and γ-globin genes are assessed by quantitative PCR analyses. HbF protein levels are assessed by the human Hemoglobin F enzyme-linked immunosorbent assay (ELISA) Quantitation Kit (Bethyl Laboratory, Montgomery, TX, USA). Percentages of cells expressing HbF are
-207assessed by flow cytometry analysis. In brief, RNA samples were prepared and complementary DNA was synthesized, according to the manufacturer’s instructions (Qiagen, Germany). The qRT-PCR analysis of human globin genes was performed using the TaqMan Gene Expression Master. The HbF induction values for certain compounds are provided in Table E below.
Table E
Compound No. | Compound Conc. (nM) | Fold Induction |
215 | 250 | 2.1 |
217 | 250 | 1.0 |
240 | 250 | 4.1 |
245 | 250 | 1.1 |
258 | 250 | 3.0 |
286 | 330 | 3.3 |
Formulation Examples
The following are représentative pharmaceutical formulations containing a compound of the présent disclosure.
Tablet Formulation
The following ingrédients are mixed intimately and pressed into single scored tablets.
Ingrédient | Quantity per tablet (mg) |
Compound of this disclosure, or a pharmaceutically acceptable sait thereof | 400 |
comstarch | 50 |
croscarmellose sodium | 25 |
lactose | 120 |
magnésium stéarate | 5 |
Capsule Formulation
The following ingrédients are mixed intimately and loaded into a hard-shell gelatin capsule.
Ingrédient | Quantity per tablet (mg) |
Compound of this disclosure, or a pharmaceutically acceptable sait thereof | 200 |
lactose spray dried | 148 |
magnésium stéarate | 2 |
-208 Iniectable Formulation
Compound of the disclosure (e.g., compound 1) in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL.
Inhalation Composition
To préparé a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% NaCl (aq). The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
Topical Gel Composition
To préparé a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropyl cellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purifïed alcohol USP. The gel mixture is then incorporated into containers, such as tubes, which are suitable for topical administration.
Ophthalmic Solution Composition
To préparé a pharmaceutical ophthalmic solution composition, 100 mg of a compound disclosed herein is mixed with 0.9 g of NaCl in 100 mL of purifïed water and filtered using a 0.2 micron filter. The isotonie solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
Nasal spray solution
To préparé a pharmaceutical nasal spray solution, 10 g of a compound disclosed herein is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 pL of spray for each application.
Furthermore, although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the présent disclosure. Therefore, it should be clearly understood that the forms disclosed herein are illustrative only and are not intended to limit the scope of the présent disclosure, but rather to also cover ail modification and alternatives coming with the true scope and spirit of the invention.
Claims (4)
1. A compound of Formula (I):
or a pharmaceutically acceptable sait thereof, wherein:
Ri is alkoxy (optionally substituted with one or more Ra, which is deuterium); and R2 is selected from halogen, cyano, alkyl, haloalkyl, hydroxy, hydroxyalkyl, aryloxy, heteroaryloxy, cycloalkyl (optionally substituted with one or more hydroxy), cycloalkoxy, cyanoalkoxy, alkoxy (optionally substituted with one or more Ra, independently selected from deuterium, hydroxy, alkoxy and (hydroxy)alkoxy), haloalkoxy and aminosulfonyl (optionally substituted with one or more alkyl); or
Ri and R2, together with the atoms to which they are attached, form a monocyclic heterocyclyl group;
Ais CH or N;
Rsa is (a) heterocyclyl;
(b) heterocyclylalkyl;
(c) spiroheterocycloamino (optionally substituted with one or more Rb, independently selected from alkyl, aryl (optionally substituted with one or more Rd, independently selected from halogen and alkyl) and alkoxycarbonyl);
(d) cycloalkylalkyl (optionally substituted with one or more Rc, independently selected from amino and alkylamino);
(e) heteroaralkyl (optionally substituted with alkyl);
(f) alkyl (optionally substituted with alkylamino); or (g) hydrogen;
wherein the heterocyclyl rings of (a) and (b) are independently optionally substituted with one or more Re, independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted
210 with (i) at least one halogen and at least one hydroxy or with (11) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy);
Rsb is hydrogen, alkyl or -(C=O)NH2;
Ring B is
, wherein the asterisks indicate the points of attachments to the pyridinyl ring of Formula (I);
m and n are independently 1, 2, 3 or 4, wherein the sum of m + n is 2, 3, 4 or 5;
X is CR4AR4B, NR4C or O;
R4A, R4B and R4C are independently hydrogen or alkyl;
each R5 is independently alkyl; and v is 0, 1, 2, 3 or 4.
2.
The compound of Claim 1, wherein A is CH.
3.
The compound of Claim 1, wherein A is N.
4.
The compound of any one of Claims 1-3, wherein Rsb is hydrogen.
AT
5.
v
The compound of any one of Claims 1-4, wherein Ring B is n .
6.
The compound of Claim 5, wherein X is CR4AR4B.
7.
The compound of Claim 6, wherein R4A and R4B are each hydrogen.
8.
The compound of any one of Claims 5-7, wherein m is 1; and n is 1.
9.
The compound of any one of Claims 5-7, wherein m is 2; and n is 1.
;QhR 5)v
10.
The compound of any one of Claims 1-4, wherein Ring B is
11.
The compound of any one of Claims 1-10, wherein Ri is methoxy.
The compound of any one of Claims 1-10, wherein Ri and R2 are each methoxy.
12.
211
13. The compound of any one of Claims 1-10, wherein Ri is methoxy; and R2 is alkoxy substituted with one or more Ra which is alkoxy.
14. The compound of any one of Claims 1-10, wherein Ri is methoxy; and R2 is alkoxy mono-substituted with Ra which is hydroxy.
15. The compound of any one of Claims 1-14, wherein R3A is heteroaralkyl (optionally substituted with alkyl).
16. The compound of any one of Claims 1-14, wherein Rsa is cycloalkylalkyl (optionally substituted with one or more Rc, independently selected from amino and alkylamino).
17. The compound of any one of Claims 1-14, wherein Rsa is spiroheterocycloamino (optionally substituted with one or more Rb, independently selected from alkyl, aryl (optionally substituted with one or more Rd, independently selected from halogen and alkyl) and alkoxycarbonyl).
18. The compound of any one of Claims 1-14, wherein Rsa is heterocyclyl optionally substituted with one or more Re, independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl (optionally substituted with (i) at least one halogen and at least one hydroxy or with (ii) alkoxy), alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy).
19. The compound of Claim 18, wherein Rsa is heterocyclyl substituted with one, two, three or four Re, which is independently an unsubstituted alkyl.
20. The compound of Claim 18, wherein Rsa is heterocyclyl independently substituted with one or more Re, which is heteroaryl (optionally substituted with one or more Rf independently selected from halogen, cyano and alkyl).
21. The compound of Claim 18, wherein Rsa is heterocyclyl independently substituted with one or more Re, which is heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy).
212
22. The compound of Claim 18, wherein Rsa is heterocyclyl independently substituted with one or more Re, which is aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy).
23. The compound of any one of Claims 1-14, wherein Rsa is heterocyclylalkyl optionally substituted with one or more Re, independently selected from halogen, hydroxy, alkoxy, hydroxyalkyl, cycloalkyl, cyanoalkyl, aralkyl, alkoxycarbonyl, aminocarbonyl, cycloalkylalkyl, alkyl, alkylcarbonyl (optionally substituted with hydroxy or benzyloxy), alkylsulfonyl, heteroaryl (optionally substituted with one or more Rf independently selected from halogen, alkyl, cyano and hydroxy), heteroaralkyl (optionally substituted with one or more Rg independently selected from halogen, alkyl, cyano and hydroxy), heterocyclyl (optionally substituted with one or more Rh independently selected from alkyl, cyano and hydroxy) and aryl (optionally substituted with one or more Ri independently selected from halogen, alkyl, alkoxy, cyano and hydroxy).
24. The compound of Claim 23, wherein Rsa is heterocyclylalkyl substituted with one or two Re, independently selected from hydroxy, alkoxy, alkyl, cycloalkyl, heteroaryl (optionally substituted with one or two Rf independently selected from halogen) and aryl (optionally substituted with one or more Ri independently selected from halogen).
25. The compound of any one of Claims 1-14, wherein Rsa is alkyl, optionally substituted with alkylamino.
26. The compound of Claim 25, wherein Rsa is methyl or isopropyl.
27. The compound of Claim 25, wherein Rsa is alkyl substituted with alkylamino.
28. The compound of Claim 1, wherein the compound is selected from the group consisting of
No
Structure
No
Structure
1
Y-
HN J''
70
HN^**
Ox 1
9
.C) h3c >
HjC. x
3 O
5
213
2
1 HNX
9
71
O JL
H,C Nm 7l^\
?
h3c . A>/Q·
3 ’o N
9
3
O — W*
72
JE JE
O O
O O
\Ί ΰΰ 0-0
I w
4
1 HNX
^^χχχ> 9
73
z
\^
qq y-A O O
O O τ’ £
5
HN
1
9
74
I x ‘o ‘o o o K7
V \ x z 7— z 0 0 0
0 z
ω
6
^-M x \ Γ \z /
o^
O
75
/\/CH3 \ H
< N
<0^
H3° VriT^
H3C% J<S xL*%Z
3 0 N
9
214
7
X
Ζ “V ζ
X <
°\ °~
76
CÛL
N CH3
Ο JL
H3C Yf||A
h,c JL* JL JLz
- *0 N
8
Η
HN ^0; \
1
77
-CH3
Ç N 0 3
HN^---
JL
H3C
H?c. JL» JL JL^z
3 'o N
5
9
ΗΝ'^ζ°\/\/0λ τχχ>
1
5
78
0^NH
H N ^00 .o^ 0^ _
h 3 c 0ρΥλ
H3C O N
5
10
0 A Η
Q0Î07 ' ι
79
Fx/S.
-0 / F
HN
-O. 0
H3C >^· Ύ^· τγ^.
h3c. 0x05· J<y
3 O N
9
11
hnX0^n 0^/^χ0;_0'> τχχ> 0^0/0^^7
1
80
Xj
F
HN
,O^ JL ^.
H3C
h3c . J<» JL JL^Z
3 '0 N
9
215
12
Ο 1
^A. HN
O 1
13
nH
HN
5
14
Q
Q4 i \ Ç °\ °“
15
(
U.Ü Z —V z x \ A °\ °~
81
I T w w
O o o* o
X7 ζΠ-i 00
82
ην^Α> III 1 N
o A^
h3c ίΑ ττΆ
2 h3c As Aï ΑΆ 3 'O N
9
83
M
X
Q
Qû Z—G z x y ^/
4/ o o o o τ’ τ’
84
T T
ω ω
Ω Ω
Ο* Ο zKi ce ο
I
217
218
219
29
-ο V / \ τ
ζ λ— ζ
/Γ \ ζ
98
ην^
.Cto χ^ -k χ\
h3c Pflll
H3C Ο 'ΧΖ^ Ν
9
30
ΗΝ X
1 5
99
χχ^ -ΟΗ < Ν Χ^
ην'χζ
. Ο - XK Α. χ^~>
h 3c yyJL Ά
h3c. JL. JL JL / O X-^ N X---'
9
31
ΗΝ ^^/CÔo ΟΗ
9
100
HN^*—
O x^ JL x^~> h3c Tt \
)
H3C. X*^.x*> xk J
3 *o N X—-'
9
32
ΗΝ'ΧΧ'
1
101
çh3
x-x X\ < N Xx*
HN^^---
.CL____ xk>--V
H3C Ύ0Κ |[ \
h3c. JL. JL Jk J O xz n X—J
9
33
ΗΝ
Αχ/Χζχ/'Λ ο-'Χ^Χν^χ—7
1
102
^N
JL
H3° \ Ίτ n >
h3cw jL^ JL· JL /
3 o N ---7
9
220
34
— Ο \)
y \ ζ λ— ζ συ χ
103
CO
X Ο UQ ο ο ο ο CO ¢0 X X
35
HN JxJ τχχ>
5
104
I X
ω ω
Ο Ο
Ο* ο
Χ7 ου > ο
I ω
36
HN -^χΑ
F Ά
5
105
Ζ^ΝΗ
,C> ____ JL /--K
h3c || )
H3C ’ Ο
5
37
HnJkJ
οΉΡ'7 I
106
I τ ω ω
Ο ο » « ο ο ZA-i ου
221
222
225
226
58
T O
x \ F
°\ °“
127
I X
ω ω
Ο Ο
Ο ο 0
59
XX
X. X F
HN
^XXXX
0 — N 5
128
0
Qû ιμ
XX ο ο ο ο
η ο
X X
60
Jjî Z—(' Z T \___/
°\ /
129
«
X
ο · ο
OQ
ζ /-f XX ο ο
ο ο
Μ rt
X X
61
/ \
O O X
O
/
130
x^N r 'νζ
H3C γ V|TA
H3C w xA >X/
3 ο N
?
62
T
0 P
p 77^
Z—(z z
X \___/
°\ /
131
T T ω ω Ω Ο « *
Ο Ο
X υ ο
X
227
63
f N—
H N'''
JT TT 5
132
1° O
<
Qû * yj
JJ O O
O ü «Ό en T T
64
I N—\
! hn
0 mJmx o I
133
χ. ΧΧχ .CHa f----- -- 3
HN^---
O JL
h3c Y· μ H)
h3c . JL. >L Jky 0 N
65
HN^\ / NH
JT T> 5
135
-OH
X N
HN^---Z
-0^ χΝ^ JL
η3ο Γ |T^>
h3c, J^y
O N
5
66
HN^\ / MeOxAjN TJ T)
9
136
x^x .CH, M N 3
,C) .N. A. χχ
H,C >r^ 7r 1
H3C. x^xk· xk^x^
3 *o —N 9
67
HnTT
TT X> MeO'^-^'N
5
137
HN^>^
.O^ JL
h3c >r> X |j ] h3c . xt^-k· JL J
5
228
68
2 2
Φ Φ
Ο Ο / \ ζ
ζ />—Ζ ρΓ '
xz^J
138
I I ω ω
Ο Ο
Ο ο z^i ΟΟ b
69
2 2
φ φ
ο ο ζ \
χζ J
139
Ζ ζ ω ω
Ο ο « » ο ο ζΜοΟ b
134
/ \
Ο Ο ο / \ I ζ /)—ζ ύο
Y
140
ην'^Ζ
JL
h3c Y if ]
h3c . xL- JL J
O N
5
149
οΖ 'ο
Ά
/ \ 1
Ζ\\Τ ζ ο Ο
X
141
•9
QQ t -yy
2m O O
O O
CO «
T Z
163
/ \ ο ο ο
0
142
ch3 ____ zx p N
JL
h3c* Y|f]
h3c . JL. J<. JL J
5
229
164
/ \
Ο ο vz ο ο
/
143
^,Ν
Ν
,0, Αχ
h3c ΓΗΙ
h3c . JL·» JL· JJL J
d o N
9
165
1
^ζ^
Z-ÇZ
I \__/
ζΑ Μ
ο ο \ /
144
Z^NH
HN^X^
.Οχ JL
h3c X fill
H,C. JL. A J
J 0 —N
5
286
ρ ζ-χζ I \__/
ο ο
\ /
145
X X ω ω Ο Ο ο’ ο zW-1 Ο0 > ο
X ω
402
HN'CInh
^O^N^Ux-
1 τ χ>
5
146
«
X
Ο
QQ
Αχ ζμ ο ο ο ο τ’ χ5
403
Ο \>
ΖΙ
147
en
X « ο Η QQ χ yy ζμ ο ο ο ο
en en X X
230
404
σ ρ
Z—Z I \__/
zQ o o \ /
148
,— ,oh
---Z
,O^ ^N. JL Λ
H3C 40 ]
h3c. JL. JL JL J
405
ό 0
’W Z î x Λ
A a kM d \ / x / ô;-4^o
150
y>. .ch3
Y N 3
,o^ 0. y—-.
h3c >> 7r \
)
H,C. J<X JL Jk /
3 O — N ---'
5
406
/ \ 1 zuH o 0
I
151
Z T
ω ω
Ο ο ο ο θ4
407
T ο n
Z—çL o o
152
. 0 _ _ Ν _ y ν
h3c >> >r^ 7Γ \ )
Η 3θ. A. J
3 O N ---'
5
408
/ \
o o o
ZJ \ %\_
Z—/ I
153
1—
.cr _N. —»
h3c Tt \
H3c. A> A J
3 ’O ------N
?
409
ΗΝ'ώΗ
154
MeCk
MeC)
zN. A
8c
λ~\ Ο Ο \ /
Ο
F F
— O
410
hn^nh
155
,c> h3c x
hn''^-'^
χ<Τ.
Ν
5
H3C. x
3 O
’I'^Z
F
ΟΗ
çh3
O
411
/0.
ΗΝ^
156
h3c
>*
'Ci
?
h3c. > Ό
---
?
F
412
ηνΌη
157
.0^
h3c
τ
x<J\ <>L^/
Ν
5
H3C. J.
3 Ό
5
F F
^NH
413
ηΑ>νη
158
,0
H3C
HN^*-
Ν^χ^χ/·
5
h3c.
3 O
J
232
414
Ο \
ΞΕ
159
CH3
ην^ΑΑ
foc ψ- P |J Ά
H3C. JïsAï >L / ο — Ν A—'
415
/ \
Ο ο
/ \ I
Ζ—'
I
160
^CH,
hn'Zs—
.<% J».
h3c Y Y|f A
h3c. JL, JL JL /
5
416
/ \ ο Ο / \ 1 νγ *
X
161
ch3
AY^CHa hn·*^---
.0. AL h 3 c y r |] A
h3c. Aï. Aï JL J
5
162
χ^^ΟΗ < Ν
ΗΝ^*^
Ο JL /—ν
H3C ψ· Ύ|[ Ά
h3c. χΐ^. JL. JL /
3 Ό Ν X—7
5
201
I I ω ω
Ο ο t *
ο ο Κ7 Ch k
166
vL ^Ν. -CH3 ΗΝ »
Ο ^Ν. JL _
Η30 ψ- ψ||--\
H3C. Αϊ Αϊ β—/
Ο Ν
5
202
JA-<1
HN*^ A
_______ X
H3c >r^ τΆ
H3c. Aï. Aï
3 0 N
?
233
167
,0
H3C h3c.
3 0
J
N—\
M CH3
5
203
.0^
H3c' Y
H3C. JL
3 *o
^Vk I Z /“z
X^N>
Χη3
168
h3c' *
H3C. z
3 Ό
G
,hk ^ζχ
—ch3
9
204
.θκ h3c' Y h3c. A
3 *0
^~Gz \\ //
^OH
9
169
O H3C
HNV
N—\
J ^-ch3
205
h3c Y
HNV^
.ch3 o 3
H3c. J
3 0
?
H3C. J^.
‘q x
JU.
N
5
170
.o. h3c h3c.
3 *o
<♦ HN ^N^ JL w
<K
206
h3c' Y h3c . JL
3 ’O
hn''^
*^N
9
171
O H3c'
HNV^ γΛ
3^
207
h3c Y
HNV\
Ίτ ilT
N-
f— OH
h3c. „ 3 'o
5
H3C. JL. 3
JL l|
9
236
237
238
240
242
243
244
246
Y
x^. .CH, < N
283
H ο ο \ (
\ ο I
ΗΙΨ
/ Ν
?
335
o
h3c Ύ
H3C,___Λ
'B
9
284
νη
ch3 C
?
336
.o^
h3c Ύ
Cl·
hn'
x*S. .CH3
Ç N 3
O
5
285
φ:
ΖΛ. ν J
ch3
G
9
294
HN
h3c
jQQ
X-NH
ch3
ch3 ô
s. .CH,
3
9
287
cça α Μ
ch3
CH3
5
338
o . h3c
HN^
Do N
'^N^'CHs
9
288
CCI
I
U
O 0-0
O I
339
.c> J
h3c Ÿ
z—Z”'z 1 y à \\ /)
9
247
289
HN
d
H
ch3
,ô
. -CH, Ko 3
9
340
.0^ h3c
Cl'^'
îjC N
‘N^CHs
9
ch3
291
CXùOi
/\>NH
HN JL ^ 043
.CH, ^o* 3
342
.o^ -zs h3c
HN^*
9
9
_ -N. -zs.
H Ί
çh3 ô
292
VUAZ
• ch3 HN . 3 0
ch3
o-CH3
9
343
,0^
h3c
HsCv^ï^
HN-^
9
293
1 /=N
yT hn) Y-NH \=
Ά -CH3 y—° o-ch3
9
344
H3C
HN^
N^
9
ch3
(—^NH
295
ΠΤΙ
Ί
CHj
346
.0 .
H3C
hn'
H 3c*<>
NH
9
9
248
296
ΟζΧ
NH
VL /
il
M
O 0-0
» Z
O w
ω
347
0^ h3c
HjC.___
i O
Y-f
z^NH
9
297
O0
N 'cHj
CHj ,0
'0-C^
9
348
h3c > c/
HN**
0^NH
9
298
S e-
ch3
/O
s. .CH3
O 3
9
302
.0^
h3c
f
HNX
<^NH
9
299
-Q n
Z—(' Z 0
ch3
ô
JL .ch3
O 3
9
350
.o^ h3c' x
'B
\ ,ch3
N 3
9
300
CQQ
'*N/
N
ch3 O
JL CH, ^0 3
9
351
-CL h3c' ' h3c.___
HN*^·
OÔC
.CH, N 3
9
249
301
y HN
oh
5
352
τ’
O
QQ * r-f
Y-< O Ô o,
303
ί^^ΝΗ
O XX
h3c pf|T\
N^
5
354
-x .CH, < N 3
HN^x^ . O χχ Jk ZX h,c ?r '
LL 1 0 N N^
?
304
r^'NH
HN**^^
O XX JY
h 3 c Vf|i—\
H3C J-ÎXxY χΥκΖ
3 XX N
355
XX .CH, r—n 3
HN^^^
.ow xx JY y—-v
H3C 7^· îT '
°
H3C. xks xk· X< J 3 ------------ ---'
5
305
[^'NH HN^^^
O χ·χ JY
H,C T^ÙÏ^X
JYXjLy Cl N
?
356
.CH3
Ç N 3
.Ok JL y-*^
h3c 7r '
JQ1 /
Cl N >—J
306
|^NH
HN^
0 χχ JY
Η3% XxjO
F F
5
358
I z ‘o Jo
X7 zK? oo ° >
O w
308
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1 ζ
Q Q
z —G z
O O
O
*0
359
Z*
O
Qp i-Gz
O 7 O O m en Z Z
309
c? O
-π O
\7
VA_z z z- z 0 0
O
JE .
360
r—n^ch3
h3c *y^ γ/ y Y
1 1 Π 0
Cl N ----
9
311
0H3
h3c r riT^
h3c J< JLv
5
362
/ NH
HN^^^
O 0^ /”0.
H,C' >0 Y 1
JUÀÀ J -------------
N^
9
312
Z w O
O O
\7 O 1 z ')— z
0 0
0 z
ω
310
m
T
O
QQ
°r\
0 z n
T
....
313
Z
w
Tl -ΠΟ
V O
\/
VAz
z '>— z
0 0
0 z
ω
364
I ω
Z O
'0
X7
VA_z 0 ω
252
378
I ζ ‘ο ο
Μ
Ο 0
391
Vf A ο ο—
379
0 0 ζ-Ζ ζ 1 γ //
4/ ο / b ο I f0
392
y ΗΝ
Heu yy Αχ Αν
9
380
I ω Ο ο ο Κ7 ο ο
393
y ΗΝ /Οχ'/^^Α^χ-'-'Χ ^ΙΛ Χ>
ΟΗ
390
y
1 ΗΝ
,Ν. °vA+-%
394
y ΗΝ /θ'χΚ^Αχ^Λ
ΗΟ
382
Ο
X Ο
<
Οΰ
ξ τΑ
ο ο
Μ
395
y ΗΝ /QxKS^Ax-^x
i
253
383
T ω
-zi Ο θ
ζ ζ
X
> ο τ ω
396
A-X T \__/
\ / x /\ ° o X \ M>
384
ρ ο ο—
397
ΑΑοη3
H Fl—
XK
h3c τγΆ
3 1 1 1JL z '^Xx***' ο
9
385
Ρ ο ο— _
398
to
T
O
Oq z —G Z h
Vy
/~\ ,o
O c/\
ÆZ ’o
co i
1 O co
T
386
^zJ^z τ \__/
—ο Ο A
399
3.
O O
387
y
1 ΗΝ
A °vvV\
Γ if II J J >
9
400
Z^nX^*ch 3 hn^Nx O ____ JL x^ h3C* >r^· 77 M
H3C . xLs. Mï- X<
9
254
or a pharmaceutically acceptable sait of any of the foregoing.
29. A pharmaceutical composition comprising a compound of any one of Claims 1-28, or a pharmaceutically acceptable sait thereof; and a pharmaceutically acceptable excipient.
5 30. A compound of any one of Claims 1-28 or a pharmaceutically acceptable thereof, for use in a method of inhibiting G9a.
31. A compound of any one of Claims 1 -28, or a pharmaceutically acceptable thereof, or the pharmaceutical composition of Claim 29, for use in a method of ameliorating and/or treating a hemoglobinopathy, wherein the hemoglobinopathy is sickle cell disease or beta-thalassemia.
10 32. A compound of any one of Claims 1-28, or a pharmaceutically acceptable thereof, or the pharmaceutical composition of Claim 29, for use in a method of ameliorating and/or treating a cancer, wherein the cancer is selected from: a Colorectal Cancer; a Osteosarcoma Cancer; an Acute Lymphoblastic Leukemia (ALL); an Acute Myeloid Leukemia (AML); an Adrenocortical Carcinoma; a Kaposi Sarcoma (Soft Tissue Sarcoma); an AIDS-Related Lymphoma (Lymphoma);
15 a Primary CNS Lymphoma; an Anal Cancer; a Gastrointestinal Carcinoid Tumor; an Astrocytoma; an Atypical Teratoid/Rhabdoid Tumor; a Basal Cell Carcinoma of the Skin; a Bile Duct Cancer; a Bladder Cancer; a Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma); a Brain Tumor; a Breast Cancer; a Bronchial Tumor; a Burkitt Lymphoma; a Cardiac Tumor; an Embryonal Tumor (Brain Cancer); a Germ Cell Tumor (Brain Cancer); a
20 Primary CNS Lymphoma; a Cervical Cancer; a Cholangiocarcinoma; a Chordoma; a Chronic Lymphocytic Leukemia (CLL); a Chronic Myelogenous Leukemia (CML); a Chronic • 255
Myeloproliferative Neoplasm; a Craniopharyngioma (Brain Cancer); a Cutaneous T-Cell Lymphoma; a Ductal Carcinoma In Situ (DCIS); an Endométrial Cancer (Uterine Cancer); an Ependymoma (Brain Cancer); an Esophageal Cancer; an Esthesioneuroblastoma; an Ewing Sarcoma (Bone Cancer); Extracranial Germ Cell Tumor; Extragonadal Germ Cell Tumor; Eye
5 Cancer; Intraocular Melanoma; a Retinoblastoma; a Fallopian Tube Cancer; a Fibrous Histiocytoma of Bone; a Gallbladder Cancer; a Gastric (Stomach) Gastrointestinal Stromal Tumor (GIST) (Soft Tissue Sarcoma); a CNS Germ Cell Tumors (Brain Cancer); an Extracranial Germ Cell Tumor; an Extragonadal Germ Cell Tumor; an Ovarian Germ Cell Tumor; a Testicular Cancer; a Gestational Trophoblastic Disease; a Hairy Cell Leukemia; a Head and Neck Cancer; a
10 Hepatocellular (Liver) Cancer; a Histiocytosis, a Langerhans Cell; Hodgkin Lymphoma; a Hypopharyngeal Cancer (Head and Neck Cancer); an Intraocular Melanoma; an Islet Cell Tumor; a Pancreatic Neuroendocrine Tumor; a Kidney (Rénal Cell) Cancer; a Langerhans Cell Histiocytosis; a Laryngeal Cancer (Head and Neck Cancer); a Leukemia; a Lip and Oral Cavity Cancer (Head and Neck Cancer); a Lung Cancer (Non-Small Cell and Small Cell); a Lymphoma;
15 a Male Breast Cancer; a Melanoma; a Merkel Cell Carcinoma (Skin Cancer); a Mesothelioma; a Malignant Mesothelioma; a Metastatic Squamous Neck Cancer with Occult Primary (Head and Neck Cancer); a Midline Tract Carcinoma involving NUT Gene; a Mouth Cancer (Head and Neck Cancer); Multiple Endocrine Neoplasia Syndromes; Multiple Myeloma/Plasma Cell Neoplasms;
a Mycosis Fungoides (Lymphoma); a Myelodysplastic Syndrome, a
20 Myelodysplastic/Myeloproliferative Neoplasm; a Nasal Cavity and Paranasal Sinus Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer — Neuroblastoma; a Non-Hodgkin Lymphoma; an Oral Cancer; Lip and Oral Cavity Cancer and Oropharyngeal Cancer (Head and Neck Cancer); an Ovarian Cancer; a Pancreatic Cancer, a Papillomatosis; a Paraganglioma; a Paranasal Sinus and Nasal Cavity Cancer (Head and Neck
25 Cancer); a Parathyroid Cancer; a Penile Cancer; a Pharyngeal Cancer (Head and Neck Cancer); a Pheochromocytoma; a Pituitary Tumor; a Pleuropulmonary Blastoma; a Primary CNS Lymphoma; a Primary Peritoneal Cancer; a Prostate Cancer; a Rectal Cancer; a Rhabdomyosarcoma (Soft Tissue Sarcoma); a Salivary Gland Cancer (Head and Neck Cancer); a Salivary Gland Tumor, a Vascular Tumor (Soft Tissue Sarcoma); an Uterine Sarcoma; a Sézary Syndrome (Lymphoma); a
30 Small Intestine Cancer; a Squamous Cell Carcinoma; a Skin Cancer; a Squamous Neck Cancer with Occult Primary, Metastatic (Head and Neck Cancer); a Cutaneous Τ-Cell Lymphoma; a
256
Throat Cancer (Head and Neck Cancer); a Nasopharyngeal Cancer; an Oropharyngeal Cancer; a Hypopharyngeal Cancer; a Thymoma and Thymie Carcinoma; a Thyroid Cancer; an Uréthral Cancer; a Vaginal Cancer; a Vascular Tumor (Soft Tissue Sarcoma); a Vulvar Cancer; a Myelodysplastic syndrome (MDS); and a Wilms Tumor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/545,936 | 2017-08-15 | ||
US62/712,864 | 2018-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19495A true OA19495A (en) | 2020-10-23 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11713299B2 (en) | Histone methyltransferase inhibitors | |
TWI826416B (en) | Chemokine receptor modulators and uses thereof | |
DK3102577T3 (en) | QUINOLONDERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | |
US11254651B2 (en) | Histone methyltransferase inhibitors | |
US20210371417A1 (en) | Azaindole compounds as histone methyltransferase inhibitors | |
US11661410B2 (en) | Tricyclic compounds as histone methyltransferase inhibitors | |
US11584734B2 (en) | Tricyclic compounds as histone methyltransferase inhibitors | |
OA19495A (en) | Tricyclic compounds as Histone Methyltransferase inhibitors. | |
TW202406902A (en) | Chemokine receptor modulators and uses thereof | |
OA19439A (en) | Azaindole compounds as histone methyltranferase inhibitors. |